<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006369.pub2" GROUP_ID="SCHIZ" ID="109706080713201380" MERGED_FROM="" MODIFIED="2012-04-18 12:31:14 +0200" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;/p&gt;" NOTES_MODIFIED="2012-03-14 13:47:25 +0000" NOTES_MODIFIED_BY="Claire Irving" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2012-04-18 12:31:14 +0200" MODIFIED_BY="Claire Irving">
<TITLE MODIFIED="2009-02-20 02:21:11 +0000" MODIFIED_BY="[Empty name]">Oral paliperidone for schizophrenia</TITLE>
<CONTACT MODIFIED="2012-04-18 12:31:14 +0200" MODIFIED_BY="Claire Irving"><PERSON ID="3DB9ECC482E26AA200837311CA3EAA81" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Abraham</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Nussbaum</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>abraham.nussbaum@dhha.org</EMAIL_1><ADDRESS><DEPARTMENT>Behavioral Health Service</DEPARTMENT><ORGANISATION>Denver Health</ORGANISATION><ADDRESS_1>MC 0490</ADDRESS_1><ADDRESS_2>777 Bannock Street</ADDRESS_2><CITY>Denver</CITY><ZIP>80204</ZIP><REGION>CO</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 303 436 8507</PHONE_1><FAX_1>+1 303 436 6660</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-04-18 12:31:14 +0200" MODIFIED_BY="Claire Irving"><PERSON ID="3DB9ECC482E26AA200837311CA3EAA81" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Abraham</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Nussbaum</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>abraham.nussbaum@dhha.org</EMAIL_1><ADDRESS><DEPARTMENT>Behavioral Health Service</DEPARTMENT><ORGANISATION>Denver Health</ORGANISATION><ADDRESS_1>MC 0490</ADDRESS_1><ADDRESS_2>777 Bannock Street</ADDRESS_2><CITY>Denver</CITY><ZIP>80204</ZIP><REGION>CO</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 303 436 8507</PHONE_1><FAX_1>+1 303 436 6660</FAX_1></ADDRESS></PERSON><PERSON ID="3DB9EEB882E26AA200837311B462EE17" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>T</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Stroup</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>scott_stroup@med.unc.edu</EMAIL_1><ADDRESS><DEPARTMENT>Psychiatry</DEPARTMENT><ORGANISATION>Columbia University</ORGANISATION><ADDRESS_1>1051 Riverside Drive</ADDRESS_1><ADDRESS_2>Room 2703, Box 100</ADDRESS_2><CITY>New York</CITY><ZIP>10032</ZIP><REGION>New York</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>212 543 5676</PHONE_1><FAX_1>212 543 5085</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-03-12 12:13:50 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="11" MONTH="11" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="11" MONTH="11" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="2" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2012-03-12 12:10:59 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-03-12 12:10:59 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>Feedback incorporated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2012-03-12 12:09:00 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>Responded to formal feedback about studies with high attrition rates by clarifying the section on dealing with missing data in the Methods portion of the review. Responded to formal feedback about change in average PANSS score and weight from the Canuso 2009 trial; previous versions of this review mistakenly used standard error instead of standard deviation. Added no clinically important change data from Canuso 2009 trial in response to feedback.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-03-12 12:09:44 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-03-12 12:09:44 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="6" YEAR="2009"/>
<DESCRIPTION>
<P>Update search run November 2008 resulting in the inclusion of two additional studies. Title amended.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2012-03-12 12:09:40 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Responded to corrections identified by the manufacturer.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-06-01 16:18:56 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="17" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Psychiatry, University of North Carolina Hospitals</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-11-25 23:30:18 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-06-05 10:14:24 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-03-17 12:09:43 +0000" MODIFIED_BY="[Empty name]">Oral paliperidone for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2009-06-05 10:14:24 +0100" MODIFIED_BY="[Empty name]">
<P>Paliperidone, 9-hydroxy-risperidone, is an active metabolite of risperidone that is now commercially available in an oral formulation. We evaluated the efficacy, adverse effects, and safety of oral paliperidone in the treatment of people with schizophrenia and schizophrenia-like illnesses. In short-term studies, oral paliperidone is a more effective antipsychotic than placebo. The adverse effects of paliperidone are similar to those of risperidone. No data comparing the efficacy of paliperidone to risperidone over a meaningful period of time was available for this review; in a six-day trial comparing paliperidone to risperidone we identified no difference in recurrence of psychotic symptoms or adverse effects. The manufacturer is also developing an intramuscular long-acting formulation, but it is not yet commercially available; its use in the treatment of schizophrenia will be considered in a separate review.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-07-23 14:26:58 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-06-20 01:34:31 +0100" MODIFIED_BY="[Empty name]">
<P>Paliperidone, an active metabolite of risperidone, is now available in an oral formulation for daily use; an intramuscular formulation for monthly administration is expected to follow shortly. Oral paliperidone is available commercially only in an extended release formulation that was used in all of the clinical trials we examined in this review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To compare effects of oral paliperidone with any other treatment for people with schizophrenia and schizophrenia-like illnesses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-11-11 18:15:13 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group's Register (November 2008) and inspected references of identified studies for further trials. We contacted the manufacturers of paliperidone, the Food and Drug Administration, and authors of relevant trials for additional material.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-06-05 09:28:15 +0100" MODIFIED_BY="[Empty name]">
<P>We included all relevant randomised controlled trials (RCTs).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We independently selected and critically appraised studies, extracted data and analysed on an intention-to-treat basis. Where possible and appropriate, we calculated risk ratios (RR) and their 95% confidence intervals (CI) with the number needed to treat (NNT). We calculated Weighted Mean Differences (WMD) for continuous data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-06-20 01:36:10 +0100" MODIFIED_BY="[Empty name]">
<P>Eight studies with 2567 participants compared paliperidone with placebo. Fewer people left studies early if they were randomised to paliperidone (n=1926, 7 RCTs, RR 0.68 CI 0.61 to 0.75, NNT 7 CI 6 to 10) and those receiving any dose of paliperidone were significantly more likely to have an improvement in global state (n=1420, 4 RCTs, RR 0.69 CI 0.63 to 0.75, NNT 5 CI 4 to 6). People randomised to paliperidone were less likely to experience a recurrence of psychosis (n=1918, 7 RCTs, RR 0.47 CI 0.34 to 0.66, NNT 17 CI 14 to 26) than those allocated to placebo. Paliperidone was associated with a greater incidence of tachycardia than placebo (n=1638, 5 RCTs, RR 1.88 CI 1.28 to 2.76, NNH 21 CI 11 to 90) and a consistent, significant elevation in serum prolactin (ng/mL) for both men (n=413, 4 RCTs, WMD 27.68 CI 23.66 to 31.69) and women (n=252, 4 RCTs, WMD 87.39 CI 74.27 to 100.51). People receiving paliperidone were more likely to experience extrapyramidal disorders (n=1680, 6 RCTs, RR 2.27 CI 1.31 to 3.95, NNH 28 CI 12 to 111) and weight gain (n=769, 4 RCTs, WMD 1.07 CI 0.65 to 1.49, I-squared 78%) compared with those allocated to placebo.</P>
<P>Three studies with 1692 participants compared paliperidone with 10 mg/day olanzapine. We found no differences between paliperidone and olanzapine for leaving in the short term (n=1332, 3 RCTs, RR 1.04 CI 0.89 to 1.21; ~40% in both groups left by six weeks). Those receiving any dose of paliperidone were no more likely to have a recurrence of psychotic symptoms than those receiving olanzapine (n=1327, 3 RCTs, RR 1.07 CI 0.64 to 1.76). Data from all three studies found that paliperidone was associated with less weight change than olanzapine (n=660, 3 RCTs, WMD -0.88 CI -1.38 to -0.37). Results for various movement disorders all favoured olanzapine.</P>
<P>One study lasting less than a week compared paliperidone with risperidone. When participants taking paliperidone were compared with participants taking 4 mg/day risperidone in this brief study, we found no significant difference in the recurrence of psychotic symptoms or in the incidence of adverse events.</P>
<P>One study compared paliperidone, with a mean dose of 9.8 mg daily, versus quetiapine, with a mean dose of 599.1 mg daily, over six weeks. Patients receiving paliperidone were less likely to leave the study early (n=314, 1 RCT, RR 0.64 CI 0.44 to 0.93, NNT 9 CI 6 to 43). No significant difference was observed in the recurrence of psychotic symptoms (n=317, 1 RCT, RR 0.65 CI 0.29 to 1.45, NNT 52 CI Not Significant). Participants receiving paliperidone were more likely to experience hypertonia (n=317, 1 RCT, RR 3.19 CI 1.31 to 7.77, NNH 13 CI 4 to 86) and tremor (n=317, 1 RCT, RR 2.60 CI 1.39 to 4.88, NNH 9 CI 4 to 34).</P>
<P>There are no clear data regarding oral paliperidone relating to social functioning, services use, quality of life, patient satisfaction or cost.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-07-23 14:26:58 +0100" MODIFIED_BY="[Empty name]">
<P>In short-term studies, oral paliperidone is an antipsychotic drug that is more efficacious than placebo. We found its adverse effects to be similar to those of its parent compound, risperidone, with movement disorders, weight gain and tachycardia all more common with paliperidone than placebo. While no difference was found in the incidence of reported adverse sexual outcomes, paliperidone is associated with substantial increases in serum prolactin. When used at doses of 6 mg per day or higher, oral paliperidone appears comparable in efficacy to olanzapine 10 mg/day. A single study of six days duration found neither an advantage nor disadvantage of paliperidone compared to risperidone. When dosed flexibly with other psychotropics available, it appears to be comparable in efficacy to flexible doses of quetiapine with other psychotropics available.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-11-25 23:30:18 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-12-01 13:44:04 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2009-06-05 10:39:49 +0100" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is a profound illness whose course varies but is often associated with significant disability (<LINK REF="REF-Lieberman-2006" TYPE="REFERENCE">Lieberman 2006</LINK>). When people with schizophrenia adhere to a prescribed antipsychotic regimen, they often experience a clinically significant improvement of their psychotic symptoms and an increased time to recurrence of psychotic symptoms (<LINK REF="REF-Freedman-2003" TYPE="REFERENCE">Freedman 2003</LINK>). However, perhaps only 20% of people with schizophrenia experience a full remission of symptoms, even while adherent to antipsychotic medication (<LINK REF="REF-Hogarty-1974" TYPE="REFERENCE">Hogarty 1974</LINK>). Since antipsychotic medications have substantial limitations and people frequently stop taking them (<LINK REF="REF-Lieberman-2005" TYPE="REFERENCE">Lieberman 2005</LINK>), clinicians need to evaluate novel treatments for their efficacy, adverse effects, and safety. We conducted this review to evaluate the efficacy, adverse effects, and safety of paliperidone which is now available to treat schizophrenia.</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-12-01 13:44:04 +0000" MODIFIED_BY="[Empty name]">
<P>Cochrane reviewers previously concluded that paliperidone's parent molecule, risperidone, is as effective in the treatment of schizophrenia as older generation antipsychotics and the newer generation drugs amisulpride and olanzapine (<LINK REF="REF-Gilbody-2000" TYPE="REFERENCE">Gilbody 2000</LINK>, <LINK REF="REF-Hunter-2003" TYPE="REFERENCE">Hunter 2003</LINK>, <LINK REF="REF-Jayaram-2006" TYPE="REFERENCE">Jayaram 2006</LINK>). Comparisons of risperidone to clozapine for treatment resistant schizophrenia were inconclusive (<LINK REF="REF-Gilbody-2000" TYPE="REFERENCE">Gilbody 2000</LINK>). However, people prescribed risperidone commonly experience adverse effects that include: anxiety, dizziness, extrapyramidal symptoms, headache, hyperprolactinaemia, insomnia, sexual dysfunction, somnolence, tachycardia and weight gain (<LINK REF="REF-Hunter-2003" TYPE="REFERENCE">Hunter 2003</LINK>, <LINK REF="REF-Mackay-1998" TYPE="REFERENCE">Mackay 1998</LINK>).</P>
<P>While risperidone is well-characterized in its efficacy and adverse effects, paliperidone is a newly available agent, so clinicians have much to learn about its effects (<LINK REF="REF-Angelucci-2009" TYPE="REFERENCE">Angelucci 2009</LINK>, <LINK REF="REF-Anonymous-2007" TYPE="REFERENCE">Anonymous 2007</LINK>, <LINK REF="REF-Anonymous-2007b" TYPE="REFERENCE">Anonymous 2007b</LINK>, <LINK REF="REF-Aravagiri-1998a" TYPE="REFERENCE">Aravagiri 1998a</LINK>, <LINK REF="REF-Aravagiri-1998b" TYPE="REFERENCE">Aravagiri 1998b</LINK>, <LINK REF="REF-Aravagiri-2000" TYPE="REFERENCE">Aravagiri 2000</LINK>, <LINK REF="REF-Aravagiri-2002" TYPE="REFERENCE">Aravagiri 2002</LINK>, <LINK REF="REF-Aravagiri-2003" TYPE="REFERENCE">Aravagiri 2003</LINK>, <LINK REF="REF-Awouters-2007" TYPE="REFERENCE">Awouters 2007</LINK>, <LINK REF="REF-Canuso-2008" TYPE="REFERENCE">Canuso 2008</LINK>, <LINK REF="REF-Canuso-2009a" TYPE="REFERENCE">Canuso 2009a</LINK>, <LINK REF="REF-Canuso-2009b" TYPE="REFERENCE">Canuso 2009b</LINK>, <LINK REF="REF-Citrome-2007" TYPE="REFERENCE">Citrome 2007</LINK>, <LINK REF="STD-Cleton-2006" TYPE="STUDY">Cleton 2006</LINK>, <LINK REF="STD-Cleton-2007b" TYPE="STUDY">Cleton 2007b</LINK>, <LINK REF="REF-Cohrs-2008" TYPE="REFERENCE">Cohrs 2008</LINK>, <LINK REF="REF-Danel-2008" TYPE="REFERENCE">Danel 2008</LINK>, <LINK REF="REF-Dirks-2006" TYPE="REFERENCE">Dirks 2006</LINK>, <LINK REF="REF-Dlugosz-2007" TYPE="REFERENCE">Dlugosz 2007</LINK>, <LINK REF="REF-Dolder-2008" TYPE="REFERENCE">Dolder 2008</LINK>, <LINK REF="REF-Dopheide-2008" TYPE="REFERENCE">Dopheide 2008</LINK>, <LINK REF="REF-Emsley-2008" TYPE="REFERENCE">Emsley 2008</LINK>, <LINK REF="REF-Feng-2008" TYPE="REFERENCE">Feng 2008</LINK>, <LINK REF="REF-Fowler-2008" TYPE="REFERENCE">Fowler 2008</LINK>, <LINK REF="REF-Freudenmann-2009" TYPE="REFERENCE">Freudenmann 2009</LINK>, <LINK REF="REF-Friberg-2009" TYPE="REFERENCE">Friberg 2009</LINK>, <LINK REF="REF-Glick-2009" TYPE="REFERENCE">Glick 2009</LINK>, <LINK REF="REF-Hough-2009" TYPE="REFERENCE">Hough 2009</LINK>, <LINK REF="REF-Hussar-2008" TYPE="REFERENCE">Hussar 2008</LINK>, <LINK REF="REF-Janicak-2008a" TYPE="REFERENCE">Janicak 2008a</LINK>, <LINK REF="REF-Jones-2008" TYPE="REFERENCE">Jones 2008</LINK>, <LINK REF="REF-Jones-2008a" TYPE="REFERENCE">Jones 2008a</LINK>, <LINK REF="REF-Knight-2009" TYPE="REFERENCE">Knight 2009</LINK>, <LINK REF="REF-Kramer-2008" TYPE="REFERENCE">Kramer 2008</LINK>, <LINK REF="REF-Kostic-2006" TYPE="REFERENCE">Kostic 2006</LINK>, <LINK REF="REF-Lautenschlager-2008" TYPE="REFERENCE">Lautenschlager 2008</LINK>, <LINK REF="REF-Marino-2008" TYPE="REFERENCE">Marino 2008</LINK>, <LINK REF="REF-Meltzer-2008" TYPE="REFERENCE">Meltzer 2008</LINK>, <LINK REF="REF-Nasrallah-2008" TYPE="REFERENCE">Nasrallah 2008</LINK>, <LINK REF="REF-Pani-2009" TYPE="REFERENCE">Pani 2009</LINK>, <LINK REF="REF-Patrick-2009" TYPE="REFERENCE">Patrick 2009</LINK>, <LINK REF="REF-Peng-2008" TYPE="REFERENCE">Peng 2008</LINK>, P&#345;ikryl 2009, <LINK REF="REF-Rado-2007" TYPE="REFERENCE">Rado 2007</LINK>, <LINK REF="REF-Roser-2009" TYPE="REFERENCE">Roser 2009</LINK>, <LINK REF="REF-Schwartzer-2009" TYPE="REFERENCE">Schwartzer 2009</LINK>, <LINK REF="REF-Simpson-2006" TYPE="REFERENCE">Simpson 2006</LINK>, <LINK REF="REF-Simpson-2007" TYPE="REFERENCE">Simpson 2007</LINK>, <LINK REF="REF-Spina-2007" TYPE="REFERENCE">Spina 2007</LINK>, <LINK REF="REF-Turkoz-2008" TYPE="REFERENCE">Turkoz 2008</LINK>, <LINK REF="REF-Vermeulen-2007" TYPE="REFERENCE">Vermeulen 2007</LINK>, <LINK REF="REF-Yang-2007" TYPE="REFERENCE">Yang 2007</LINK>). Previous studies have suggested that the prolactin elevation people often experience with risperidone administration is chiefly related to paliperidone (<LINK REF="REF-Byerly-2007" TYPE="REFERENCE">Byerly 2007</LINK>, <LINK REF="REF-Duval-2008" TYPE="REFERENCE">Duval 2008</LINK>, <LINK REF="REF-Knegtering-2005" TYPE="REFERENCE">Knegtering 2005</LINK>, <LINK REF="REF-Melkersson-2006" TYPE="REFERENCE">Melkersson 2006</LINK>), that paliperidone does not undergo significant hepatic metabolism (<LINK REF="REF-Urichuk-2008" TYPE="REFERENCE">Urichuk 2008</LINK>, <LINK REF="REF-Vermeir-2008" TYPE="REFERENCE">Vermeir 2008</LINK>, <LINK REF="REF-Vermeir-2005" TYPE="REFERENCE">Vermeir 2005</LINK>), that the time to maximum plasma concentration for paliperidone is significantly longer than for risperidone (<LINK REF="STD-Cleton-2007" TYPE="STUDY">Cleton 2007</LINK>), that age is a significant covariate of paliperidone clearance (<LINK REF="REF-Feng-2008" TYPE="REFERENCE">Feng 2008</LINK>), that paliperidone is expressed in the breast milk of nursing mothers but cannot be detected in the plasma of breast fed infants (<LINK REF="REF-Ilett-2004" TYPE="REFERENCE">Ilett 2004</LINK>), that paliperidone use has been associated with the development of neuroleptic malignant syndrome (<LINK REF="REF-Duggal-2007" TYPE="REFERENCE">Duggal 2007</LINK>, <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK>), choreatic symptoms (<LINK REF="REF-Huther-2008" TYPE="REFERENCE">Huther 2008</LINK>) and atrial fibrillation and a possible seizure (<LINK REF="REF-Schneider-2008" TYPE="REFERENCE">Schneider 2008</LINK>). While the manufacturer funded a virtual analysis comparing paliperidone and risperidone (<LINK REF="REF-Schooler-2007" TYPE="REFERENCE">Schooler 2007</LINK>), we are aware of only a single small, six-day clinical trial (<LINK REF="STD-Cleton-2007" TYPE="STUDY">Cleton 2007</LINK>) that directly compares the effects experienced by people taking risperidone and those experienced by people taking paliperidone.</P>
<P>The cost effectiveness of paliperidone, especially in comparison to risperidone which is now available in a generic formulation, remains unknown. We identified only a single study of the cost-effectiveness of paliperidone and note that it was funded by paliperidone's manufacturer, conducted in Greece, and was based on the estimated, rather than the actual, cost of paliperidone (<LINK REF="REF-Geitona-2008" TYPE="REFERENCE">Geitona 2008</LINK>). A recent study that favoured paliperidone for cost-effectiveness was based on statistical models (<LINK REF="REF-Edwards-2008" TYPE="REFERENCE">Edwards 2008</LINK>).</P>
<P>Paliperidone is of special interest because the manufacturer intends to release a long-acting intramuscular formulation. At this time, risperidone is the only new generation antipsychotic available in a long-acting intramuscular formulation (<LINK REF="REF-Hosalli-2003" TYPE="REFERENCE">Hosalli 2003</LINK>). However, long-acting formulations of risperidone must be administered bi-weekly, refrigerated, reconstituted with a diluent supplied by the manufacturer and administered within six hours of reconstitution (<LINK REF="REF-Janssen-2003" TYPE="REFERENCE">Janssen 2003</LINK>). In contrast, the long-acting intramuscular formulation of paliperidone, which is not yet commercially available, is expected to be administered monthly and not to require refrigeration or reconstitution. The long-acting intramuscular formulation, because of its more convenient administration schedule compared with risperidone microspheres, will be of particular interest when information regarding its use is publicly available; its use in the treatment of schizophrenia will be considered in a separate review.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-06-05 10:47:41 +0100" MODIFIED_BY="[Empty name]">
<P>Risperidone is metabolized to 9-hydroxy-risperidone (paliperidone) by cytochrome P450 2D6 ( <LINK REF="REF-Leon-2007" TYPE="REFERENCE">Leon 2007</LINK>, <LINK REF="REF-Mannens-1993" TYPE="REFERENCE">Mannens 1993</LINK>). Risperidone has a ratio of 5HT2A to dopamine 2 receptor occupancy of approximately 20 (<LINK REF="REF-Janicak-2006" TYPE="REFERENCE">Janicak 2006</LINK>). An association between the occupancy of dopamine 2 receptors and daily risperidone doses, with 66% occupancy at 2 mg, 73% at 4 mg, and 79% at 6 mg has been demonstrated (<LINK REF="REF-Kapur-1995" TYPE="REFERENCE">Kapur 1995</LINK>). Higher doses of risperidone, especially over 10 mg per day, are associated with the development of extra-pyramidal symptoms (<LINK REF="REF-Mannens-1993" TYPE="REFERENCE">Mannens 1993</LINK>).</P>
<P>In a small study using paliperidone in healthy people, researchers demonstrated an association between the occupancy of dopamine 2 receptors and daily paliperidone doses, with 75-78% occupancy of dopamine 2 receptors at 6 mg (<LINK REF="REF-Karlsson-2006" TYPE="REFERENCE">Karlsson 2006</LINK>). In a larger PET study using paliperidone in males with schizophrenia, researchers found that 70-80% occupancy of dopamine 2 receptors occurs when people take paliperidone dosed at 6 to 9 mg daily (<LINK REF="REF-Arakawa-2008" TYPE="REFERENCE">Arakawa 2008</LINK>).</P>
<P>Since paliperidone has a longer half-life and is less lipophilic than risperidone, it permeates the blood-brain barrier less easily, so that it may take higher doses of paliperidone to achieve central dopamine blockade. Researchers postulate that since the pituitary lies outside the blood-brain barrier, the clinical use of paliperidone will cause a greater number of dopamine receptors in the pituitary to be blocked, so that hyperprolactinaemia will result more readily than with risperidone (<LINK REF="REF-Fitzgerald-2008" TYPE="REFERENCE">Fitzgerald 2008</LINK>). However, a small randomised clinical trial in patients taking risperidone at baseline found that subjects treated with paliperidone experienced lower mean elevations in serum prolactin and a longer time to peak elevation in mean prolactin concentration (<LINK REF="STD-Cleton-2007" TYPE="STUDY">Cleton 2007</LINK>). Further, the relationship between the hyperprolactinaemia that is associated with the use of paliperidone and the clinical outcomes of sexual dysfunction, amenorrhoea, galactorrhoea, gynaecomastia, obesity, hirsutism, decreased bone mineral density, osteoporosis, cardiovascular disorders, and breast cancer remains a contested question (<LINK REF="REF-Bostwick-2009" TYPE="REFERENCE">Bostwick 2009</LINK>, <LINK REF="REF-Byerly-2007" TYPE="REFERENCE">Byerly 2007</LINK>, <LINK REF="REF-Pandina-2007" TYPE="REFERENCE">Pandina 2007</LINK>, <LINK REF="REF-Wang-2007" TYPE="REFERENCE">Wang 2007</LINK>).</P>
<P>Researchers have demonstrated that paliperidone, like risperidone, blocks both 5HT2A and dopamine 2 receptors, as well as alpha 1 and alpha 2 adrenoceptors, histamine 1 receptors, but not beta adrenoceptors, muscarinic cholinoceptors or peptidergic receptors (<LINK REF="REF-Janssen_x002d_Cilag-1996" TYPE="REFERENCE">Janssen-Cilag 1996</LINK>, <LINK REF="REF-Janssen-2006" TYPE="REFERENCE">Janssen 2006</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-02-20 02:47:13 +0000" MODIFIED_BY="[Empty name]">
<P>This review updates a previous version by adding additional data comparing paliperidone to olanzapine and placebo, along with comparisons to quetiapine and risperidone (<LINK REF="REF-Nussbaum-2008" TYPE="REFERENCE">Nussbaum 2008</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-11-04 16:53:22 +0000" MODIFIED_BY="[Empty name]">
<P>To compare the efficacy, adverse effects, and safety of oral paliperidone with any other treatment, including placebo, for people with schizophrenia and schizophrenia-like illnesses.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-11-25 19:40:49 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-07-23 14:43:28 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-06-08 18:01:18 +0100" MODIFIED_BY="[Empty name]">
<P>We included all relevant randomised controlled trials. Quasi-randomised trials such as those where allocation is undertaken based on time of admission to the hospital were also eligible. Randomised cross-over studies will be eligible but only data up to the point of first cross-over because of the instability of the problem behaviours and the likely carry-over effects of all treatments.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included people diagnosed with schizophrenia or schizophrenia-like illnesses, diagnosed by any criteria, irrespective of age or gender.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-02-20 14:23:59 +0000" MODIFIED_BY="[Empty name]">
<P>1. Paliperidone (trade name Invega), of any dose, by either oral or intramuscular administration, either alone or as an adjunct or augmenting agent.<BR/>2. Placebo.<BR/>3. Alternative psychotropic agent, of any dose or route of administration, either alone or as an adjunct or augmenting agent.<BR/>4. Other methods of treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-07-23 14:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>We grouped outcomes by duration of treatment into short term (up to 12 weeks), medium term (13 to 26 weeks), and long term (over 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-06-05 11:09:09 +0100" MODIFIED_BY="[Empty name]">
<P>1. Global state<BR/>1.1 Relapse: recurrence of psychotic symptoms<BR/>1.2 No clinically important change in global state (as defined by individual studies) </P>
<P>2. Discontinuation of treatment or leaving the study early.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-07-23 14:43:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Death - suicide and natural causes</P>
<P>2. Global state<BR/>2.1 Time to recurrence of psychotic symptoms<BR/>2.2 No change in global state score<BR/>2.3 Average endpoint global state score<BR/>2.4 Average change in global state scores</P>
<P>3. Service outcomes<BR/>3.1 Hospitalisation<BR/>3.2 Time to hospitalisation<BR/>3.3 Duration of hospitalisation</P>
<P>4. Mental state (with particular reference to the positive and negative symptoms of schizophrenia spectrum disorders)<BR/>4.1 No clinically important change in general mental state<BR/>4.2 Average endpoint general mental state score<BR/>4.3 Average change in general mental state scores<BR/>4.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia, depression, mania)<BR/>4.5 Average endpoint specific symptom score<BR/>4.6 Average change in specific symptom scores</P>
<P>5. Leaving the study early<BR/>5.1 Any reason<BR/>5.2 Specific reason<BR/>5.3 Time to leaving the study early</P>
<P>6. Social functioning<BR/>6.1 No clinically important change in general functioning<BR/>6.2 Average endpoint social functioning score<BR/>6.3 Average change in social functioning scores<BR/>6.4 No clinically important change in specific aspects of functioning, such as social or life skills<BR/>6.5 Average endpoint specific aspects of social functioning, such as life skills<BR/>6.6 Average change in specific aspects of social functioning, such as life skills</P>
<P>7. Behaviour<BR/>7.1 No clinically important change in general behaviour<BR/>7.2 Average endpoint general behaviour score<BR/>7.3 Average change in general behaviour scores<BR/>7.4 No clinically important change in specific aspects of behaviour<BR/>7.5 Average endpoint in specific aspects of behaviour<BR/>7.6 Average change in specific aspects of behaviour</P>
<P>8. Adverse effects<BR/>8.1 Clinically important general adverse effects<BR/>8.2 Average endpoint general adverse effect score<BR/>8.3 Average change in general adverse effect scores<BR/>8.4 Clinically important specific adverse effects (particularly movement disorders, and those known to occur more commonly with risperidone such as anxiety, dizziness, extrapyramidal symptoms, headache, hyperprolactinaemia, insomnia, sexual dysfunction, somnolence, tachycardia, and weight gain)<BR/>8.5 Average endpoint specific adverse effects<BR/>8.6 Average change in specific adverse effects</P>
<P>9. Engagement with services<BR/>9.1 No clinically important engagement<BR/>9.2 Not any engagement<BR/>9.3 Average endpoint engagement score<BR/>9.4 Average change in engagement scores</P>
<P>10. Satisfaction with treatment<BR/>10.1 Recipient of care not satisfied with treatment<BR/>10.2 Recipient of care average satisfaction score<BR/>10.3 Recipient of care average change in satisfaction scores<BR/>10.4 Caregiver not satisfied with treatment<BR/>10.5 Caregiver average satisfaction score<BR/>10.6 Caregiver average change in satisfaction scores</P>
<P>11. Quality of life<BR/>11.1 No clinically important change in quality of life<BR/>11.2 Average quality of life endpoint score<BR/>11.3 Average change of quality of life score<BR/>11.4 No clinically important change in specific aspects of quality of life<BR/>11.5 Average endpoint specific aspects of quality of life<BR/>11.6 Average change in specific aspects of quality of life</P>
<P>12. Economic outcomes<BR/>12.1 Direct costs<BR/>12.2 Indirect costs</P>
<P>13. Cognitive functioning<BR/>13.1 No clinically important change in cognitive functioning<BR/>13.2 Average endpoint cognitive functioning score<BR/>13.3 Average change in cognitive functioning scores<BR/>13.4 No clinically important change in specific aspects of cognitive functioning<BR/>13.5 Average endpoint specific aspects of cognitive functioning<BR/>13.6 Average change in specific aspects of cognitive functioning</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-06-08 18:01:29 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-06-08 18:01:29 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group's Specialised Register (December 2006, November 2008) with the phrase:</P>
<P>[((*paliperid* or *9-OH-risper*) in title, abstract, index terms of REFERENCE) OR ((*paliperid* or *9-OH-risper*) in interventions field in STUDY)]</P>
<P>We used the same search strategy in 2006 and 2008. This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). The Cochrane Schizophrenia Group's Specialised Register is maintained on Meerkat 1.5. This version of Meerkat stores references which have been identified as the same study are also selected.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-02-20 11:54:01 +0000" MODIFIED_BY="[Empty name]">
<P>1. Reference searching<BR/>We inspected references of all identified studies for more studies.</P>
<P>2. Personal communication<BR/>We contacted the first author of each included study for more information regarding unpublished trials.</P>
<P>3. Pharmaceutical companies<BR/>We contacted Janssen-Cilag Limited for further data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-11-25 19:40:49 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-06-05 11:33:40 +0100" MODIFIED_BY="[Empty name]">
<P>Authors AN and SS independently inspected the study citations identified from the search. We identified potentially relevant abstracts, ordered full papers and reassessed these for inclusion and methodological quality. We discussed and reported any disagreement.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-06-08 18:03:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. Data extraction<BR/>We independently extracted data from included studies and, where further clarification was needed, we contacted authors of trials to provide missing data.</P>
<P>2. Management<BR/>We extracted the data onto standard, simple forms. Where possible, we entered data in such a way that the area to the left of the 'line of no effect' indicated a favourable outcome for the experimental treatment.</P>
<P>3. Scale-derived data<BR/>3.1 Valid scales<BR/>A wide range of instruments are available to measure outcomes in mental health studies. These instruments vary in quality and many are not validated, or are even ad hoc. It is accepted generally that measuring instruments should have the properties of reliability (the extent to which a test effectively measures anything at all) and validity (the extent to which a test measures that which it is supposed to measure) (<LINK REF="REF-Rust-1989" TYPE="REFERENCE">Rust 1989</LINK>). Unpublished scales are known to be subject to bias in trials of treatments for schizophrenia (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>). Therefore continuous data from rating scales were included only if the measuring instrument had been described in a peer-reviewed journal. In addition, the following minimum standards for instruments were set: the instrument should either be (a) a self-report or (b) completed by an independent rater or relative (not the therapist) and (c) the instrument should be a global assessment of an area of functioning.</P>
<P>3.2 Binary outcomes from scale data<BR/>Where possible, efforts were made to convert outcome measures to binary data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005" TYPE="REFERENCE">Leucht 2005</LINK>, <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>). It was recognised that for many people, especially those with chronic or severe illness, a less rigorous definition of important improvement (e.g. 25% on the BPRS) would be equally valid. If individual patient data were available, the 50% cut-off was used for the definition in the case of non-chronically ill people and 25% for those with chronic illness. If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.<BR/>
</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-06-05 11:52:26 +0100" MODIFIED_BY="[Empty name]">
<P>Working independently, authors AN and SS allocated trials to three quality categories, as described in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). When we determined that a trial had a low or moderate risk of bias, we assigned them to category A or B, respectively; when we determined that a trial had a high risk of bias, we assigned them to category C. When disputes arose as to which category a trial ought to be allocated, we attempted resolution by discussion. When this was not possible, and further information was necessary, we did not enter data into the analyses and allocated the study to the list of those awaiting assessment. We only included trials in Category A or B in the review.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-07-23 15:00:50 +0100" MODIFIED_BY="[Empty name]">
<P>1. Binary data<BR/>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). We calculated the number needed to treat (NNT) and, where possible, the number needed to harm (NNH) for the primary outcomes. If heterogeneity was found, a random-effects model was used.</P>
<P>2. Continuous data<BR/>2.1 Summary statistic<BR/>For continuous outcomes we estimated a weighted mean difference (WMD) between groups, using a random-effects model.</P>
<P>2.2 Rating scales<BR/>A wide range of instruments are available to measure mental health outcomes, but these instruments vary in quality and many are not valid. We included continuous data from rating scales only if the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>), the instrument was either a self report or completed by an independent rater or relative (not the therapist), and the instrument was considered a global assessment of an area of functioning. When therapists were simultaneously treating and rating a person, we considered the therapist's observations as prone to bias.</P>
<P>2.3 Skewed data<BR/>Mental health continuous data are often not 'normally' distributed. Most statistics assume a normal distribution. To avoid including non-normally distributed data in the statistical analysis, we applied the following criteria to all data before inclusion:<BR/>a. Standard deviations and means were reported or derivable from data in the paper, or were obtainable from the authors.<BR/>b. When a scale starts from zero, the standard deviation, when multiplied by two, was less than the mean (as otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Endpoint scores on scales often have a finite start and end point, and so we could apply this rule to them.<BR/>c. When continuous data were presented on a scale that included a possibility of negative values (such as change on a scale) it is impossible to tell whether data are non-normally distributed (skewed) or not. It is thus preferable to use scale endpoint data, which typically cannot have negative values. If endpoint data were not available, we used change data, because the statistics used in MetaView are rather robust towards skew.<BR/>d. If a scale starts from a positive value (such as PANSS, which can have values from 30-210) the calculation described above (b) was modified to take the scale starting point into account. In these cases skew was considered present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).<BR/>e. When we determined that data was profoundly skewed, we excluded it from the meta-analysis, but presented it in additional tables. When we determined that data was only modestly skewed, we included it within the meta-analysis.</P>
<P>2.4 Endpoint versus change data<BR/>Endpoint scale-derived data are finite, ranging from one score to another. Change data are more problematic because most change scores are likely to be skewed. Where both endpoint and change data were available for the same outcome, we preferred to present scale endpoint date, which typically cannot have negative values and is easier to interpret from a clinical point of view.</P>
<P>2.5 Intention-to-treat analyses<BR/>With regards to intention-to-treat analyses versus completer's analyses (which only evaluate the patients who complete the study), when both analyses were available, we preferred the intention-to-treat analysis. When only a completer's analysis was reported, we scrutinised the analysis separately and, when possible, re-analysed on an intention-to-treat basis.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-11-25 19:24:23 +0000" MODIFIED_BY="[Empty name]">
<P>1. Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>If clustering was not accounted for in primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intraclass correlation coefficients of their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering had been incorporated into the analysis of primary studies, we present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies had been appropriately analysed taking into account intraclass correlation coefficients and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
<P>2. Cross-over design<BR/>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological, or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason, cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in schizophrenia, we used only data of the first phase of cross-over studies.</P>
<P>3. Studies with multiple treatment groups<BR/>Where a study involved more than two treatment arms, if relevant, the additional treatment arms were presented in comparisons. Where the additional treatment arms were not relevant, these data were not reproduced.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-11-25 19:40:49 +0000" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>We attempted to include all people who had been randomised to paliperidone. Where possible, we gave cases lost to follow up at the end of the study the worst outcome. For example, those lost to follow up for the outcome of relapse were treated in the analysis as having relapsed.</P>
<P>2. Overall loss of credibility<BR/>At some degree of loss to follow up data must lose credibility (<LINK REF="REF-Xia-2007" TYPE="REFERENCE">Xia 2007</LINK>). We are forced to make a judgment where this is for the trials likely to be included in this review. Since we had identified discontinuation as a primary outcome, we planned to exclude data from studies only where more than 50% of participants in any group discontinued treatment because they were 'lost to follow up.' If participants left a study early for any reason, we considered them to have had the negative outcome, except for the event of death. If we had identified a study as having a high rate (25-50%) of subjects &#8216;lost to follow up,&#8217; we would have analysed the impact of including these studies in a sensitivity analysis for primary outcomes. If inclusion of data from this latter group resulted in a substantive change in the estimate of effect, we would not add the data to trials with less attrition, but would present the data separately.</P>
<P>3. Binary<BR/>If attrition had been reported as a binary outcome between 0 and 50%, and outcomes of these subjects had been described, we would have included these data as reported. Where the outcomes of such people were not clearly described, we would assumed the worst primary outcome, and rates of adverse effects similar to those who did continue to have their data recorded. Attrition was not reported in this fashion in the studies we included, so we did not report the data in this fashion.</P>
<P>4. Continuous<BR/>In the case where attrition for a continuous outcome is between 0 and 50% and completer-only data were reported, we would have reproduced these. Attrition was not reported in this fashion in the studies we includes, so we did not report the data in this fashion.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-07-23 15:02:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical heterogeneity<BR/>We considered all included studies without any comparison to judge clinical heterogeneity.</P>
<P>2. Statistical<BR/>We used a Chi-square test, as well as visual inspection of graphs, to investigate the possibility of heterogeneity. We interpreted a significance level less than 0.10 as evidence of heterogeneity. We calculated the value of I-squared to provide an estimate of the percentage of variability due to heterogeneity rather than chance alone. We interpreted an I-squared value of 50% or greater as indicating high levels of heterogeneity (<LINK REF="REF-Deeks-2005" TYPE="REFERENCE">Deeks 2005</LINK>). If inconsistency was high, we did not summate data, but presented them separately and investigated the reasons for heterogeneity. In any event, if substantial heterogeneity was present, we used a random-effects model and undertook a sensitivity analysis to the presence or absence of these data.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-06-08 18:05:56 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We entered data from all identified and selected trials into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-06-05 13:01:39 +0100" MODIFIED_BY="[Empty name]">
<P>We employed a fixed-effect model for analyses. While there is no settled argument in favour of either fixed or random-effects models, the random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. While this seems true to us, random-effects put added weight onto the smaller of the studies - the trials that are most vulnerable to bias. For this reason, we favour using the fixed-effect model.<BR/>
</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-07-23 15:03:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. Investigation of heterogeneity<BR/>If data was clearly heterogeneous, we checked that data were correctly extracted and entered and that we had made no unit of analysis errors. If the high levels of heterogeneity remained, we did not include them in our meta-analysis.</P>
<P>2. Subgroup analysis<BR/>No subgroup analyses were anticipated to be undertaken for this review.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2009-02-20 11:55:11 +0000" MODIFIED_BY="[Empty name]">
<P>We used a sensitivity analysis to gauge the effect of including studies with high attrition rates, to investigate the effects of heterogeneity and of differing study designs.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-11-25 23:29:08 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-12-01 13:28:06 +0000" MODIFIED_BY="[Empty name]">
<P>For substantive descriptions of studies please see the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2009-06-08 18:06:16 +0100" MODIFIED_BY="[Empty name]">
<P>1. 2006 search<BR/>We identified six randomised controlled trials of oral paliperidone for inclusion in the initial review.</P>
<P>The Cochrane Schizophrenia Group identified 11 citations in the initial search. We inspected each of these citations, yielding eight reports of the six included trials. We identified several other citations by hand-searching the initial citations, reviewing the publicly available data posted by the U.S. Food and Drug Administration, and searching MEDLINE. However, these additional citations did not represent additional unique trials.</P>
<P>2. 2008 search<BR/>We identified two additional randomised controlled trials of oral paliperidone for inclusion in the revised review, received additional information from the manufacturer, and identified many additional references.</P>
<P>The Cochrane Schizophrenia Group identified 127 citations form 39 studies in the second search. We inspected each of these citations, yielding eight reports of the three trials new to this edition of the review. We identified several other citations by hand-searching the initial citations, reviewing the publicly available data posted by the U.S. Food and Drug Administration, and searching MEDLINE. However, these additional citations did not represent additional unique trials.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-07-23 15:11:30 +0100" MODIFIED_BY="[Empty name]">
<P>The current update of this review includes 25 studies describing eight trials. All were described as randomised.</P>
<P>1. Duration of trials<BR/>All of the trials were of a short duration. The shortest of the trials, <LINK REF="STD-Cleton-2007" TYPE="STUDY">Cleton 2007</LINK>, lasted only six days. The <LINK REF="STD-Luthringer-2007" TYPE="STUDY">Luthringer 2007</LINK> trial lasted only fourteen days.</P>
<P>Researchers designed <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> as a relapse prevention study, and the initial phases of the trial were conducted over a specified duration. However, the randomised phase of the trial was of a variable duration. The study was designed to be terminated after 43 recurrence events if efficacy (P = 0.01) for the intervention was established. Participants randomised to placebo were exposed for a median duration of 29 days, while those randomised to paliperidone were exposed for a median duration of 45 days.</P>
<P>The <LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK> trial had both a two week monotherapy and a four week additive phase. During the initial monotherapy phase, subjects were randomised to paliperidone, placebo or quetiapine. They received standardised, escalating doses. At the end of the monotherapy phase, subjects were continued on their last dose and additional psychotropics, including antipsychotics, were provided as deemed appropriate by the examiner.</P>
<P>The remaining four trials (<LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK>, <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK>, <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> and <LINK REF="STD-Tzimos-2008" TYPE="STUDY">Tzimos 2008</LINK>) lasted six weeks. While the studies assessed clinical outcomes throughout the period of the trial, researchers reported complete outcome data only from the beginning and end of the trial, using a last observation carried forward analysis.</P>
<P>2. Trial size<BR/>The eight trials randomised a total of 2562 participants, 1400 received or continued paliperidone, 366 received olanzapine, 157 received quetiapine, 38 received risperidone, and 601 were randomised to placebo groups. These groups are of uneven size as trials often compared a single placebo or a single active treatment group to more than one paliperidone group. Trial size ranged from 42 (<LINK REF="STD-Luthringer-2007" TYPE="STUDY">Luthringer 2007</LINK>) to 630 (<LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK>).</P>
<P>3. Participants<BR/>All participants were over 18 and diagnosed with DSM-IV schizophrenia. Their PANSS score ranged between 70 and 120. All trials included both males and females, but the majority (about 60%) were male. <LINK REF="STD-Tzimos-2008" TYPE="STUDY">Tzimos 2008</LINK> only included participants who were over the age of 65.</P>
<P>4. Settings<BR/>The setting of the <LINK REF="STD-Cleton-2007" TYPE="STUDY">Cleton 2007</LINK> trial is not well characterized. Participants in the other seven trials began the study with at least 14 days of hospitalisation, and continued the trial in an outpatient setting. With the exception of <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK>, which was conducted at multiple centres only within the United States, the included trials were conducted at multiple centres in countries including Canada, Czech Republic, Israel, Greece, Latvia, Lithuania, Mexico, Romania, Turkey, South Africa, Ukraine and the United States.</P>
<P>5. Interventions<BR/>5.1 Paliperidone<BR/>Four studies used fixed daily oral doses of paliperidone. <LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK> randomised participants to receive 3, 9, or 15 mg of paliperidone. Those randomised to receive 3 or 9 mg began treatment at the target dose, but participants randomised to 15 mg received 12 mg for the first seven days of the trial and thereafter received 15 mg. <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK> randomised participants to receive 6, 9 or 12 mg of paliperidone and in <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> the fixed daily oral dose was 6 or 12 mg of paliperidone. <LINK REF="STD-Luthringer-2007" TYPE="STUDY">Luthringer 2007</LINK> randomised participants to receive 9 mg of paliperidone. All participants in <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK>, <LINK REF="STD-Luthringer-2007" TYPE="STUDY">Luthringer 2007</LINK>, and <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> began treatment at the target dose.</P>
<P>Four studies (<LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK>, <LINK REF="STD-Cleton-2007" TYPE="STUDY">Cleton 2007</LINK>, <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK>, and <LINK REF="STD-Tzimos-2008" TYPE="STUDY">Tzimos 2008</LINK>) used flexible daily doses of paliperidone. In <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK>, participants who had achieved clinical stability on oral paliperidone were randomised to receive oral placebo or paliperidone, starting at the dose at which they had reached stability. After entry into the randomised phase, researchers prescribed flexible doses of paliperidone according to clinical response, ranging from a minimum of 3 mg to a maximum of 15 mg; they report the mean daily dose of paliperidone as 10.8 mg. <LINK REF="STD-Tzimos-2008" TYPE="STUDY">Tzimos 2008</LINK> randomised participants to receive a daily oral placebo or paliperidone flexibly dosed according to clinical response at 3, 6, 9 or 12 mg; they report the mean daily dose of paliperidone as 8.3 +/- 3.0 mg. <LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK> randomised participants to receive escalating doses of paliperidone, 6 mg for the first three days, 9 mg on the fourth day, and, if clinically necessary, to 12 mg on the eighth day of the study; they report the mean dose during monotherapy as 10.4 +/- 1.7 mg.During the additive phase, they report the mean dose as 9.8 +/- 1.5 mg.In <LINK REF="STD-Cleton-2007" TYPE="STUDY">Cleton 2007</LINK>, participants received paliperidone on one of two schedules.In the first schedule, they received placebo on the first day of the trial, then 12 mg of paliperidone on the second through sixth days of the trial.On the second schedule, they received 12 mg of paliperidone on each day of the six day trial.</P>
<P>5.2 Control interventions<BR/>5.2.1 Olanzapine<BR/>
<LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK>, <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK> and <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> included two control groups: one group received a daily placebo and another group received a fixed daily dose of 10 mg of oral olanzapine. Researchers reported including olanzapine only to ensure 'assay sensitivity', but we obtained sufficient data to conduct many comparisons between olanzapine and paliperidone. The other two included trials, <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> and <LINK REF="STD-Tzimos-2008" TYPE="STUDY">Tzimos 2008</LINK>, compared paliperidone only to placebo.</P>
<P>5.2.2 Quetiapine<BR/>
<LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK> included two control groups: one group received a daily placebo and another received an escalating dose of quetiapine, 50 mg on the first day, 100 mg on the second day, 200 mg on the third day, 400 mg on the fourth day, 600 mg on the fifth day, and, if clinically necessary, 800 mg on the eighth day.They report the mean quetiapine dose during monotherapy as 690.9 mg +/- 134.3 mg.</P>
<P>When the two weeks of monotherapy ended, the patient was continued on their last dose, and additional psychotropics were provided as deemed appropriate by the examiner. Study clinicians were allowed to select any psychotropic with the exception of paliperidone, quetiapine, risperidone or the other agents described in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.They report the mean dose of quetiapine during the additive phase as 599.1 mg +/- 142.0 mg.</P>
<P>5.2.3 Risperidone<BR/>
<LINK REF="STD-Cleton-2007" TYPE="STUDY">Cleton 2007</LINK> included one control group, participants randomised to receive risperidone on a fixed schedule, 2 mg on the first day and 4 mg on the second through sixth days of the trial.The study ended after the sixth day.</P>
<P>6. Outcomes<BR/>6.1 General<BR/>Five trials, <LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK>, <LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK>, <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK>, <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> and <LINK REF="STD-Tzimos-2008" TYPE="STUDY">Tzimos 2008</LINK>, defined a clinical response as a 30% or greater improvement in PANSS total score from entry into the trial until the last observed analysis. The chief clinical outcome in <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> was the time to first recurrence of psychotic symptoms; recurrence could be indicated by any number of events, which are summarised in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. The chief outcome in <LINK REF="STD-Cleton-2007" TYPE="STUDY">Cleton 2007</LINK> was orthostatic tolerability, and the only available outcomes relate to adverse events.The chief outcomes in <LINK REF="STD-Luthringer-2007" TYPE="STUDY">Luthringer 2007</LINK> were pharmacodynamic evaluations of sleep. Since these measures do not directly address the use of paliperidone for schizophrenia, they were not included in this review.</P>
<P>6.2 Outcome scales<BR/>Scales which provided usable data are described below.</P>
<P>6.2.1 Global improvement<BR/>6.2.1.1 Clinical Global Impression-Severity Scale - CGI-S (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>Researchers employ this scale to assess the severity of a person's illness by comparing the global state of a participant standardised against other participants with the same diagnosis; a seven-point scoring system is used with lower scores indicating less severity. Changes over time are used to indicate worsening or improvement.</P>
<P>6.2.2 Mental state<BR/>6.2.2.1 Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>, <LINK REF="REF-Marder-1997" TYPE="REFERENCE">Marder 1997</LINK>)<BR/>Researchers use this scale to measure the severity of psychopathology is psychotic disorders. The PANSS has 30 items, each of which can be defined on a seven-point scoring system ranging from one (absent) to seven (extreme) to indicate the participant's degree of impairment. Total scores range from 30 to 210, with lower scores indicating less severe impairment. The scale has Marder factor scores for measuring the severity of general psychopathology, negative symptoms, positive symptoms, disorganised thought, uncontrolled hostility/excitement and anxiety/depression.</P>
<P>6.2.3 Social function<BR/>6.2.3.1 Personal and Social Performance Scale - PSP (<LINK REF="REF-Gagnon-2006" TYPE="REFERENCE">Gagnon 2006</LINK>, <LINK REF="REF-Patrick-2006" TYPE="REFERENCE">Patrick 2006</LINK>, <LINK REF="REF-Patrick-2009" TYPE="REFERENCE">Patrick 2009</LINK>)<BR/>Researchers assess participants in four domains: socially useful activities, relationships, self-care and disturbing and aggressive behaviours. Like the Social and Occupational Functioning Assessment Scale, from which it is derived, the scale ranges from one (severe impairment) to 100 (excellent functioning).</P>
<P>6.2.3.2 Schizophrenia Quality of Life Scale - SQLS ( <LINK REF="REF-Heinrichs-1984" TYPE="REFERENCE">Heinrichs 1984</LINK>, <LINK REF="REF-Wilkinson-2000" TYPE="REFERENCE">Wilkinson 2000</LINK>)<BR/>Researchers use this semi-structured interview to assess the psychosocial function of participants. Scores range from 0 (best health) to 100 (worst health), with lower scores indicating better functioning.</P>
<P>6.2.4 Adverse effects<BR/>6.2.4.1 Barnes Akathisia Rating Scale - BARS (<LINK REF="REF-Barnes-1989" TYPE="REFERENCE">Barnes 1989</LINK>)<BR/>Akathisia is a short-term, drug-induced movement disorder. Researchers use this scale to rate observable restless movements that characterize akathisia, the person's awareness of restlessness and any distress associated with the condition. These items are rated from zero (normal) to three (severe). There is also an item for rating global severity ranging from zero (absent) to five (severe). A low BARS score indicates low levels of akathisia.</P>
<P>6.3 Clinical and laboratory outcomes<BR/>Researchers in each of the eight trials also assessed clinical and laboratory outcomes including vital signs, erectile and orgasmic dysfunction, physical examinations, 12-lead electrocardiograms, and serum laboratory values including cholesterol, complete blood cell count, C-peptide, fasting serum chemistry, glucose, HDL, insulin, LDL, prolactin and triglycerides. Not all of these outcomes had usable data, details are given in the results section and the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-12-01 13:28:06 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded six studies because they assessed biological parameters rather than clinical outcomes. <LINK REF="STD-Borison-1994" TYPE="STUDY">Borison 1994</LINK> measured the serum levels of risperidone and paliperidone after administration of a single dose of risperidone, but did not assess clinical outcomes. Although the integrity of the data has been questioned, they concluded a single dose of risperidone had a half-life of 3.74 hours and that its metabolite, paliperidone, had a half-life of 23.04 hours. <LINK REF="STD-Cleton-2006" TYPE="STUDY">Cleton 2006</LINK> assessed the effect of concomitant trimethoprim administration on the serum concentration and renal clearance of oral paliperidone in healthy participants. Cleton 2007a compared the effects of paliperidone and risperidone for schizophrenia, but measured serum levels of paliperidone and risperidone rather than clinical outcomes. <LINK REF="STD-Cleton-2007b" TYPE="STUDY">Cleton 2007b</LINK> conducted an open-label trial among healthy participants to assess serum and urine concentrations of paliperidone. Finally, we excluded data from the initial phases of <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> because participants received open-label paliperidone during these parts of the study. </P>
<SUBSECTION>
<HEADING LEVEL="4">Awaiting assessment</HEADING>
<P>Researchers designed <LINK REF="STD-Rossenu-2008" TYPE="STUDY">Rossenu 2008</LINK> to assess the pharmacodynamics of paliperidone and risperidone in people with schizophrenia. The study appears to meet the selection criteria for this review, but we were only able to obtain a very limited description of the participants and outcomes of this trial. We sought unpublished data from the manufacturer.</P>
<P>
<LINK REF="STD-Armenteros-2001" TYPE="STUDY">Armenteros 2001</LINK> is a study designed to assess the efficacy and safety of risperidone in adolescents with schizophrenia; as part of the protocol, they propose to assess the plasma levels of both risperidone and 9-OH-risperidone (paliperidone). While the proposed trial is described as a randomised, blinded clinical trial, we have not been able to identify any information beyond the summary in the National Institute of Health's CRISP database.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing studies</HEADING>
<P>The U.S. National Institutes of Health website, <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>, indicates that several paliperidone studies are either active or recruiting; these studies variously examine the effects of paliperidone on metabolic outcomes, on time to recurrence, on economic outcomes, on people with schizophrenia and liver disease, on people with acute schizophrenia, on people with schizoaffective disorder and on adolescents with schizophrenia.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-07-23 15:20:11 +0100" MODIFIED_BY="[Empty name]">
<P>Judgement of risks illustrated in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<ALLOCATION MODIFIED="2009-07-23 15:15:12 +0100" MODIFIED_BY="[Empty name]">
<P>The eight included trials were randomised and seven trials described allocation. In these seven trials, participants were allocated treatment through a computer-generated randomisation scheme that used permuted blocks of treatment, stratified by site. These studies were assigned to category 'A' (adequate). The exception was <LINK REF="STD-Cleton-2007" TYPE="STUDY">Cleton 2007</LINK>, in which the allocation strategy was not described. At this time, we have only a preliminary report of this trial, so we are able to characterize its allocation concealment only as 'unclear'.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-06-05 14:35:03 +0100" MODIFIED_BY="[Empty name]">
<P>Each of the eight included trials was described as double-blind, but none described how this blinding was achieved.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-07-23 15:20:11 +0100" MODIFIED_BY="[Empty name]">
<P>Seven of the eight trials reported the number of participants who left early or discontinued the treatment. The authors used several categories to describe why participants left early: adverse event; death; lack of efficacy; lost to follow up; non-compliance; non-specified reason; unspecified participant decision and withdrawal of consent.</P>
<P>Adequate data reporting was provided regarding PANSS and PSP scores, the incidence of adverse events experienced by at least 5% of the people in a treatment group and most clinical and laboratory outcomes, especially metabolic parameters.</P>
<P>However, the following clinically relevant outcomes were not reported or were reported in ways that were not usable in this review: the use of rescue antiparkinsonism and benzodiazepine medications; changes from baseline of serum prolactin; the incidence of suicidal ideation and attempts and orthostatic hypotension. Several of the authors provided data on change from baseline on the AIMS, BARS, and SAS scales in a fashion that was difficult to interpret, often in percentiles or median changes, rather than as mean changes from baseline with associated standard deviations. Several of the authors provided the median change on CGI-S scores from baseline, but did not provide the mean change with associated standard deviations, so we were unable to use CGI-S data. In addition, we were unable at this time to obtain complete outcome data on movement disorders. Details of unusable data are also given in the included studies tables.</P>
<P>The authors of <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> did not report the standard deviations associated with the mean increases in body weight.</P>
<P>Finally, the authors of <LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK>, <LINK REF="STD-Cleton-2007" TYPE="STUDY">Cleton 2007</LINK>, and <LINK REF="STD-Luthringer-2007" TYPE="STUDY">Luthringer 2007</LINK> have not yet provided all of the requested data.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-06-20 01:26:33 +0100" MODIFIED_BY="[Empty name]">
<P>None of the included trials have provided all of the outcomes specified in their study protocols. Further, none of the trials address economic outcomes, employment status, hospital outcomes, long-term efficacy and safety or satisfaction with care. </P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-06-05 14:38:22 +0100" MODIFIED_BY="[Empty name]">
<P>The authors of each trial reported that Johnson &amp; Johnson, the parent company of Janssen Products L.P., funded their studies.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-11-25 23:29:08 +0000" MODIFIED_BY="[Empty name]">
<P>1. COMPARISON 1. PALIPERIDONE (ANY DOSE) versus PLACEBO<BR/>Seven of the eight studies compared paliperidone with placebo. The authors reported the majority of scale data as mean change scores rather than the preferred total end scores. Most scale data were also skewed. We contacted the study authors to seek additional data, but we have not yet received all of the relevant material.</P>
<P>1.1 Primary Outcomes<BR/>1.1.1 Global state<BR/>1.1.1.1 Recurrence of psychotic symptoms<BR/>
<LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK>, a relapse prevention study, defined a clinically important change as the time to first recurrence of psychotic symptoms. We found that people randomised to paliperidone were less likely to experience a recurrence (n=206, 1 RCT, RR 0.30 CI 0.31 to 0.66, NNT 7 CI 6 to 14) than those randomised to placebo. However, while only <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> had 'recurrence of symptoms' as a primary focus of the trial, six other studies did report recurrence of psychosis as an adverse event. On this basis, results from seven studies found that those receiving any dose of paliperidone were significantly less likely to have a recurrence of psychotic symptoms by the end of the trial than those receiving placebo (n=1918, 7 RCTs, RR 0.47 CI 0.34 to 0.66, NNT 17 CI 14 to 26).</P>
<P>1.1.1.2 No clinically important change<BR/>
<LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK>, <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK>, <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK>, and <LINK REF="STD-Tzimos-2008" TYPE="STUDY">Tzimos 2008</LINK> defined a clinically important favourable change in global state as reduction in PANSS score from baseline to the endpoint by at least 30%. Participants whose PANSS score increased or decreased by less than 30% were considered not to experience a clinically important change. The <LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK> trial defined treatment response by PANSS total score reduction by at least 30% and CGI-C score by 2 or less. The number of respondents was reported only as a composite; by this criteria, participants whose PANSS score increased or decreased by less than 30% and whose CGI-C were considered not to experience a clinically important change. By this criteria, those receiving any dose of paliperidone were significantly more likely to have an improvement in global state (n=1658, 5 RCTs, RR 0.71 CI 0.66 to 0.77, NNT 5 CI 5 to 6).</P>
<P>1.1.2 Leaving the study early<BR/>Seven studies provided data for leaving the study early for any reason. Overall results were favourable for paliperidone with significantly fewer people leaving early if they were randomised to paliperidone (n=1926, 7 RCTs, RR 0.68 CI 0.61 to 0.75, NNT 7 CI 6 to 9). Some of the studies reported specific reasons for leaving early. When we explored the eight reported reasons for leaving early only one reason, lack of efficacy, produced significant differences between groups. Again, those receiving paliperidone were less likely to leave early due to lack of efficacy (n=1677, 5 RCTs, RR 0.40 CI 0.33 to 0.48, NNT 5 CI 5 to 3). Results for the other six specific reasons were all equivocal with no significant differences between groups for adverse events (n=1926, 7 RCTs, RR 1.04 CI 0.69 to 1.57), loss to follow up (n=1770, 5 RCTs, RR 0.92 CI 0.51 to 1.68), non compliance (n=1157, 4 RCTs, RR 0.86 CI 0.25 to 2.90), withdrawal of consent (n=841, 3 RCTs, RR 1.13 CI 0.69 to 1.86), unspecified reason (n=1884, 6 RCTs, RR 0.61 CI 0.30 to 1.24) or otherwise unspecified reason (n=1770, 5 RCTs, RR 1.38 CI 0.99 to 1.92).</P>
<P>1.2 Secondary Outcomes<BR/>1.2.1 Death<BR/>Mortality data were provided by seven of the studies. A total of four deaths occurred in three trials (<LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK>, <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> and <LINK REF="STD-Tzimos-2008" TYPE="STUDY">Tzimos 2008</LINK>), and in all three studies these deaths were in the placebo groups. Overall, the difference between groups was not significant (n=1927, 7 RCTs, RR 0.18 CI 0.03 to 1.10).</P>
<P>1.2.2 Global State<BR/>1.2.2.1 Use of additional benzodiazepine<BR/>
<LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK>, <LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK>, <LINK REF="STD-Luthringer-2007" TYPE="STUDY">Luthringer 2007</LINK> and <LINK REF="STD-Tzimos-2008" TYPE="STUDY">Tzimos 2008</LINK> reported data for use of additional benzodiazepine but found no difference between groups (n=833, 4 RCTs, RR 0.93 CI 0.78 to 1.10).</P>
<P>1.2.3 Mental state<BR/>1.2.3.1 Average change score (PANSS total, decline=good, all data likely to be skewed)<BR/>Seven studies measured mental state by total PANSS scores. From pooled data, we found those receiving any dose of paliperidone had a statistically significant improvement in mental state by the end of the trial (n=1395, 7 RCTs, WMD -8.99 CI -11.05 to -6.93, I-squared 29%).</P>
<P>1.2.4 Social functioning<BR/>1.2.4.1 Average change score (PSP total, increase=good, all data likely to be skewed)<BR/>Five studies reported change from baseline scores on the PSP. While data are likely to be skewed for this outcome, we found that those receiving paliperidone performed better on the PSP scale (n=1520, 5 RCTs, WMD 6.30 CI 4.78 to 7.81).</P>
<P>1.2.5 Quality of life<BR/>1.2.5.1 Average change score (SQLS total, decrease=good, all data likely to be skewed)<BR/>Five studies reported SQLS data and researchers identified a beneficial trend with any dose of paliperidone administration compared with placebo (n=996, 5 RCTs, WMD -4.30 CI -6.22 to -2.38).</P>
<P>1.2.6 Adverse effects<BR/>1.2.6.1 Anticholinergic effect<BR/>The study authors inconsistently reported the incidence of anticholinergic effects. We can examine the outcome indirectly by observing that <LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK>, <LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK> and <LINK REF="STD-Luthringer-2007" TYPE="STUDY">Luthringer 2007</LINK> found no difference in the use of anticholinergic medications (n=767, 3 RCTs, RR 1.33 CI 1.00 to 1.78). <LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK> and <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> also found no difference between groups for numbers experiencing decreased saliva (n=568, 2 RCTs, RR 4.12 CI 0.96 to 17.73). <LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK> and <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK> had similar findings for increased saliva (n=739, 2 RCTs, RR 5.41 CI 1.30 to 22.42).</P>
<P>1.2.6.2 Cardiovascular<BR/>1.2.6.2.1 Cardiovascular events<BR/>Overall, results were equivocal for cardiovascular events. Data reporting was varied with no outcome reported by all eight studies. Changes in blood pressure were recorded by two studies. <LINK REF="STD-Tzimos-2008" TYPE="STUDY">Tzimos 2008</LINK> found no difference between groups for occurrence of hypertension (n=114, 1 RCT, RR 2.00 CI 0.23 to 17.28) and although data from <LINK REF="STD-Tzimos-2008" TYPE="STUDY">Tzimos 2008</LINK> and <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK> appeared to show a higher incidence of hypotension in those receiving paliperidone, the difference failed to reach statistical significance (n=615, 2 RCTs, RR 4.66 CI 0.89 to 24.46). Four studies found no difference in the number of participants experiencing dizziness (n=724, 4 RCTs, RR 1.12 CI 0.60 to 2.10). All ECG results were equivocal with no significant differences between groups for abnormal ECG (n=945, 3 RCTs, RR 1.44 CI 0.69 to 3.00), prolonged QTc LD (n=683, 3 RCTs, RR 2.19 CI 0.48 to 9.96), T-wave inversion (n=114, 1 RCT, RR 0.25 CI 0.02 to 2.67) or acute coronary syndrome (n=114, 1 RCT, RR 1.52 CI 0.06 to 36.44). Effect on pulse rate, however, was noticeable with paliperidone producing a significantly greater incidence of tachycardia than placebo (n=1638, 5 RCTs, RR 1.88 CI 1.28 to 2.76, NNH 21 CI 11 to 90). <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> presented results for an increase of more than 15 beats per minute but found no statistically significant difference between groups (n=206, 1 RCT, RR 1.96 CI 0.88 to 4.38).</P>
<P>1.2.6.2.2 Average change in QTLc LD (QT interval linear derived formula, msec, data likely to be skewed)<BR/>
<LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> identified increases in QTc LD at the end of the trial for participants randomised to 6 mg paliperidone (n=216, 1 RCT, WMD 1.50 CI 1.12 to 1.88) but decreases in QTc LD for those randomised to 12 mg (n=216, 1 RCT, WMD -1.80 CI -2.16 to -1.44).</P>
<P>1.2.6.2.3 Average change in serum lipid levels (data likely to be skewed)<BR/>
<LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK>, <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK>, <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK>, <LINK REF="STD-Luthringer-2007" TYPE="STUDY">Luthringer 2007</LINK> and <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> all presented data for change in serum lipid levels. No effect was found for any of the outcomes in these short-term trials; LDL (n=812, 4 RCTs, WMD 0.09 CI -0.02 to 0.21), HDL (n=835, 4 RCTs, WMD -0.04 CI -0.07 to 0.00), cholesterol (n=877, 5 RCTs, WMD 0.12 CI -0.00 to 0.24) or triglycerides (n=880, 5 RCTs, WMD 0.11 CI -0.03 to 0.24).</P>
<P>1.2.6.3 Central nervous system - levels of arousal<BR/>Data pooled from seven of the studies showed those receiving any dose of paliperidone were less likely to experience agitation or aggression than those receiving placebo (n=1876, 6 RCTs, RR 0.64 CI 0.44 to 0.95, NNT 39 CI 25 to 275). No such effect was found for anxiety (n=1474, 5 RCTs, RR 0.80 CI 0.53 to 1.20), insomnia (n=1918, 7 RCTs, RR 0.89 CI 0.69 to 1.15), sleepiness (n=1712, 6 RCTs, RR 1.50 CI 1.03 to 2.17), mania (n=114, 1 RCT, RR 1.52 CI 0.06 to 36.44) or fatigue (n=352, 2 RCTs, RR 0.90 CI 0.35 to 2.27).</P>
<P>1.2.6.4 Endocrine: average change in serum level (data likely to be skewed)<BR/>
<LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK>, <LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK>, <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK>, <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> and <LINK REF="STD-Tzimos-2008" TYPE="STUDY">Tzimos 2008</LINK> presented average change in serum level for some endocrine outcomes. A consistent, significant elevation in serum prolactin (ng/mL) was found for both men (n=568, 4 RCTs, WMD 22.12 CI 21.34 to 22.89) and women (n=335, 4 RCTs, WMD 82.50 CI 78.88 to 86.12) receiving any dose of paliperidone. This effect was not seen in levels of insulin (n=631, 3 RCTs, WMD -0.05 CI -3.56 to 3.47).</P>
<P>1.2.6.5 Gastrointestinal events<BR/>Slightly fewer participants felt nauseated after receiving paliperidone compared with placebo and this difference was significant (n=592, 4 RCTs, RR 0.49 CI 0.25 to 0.93). No differences between groups were found for participants experiencing constipation (n=568, 2 RCTs, RR 0.69 CI 0.34 to 1.40), diarrhoea (n=238, 1 RCT, RR 0.51 CI 0.07 to 3.53), dyspepsia (n=610, 3 RCTs, RR 0.93 CI 0.52 to 1.66) or vomiting (n=1225, 5 RCTs, RR 1.13 CI 0.61 to 2.09).</P>
<P>1.2.6.6 Metabolic<BR/>1.2.6.6.1 Average change in weight (kg) (data likely to be skewed)<BR/>The authors of five studies presented mean change in weight (kg) by the end of the trial. Data found that people receiving paliperidone had a significantly greater increase in weight than those allocated to placebo (n=1007, 5 RCTs, WMD 1.07 CI 0.65 to 1.49, I-squared 70%).</P>
<P>1.2.6.6.2 Average change in BMI (data likely to be skewed)<BR/>Average change in BMI by the end of trial was reported by <LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK>, <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK> and <LINK REF="STD-Tzimos-2008" TYPE="STUDY">Tzimos 2008</LINK>. Again, data were likely to be skewed, but a difference favouring placebo was found (n=573, 3 RCTs, WMD 0.47 CI 0.30 to 0.63, I-squared 81%).</P>
<P>1.2.6.6.3 Average change in serum level (data likely to be skewed)<BR/>Three studies found serum levels of glucose were similar between treatment groups (n=650, 3 RCTs, WMD -0.05 CI -0.24 to 0.13).</P>
<P>1.2.6.7 Movement disorders<BR/>1.2.6.7.1 Various events<BR/>People receiving paliperidone were more likely to experience extrapyramidal disorders (n=1680, 6 RCTs, RR 2.27 CI 1.31 to 3.95, NNH 28 CI 12 to 111) and hypertonia (n=1225, 5 RCTs, RR 3.24 CI 1.46 to 7.22, NNH 28 CI 10 to 135). Studies also suggest that people who receive paliperidone are more likely to experience hyperkinesia, but the effect is not significant (n=1360, 4 RCTs, RR 1.67 CI 0.97 to 2.89). We found no consistent effect of paliperidone on the incidence of asthenia (n=114, 1 RCT, RR 1.00 CI 0.19 to 5.22), tremor (n=352, 2 RCTs, RR 1.36 CI 0.75 to 2.47), akathisia (n=352, 2 RCTs, RR 1.43 CI 0.58 to 3.52), tardive dyskinesia (n=156, 2 RCTs, RR 3.00 CI 0.13 to 69.70) and oculogyric crisis (n=42, 1 RCT, RR 5.00 CI 0.25 to 98.27).</P>
<P>1.2.6.7.2 Akathisia BARS scores<BR/>Four of the studies reported average change in BARS score, and no difference was identified (n=1496, 4 RCTs, WMD 0.02 CI -0.02 to 0.16). <LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK> further reported Barnes Akathisia Rating Scale (BARS) data and found no significant difference in the final BARS assessments at the end of the trial, for either absent (n=487, 1 RCT, RR 1.06 CI 0.94 to 1.19), questionable (n=487, 1 RCT, RR 0.75 CI 0.45 to 1.23), mild (n=487, 1 RCT, RR 2.11 CI 0.75 to 5.95), moderate (n=487, 1 RCT, RR 3.06 CI 0.17 to 56.39) or severe akathisia (n=487, 1 RCT, RR 0.07 CI 0.00 to 1.41).</P>
<P>1.2.6.8 Renal: average change in serum level (data likely to be skewed)<BR/>Changes in serum levels of creatine kinase were not significantly different between groups (n=111, 1 RCT, WMD 38.30 CI -68.59 to 145.19).</P>
<P>1.2.6.9 Sexual dysfunction<BR/>The parent compound of paliperidone, risperidone, is associated with sexual dysfunction (<LINK REF="REF-Hunter-2003" TYPE="REFERENCE">Hunter 2003</LINK>). However, in these short-term studies, we identified no significant increase or decrease in the incidence of gynaecomastia (n=1032, 4 RCTs, RR 0.99 CI 0.04 to 23.90), impotence (n=1187, 5 RCTs, RR 0.70 CI 0.16 to 3.03), nonpuerperal lactation (n=576, 4 RCTs, RR 1.43 CI 0.31 to 6.71), amenorrhoea or dysmenorrhoea (n=938, 5 RCTs, RR 1.46 CI 0.31 to 6.92), anorgasmia (n=1524, 4 RCTs, RR 1.02 CI 0.11 to 9.73), abnormal sexual function (n=1763, 5 RCTs, RR 0.61 CI 0.12 to 3.11) or decreased libido (n=1524, 4 RCTs, RR 1.67 CI 0.28 to 10.08).</P>
<P>1.2.6.10 Other events<BR/>The reporting of other adverse events was inconsistent. When compared with placebo, paliperidone was associated with a significantly lower incidence of rash (n=372, 2 RCTs, RR 0.09 CI 0.01 to 0.63). Otherwise, paliperidone was not different from placebo in the incidence of body pain (n=372, 2 RCTs, RR 0.45 CI 0.17 to 1.20), headache (n=1712, 6 RCTs, RR 1.19 CI 0.90 to 1.58), musculoskeletal pain (n=372, 2 RCTs, RR 3.92 CI 0.69 to 22.12), toothache (n=330, 1 RCT, RR 1.10 CI 0.29 to 4.19) or upper respiratory infection (n=486, 3 RCTs, RR 1.04 CI 0.40 to 2.70).</P>
<P>1.2.7 Serious psychiatric event<BR/>We identified no significant difference between participants receiving paliperidone and placebo in the incidence of suicide attempt (n=1566, 5 RCTs, RR 0.62 CI 0.22 to 1.77) or treatment-emergent psychiatric disorder (n=1614, 4 RCTs, RR 0.85 CI 0.57 to 1.26).</P>
<P>2. COMPARISON 2. SENSITIVITY ANALYSIS 1. INCREASING DOSES OF PALIPERIDONE versus PLACEBO (primary outcomes only)<BR/>Although not stated as an objective in our initial protocol, we were able to carry out a further analysis of data assessing the effects of different doses of paliperidone administration because the largest studies presented data for specific doses of paliperidone administration. We conducted this analysis only for our pre-stated primary outcomes.</P>
<P>2.1 Global state<BR/>2.1.1 Relapse: recurrence of psychotic symptoms<BR/>Only two doses found a significant difference, favouring paliperidone, for recurrence of psychotic symptoms. They were trials using a dose of 12 mg/day (n=474, 2 RCTs, RR 0.45 CI 0.22 to 0.94, NNT 21 CI 15 to 186) and the flexible dosing trials <LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK>, <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK>, and <LINK REF="STD-Tzimos-2008" TYPE="STUDY">Tzimos 2008</LINK> (n=558, 3 RCTs, RR 0.36 CI 0.20 to 0.63, NNT 10 CI 8 to 17). Although some other results appeared to favour paliperidone, no statistically significant differences were found for 3 mg/day (n=250, 1 RCT, RR 0.70 CI 0.29 to 1.69), 6 mg/day (n=467, 2 RCTs, RR 0.51 CI 0.25 to 1.03) or 15 mg/day (n=236, 1 RCT, RR 0.49 CI 0.18 to 1.38).</P>
<P>2.1.2 No clinically important change in global state (&gt;30% reduction in total PANSS score)<BR/>Studies that defined a clinically important favourable change to be a greater than 30% reduction in PANSS total score presented results that showed a favourable effect of paliperidone administration, with comparatively greater differences in global improvement for higher doses of paliperidone, 3 mg/day (n=243, 1 RCT, RR 0.74 CI 0.62 to 0.87, NNT 5 CI 4 to 10), 6 mg/day (n=465, 2 RCTs, RR 0.69 CI 0.58 to 0.82, NNT 5 CI 4 to 9), 9 mg/day (n=491, 2 RCTs, RR 0.68 CI 0.59 to 0.79, NNT 5 CI 4 to 7), 12 mg (n=471, 2 RCTs, RR 0.64 CI 0.48 to 0.85, NNT 5 CI 3 to 10), 15 mg/day (n=233, 1 RCT, RR 0.46 to 0.71, NNT 3 CI 3 to 5), and when flexibly dosed (n=558, 3 RCTs, RR 0.36, CI 0.20 to 0.63, NNT 10 CI 8 to 17).</P>
<P>2.2 Leaving the study early: any reason<BR/>Results for leaving the study early for any reason were favourable for specific doses of paliperidone. Except for the flexible dose studies, all results were statistically significant, with fewer people leaving the studies early if they were receiving 3 mg/day (n=250, 1 RCT, RR 0.73 CI 0.57 to 0.92, NNT 7 CI 4 to 21), 6 mg/day (n=472, 2 RCTs, RR 0.74 CI 0.62 to 0.88, NNT 7 CI 5 to 14), 9 mg/day (n=539, 3 RCTs, RR 0.60 CI 0.49 to 0.73, NNT 5 CI 4 to 7), 12 mg/day (n=479, 2 RCTs, RR 0.60 CI 0.49 to 0.73, NNT 5 CI 4 to 7) and 15 mg/day (n=238, 1 RCT, RR 0.46 CI 0.34 to 0.64, NNT 4 CI 3 to 5). The effect became more pronounced with higher doses of paliperidone with the greatest difference between groups apparent at doses over 9 mg/day.</P>
<P>3. COMPARISON 3. ANY DOSE PALIPERIDONE versus 10 mg/day OLANZAPINE<BR/>The researchers in the <LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK>, <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK> and <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> trials compared several fixed doses of paliperidone to a single fixed dose of olanzapine (10 mg daily).</P>
<P>3.1 Primary Outcomes<BR/>3.1.1 Global state<BR/>3.1.1.1 Relapse: recurrence of psychotic symptoms<BR/>In these trials, no specific recurrence outcome was identified, but the authors reported psychosis as an adverse event. Results showed those receiving any dose of paliperidone were no more likely to have a recurrence of psychotic symptoms than those receiving 10 mg/day olanzapine (n=1327, 3 RCTs, RR 0.1.07 CI 0.64 to 1.76).</P>
<P>3.1.1.2 No clinically important change in global state (&gt;% 30 change in PANSS)<BR/>The authors of all three studies defined a clinically important change in global state as reduction in PANSS score from baseline to the endpoint by at least 30%. People whose PANSS score increased or decreased by less than 30% did not experience a clinically important change. We were only able to utilize the data from <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> and found no significant difference (n=327, 1 RCT, RR 0.90 CI 0.73 to 1.13).</P>
<P>3.1.2 Leaving the study early<BR/>All three studies reported on leaving the study early for any reason. Overall no differences between paliperidone and olanzapine were found for this outcome (n=1332, 3 RCTs, RR 1.04 CI 0.89 to 1.21). About 40% of people in both groups left the studies by six weeks. There were eight reported reasons for discontinuation or leaving early. There were no statistically significant differences, because of adverse events (n=1332, 3 RCTs, RR 0.83 CI 0.51 to 1.35), lack of efficacy (n=1332, 3 RCTs, RR 1.06 CI 0.81 to 1.40), loss to follow up (n=1332, 3 RCTs, RR 0.96 CI 0.49 to 1.91), non-compliance (n=1332, 3 RCTs, RR 0.59 CI 0.18 to 1.94), unspecified participant reason (n=1332, 3 RCTs, RR 1.35 CI 0.93 to 1.95), unspecified other reason (n=1332, 3 RCTs, RR 0.65 CI 0.27 to 1.57) or withdrawal of consent (n=495, 1 RCT, RR 1.36 CI 0.73 to 2.56).</P>
<P>3.2 Secondary Outcomes<BR/>3.2.1 Death<BR/>There was one death reported by <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK>, in the olanzapine group (n=1332, 3 RCTs, RR 0.11 CI 0.0 to 2.79).</P>
<P>3.2.2 Global State<BR/>3.2.2.1 Use of additional benzodiazepine<BR/>
<LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK> was the only study to present results for use of additional benzodiazepine and found no differences between the two treatment drugs (n=487, 1 RCT, RR 1.01 CI 0.84 to 1.22).</P>
<P>3.2.3 Mental state: Average change score (PANSS total, decline=good, data likely to be skewed)<BR/>All three authors presented skewed data for changes in PANSS scores. They observed a trend, favouring olanzapine, that was not statistically significant (n=715, 3 RCTs, WMD 2.42 CI -0.52 to 5.35).</P>
<P>3.2.4 Social functioning: Average change score (PSP total, increase=good, data likely to be skewed)<BR/>Again, data that are likely to be skewed from all three studies found no significant differences in social functioning change scores (n=696, 3 RCTs, WMD -0.37 CI -2.50 to 1.76).</P>
<P>3.2.5 Adverse events<BR/>3.2.5.1 Anticholinergic events<BR/>Each study reported the incidence of adverse events that could signify anticholinergic effects, but none of the data could be pooled for each outcome. Overall no differences between any dose paliperidone and 10 mg/day olanzapine were found. <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> reported incidence of constipation but found no differences between groups (n=333, 1 RCT, RR 0.97 CI 0.34 to 2.78) and also found no difference for the outcome 'decrease in salivation' (n=333, 1 RCT, RR 2.92 CI 0.67 to 12.82). <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK> reported incidence of increased saliva, results were equivocal (n=503, 1 RCT, RR 9.26 CI 0.55 to 154.72).</P>
<P>3.2.5.2 Cardiovascular<BR/>3.2.5.2.1 Cardiovascular events<BR/>Authors inconsistently reported the incidence of cardiovascular events. Blood pressure results were equivocal with no differences in the numbers experiencing hypotension (n=503, 1 RCT, RR 0.80 CI 0.31 to 2.03). Olanzapine caused more dizziness, but data for this outcome were reported only by <LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK> (n=476, 1 RCT, RR 0.33 CI 0.13 to 0.85, NNT 21 CI 16 to 91). ECG results were similar in the incidence of both abnormal ECG (n=836, 2 RCTs, RR 1.36 CI 0.61 to 3.02) and prolonged QTc LD (n=333, 1 RCT, RR 0.73 CI 0.12 to 4.30). All three studies presented pulse rate data but found no differences between groups for numbers experiencing tachycardia after receiving treatment (n=1214, 3 RCTs, RR 1.30 CI 0.91 to 1.87). No data were available for hypertension, T-wave inversion or increase in pulse rate of over 15 beats/min.</P>
<P>3.2.5.2.2 Average change in QTc LD (QT interval linear derived formula, msec)<BR/>
<LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> identified increases in QTc LD at the end of the trial for participants randomised 6 mg paliperidone (n=216, 1 RCT, WMD 1.50 CI 1.12 to 1.88) but decrease in QTc LD for 12 mg (n=216, 1 RCT, WMD -3.20 CI -3.59 to -2.81).</P>
<P>3.2.5.2.3 Average change in serum lipid levels (data likely to be skewed)<BR/>No differences in serum levels were found for any of the outcomes; HDL (n=683, 3 RCTs, WMD 0.00 CI -0.03 to 0.03), cholesterol (n=687, 3 RCTs, WMD -0.31 CI -0.44 to -0.19) or triglycerides (n=687, 3 RCTs, WMD -0.32 CI -0.46 to -0.17).</P>
<P>3.2.5.3 Central nervous system - levels of arousal<BR/>Participants who received any dose of paliperidone less frequently experienced sleepiness than people randomised to 10 mg/day olanzapine (n=1327, 3 RCTs, RR 0.49 CI 0.37 to 0.65, NNT 11 CI 9 to 15). All three studies presented equivocal data for levels of agitation or aggression (n=1327, 3 RCTs, RR 0.85 CI 0.54 to 1.35), anxiety (n=1327, 3 RCTs, RR 1.09 CI 0.68 to 1.73) and insomnia (n=1327, 3 RCTs, RR 1.11 CI 0.0.80 to 1.53).</P>
<P>3.2.5.4 Endocrine: average change in serum level (data likely to be skewed)<BR/>All three studies reported change in serum prolactin data (ng/mL). We found a consistent, significant elevation for both men (n=433, 3 RCTs, WMD 26.81 CI 22.94 to 30.68) and women (n=253, 3 RCTs, WMD 81.63 CI 68.31 to 94.94) receiving any dose of paliperidone compared with olanzapine 10 mg/day. Changes in serum levels of insulin were similar between groups (n=656, 3 RCTs, WMD -2.55 CI -5.67 to 0.56).</P>
<P>3.2.5.5 Gastrointestinal events<BR/>Only <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK> and <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> reported data. Paliperidone had similar gastrointestinal adverse effects when compared to olanzapine. No significant differences between groups were found for constipation (n=333, 1 RCT, RR 0.97 CI 0.34 to 2.78), dyspepsia (n=333, 1 RCT, RR 1.01 CI 0.53 to 1.94), nausea (n=333, 1 RCT, RR 2.68 CI 0.60 to 11.87) or vomiting (n=836, 2 RCTs, RR 1.69 CI 0.63 to 4.53).</P>
<P>3.2.5.6 Metabolic<BR/>3.2.5.6.1 Average change in weight (kg) and BMI (Body Mass Index, data likely to be skewed)<BR/>Data from all three studies found paliperidone was less likely to produce a weight change than olanzapine (n=660, 3 RCTs, WMD -0.88 CI -1.38 to -0.37). <LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK> and <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK> also found this effect when looking at average change in BMI (n=239, 2 RCTs, RR -0.30 CI -0.49 to -0.11).</P>
<P>3.2.5.6.2 Average change in serum level<BR/>Levels of serum glucose were equivocal between groups (n=673, 3 RCTs, WMD -0.05 CI -0.22 to 0.12).</P>
<P>3.2.5.7 Movement disorders<BR/>3.2.5.7.1 Various movement disorders<BR/>Results for various movement disorders all favoured olanzapine. Those receiving paliperidone were more likely to experience movement disorders than those receiving olanzapine. Differences were statistically significant for extrapyramidal disorder (n=1327, 3 RCTs, RR 2.99 CI 1.44 to 6.18, NNH 32 CI 13 to 143), hyperkinesia (n=1327, 3 RCTs, RR 3.14 CI 1.53 to 6.42, NNH 23 CI 9 to 90) and hypertonia (n=836, 2 RCTs, RR 9.28 CI 1.26 to 68.51).</P>
<P>3.2.5.7.2 BARS scores by end of trial<BR/>
<LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK> found a slight difference, favouring olanzapine, between groups for absent BARS scores (n=492, 1 RCT, RR 0.90 CI 0.82 to 0.98) but there was no effect for questionable (n=492, 1 RCT, RR 1.19 CI 0.64 to 2.18), mild (n=492, 1 RCT, RR 1.02 CI 0.38 to 2.74) or moderate (n=492, 1 RCT, RR 3.06 CI 0.17 to 56.52) scores.</P>
<P>3.2.5.8 Sexual dysfunction<BR/>In these short-term studies, we identified no significant difference in the incidence of gynaecomastia (n=836, 3 RCTs, RR 0.90, CI 0.04 to 21.74), impotence (n=836, 3 RCTs, RR 0.58, CI 0.08 to 4.54), nonpuerperal lactation (n=491, 3 RCTs, RR 0.74 CI 0.14 to 3.93), amenorrhoea or dysmenorrhoea (n=491, 3 RCTs, RR 0.79 CI 0.07 to 8.58), anorgasmia (n=1327, 3 RCTs, RR 1.04, CI 0.11 to 9.96), abnormal sexual function (n=1327, 3 RCTs, RR 1.03, CI 0.04 to 25.11) or decreased libido (n=1327, 3 RCTs, RR 1.25 CI 0.13 to 11.87).</P>
<P>3.2.5.9 Other events<BR/>Authors reported several other adverse events but the reports were not consistent across studies. Pooled data from all three studies show how those receiving paliperidone experienced slightly fewer headaches (n=722, 3 RCTs, RR 1.45 CI 1.03 to 2.04, NNT 23 CI 10 to 341). Other results from single studies were equivocal; no significant differences between paliperidone and olanzapine administration were found for incidence of body pain (n=333, 1 RCT, RR 1.70 CI 0.36 to 8.06), musculoskeletal pain (n=333, 1 RCT, RR 4.38 CI 0.56 to 34.13), toothache (n=333, 1 RCT, RR 0.68 CI 0.22 to 2.10), rash (n=333, 1 RCT, RR 0.16 CI 0.01 to 3.97) or upper respiratory infection (n=333, 1 RCT, RR 1.46 CI 0.40 to 5.28).</P>
<P>3.2.6 Serious psychiatric event<BR/>We identified no difference in the incidence of suicide attempt (n=1327, 3 RCTs, RR 0.69, CI 0.21 to 2.30) or in treatment-emergent psychiatric disorder (n=1327, 3 RCTs, RR 0.72 CI 0.43 to 1.21).</P>
<P>4. COMPARISON 4. SENSITIVITY ANALYSIS 2. INCREASING DOSES OF PALIPERIDONE versus 10 mg/day OLANZAPINE (primary outcomes only)<BR/>4.1 Global state<BR/>4.1.1 Relapse: recurrence of psychotic symptoms<BR/>We found no significant difference in the recurrence of psychosis for subjects randomised to paliperidone at 3 mg (n=254, 1 RCT, RR 1.33 CI 0.48 to 3.73), 6 mg (n=472, 2 RCTs, RR 0.78 CI 0.36 to 1.68), 9 mg (n=501, 2 RCTs, RR 0.65 CI 0.04 to 10.17), 12 mg (n=479, 2 RCTs, RR 0.70 CI 0.31 to 1.54) and 15 mg (n=240, 1 RCT, RR 0.94 CI 0.29 to 2.99) when compared with those receiving olanzapine.</P>
<P>4.1.2 No clinically important change<BR/>Again data from one study only (<LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK>) showed no difference in paliperidone's effect on global state compared with olanzapine either when dosed at 6 mg (n=215, 1 RCT, RR 0.91 CI 0.71 to 1.18, NNT 21) or 12 mg (n=216, 1 RCT, RR 0.90 CI 0.69 to 1.16, NNT 19).</P>
<P>4.2 Leaving the study early: any reason<BR/>Data from <LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK> found those randomised to 3 mg of paliperidone were more likely to leave early (n=255, 1 RCT, RR 1.44 CI 1.04 to 1.98, NNH 7) compared with those randomised to 10 mg of olanzapine. However, data from other studies did not identify a difference in numbers leaving for 6 mg (n=473, 2 RCTs, RR 1.05 CI 0.86 to 1.28, NNH 54), 9 mg (n=503, 2 RCTs, RR 1.11 CI 0.86 to 1.43, NNH 25), 12 mg (n=480, 2 RCTs, RR 0.89 CI 0.72 to 1.11, NNT 25) or 15 mg (n=243, 1 RCT, RR 0.92 CI 0.62 to 1.35, NNT 34).</P>
<P>5. COMPARISON 5. PALIPERIDONE - ANY DOSE OR FLEXIBLE DOSES versus RISPERIDONE (fixed dose, all short term)<BR/>Only one study, <LINK REF="STD-Cleton-2007" TYPE="STUDY">Cleton 2007</LINK>, compares paliperidone with risperidone. The study lasted only six days and was designed to assess plasma concentrations of paliperidone, the active moiety of risperidone, and prolactin. While the reports of this study are preliminary, to our knowledge, no efficacy or recurrence data was collected. We are unable to report any data on leaving the study early, one of the primary outcomes of our review. Since the study did not compare different doses of paliperidone, we conducted no sensitivity analyses. However, the study did report a few adverse events, which are reported below. We await further data from this study.</P>
<P>5.1 Primary Outcomes<BR/>5.1.1 Relapse: recurrence of psychotic symptoms<BR/>We found no significant difference in the incidence of psychotic symptoms (n=113, 1 RCT, RR 0.17 CI 0.01 to 4.10). This result is based on zero participants in the paliperidone group experiencing a recurrence of psychosis and a single participant in the risperidone group experiencing a recurrence of psychosis.</P>
<P>5.2 Secondary Outcomes<BR/>5.2.1 Death<BR/>No deaths occurred in either the paliperidone or risperidone group, so the effect could not be estimated.</P>
<P>5.2.2 Adverse events<BR/>5.2.2.1 Cardiovascular events<BR/>No difference was observed in the incidence of hypotension (n=100, 1 RCT, RR 0.74 CI 0.48 to 1.15), tachycardia (n=113, 1 RCT, RR 0.34, CI 0.06 to 1.94) or palpitation (n=113, 1 RCT, RR 2.57 CI 0.13 to 52.14).</P>
<P>5.2.2.2 Central nervous system - levels of arousal<BR/>No difference was observed in the incidence of anxiety (n=113, 1 RCT, RR 0.25 CI 0.05 to 1.32), insomnia (n=113, 1 RCT, RR 0.43 CI 0.16 to 1.20) or sleepiness (n=113, 1 RCT, RR 3.59 CI 0.19 to 67.81).</P>
<P>5.2.2.3 Gastrointestinal events<BR/>No difference was reported in the incidence of nausea (n=113, 1 RCT, RR 3.59 CI 0.19 to 67.81).</P>
<P>5.2.2.4 Movement disorders<BR/>No difference was observed in the incidence of extrapyramidal disorder (n=113, 1 RCT, RR 1.52 CI 0.44 to 5.29) or hyperkinesia (n=113, 1 RCT, RR 1.01 CI 0.19 to 5.29).</P>
<P>5.2.2.5 Other events<BR/>Results were reported only for the incidence of headache and while they favoured risperidone, the results were not significant (n=113, 1 RCT, RR 4.62 CI 0.26 to 83.61).</P>
<P>6. COMPARISON 6. PALIPERIDONE - ANY DOSE OR FLEXIBLE DOSES versus QUETIAPINE (flexible dose, all short term)<BR/>Only one study, <LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK>, compares paliperidone with quetiapine. Since the study used flexible dosing of paliperidone rather than a fixed schedule of doses, we did not conduct a sensitivity analysis to determine if there were dose effects.</P>
<P>6.1 Primary Outcomes<BR/>6.1.1 Global state<BR/>6.1.1.1 Relapse: recurrence of psychotic symptoms<BR/>We observed no difference in the recurrence of psychotic symptoms (n=317, 1 RCT, RR 0.65 CI 0.29 to 1.45).</P>
<P>6.1.1.2 No clinically important change in global state (&gt;% 30 change in PANSS and CGI-C score <U>&lt;</U>2).<BR/>The authors defined a treatment response as defined by PANSS total score reduction <U>&gt;</U>30% and CGI-C score <U>&lt;</U>2. On this basis, we observed no difference between subjects randomised to paliperidone and those who received quetiapine (n=315, 1 RCT, RR 0.86 CI 0.73 to 1.02).</P>
<P>6.1.2 Leaving the study early<BR/>We found that participants randomised to paliperidone were significantly less likely to leave the study early (n=314, 1 RCT, RR 0.64 CI 0.44 to 0.93, NNT 9 CI 6 to 43). With regards to specific reasons for leaving the study early, many of the results favoured paliperidone but the differences were not quite significant, including adverse event (n=314, 1 RCT, RR 0.62 CI 0.29 to 1.33), lack of efficacy (n=314, 1 RCT, RR 0.30 CI 0.08 to 1.07), or loss to follow up (n=314, 1 RCT, RR 0.40 CI 0.13 to 1.25). Several other outcomes were equivocal, including unspecified participant reason (n=314, 1 RCT, RR 0.80 CI 0.22 to 2.92), unspecified reason (n=314, 1 RCT, RR 3.00 CI 0.12 to 73.08) or withdrawal of consent (n=314, 1 RCT, RR 1.00 CI 0.46 to 2.16).</P>
<P>6.2 Secondary Outcomes<BR/>6.2.1 Death<BR/>The authors reported a single death in the study, a patient randomised to placebo who died by unknown cause nine days after leaving the study because of lack of efficacy (n=315, 1 RCT, RR not estimable).</P>
<P>6.2.2 Global State<BR/>6.2.2.1 Use of additional benzodiazepine<BR/>The authors extensively reported the use of concomitant psychotropics prescribed during the four-week additive phase of their trial. They reported the additional prescription of antipsychotics, anticonvulsants, anxiolytics, mood stabilizers, sedative/hypnotics and antidepressants. Since this data was not reported in other trials, we included only the data for additional use of anxiolytics (n=259, 1 RCT, RR 0.93 CI 0.50 to 1.72), which showed no significant difference in the use of benzodiazepines between participants randomised to paliperidone and those randomised to quetiapine.</P>
<P>6.2.3 Mental state: Average change score (PANSS total, decline=good, data likely to be skewed)<BR/>The authors identified a significantly greater reduction in PANSS score experienced by patients randomised to paliperidone (n=314, 1 RCT, WMD -4.60 CI -5.02 to -4.18), but the data is likely to be skewed.</P>
<P>6.2.4 Adverse events<BR/>6.2.4.1 Anticholinergic events<BR/>The authors identified more use of anticholinergic medications (n=317, 1 RCT, RR 1.43 CI 1.07 to 1.90, NNH 7 CI 3 to 37) and a higher incidence of increased saliva (n=317, 1 RCT, RR 3.27 CI 1.09 to 9.81, NNH 36 CI 10 to 889) in participants receiving paliperidone. The authors identified no significant difference in the incidence of decreased saliva (n=317, 1 RCT, RR 0.50 CI 0.18 to 1.44).</P>
<P>6.2.4.2 Cardiovascular events<BR/>The authors reported only two cardiovascular events. They reported lower incidence of dizziness in participants receiving paliperidone (n=317, 1 RCT, RR 0.25 CI 0.11 to 0.60, NNT 9 CI 8 to 17). They reported no prolongation of QTc LD in participants randomised to either paliperidone or quetiapine.</P>
<P>6.2.4.3 Central nervous system - levels of arousal<BR/>The authors identified a significant difference favouring paliperidone in the incidence of sleepiness (n=317, 1 RCT, RR 0.61 CI 0.39 to 0.96, NNT 10 CI 7 to 97). The authors identified no significant differences in the incidence of agitation or aggression (n=317, 1 RCT, RR 1.41 CI 0.46 to 4.35), insomnia (n=317, 1 RCT, RR 1.20 CI 0.64 to 2.24) and fatigue (n=317, 1 RCT, RR 1.26 CI 0.51 to 3.10).</P>
<P>6.2.4.4 Endocrine: average change in serum level (data likely to be skewed)<BR/>The authors identified a significantly greater increase in serum prolactin (ng/mL) among both men (n=212, 1 RCT, WMD 23.30 CI 22.83 to 23.77) and women (n=105, 1 RCT, WMD 86.40 CI 83.61 to 89.19) randomised to paliperidone.</P>
<P>6.2.4.5 Gastrointestinal events<BR/>The authors identified no significant difference in the occurrence of constipation (n=317, 1 RCT, RR 0.59 CI 0.24 to 1.45), dyspepsia (n=317, 1 RCT, RR 0.50 CI 0.15 to 1.64), vomiting (n=317, 1 RCT, RR 1.21 CI 0.54 to 2.71) or diarrhoea (n=371, 1 RCT, RR 0.25, CI 0.05 to 1.17).</P>
<P>6.2.4.6 Metabolic<BR/>6.2.4.6.1 Average change in weight (kg) (data likely to be skewed)<BR/>The authors found that patients receiving paliperidone and quetiapine both experienced, on average, increase in weight and were unable to identify in the weight gain between participants receiving paliperidone (n=317, 1 RCT, WMD -0.70 CI -16.31 to 14.91).</P>
<P>6.2.4.7 Movement disorders<BR/>The authors identified a significantly greater increase in the incidence of hypertonia (n=317, 1 RCT, RR 3.19 CI 1.31 to 7.77, NNH 13 CI 4 to 86) and tremor (n=317, 1 RCT, RR 2.60 CI 1.39 to 4.88, NNH 9 CI 4 to 34) for patients randomised to paliperidone. With regards to akathisia, the difference was not significant (n=317, 1 RCT, RR 1.51 CI 0.70 to 3.26).</P>
<P>6.2.4.8 Sexual dysfunction<BR/>The authors reported this data inconsistently, but the available data found no significant difference in the occurrence of abnormal sexual dysfunction (n=317, 1 RCT, RR 3.02 CI 0.12 to 73.55) or impotence (n=212, 1 RCT, RR 3.06 CI 0.13 to 74.19).</P>
<P>6.2.4.9 Other events<BR/>The authors identified no difference in the occurrence of headache (n=317, 1 RCT, RR 1.22 CI 0.69 to 2.15).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-11-25 23:30:18 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-11-25 23:30:18 +0000" MODIFIED_BY="[Empty name]">
<P>1. COMPARISON 1. PALIPERIDONE versus PLACEBO<BR/>Seven studies compared paliperidone with placebo.</P>
<P>1.1 Primary Outcomes<BR/>1.1.1 Global state<BR/>1.1.1.1 Relapse: recurrence of psychotic symptoms<BR/>Overall those in the paliperidone groups were significantly less likely to experience a recurrence of psychotic symptoms compared with placebo. For individual doses, the effects were small and only pronounced at a fixed dose of 12 mg/day and in the context of flexible dosing in the <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> relapse prevention study. Given that the difference was most notable in the longer-term <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> relapse prevention study, most of the other studies may simply be of too short a duration to measure this difference. Further studies of a longer duration are needed to address this question.</P>
<P>1.1.1.2 No clinically important change in global state (&gt;30% reduction in total PANSS score)<BR/>Participants randomised to any dose of paliperidone were significantly more likely to experience a clinically important change in global state than those randomised to placebo. Higher doses of paliperidone, over 6 mg per day, seemed more effective. It should be remembered, however, that all data are weakened by issues of methodology within the studies (see above). In addition, these data were based on defining a clinically important change as at least a 30% reduction in PANSS scores, and PANSS scores are uncommonly used in the clinical care of people with schizophrenia. PANSS scores include a restricted range of items relating to various aspects of psychopathology and each individual item is equally weighted. Researchers can record improvement amongst a small number of the items to achieve a 30% reduction, while the participant can still retain the disabling and distressing features of their illness. We were not able to analyse data from a continuous measure of global change, change in CGI-S score, because no author reported it in a format that could be used for this review. The change in CGI-S score is less focused on specific symptoms than the PANSS scale, and accounts for behavioural and social aspects of a person's psychosocial functioning, and so may be a more valid global measure of global state than the PANSS scales used by the authors of these studies to define a clinically important change in global state.</P>
<P>1.1.2 Leaving the study early<BR/>A little over one third of people left these short studies before completion. In comparison to people treated with placebo, those exposed to paliperidone were significantly and consistently less likely to discontinue treatment or leave early at all studied doses. We note that the effect was more pronounced with doses of paliperidone greater than 6 mg/day.</P>
<P>Results from <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK>, a relapse prevention study, were notably different from the other trials. In this study significantly more people left early from the paliperidone group (n=207, 1 RCT, RR 2.43 CI 1.12 to 5.26) and adding this outlier result to the other six sets of data resulted in the findings becoming heterogeneous (I-squared 73%). <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> reported that participants who experienced a recurrence of psychotic symptoms were no longer enrolled in the double-blind portion of the study, but were not considered to have discontinued treatment. Since the authors apparently made this designation before beginning the trial, we reported the data accordingly, but we believe it is more accurate to count those who are no longer enrolled in double-blind treatment as having left the study. The authors of <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> also only selected people for the randomised, double-blind portion of their study with a history of responding to and tolerating paliperidone over the 14 weeks preceding randomisation.</P>
<P>When we removed <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> from the pooled data, the overall results became only a little more homogeneous and more favourable for paliperidone (n=1719, 6 RCTs, RR 0.64 CI 0.57 to 0.71, I-squared 57%). We can only conclude that the long-term tolerability of paliperidone has not yet been demonstrated adequately.</P>
<P>1.2 Secondary Outcomes<BR/>1.2.1 Mental state: change in total PANSS score by end of trial<BR/>The authors identified a significant decrease in total PANSS score for those randomised to paliperidone at all fixed and flexible doses when compared with placebo. However, only mean changes in scores, not total end scores were presented and the data were likely to be skewed. The analyses for continuous data presume data to be 'normal' and although the parametric tests we employ can cope with some degree of skew no one is quite sure how much would be inappropriate. They are not intention-to-treat, they are likely to be skewed, they are from trials at risk of observation biases and are from a scale not used in everyday practice. These data are therefore doubly and triply weakened. We therefore cannot make any certain conclusions from these results about paliperidone's effect on mental state.</P>
<P>1.2.2 Social function: Change in PSP and SQLS scores<BR/>The authors of five studies assessed social function using the Personal and Social Performance (PSP) scale and found a significant improvement for people treated with all fixed or flexible doses of paliperidone. While the PSP scale is not widely used in clinical practice, its assessment of socially useful activities, personal and social relationship, self-care, and disturbing and aggressive behaviours, is laudable. However, the statistically significant differences we observed in these studies was relatively modest and, again, based on data that are probably skewed. The authors of five studies also assessed Schizophrenia Quality of Life Scale (SQLS) scores, and found inconsistently significant improvement in participants receiving paliperidone that did not appear to be dose-related. Based on the available evidence, we cannot conclude that there is a profound difference in social function for those receiving paliperidone in comparison to placebo.</P>
<P>1.2.3 Adverse events<BR/>Most of the authors reported adverse events only when experienced by at least 5% of people in a given treatment group. By doing so, they may not have reported infrequent but potentially serious adverse events. We note that <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> reported adverse events as percentages experienced by a given treatment group, and this allows calculation of the number of people with an adverse event. We requested, but have not yet received, the observed number of adverse events in other studies. Accordingly, we note that rates of adverse events may be under or over estimated.</P>
<P>1.2.3.1 Movement disorders<BR/>People allocated to paliperidone were more likely to experience an extrapyramidal movement disorder (~7%, 1 in 14) and more so at higher doses. We found it difficult to assess the extent to which people experienced discomfort due to associated movement disorders because authors inconsistently reported use of anticholinergic or antiparkinsonism agents.</P>
<P>1.2.3.2 Weight change<BR/>In the shorter six-week studies, we found a consistent and significant increase in the body weight and body mass index of participants exposed to any fixed dose of paliperidone and that higher doses produced more pronounced gains. However, data were likely to be skewed and again no firm conclusions can be made from these results. We were unable to use data from <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> which was the study in which participants had received paliperidone for the longest duration.</P>
<P>1.2.3.3 Other events<BR/>Data reporting for several other adverse events was varied and inconsistent. The majority of outcomes found no real differences between paliperidone and placebo administration. The only cardiovascular event to be affected by paliperidone was tachycardia; those receiving paliperidone were more likely to experience tachycardia (~12%, 1 in 8) and this effect did not seem to be dose dependent. We observed no significant differences in the incidence of any anticholinergic events and found no clear association between the use of paliperidone and the incidence of insomnia and somnolence. It is difficult to draw any firm conclusions about any of the above results as data were fragmentary and inconsistent.</P>
<P>We observed no difference in the change in serum glucose and insulin from baseline to the end of trial in these short-term studies. We observed occasionally significant but exceedingly modest elevations in serum lipids among people randomised to paliperidone in these short-term studies at some doses. There do seem to be consistent and significant dose-related elevations in serum prolactin during these trials that confirm an association between paliperidone and prolactin elevations. The elevations were more pronounced for women than men. However, we were unable to correlate these elevations to clinical implications as these studies identified no consistent relationship between the use of paliperidone and the incidence of gynaecomastia, impotence, nonpuerperal lactation, amenorrhoea or dysmenorrhoea, anorgasmia, abnormal sexual function or decreased libido. We are, however, uncertain of the clinical implications of this finding because of the short duration of these studies.</P>
<P>2. COMPARISON 3. PALIPERIDONE versus 10 mg/day OLANZAPINE<BR/>The <LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK>, <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK> and <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> trials compared several fixed doses of paliperidone to a single fixed dose of olanzapine of 10 mg daily.</P>
<P>2.1 Primary Outcomes<BR/>2.1.1 Global state<BR/>2.1.1.1 Relapse: recurrence of psychotic symptoms<BR/>We identified no difference in the recurrence of psychotic symptoms, when reported as an adverse event by treatment group, between any dose of paliperidone and olanzapine 10 mg.</P>
<P>2.1.1.2 No clinically important change in global state (as defined by individual studies)<BR/>We identified no difference between people randomised to any fixed dose of paliperidone and those allocated olanzapine 10 mg in the occurrence of no clinically important change in global state. However, the authors defined a clinically important change in global state as at least a 30% reduction in PANSS score, and we have reservations, elucidated above, about using this research scale to measure global state. In addition, <LINK REF="STD-Davidson-2007" TYPE="STUDY">Davidson 2007</LINK> and <LINK REF="STD-Kane-2007" TYPE="STUDY">Kane 2007</LINK> reported these data in an incomplete fashion, so we were able to use data only from the <LINK REF="STD-Marder-2007" TYPE="STUDY">Marder 2007</LINK> trial, further limiting the conclusiveness of this finding.</P>
<P>2.1.2 Discontinuation of treatment or leaving the study early<BR/>In comparison to people treated with olanzapine 10 mg, those exposed to paliperidone 3 mg were significantly more likely to discontinue treatment or leave early for all causes and for lack of efficacy; this suggests that paliperidone 3 mg is not an equivalent treatment to olanzapine 10 mg in terms of discontinuation or efficacy. We found no significant differences in discontinuation or leaving early for people randomised to 6, 9, 12 or 15 mg doses of paliperidone.</P>
<P>2.2 Secondary Outcomes<BR/>2.2.1 Change in global state<BR/>All the authors report assessing CGI-S scores, but none reported mean changes and associated standard deviations, so we were unable to analyse this outcome.</P>
<P>2.2.2 Change in mental state<BR/>We identified no significant difference between people randomised to any dose of paliperidone and those allocated olanzapine 10 mg with regards to change in total PANSS score.</P>
<P>2.2.3 Change in social function<BR/>Using data from the Personal and Social Performance (PSP) scale, we identified no significant difference in social function between people randomised to paliperidone and those randomised to olanzapine 10 mg.</P>
<P>2.2.4 Adverse events<BR/>All three authors reported adverse events only when experienced by at least five per cent of the people in a given treatment group. By doing so, they may not have reported infrequent but potentially serious adverse events.</P>
<P>However, we observed that people receiving paliperidone were significantly more likely to experience a movement disorder than people receiving olanzapine 10 mg. We found it difficult to assess the extent to which people experienced discomfort because of associated movement disorders because of inconsistent reporting of use of anticholinergic or antiparkinsonism agents. Further, no authors reported the Barnes Akathisia Rating Scale (BARS) data in a manner useful for analyses.</P>
<P>There was also inconsistent reporting of several other adverse events that are well associated with risperidone administration. We observed no differences in the incidence of anticholinergic effects, aggression, agitation, and anxiety but did not have access to data about the concomitant use of benzodiazepines. We observed no consistent and significant relationships between the use of paliperidone and cardiovascular events, but poor reporting of cardiovascular data precludes any firm conclusions. We identified no significant difference in the incidence of insomnia.</P>
<P>2.2.5 Clinical and laboratory outcomes<BR/>In these studies, people who received paliperidone dosed experienced less weight gain than that experienced by people who received olanzapine 10 mg. However, when people received paliperidone dosed at 12 mg or 15 mg, they experienced a weight gain that was not different from that experienced by those allocated olanzapine 10 mg.</P>
<P>We were unable to identify a difference in the alteration of serum glucose and insulin values for people randomised to any dose of paliperidone and those receiving olanzapine 10 mg. In these short-term trials, no dose of paliperidone was more or less likely to affect serum glucose and insulin than olanzapine 10 mg.</P>
<P>In these studies, people randomised to olanzapine 10 mg experienced modest elevations in serum cholesterol, LDL and triglycerides. We found that people randomised to paliperidone were less likely to experience these modest elevations, and these differences were often statistically significant. Given the short duration of theses studies, we do not believe these findings are clinically significant, but cannot comment on potential long-term effects.</P>
<P>We observed consistent and significant dose-related elevations in serum prolactin for people randomised to paliperidone. We note that while the difference was significant for both women and men, the difference between people randomised to paliperidone and olanzapine 10 mg was more pronounced for women. However, we were unable to correlate these elevations to clinical implications as these studies identified no consistent relationship between the use of paliperidone and the incidence of gynaecomastia, impotence, nonpuerperal lactation, amenorrhoea or dysmenorrhoea, anorgasmia, abnormal sexual function or decreased libido. We are, however, uncertain of the clinical implications of this finding because of the short duration of these studies.</P>
<P>3. COMPARISON 5: PALIPERIDONE versus RISPERIDONE<BR/>A single study, <LINK REF="STD-Cleton-2007" TYPE="STUDY">Cleton 2007</LINK>, compared paliperidone to risperidone over six days.</P>
<P>3.1 Primary Outcomes<BR/>3.1.1 Global State<BR/>3.1.1.1 Relapse: recurrence of psychotic symptoms<BR/>The authors reported this outcome only as an adverse event. During the short duration of this trial, six days, they observed only one participant experiencing psychosis in the risperidone group. Given the small sample size and the duration of trial, we are unable to reach any conclusion about the recurrence of psychosis.</P>
<P>3.1.1.2 No clinically important change in global state (as defined by individual studies)<BR/>No data was available on this primary outcome.</P>
<P>3.1.2 Discontinuation of treatment or leaving the study early<BR/>No data was available on this primary outcome.</P>
<P>3.2 Secondary Outcomes<BR/>3.2.1 Change in global state<BR/>No data was available on this outcome.</P>
<P>3.2.2 Change in mental state<BR/>No data was available on this outcome.</P>
<P>3.2.3 Change in social function<BR/>No data was available on this outcome.</P>
<P>3.2.4 Adverse events<BR/>The authors reported adverse events only when experienced by at least five per cent of the people in a given treatment group. By doing so, they may not have reported infrequent but potentially serious adverse events.</P>
<P>As we prepared this iteration of the review, we had only three posters summarizing the data from this trial, and the data was inconsistently reported. Adverse events were reported only as percentages for a small number of outcomes, so we do not have a complete picture of the adverse events experienced in this trial. From the data we do have, we are able to discern no significant difference in the occurrence of adverse effects between participants randomised to paliperidone and those randomised to risperidone. These include the occurrence of hypotension, tachycardia, palpitation, anxiety, insomnia, sleepiness, nausea, extrapyramidal disorder, hyperkinesia and headache.</P>
<P>Based on this preliminary data, we are unable to discern a difference in the tolerability of paliperidone and risperidone in this six-day trial.</P>
<P>3.2.5 Clinical and laboratory outcomes<BR/>Although this study was designed to measure multiple relevant outcomes, the authors have not yet reported them in a fashion appropriate for this review.</P>
<P>4. COMPARISON 6: PALIPERIDONE versus QUETIAPINE<BR/>A single study, <LINK REF="STD-Canuso-2009" TYPE="STUDY">Canuso 2009</LINK>, compares flexible doses of paliperidone with flexible doses of quetiapine. The trial has two phases, two weeks of monotherapy followed by an additional four weeks during which participants could receive additional psychotropics as clinically indicated. We only included data from the study's six-week endpoint.</P>
<P>4.1 Primary Outcomes<BR/>4.1.1 Global state<BR/>4.1.1.1 Relapse: recurrence of psychotic symptoms<BR/>We identified a non-significant trend, favouring paliperidone, in the recurrence of psychotic symptoms.</P>
<P>4.1.1.2 No clinically important change in global state (as defined by individual studies)<BR/>No data was available on this primary outcome.</P>
<P>4.1.2 Discontinuation of treatment or leaving the study early<BR/>Over a quarter of the participants left this study before its completion. In comparison to people treated with quetiapine, the participants treated with paliperidone were significantly less likely to discontinue treatment in overall reasons for leaving the study early. The precise reasons for this difference are unclear, because no significant difference was found for any of the specific reasons for discontinuation or leaving the study early. However, the data suggest that the participants in this study may have found paliperidone, with a mean dose of 9.8 mg daily, to be more efficacious and associated with fewer adverse effects than quetiapine, with a mean dose of 599.1 mg daily.</P>
<P>4.2 Secondary Outcomes<BR/>4.2.1 Change in global state<BR/>The authors identified no difference between treatment groups for this outcome.</P>
<P>4.2.2 Change in mental state<BR/>The authors identified a significantly greater decrease in total PANSS score for those randomised to paliperidone when compared with those randomised to quetiapine. However the data is likely to be skewed, are not intention-to-treat data, and are from a scale not used in everyday practice, so the clinical significance of this difference is unclear.</P>
<P>4.2.3 Change in social function<BR/>No data was available on this outcome.</P>
<P>4.2.4 Adverse events<BR/>The authors reported adverse events only when experienced by at least five per cent of the people in a given treatment group. By doing so, they may not have reported infrequent but potentially serious adverse events.</P>
<P>However, in comparison to participants randomised to quetiapine, we did observe that participants randomised to paliperidone were significantly more likely to experience hypertonia, tremor, increased saliva and to require anticholinergic medications. Participants randomised to paliperidone were significantly less likely to experience dizziness and sleepiness.</P>
<P>Other adverse events were equivocal or not well-reported.</P>
<P>4.2.5 Clinical and laboratory outcomes<BR/>Both male and female participants randomised to paliperidone were significantly more likely to experience an increase in serum prolactin. The clinical implications of this increase are uncertain because the authors incompletely reported the incidence of adverse effects potentially related to elevated prolactin.<BR/>
</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-08-05 15:15:26 +0100" MODIFIED_BY="[Empty name]">
<P>Authors of included studies selected participants by DSM-IV criteria and initial PANSS scores, which improves the internal validity of the studies by selecting a homogeneous population of acutely psychotic people with a history of schizophrenia. The authors also excluded participants with substance dependence, those who previously have not responded to antipsychotic agents, those with a history of tardive dyskinesia and the other exclusion criteria summarised in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables. We note that these criteria exclude many of the people for whom clinicians would be most interested in considering for a novel treatment. The authors of <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK> were especially assiduous in their selection of people likely to respond to treatment with paliperidone, which particularly limits application of their findings to those who have previously tolerated and responded to open-label treatment with paliperidone.</P>
<P>The external validity, the extent to which these findings are applicable to the quotidian treatment of people who need treatment with antipsychotic medication, is likely to be limited by the strict inclusion criteria.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-08-05 15:16:14 +0100" MODIFIED_BY="[Empty name]">
<P>The authors of most studies described the method by which they allocated participants to treatments. The authors of <LINK REF="STD-Cleton-2007" TYPE="STUDY">Cleton 2007</LINK> did not describe their method of allocation in the preliminary presentations of their study that were available for our analysis.</P>
<P>None of the authors described their blinding procedures or if they tested how blind the study was. In the absence of an adequate account of blindness, we observe that this poses a risk for both attrition and performance bias.</P>
<P>With the exception of <LINK REF="STD-Kramer-2007" TYPE="STUDY">Kramer 2007</LINK>, the included studies were designed to last between six days and six weeks, yet only 46 - 81% of people randomised to paliperidone completed these studies. Studies used a last observation carried forward analysis, which further reduces the duration of these trials, and the authors did not report the mean duration of treatment. Given the limited duration of these trials, the low rates of completion and other issues of study quality, we can make only tentative inferences about the long-term efficacy and safety of paliperidone for people with schizophrenia, which is often a chronic illness.</P>
<P>Although over 2500 people were randomised in the included studies, the authors reported only a portion of the collected data, and the remaining data has not been made available for review. This phenomenon is well illustrated by the reporting of adverse effects. Authors reported adverse events only when experienced by at least five per cent of participants in a given treatment group. By using this convention, authors may have under-reported rare but clinically relevant adverse effects. We advocate reporting all adverse events to identify adverse events that may affect people with schizophrenia.</P>
<P>Additionally, because some data were reported incompletely, we could not always make comparisons between studies. While PANSS data and information about discontinuation of treatment or leaving the study early tended to be reported clearly and consistently, information about adverse events, concomitant use of anxiolytics and anticholinergic medications, global state, and movement disorders was neither clear nor consistent. In their filing with the Food and Drug Administration, the manufacturer of paliperidone made most of this data available, but has not yet been able to supply this data with the detail required for our review. We further regret the lack of data regarding economic outcomes, employment status, hospital outcomes, long-term efficacy and safety and satisfaction with care.</P>
<P>We found no studies comparing oral paliperidone with anything other than itself, placebo, olanzapine (10 mg), risperidone, or quetiapine (mean dose 599.1 mg). We await additional studies, especially extended comparisons with risperidone, with interest.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-06-05 16:19:08 +0100" MODIFIED_BY="[Empty name]">
<P>We were able to use only the reported studies, the published data from these studies, and the unpublished data supplied by the study authors and the manufacturer of paliperidone. Our review is necessarily skewed by the unavailability of data. Finally, all of these studies were funded by the manufacturer of paliperidone.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-08-05 15:18:09 +0100" MODIFIED_BY="[Empty name]">
<P>In this review, we substantially revised and updated our initial review, but our conclusions are largely consistent with those of our first review.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-08-05 15:24:23 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-08-05 15:21:13 +0100" MODIFIED_BY="[Empty name]">
<P>1. For people with schizophrenia<BR/>We have much to learn about the effects of paliperidone. The available studies were short and the resulting data were incompletely reported and often did not meet the demands of a Cochrane review. Oral paliperidone does seem to reduce psychotic symptoms and has a profile of adverse effects similar to its parent compound, risperidone. For people who respond to paliperidone, its continued use may well delay recurrence of psychotic symptoms. Weight gain and movement disorders occur frequently and become more common as the daily dose increases. Serum prolactin levels, which are associated with sexual dysfunction, are substantially raised in those taking paliperidone, but we were unable to identify any effect on sexual dysfunction in these short trials. While it was compared with risperidone only in a short six-day trial, we were unable to identify any difference in initial tolerability of paliperidone when compared to risperidone. We know very little about the long-term effects of paliperidone, and have scant data on quality of life or social functioning.</P>
<P>2. For clinicians<BR/>Oral paliperidone is an effective antipsychotic whose optimal dose appears to be between 6 mg and 12 mg per day, a dose range in which its effectiveness is comparable to olanzapine 10 mg per day and, perhaps, quetiapine 600 mg per day. We found its adverse effects to be similar to those of its parent compound, risperidone, with higher doses more likely to cause movement disorders than lower doses. We observed that people who received paliperidone 3 mg, 6 mg or 9 mg per day experienced less weight gain than those receiving olanzapine 10 mg per day, but found no difference for people receiving paliperidone 12 mg or 15 mg per day. People who received paliperidone 9 mg, 12 mg or 15 mg per day experienced more movement disorders than those who received olanzapine 10 mg per day, but we identified no difference for those receiving paliperidone 3 mg or 6 mg per day. Paliperidone is associated with substantial increases in serum prolactin in men and women, with larger effects in women than men, but these studies identified no significant difference in the incidence of sexual dysfunction. We found a single trial comparing flexible doses of paliperidone, mean dose 9.8 mg daily, to flexible doses of paliperidone, mean dose 599.1 mg daily, in which paliperidone appears to be as least as efficacious as quetiapine. The study found that participants randomised to paliperidone were significantly more likely to experience hypertonia, tremor, elevated prolactin, and significantly less likely to experience dizziness and sleepiness than those randomised to quetiapine. We found one study of six-days duration that compared paliperidone, titrated to 12 mg, with risperidone, titrated to 4 mg. No efficacy data was available for this study, but we found no difference in the reported adverse events; accordingly, we were unable to identify any difference in the initial tolerability of paliperidone in comparison to that of risperidone. </P>
<P>3. For managers/policy makers<BR/>We conclude that oral paliperidone is an additional antipsychotic whose efficacy, when dosed between 6 mg and 12 mg daily, may well compare to olanzapine 10 mg daily and quetiapine 600 mg per day. We have no data assessing paliperidone's long-term efficacy and tolerability, service utilization, or satisfaction with care, so we can make no conclusions about these important criteria; the available data on this subject comes from post hoc analyses of open-label extension data (<LINK REF="REF-Janicak-2008b" TYPE="REFERENCE">Janicak 2008b</LINK>). The only available data directly comparing paliperidone to its parent compound risperidone, which is now off patent worldwide, is preliminary data from a six-day trial which shows no difference in the occurrence of adverse events. We have no evidence that paliperidone has novel qualities or delivers additional benefits over and above those available with the use of risperidone.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-08-05 15:24:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>Researchers should report data in a more transparent manner to enable clinical decision-making, ideally including intention-to-treat analyses on all outcomes. When data are presented, they should be presented as numbers rather than as percentages, and continuous data should be reported with means, standard deviations (or standard errors) and the number of participants. Researchers should compare active metabolites to their parent compounds when both are clinically available.</P>
<P>Both editors and authors of trials should ensure strict adherence to CONSORT reporting guidelines (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>).</P>
<P>To ease analysis, we suggest that Cochrane Groups incorporate a number needed to treat calculator in future iterations of RevMan and allow review authors to simultaneously compare both subtotals for exposure groups by individual dose and by total for each outcome so we can better understand both the class and dose effects of a medication.</P>
<P>2. Specific<BR/>In this version of the review, we were able to incorporate data, albeit from a six-day trial, comparing paliperidone with risperidone. In this study, we found no difference in the adverse events experienced by those randomised to paliperidone or risperidone. This study confirms our suspicion that oral paliperidone will affect people with schizophrenia in a similar fashion to risperidone. For individual clinicians to select paliperidone over risperidone on the basis of appropriate evidence, researchers will need to conduct pragmatic studies that more closely resemble the lived experience of patients with schizophrenia and include comparisons with risperidone. Clinicians would also benefit from studies that assess the efficacy, adverse effects, and safety of long-term use of paliperidone, including behaviour, mortality, satisfaction with treatment and cost-effective in comparisons to older and newer generation antipsychotics. An outline for a suggested design is given in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-08-05 15:22:52 +0100" MODIFIED_BY="[Empty name]">
<P>We thank Clive Adams, Claire Irving, Tessa Grant, Prathap Tharyan, and Bethany York of the Cochrane Schizophrenia Group. We thank the Psychiatry Department at the University of North Carolina for its support. We also thank Stephen Marder, Professor of Psychiatry at UCLA Neuropsychiatric Hospital, M. Deborah Nicholl, Associate Director of Health Economics for Johnson and Johnson Pharmaceutical Services and Clive M. Rogers, Clinical Evidence Liaison Manager of Janssen-Cilag Ltd, for sharing unpublished data.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>The authors received no financial consideration from any parties for the preparation of this review. Dr. Stroup has been a consultant for AstraZeneca, Janssen, Lilly, and Pfizer, and has spoken at events sponsored by Lilly, Lundbeck, and Pfizer.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Abraham Nussbaum - wrote the protocol and review.<BR/>Scott Stroup - wrote the protocol and review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-08-05 15:23:49 +0100" MODIFIED_BY="[Empty name]">
<P>We have divided our original review into two separate reviews, one for oral paliperidone and another in preparation for the intramuscular formulation. We have also reformatted the review in light of changes to software (RevMan 5).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-05-26 13:30:18 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-05-26 13:30:18 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-05-26 13:30:18 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Canuso-2009" MODIFIED="2009-11-30 13:48:01 +0000" MODIFIED_BY="[Empty name]" NAME="Canuso 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-06-06 19:34:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Canuso C, Carothers J, Dirks B, Zhu Y, Kosik-Gonzalez C</AU>
<TI>A double-blind placebo-controlled trial comparing paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia</TI>
<SO>Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-6; Washington DC</SO>
<YR>2008</YR>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-06 19:11:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Canuso C, Carothers J, Dirks B, Zhu Y, Schreiner A, Kosik-Gonzalez C</AU>
<TI>A double-blind placebo-controlled trial comparing paliperidone er and quetiapine in patients with a recent acute exacerbation of schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>102</VL>
<NO>Suppl 2</NO>
<PG>252</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-06 19:14:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Canuso C, Dirks B, Carothers J, Zhu T, Kosik-Gonzalez C</AU>
<TI>A double-blind, placebo-controlled trial of paliperidone er and quetiapine in patients with a recent acute exacerbation of schizophrenia</TI>
<SO>Proceedings of the 20th Annual U.S. Psychiatric &amp; Mental Health Congress; 2007 11-14 Oct; Orlando, Florida</SO>
<YR>2007</YR>
<CY>Orlando, Florida</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-03 09:04:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Canuso C, Dirks B, Carothers J, Zhu Y, Kosik-Gonzalez C</AU>
<TI>A comparative analysis of paliperidone er and quetiapine in patients with a recent, acute exacerbation of schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>98</VL>
<PG>158-9</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:04:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:04:07 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.schres.2007.12.372"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-30 13:48:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Canuso CM, Dirks B, Carothers J, Kosik-Gonzalez C, Bossie CA, Zhu Y, Damaraju CV, Kalali AH, Mahmoud R</AU>
<TI>Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>116</VL>
<NO>6</NO>
<PG>691-701</PG>
<IDENTIFIERS MODIFIED="2009-11-30 13:48:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:05:52 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1176/appi.ajp.2009.08040613 "/>
<IDENTIFIER MODIFIED="2009-11-30 13:48:01 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19411369"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Cleton-2007" MODIFIED="2010-05-26 13:30:18 +0100" MODIFIED_BY="[Empty name]" NAME="Cleton 2007" YEAR="2006">
<REFERENCE MODIFIED="2010-05-26 13:30:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cleton A, Rossenu S, Talluri K, Francetic I, Remmerie B, Janssens L, Eerdekens M, Boom S</AU>
<TI>Evaluation of the pharmacokinetics of an extended-release formulation of paliperidone with an immediate-release formulation of risperidone</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2007</YR>
<VL>81</VL>
<NO>Suppl 1</NO>
<PG>S62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-30 13:48:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cleton A, Rossenu S, Talluri K,Francetic I, Remmerie B, Janssens L, Eerdekens M, Boom S</AU>
<TI>Comparison of pharmacodynamic parameters resulting from administration of an paliperidone extended-release tablet formulation and an immediate-release formulation of risperidone in subjects with schizophrenia</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2007</YR>
<VL>81</VL>
<NO>Suppl 1</NO>
<PG>S61-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-06 21:27:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Eerdekens M, Kramer M, Rossenu S, Pandina G, Boom S, Francetic I, Janssens L, Cleton A</AU>
<TI>Effect of paliperidone extended-release tablets on prolactin exposure in patients with stable schizophrenia (Poster no. 335)</TI>
<SO>Proceedings of the USP and MHC; 2006 16-19 Nov; New Orleans, USA</SO>
<YR>2006</YR>
<CY>New Orleans, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Davidson-2007" MODIFIED="2009-07-03 09:08:53 +0100" MODIFIED_BY="[Empty name]" NAME="Davidson 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-03 09:08:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M</AU>
<TI>Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study</TI>
<SO>Schizophrenia Research</SO>
<YR>2007</YR>
<VL>93</VL>
<NO>1-3</NO>
<PG>117-30</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:08:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:08:53 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.schres.2007.03.003 "/>
<IDENTIFIER MODIFIED="2009-07-03 09:08:46 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17466492"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-06 19:38:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Davidson M, Emsley R, Kramer M, Ford L</AU>
<TI>Efficacy, safety and effect on functioning of paliperidone extended-release tablets in schizophrenia: an international 6-week placebo-controlled study</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia; 2006 Feb 4-10; Davos, Switzerland</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Poster presentation from 159th Annual Meeting of the American Psychiatric Association; Toronto, Canada; 2006 May 20-25&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson M, Emsley R, Kramer M, Gassmann-Mayer C, Lim P, Pan J, Eerdekens M</AU>
<TI>Efficacy, safety and effect on functioning of oral paliperidone extended-release tablets in the acute treatment of schizophrenia: an international 6-week placebo-controlled study</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>81</VL>
<NO>Suppl 1</NO>
<PG>43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Janssen-Cilag Ltd</AU>
<TI>Data on File PCDoF2</TI>
<SO>Communication from Janssen-Cilag Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kane-2007" MODIFIED="2009-08-06 10:30:59 +0100" MODIFIED_BY="[Empty name]" NAME="Kane 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Janssen-Cilag Ltd</AU>
<TI>Data on File PCDoF2</TI>
<SO>Communication from Janssen-Cilag Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-03 09:09:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M</AU>
<TI>Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo -controlled trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2007</YR>
<VL>90</VL>
<NO>3</NO>
<PG>147-61</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:09:35 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:09:35 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17092691"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-06 21:30:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kane J, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M</AU>
<TI>Patients with acute schizophrenia: treatment with three fixed dosages of oral paliperidone extended-release tablets in an international 6-week placebo-controlled study</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-06 10:30:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kane J, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M</AU>
<TI>Treatment of schizophrenia using oral paliperidone extended-release tablets: a 6-week placebo-controlled study</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia; 2006 Feb 4-10; Davos, Switzerland</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kramer-2007" MODIFIED="2009-07-03 09:10:25 +0100" MODIFIED_BY="[Empty name]" NAME="Kramer 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kramer M, Kushner S, Vijapurkar U, Lim P, Eerdekens M</AU>
<TI>Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>s386</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-03 09:10:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M</AU>
<TI>Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>1</NO>
<PG>6-14</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:10:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:10:25 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17224706"/>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00086320"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Luthringer-2007" MODIFIED="2009-07-03 09:11:19 +0100" MODIFIED_BY="[Empty name]" NAME="Luthringer 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-03 09:11:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, Cleton A, Eerdekens M, Battisti W, Palumbo J</AU>
<TI>A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>5</NO>
<PG>299-308</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:11:19 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:11:19 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1097/YIC.0b013e3281c55f4f "/>
<IDENTIFIER MODIFIED="2009-07-03 09:11:13 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17690599"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-06-01 20:14:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-06-01 20:14:49 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Marder-2007" MODIFIED="2009-11-30 13:54:57 +0000" MODIFIED_BY="[Empty name]" NAME="Marder 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Janssen-Cilag Ltd</AU>
<TI>Data on File PCDoF2</TI>
<SO>Communication from Janssen-Cilag Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-03 09:12:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marder S, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A</AU>
<TI>Efficacy and safety of paliperidone extended-release tablets: results of a six-week, randomized, placebo-controlled study</TI>
<SO>Biological Psychiatry</SO>
<YR>2007</YR>
<VL>62</VL>
<NO>12</NO>
<PG>1363-70</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:12:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:12:11 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.biopsych.2007.01.017 "/>
<IDENTIFIER MODIFIED="2009-07-03 09:12:03 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17601495"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-06 21:32:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Marder S, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M</AU>
<TI>A 6-week, US-based placebo-controlled study on the efficacy and tolerability of two fixed dosages of oral paliperidone extended-release tablets in the treatment of acute schizophrenia</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-30 13:54:57 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Poster presentation from 13th Biennial Winter Workshop on Schizophrenia; Davos, Switzerland; 2006 February 4-10&lt;/p&gt;" NOTES_MODIFIED="2009-11-30 13:54:57 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marder S, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M</AU>
<TI>A 6-week, US-based placebo-controlled study on the efficacy and tolerability of two fixed dosages of oral paliperidone extended-release tablets in the treatment of acute schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>81</VL>
<NO>Suppl 1</NO>
<PG>56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Tzimos-2008" MODIFIED="2009-07-03 09:12:49 +0100" MODIFIED_BY="[Empty name]" NAME="Tzimos 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-06-06 21:34:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tzimos A, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M</AU>
<TI>A 6-week placebo-controlled study of the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients</TI>
<SO>Proceedings of the 25th Collegium Internationale Neuro-psychopharmacologicum; 2006 Jul 9-13; Chicago, Illinois</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-06 21:35:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tzimos A, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M</AU>
<TI>A 6-week placebo-controlled study on the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-06 21:35:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Poster presentation from 11th International Congress on Schizophrenia Research; Colorado Springs, Colorado; 28 March - 1 April 2007&lt;/p&gt;" NOTES_MODIFIED="2009-06-06 21:35:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tzimos A, Kramer M, McLemore J, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M</AU>
<TI>A 6-week placebo-controlled study of the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>Suppl 2</NO>
<PG>s464</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-03 09:12:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M</AU>
<TI>Safety and Tolerability of Oral Paliperidone Extended-Release Tablets in Elderly Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Study With Six-Month Open-Label Extension</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>1</NO>
<PG>31-43</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:12:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:12:49 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18165460"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-12-01 13:28:06 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Arakawa-2008" MODIFIED="2009-07-03 09:13:44 +0100" MODIFIED_BY="[Empty name]" NAME="Arakawa 2008" YEAR="2007">
<REFERENCE MODIFIED="2009-07-03 09:13:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T , Ohta K, Kato M, Okubo Y, Suhara T</AU>
<TI>Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D(2) receptor occupancy in patients with schizophrenia</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>2</NO>
<PG>229-35</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:13:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:13:44 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/s00213-007-1029-z "/>
<IDENTIFIER MODIFIED="2009-07-03 09:13:38 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18058087"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borison-1994" MODIFIED="2009-07-03 09:14:16 +0100" MODIFIED_BY="[Empty name]" NAME="Borison 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-07-03 09:14:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borison R, Diamond B, Pathiraja A, Meibach R</AU>
<TI>Pharmacokinetics of risperidone in chronic schizophrenic patients</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1994</YR>
<VL>30</VL>
<NO>2</NO>
<PG>193-7</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:14:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:14:16 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="7530379"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cleton-2006" MODIFIED="2009-12-01 13:28:06 +0000" MODIFIED_BY="[Empty name]" NAME="Cleton 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cleton A, Talluri K, Leempoels A, Thyssen A, Janssens L, Eerdekens M, Boom S</AU>
<TI>No pharmacokinetic interaction between trimethoprim and paliperidone ER in healthy subjects</TI>
<SO>Clinical pharmacology and therapeutics</SO>
<YR>2006</YR>
<VL>79</VL>
<NO>2</NO>
<PG>22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cleton-2007b" MODIFIED="2009-06-06 19:22:56 +0100" MODIFIED_BY="[Empty name]" NAME="Cleton 2007b" YEAR="2007">
<REFERENCE MODIFIED="2009-06-06 19:22:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cleton A, Rossenu S, Boom S, Remmerie B, Alnabawy A, Talluri K, Eerdekens M</AU>
<TI>Evaluation of the pharmacokinetics of paliperidone extended-release tablets in healthy elderly subjects</TI>
<SO>Clinical pharmacology and therapeutics</SO>
<YR>2007</YR>
<VL>81</VL>
<NO>Suppl 1</NO>
<PG>S62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2009-03-05 01:18:50 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Armenteros-2001" NAME="Armenteros 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Armenteros J</AU>
<TI>Risperidone treatment of adolescents with schizophrenia</TI>
<SO>CRISP database</SO>
<NO>2001</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CRISP Grant Number 5R29MH57084-04"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Rossenu-2008" MODIFIED="2009-03-05 01:18:50 +0000" MODIFIED_BY="[Empty name]" NAME="Rossenu 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-03-05 01:18:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rossenu S, Cleton A, Talluri K, Francetic I, Canuso C, Remmerie B, Janssens L, Eerdekens M, Boom S</AU>
<TI>Pharmacodynamics of paliperidone extended-release tablets and immediate-release risperidone in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>98</VL>
<PG>159</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1016/j.schres.2007.12.373"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-12-01 13:42:47 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-12-01 13:42:47 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<NO>7066</NO>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Angelucci-2009" MODIFIED="2009-12-01 13:42:47 +0000" MODIFIED_BY="[Empty name]" NAME="Angelucci 2009" TYPE="JOURNAL_ARTICLE">
<AU>Angelucci F, Ricci V, Martinotti G, Caltagirone C, Bria P</AU>
<TI>Paliperidone for treatment of obsessive-compulsive resistant symptoms in schizophrenia: A case report</TI>
<SO>Prog Neuropsychopharmacol Biol Psychiatry</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2009-12-01 13:42:47 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-12-01 13:42:47 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19555731"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-2007" MODIFIED="2009-07-03 09:17:06 +0100" MODIFIED_BY="[Empty name]" NAME="Anonymous 2007" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Molecule of the month. Paliperidone</TI>
<SO>Drug News Perspective</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>5</NO>
<PG>333</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:17:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:17:06 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17878961"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-2007b" MODIFIED="2009-07-03 09:17:24 +0100" MODIFIED_BY="[Empty name]" NAME="Anonymous 2007b" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent</TI>
<SO>Prescrire International</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>92</NO>
<PG>236-7</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:17:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:17:24 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18092400"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arakawa-2008" MODIFIED="2009-07-03 09:17:39 +0100" MODIFIED_BY="[Empty name]" NAME="Arakawa 2008" TYPE="JOURNAL_ARTICLE">
<AU>Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T</AU>
<TI>Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>2</NO>
<PG>229-35</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:17:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:17:39 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18058087"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aravagiri-1998a" MODIFIED="2009-07-03 09:17:53 +0100" MODIFIED_BY="[Empty name]" NAME="Aravagiri 1998a" TYPE="JOURNAL_ARTICLE">
<AU>Aravagiri M, Yuwiler A, Marder S</AU>
<TI>Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat</TI>
<SO>Psychopharmacology</SO>
<YR>1998</YR>
<VL>139</VL>
<NO>4</NO>
<PG>356-63</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:17:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:17:53 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9809856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aravagiri-1998b" MODIFIED="2009-07-03 09:18:08 +0100" MODIFIED_BY="[Empty name]" NAME="Aravagiri 1998b" TYPE="JOURNAL_ARTICLE">
<AU>Aravagiri M, Marder S, Wirshing D, Wirshing W</AU>
<TI>Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>3</NO>
<PG>102-9</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:18:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:18:08 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9657237"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aravagiri-2000" MODIFIED="2009-07-03 09:18:24 +0100" MODIFIED_BY="[Empty name]" NAME="Aravagiri 2000" TYPE="JOURNAL_ARTICLE">
<AU>Aravagiri M, Marder S</AU>
<TI>Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry</TI>
<SO>Journal of Mass Spectrometry</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>6</NO>
<PG>718-24</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:18:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:18:24 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10862124"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aravagiri-2002" MODIFIED="2009-07-03 09:18:45 +0100" MODIFIED_BY="[Empty name]" NAME="Aravagiri 2002" TYPE="JOURNAL_ARTICLE">
<AU>Aravagiri M, Marder S</AU>
<TI>Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats</TI>
<SO>Psychopharmacology</SO>
<YR>2002</YR>
<VL>159</VL>
<NO>4</NO>
<PG>424-31</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:18:45 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:18:45 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11823895 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aravagiri-2003" MODIFIED="2009-07-03 09:18:59 +0100" MODIFIED_BY="[Empty name]" NAME="Aravagiri 2003" TYPE="JOURNAL_ARTICLE">
<AU>Aravagiri M, Marder S, Nuechterlein K, Gitlin M</AU>
<TI>Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone</TI>
<SO>Therapeutic Drug Monitoring</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>6</NO>
<PG>657-64</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:18:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:18:59 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="14639051"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Awouters-2007" MODIFIED="2009-07-03 09:19:12 +0100" MODIFIED_BY="[Empty name]" NAME="Awouters 2007" TYPE="JOURNAL_ARTICLE">
<AU>Awouters FH , Lewi PJ</AU>
<TI>Forty years of antipsychotic Drug research from haloperidol to paliperidone with Dr. Paul Janssen</TI>
<SO>Arzneimittelforschung</SO>
<YR>2007</YR>
<VL>57</VL>
<NO>10</NO>
<PG>625-32</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:19:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:19:12 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18074755"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1989" MODIFIED="2009-07-03 09:19:24 +0100" MODIFIED_BY="[Empty name]" NAME="Barnes 1989" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TR</AU>
<TI>A rating scale for drug-induced akathisia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>672-6</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:19:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:19:24 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2574607"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" MODIFIED="2009-07-03 09:19:37 +0100" MODIFIED_BY="[Empty name]" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7108</NO>
<PG>600</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:19:37 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:19:37 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9302962"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bostwick-2009" MODIFIED="2009-07-03 09:29:49 +0100" MODIFIED_BY="[Empty name]" NAME="Bostwick 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bostwick JR, Guthrie SK, Ellingrod VL</AU>
<TI>Antipsychotic-induced hyperprolactinemia</TI>
<SO>Pharmacotherapy</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>1</NO>
<PG>64-73</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:29:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:29:49 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19113797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Byerly-2007" MODIFIED="2009-07-03 09:30:06 +0100" MODIFIED_BY="[Empty name]" NAME="Byerly 2007" TYPE="JOURNAL_ARTICLE">
<AU>Byerly M , Suppes T, Tran QV, Baker RA</AU>
<TI>Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectives</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>6</NO>
<PG>639-61</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:30:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:30:06 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18004132"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Canuso-2008" MODIFIED="2009-07-03 09:30:22 +0100" MODIFIED_BY="[Empty name]" NAME="Canuso 2008" TYPE="JOURNAL_ARTICLE">
<AU>Canuso CM, Youssef EA, Bossie CA, Turkoz I, Schreiner A, Simpson GM</AU>
<TI>Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>4</NO>
<PG>209-15</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:30:22 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:30:22 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18545059"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Canuso-2009a" MODIFIED="2009-12-01 13:33:53 +0000" MODIFIED_BY="[Empty name]" NAME="Canuso 2009a" TYPE="JOURNAL_ARTICLE">
<AU>Canuso CM, Turkoz I, Sheehanssie JJ, Bo CA</AU>
<TI>Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms</TI>
<SO>Journal of Affective Disorders</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2009-12-01 13:32:00 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-12-01 13:32:00 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19552963"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Canuso-2009b" MODIFIED="2009-12-01 13:35:00 +0000" MODIFIED_BY="[Empty name]" NAME="Canuso 2009b" TYPE="JOURNAL_ARTICLE">
<AU>Canuso CM, Bossie CA, Turkoz I, Alphs L</AU>
<TI>Paliperidone extended-release for schizophrenia: Effects on symptoms and functioning in acutely ill patients with negative symptoms</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2009-12-01 13:35:00 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-12-01 13:35:00 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19560322"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Citrome-2007" MODIFIED="2009-07-03 09:30:35 +0100" MODIFIED_BY="[Empty name]" NAME="Citrome 2007" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L</AU>
<TI>Paliperidone: quo vadis?</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2007</YR>
<VL>61</VL>
<NO>4</NO>
<PG>653-62</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:30:35 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:30:35 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17343660"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cohrs-2008" MODIFIED="2009-07-03 09:31:07 +0100" MODIFIED_BY="[Empty name]" NAME="Cohrs 2008" TYPE="JOURNAL_ARTICLE">
<AU>Cohrs S</AU>
<TI>Sleep disturbances in patients with schizophrenia : Impact and effect of antipsychotics</TI>
<SO>CNS Drugs</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>11</NO>
<PG>939-62</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:31:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:31:07 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18840034"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Danel-2008" MODIFIED="2009-07-03 09:34:47 +0100" MODIFIED_BY="[Empty name]" NAME="Danel 2008" TYPE="JOURNAL_ARTICLE">
<AU>Danel C, Azaroual N, Brunel A, Lannoy D, Vermeersch G, Odou P, Vaccher C</AU>
<TI>Study of the complexation of risperidone and 9-hydroxyrisperidone with cyclodextrin hosts using affinity capillary electrophoresis and (1)H NMR spectroscopy</TI>
<SO>Journal of chromatography</SO>
<YR>2008</YR>
<VL>1215</VL>
<NO>1-2</NO>
<PG>185-93</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:34:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:34:47 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19013582"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2005" MODIFIED="2009-06-08 11:07:24 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2005" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG</AU>
<TI>Analysing and presenting results. Section 8: The Cochrane Library</TI>
<SO>In Deeks JJ, Higgins JPT, Altman DG (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008] The Cochrane Collaboration</SO>
<YR>2008</YR>
<ED>Higgins JPT, Green S</ED>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dirks-2006" MODIFIED="2009-07-03 09:35:16 +0100" MODIFIED_BY="[Empty name]" NAME="Dirks 2006" NOTES="&lt;p&gt;Janssen-funded meta-analysis of the data presented in Kane 2007, Kramer 2007, and Marder 2007.&lt;/p&gt;" NOTES_MODIFIED="2009-07-03 09:35:16 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="CONFERENCE_PROC">
<AU>Dirks B, Canuso C, Eerdekens M, Turkoz I, Alberio R, Gharabawi G</AU>
<TI>Efficacy of paliperidone extended-release tablets in patients with schizophrenia and predominant negative symptoms</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>9</VL>
<PG>162</PG>
<EN>S1</EN>
<IDENTIFIERS MODIFIED="2009-07-03 09:35:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:35:16 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1017/S1461145706007292"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" MODIFIED="2009-07-03 09:35:34 +0100" MODIFIED_BY="[Empty name]" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:35:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:35:34 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1453246"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dlugosz-2007" MODIFIED="2009-07-03 09:35:55 +0100" MODIFIED_BY="[Empty name]" NAME="Dlugosz 2007" TYPE="JOURNAL_ARTICLE">
<AU>Dlugosz H, Nasrallah HA</AU>
<TI>Paliperidone: a new extended-release oral atypical antipsychotic</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>14</NO>
<PG>2307-13</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:35:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:35:55 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17927485"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dolder-2008" MODIFIED="2009-07-03 09:36:13 +0100" MODIFIED_BY="[Empty name]" NAME="Dolder 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dolder C, Nelson M, Deyo Z</AU>
<TI>Paliperidone for schizophrenia</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2008</YR>
<VL>65</VL>
<NO>5</NO>
<PG>403-13</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:36:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:36:13 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18281731"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" MODIFIED="2009-07-03 09:36:37 +0100" MODIFIED_BY="[Empty name]" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>19</NO>
<PG>2971-80</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:36:37 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:36:37 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12325113"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dopheide-2008" MODIFIED="2009-07-03 09:36:58 +0100" MODIFIED_BY="[Empty name]" NAME="Dopheide 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dopheide JA</AU>
<TI>Paliperidone: an improvement over risperidone?</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2008</YR>
<VL>65</VL>
<NO>5</NO>
<PG>401</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:36:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:36:58 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18281730"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duggal-2007" MODIFIED="2009-07-03 09:37:14 +0100" MODIFIED_BY="[Empty name]" NAME="Duggal 2007" TYPE="JOURNAL_ARTICLE">
<AU>Duggal HS</AU>
<TI>Possible neuroleptic malignant syndrome associated with paliperidone</TI>
<SO>Journal of Neuropsychiatry Clinical Neuroscience</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>4</NO>
<PG>477-8</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:37:14 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:37:14 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18070861"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duval-2008" MODIFIED="2009-07-03 09:37:27 +0100" MODIFIED_BY="[Empty name]" NAME="Duval 2008" TYPE="JOURNAL_ARTICLE">
<AU>Duval F, Guillon MS, Mokrani MC, Crocq MA, Garcia Duarte F</AU>
<TI>Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2008</YR>
<VL>33</VL>
<NO>2</NO>
<PG>255-9</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:37:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:37:27 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18053652"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Edwards-2008" MODIFIED="2009-07-03 09:37:43 +0100" MODIFIED_BY="[Empty name]" NAME="Edwards 2008" TYPE="JOURNAL_ARTICLE">
<AU>Edwards NC, Pesa J, Meletiche DM, Engelhart L, Thompson AK, Sherr J, Dirani R</AU>
<TI>One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia</TI>
<SO>Current Medical Research Opinion</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>12</NO>
<PG>3341-55</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:37:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:37:43 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18954497"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2009-07-03 09:37:56 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder CSO</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>629-34</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:37:56 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:37:56 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9310563"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2009-07-03 09:38:10 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials:methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:38:10 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:38:10 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11914310"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Emsley-2008" MODIFIED="2009-07-03 09:38:23 +0100" MODIFIED_BY="[Empty name]" NAME="Emsley 2008" TYPE="JOURNAL_ARTICLE">
<AU>Emsley R, Berwaerts J, Eerdekens M, Kramer M, Lane R, Lim P, Hough D, Palumbo J</AU>
<TI>Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled ate from three 52-week open-label studies</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>6</NO>
<PG>343-56</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:38:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:38:23 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18854723"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Feng-2008" MODIFIED="2009-07-03 09:38:41 +0100" MODIFIED_BY="[Empty name]" NAME="Feng 2008" TYPE="JOURNAL_ARTICLE">
<AU>Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, Aravagiri M, Schneider L, Bies RR</AU>
<TI>Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>2008</YR>
<VL>66</VL>
<NO>5</NO>
<PG>629-39</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:38:41 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:38:41 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18771484"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fitzgerald-2008" MODIFIED="2009-07-03 09:38:53 +0100" MODIFIED_BY="[Empty name]" NAME="Fitzgerald 2008" TYPE="JOURNAL_ARTICLE">
<AU>Fitzgerald P, Dinan TG</AU>
<TI>Prolactin and dopamine: what is the connection? A review article</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>Suppl 2</NO>
<PG>12-9</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:38:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:38:53 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18477617"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fowler-2008" MODIFIED="2009-07-03 09:39:06 +0100" MODIFIED_BY="[Empty name]" NAME="Fowler 2008" TYPE="JOURNAL_ARTICLE">
<AU>Fowler JA, Bettinger TL, Argo TR</AU>
<TI>Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia</TI>
<SO>Clinical Therapeutics</SO>
<YR>2008</YR>
<VL>30</VL>
<NO>2</NO>
<PG>231-48</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:39:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:39:06 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18343262"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Freedman-2003" NAME="Freedman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Freedman R</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>18</NO>
<PG>1738-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freudenmann-2009" MODIFIED="2009-07-03 09:39:21 +0100" MODIFIED_BY="[Empty name]" NAME="Freudenmann 2009" TYPE="JOURNAL_ARTICLE">
<AU>Freudenmann RW, Khnlein P, Lepping P, Schnfeldt-Lecuona C</AU>
<TI>Secondary delusional parasitosis treated with paliperidone</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>2009</YR>
<VL>34</VL>
<NO>3</NO>
<PG>375-7</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:39:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:39:21 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19040517"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Friberg-2009" MODIFIED="2009-07-03 09:39:56 +0100" MODIFIED_BY="[Empty name]" NAME="Friberg 2009" TYPE="JOURNAL_ARTICLE">
<AU>Friberg L, Vermeulen A, Petersson K, Karlsson M</AU>
<TI>An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2009</YR>
<VL>85</VL>
<NO>4</NO>
<PG>409-17</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:39:56 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:39:56 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1038/clpt.2008.234 "/>
<IDENTIFIER MODIFIED="2009-07-03 09:39:34 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19109590"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gagnon-2006" NAME="Gagnon 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gagnon D, Adriaenssen I, Nasrallah H, Morosini P</AU>
<TI>Reliability, validity and sensitivity to change of the personal and social performance scale in patients with stable schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>Suppl 1</NO>
<PG>288</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geitona-2008" MODIFIED="2009-07-03 09:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Geitona 2008" TYPE="JOURNAL_ARTICLE">
<AU>Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I</AU>
<TI>Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study</TI>
<SO>Annals of General Psychiatry</SO>
<YR>2008</YR>
<VL>7</VL>
<PG>16-28</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:40:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-02 15:51:12 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PMCID: PMC2553072"/>
<IDENTIFIER MODIFIED="2009-07-03 09:40:18 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18755025"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gilbody-2000" MODIFIED="2009-07-03 09:40:36 +0100" MODIFIED_BY="[Empty name]" NAME="Gilbody 2000" TYPE="COCHRANE_REVIEW">
<AU>Gilbody SM, Bagnall AM, Duggan L, Tuunainen A.</AU>
<TI>Risperidone versus other atypical antipsychotic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-07-03 09:40:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:40:36 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=" 10.1002/14651858.CD002306"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glick-2009" MODIFIED="2009-12-01 13:20:04 +0000" MODIFIED_BY="[Empty name]" NAME="Glick 2009" TYPE="JOURNAL_ARTICLE">
<AU>Glick ID, Bossie CA, Alphs L, Canuso CM.</AU>
<TI>Onset and persistence of antipsychotic response in patients with schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>6</NO>
<PG>542-7</PG>
<IDENTIFIERS MODIFIED="2009-12-01 13:20:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-12-01 13:20:04 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
<IDENTIFIER MODIFIED="2009-12-01 13:20:04 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19910718"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<NO>9</NO>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<PB>National Institute of Mental Health</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heinrichs-1984" MODIFIED="2009-07-03 09:40:56 +0100" MODIFIED_BY="[Empty name]" NAME="Heinrichs 1984" TYPE="JOURNAL_ARTICLE">
<AU>Heinrichs DW, Hanlon ET, Carpenter WT</AU>
<TI>The quality of life scale: an instrument for rating the schizophrenic deficit syndrome</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1984</YR>
<VL>10</VL>
<NO>3</NO>
<PG>388-96</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:40:56 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:40:56 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="6474101"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2009-06-06 22:06:04 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]</TI>
<SO>The Cochrane Collaboration</SO>
<YR>2008</YR>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hogarty-1974" NAME="Hogarty 1974" TYPE="JOURNAL_ARTICLE">
<AU>Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF</AU>
<TI>Drug and sociotherapy in the aftercare of schizophrenic patients: two-year relapse rates</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1974</YR>
<VL>31</VL>
<PG>603-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hosalli-2003" MODIFIED="2009-07-03 09:41:11 +0100" MODIFIED_BY="[Empty name]" NAME="Hosalli 2003" TYPE="COCHRANE_REVIEW">
<AU>Hosalli P, Davis JM</AU>
<TI>Depot risperidone for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-07-03 09:41:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:41:11 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004161"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hough-2009" MODIFIED="2009-12-01 13:24:05 +0000" MODIFIED_BY="[Empty name]" NAME="Hough 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hough D, Nuamah IF, Lim P, Sampson A, Gagnon DD, Rothman M</AU>
<TI>Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysis</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>5</NO>
<PG>496-7</PG>
<IDENTIFIERS MODIFIED="2009-12-01 13:24:05 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-12-01 13:24:05 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19745652"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hunter-2003" MODIFIED="2009-07-03 09:41:26 +0100" MODIFIED_BY="[Empty name]" NAME="Hunter 2003" TYPE="COCHRANE_REVIEW">
<AU>Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F</AU>
<TI>Risperidone versus typical antipsychotic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-07-03 09:41:26 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:41:23 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000440"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hussar-2008" MODIFIED="2009-07-03 09:41:40 +0100" MODIFIED_BY="[Empty name]" NAME="Hussar 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hussar DA</AU>
<TI>New drug update: 2007</TI>
<SO>The Consultant Pharmacist</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>4</NO>
<PG>276-96</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:41:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:41:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18454587"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Huther-2008" MODIFIED="2009-07-03 09:41:55 +0100" MODIFIED_BY="[Empty name]" NAME="Huther 2008" TYPE="JOURNAL_ARTICLE">
<AU>Huther R, Gebhart C, Mirisch S, Bauml J, Forstl H</AU>
<TI>Choreatic symptoms during and after treatment with paliperidone and escitalopram</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2008</YR>
<VL>41</VL>
<NO>5</NO>
<PG>203-4</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:41:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:41:55 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18763225"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ilett-2004" MODIFIED="2009-07-03 09:42:13 +0100" MODIFIED_BY="[Empty name]" NAME="Ilett 2004" TYPE="JOURNAL_ARTICLE">
<AU>Illett KF, Hackett LP, Kristensen JH, Vaddadi KS, Gardiner SJ, Begg EJ</AU>
<TI>Transfer of risperidone and 9-hydroxyrisperidone into human milk</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2004</YR>
<VL>38</VL>
<NO>2</NO>
<PG>273-6</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:42:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:42:13 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14742766"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Janicak-2006" MODIFIED="2009-07-03 09:42:25 +0100" MODIFIED_BY="[Empty name]" NAME="Janicak 2006" TYPE="BOOK">
<AU>Janicak PG, Davis JM, Preskorn SH, Ayd FJ, Marder SR, Pavuluri MN</AU>
<SO>Principles and Practice of Psychopharmacology</SO>
<YR>2006</YR>
<EN>4th</EN>
<PB>Lippincott Williams and Wilkins</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS MODIFIED="2009-07-03 09:42:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:42:25 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="0781760577"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Janicak-2008a" MODIFIED="2009-07-03 09:42:52 +0100" MODIFIED_BY="[Empty name]" NAME="Janicak 2008a" TYPE="JOURNAL_ARTICLE">
<AU>Janicak PG, Wu JH, Mao L</AU>
<TI>Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>6</NO>
<PG>1807-15</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:42:52 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:42:52 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18559166"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Janicak-2008b" MODIFIED="2009-06-06 22:12:44 +0100" MODIFIED_BY="[Empty name]" NAME="Janicak 2008b" TYPE="CONFERENCE_PROC">
<AU>Janicak PG, Jasmanda HW, Amatniek J, Mao L, Pesa J, Trott J, Kozma C, Canuso CM</AU>
<TI>Changes in mental health resource use after initiation of paliperidone ER in patients with schizophrenia</TI>
<SO>Proceedings of the Institute of Psychiatrics Services Annual Meeting; 2008 Oct 2-5; Chicago</SO>
<YR>2008</YR>
<CY>Chicago</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Janssen-2003" MODIFIED="2009-06-06 22:13:24 +0100" MODIFIED_BY="[Empty name]" NAME="Janssen 2003" TYPE="OTHER">
<AU>Janssen Pharmaceutica Products LP</AU>
<TI>Risperdal Consta (risperidone) long-acting injection prescribing information</TI>
<SO>Janssen Pharmaceutica Products, L.P.</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Janssen-2006" MODIFIED="2009-06-06 22:13:18 +0100" MODIFIED_BY="[Empty name]" NAME="Janssen 2006" TYPE="OTHER">
<AU>Janssen Pharmaceutica Products LP</AU>
<TI>Invega (paliperidone) extended-release tablets prescribing information</TI>
<SO>Janssen Pharmaceutica Products, L.P.</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Janssen_x002d_Cilag-1996" MODIFIED="2009-06-06 22:13:41 +0100" MODIFIED_BY="[Empty name]" NAME="Janssen-Cilag 1996" TYPE="OTHER">
<AU>Janssen-Cilag Ltd</AU>
<TI>Risperidal (risperidone) summary of product characteristics</TI>
<SO>UK: Janssen-Cilag Ltd</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jayaram-2006" MODIFIED="2009-06-06 22:13:54 +0100" MODIFIED_BY="[Empty name]" NAME="Jayaram 2006" TYPE="COCHRANE_REVIEW">
<AU>Jayaram MB, Hosalli P, Stroup S</AU>
<TI>Risperidone versus olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-06-06 22:13:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-06-06 22:13:54 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005237.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jones-2008" MODIFIED="2009-07-03 09:43:28 +0100" MODIFIED_BY="[Empty name]" NAME="Jones 2008" TYPE="JOURNAL_ARTICLE">
<AU>Jones A</AU>
<TI>What are the nursing implications when using paliperidone prolonged release for people with schizophrenia</TI>
<SO>Journal of Psychiatric and Mental Health Nursing</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>10</NO>
<PG>792-9</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:43:28 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:43:28 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19012670"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jones-2008a" MODIFIED="2009-06-06 22:16:14 +0100" MODIFIED_BY="[Empty name]" NAME="Jones 2008a" TYPE="CONFERENCE_PROC">
<AU>Jones MP, Nicholl D, Trakas K</AU>
<TI>Efficacy-tolerability profiles of oral atypical antipsychotics for schizophrenia: a meta-analysis including paliperidone extended-release</TI>
<SO>Proceedings of the 11th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2008 Nov 8-11; Athens, Greece</SO>
<YR>2008</YR>
<CY>Athens, Greece</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kapur-1995" MODIFIED="2009-07-03 09:44:00 +0100" MODIFIED_BY="[Empty name]" NAME="Kapur 1995" TYPE="JOURNAL_ARTICLE">
<AU>Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S</AU>
<TI>The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study</TI>
<SO>Life Science</SO>
<YR>1995</YR>
<VL>57</VL>
<NO>10</NO>
<PG>103-7</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:44:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:44:00 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="7543969"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Karlsson-2006" MODIFIED="2009-06-08 11:09:02 +0100" MODIFIED_BY="[Empty name]" NAME="Karlsson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Karlsson P, Dencker E, Nyberg S, Cselenyi Z, Mannaert E, Boom S, Talluri K, Rossenu S, Eriksson B, Eerdekens M, Farde L</AU>
<TI>Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>81</VL>
<NO>Suppl 1</NO>
<PG>85-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay S, Opler L, Fizbein A</AU>
<SO>The positive and negative syndrome scale (PANSS) manual</SO>
<YR>1986</YR>
<PB>Multi-Health System</PB>
<CY>North Tohawanda, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knegtering-2005" MODIFIED="2009-07-03 09:44:20 +0100" MODIFIED_BY="[Empty name]" NAME="Knegtering 2005" TYPE="JOURNAL_ARTICLE">
<AU>Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch R</AU>
<TI>Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<NO>5</NO>
<PG>1010-2</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:44:20 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:44:20 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15863810"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Knight-2009" MODIFIED="2009-07-03 09:44:41 +0100" MODIFIED_BY="[Empty name]" NAME="Knight 2009" TYPE="JOURNAL_ARTICLE">
<AU>Knight JA, Smith C, Toohey N, Klein MT, Teitler M</AU>
<TI>Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists</TI>
<SO>Molecular Pharmacology</SO>
<YR>2009</YR>
<VL>75</VL>
<NO>2</NO>
<PG>374-80</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:44:41 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:44:41 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18996971"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kostic-2006" MODIFIED="2009-07-03 09:45:01 +0100" MODIFIED_BY="[Empty name]" NAME="Kostic 2006" NOTES="&lt;p&gt;Janssen-funded meta-analysis of the data presented in Kane 2007, Kramer 2007, and Marder 2007.&lt;/p&gt;" NOTES_MODIFIED="2009-07-03 09:45:01 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Kostic D, Bossie C, Turkoz I, Bouhours P, Canuso C</AU>
<TI>Paliperidone extended-release tablets in patients recently diagnosed with schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>9</VL>
<PG>161</PG>
<EN>S1</EN>
<IDENTIFIERS MODIFIED="2009-07-03 09:45:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:45:01 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1017/S1461145706007292"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kramer-2008" MODIFIED="2009-07-03 09:45:18 +0100" MODIFIED_BY="[Empty name]" NAME="Kramer 2008" NOTES="&lt;p&gt;Janssen-funded meta-analysis of the data presented in Kane 2007, Kramer 2007, and Marder 2007.&lt;/p&gt;" NOTES_MODIFIED="2009-07-03 09:45:18 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Kramer M, Eerdekens M, Lane R, Schreiner A, Lim P, Sherr J, Palumbo J</AU>
<TI>Oral paliperidone extended-release treatment: long-term metabolic outcomes in patients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>98</VL>
<PG>173-4</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:45:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:45:18 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.schres.2007.12.408"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lautenschlager-2008" MODIFIED="2009-07-03 09:45:35 +0100" MODIFIED_BY="[Empty name]" NAME="Lautenschlager 2008" TYPE="JOURNAL_ARTICLE">
<AU>Lautenschlager M, Heinz A</AU>
<TI>Paliperidone-ER: first atypical antipsychotic with oral extended release formulation</TI>
<SO>Expert Review of Neurotherapeutics</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>2</NO>
<PG>193-200</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:45:35 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:45:35 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18271706"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leon-2007" MODIFIED="2009-07-03 09:46:25 +0100" MODIFIED_BY="[Empty name]" NAME="Leon 2007" TYPE="JOURNAL_ARTICLE">
<AU>Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz JF</AU>
<TI>A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2007</YR>
<VL>40</VL>
<NO>3</NO>
<PG>93-102</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:46:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:46:25 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17541883"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005" MODIFIED="2009-07-03 09:46:40 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale scores</TI>
<SO>The British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:46:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:46:40 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16199797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2009-07-03 09:46:53 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia research</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2-3</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:46:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:46:53 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15982856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lieberman-2005" MODIFIED="2009-07-03 09:47:07 +0100" MODIFIED_BY="[Empty name]" NAME="Lieberman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>12</NO>
<PG>1209-23</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:47:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:47:07 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16172203"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lieberman-2006" MODIFIED="2009-07-03 09:47:16 +0100" MODIFIED_BY="[Empty name]" NAME="Lieberman 2006" NOTES="&lt;p&gt;The American Psychiatric Publishing Textbook of Schizophrenia &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-07-03 09:47:16 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="BOOK">
<AU>Lieberman JA, Stroup TS, Perkins DO</AU>
<SO>The American Psychiatric Publishing Textbook of Schizophrenia</SO>
<YR>2006</YR>
<PB>American Psychiatric Publishing</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS MODIFIED="2009-07-03 09:47:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:47:16 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISBN 1585621919"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mackay-1998" NAME="Mackay 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD</AU>
<TI>The safety of risperidone: a post-marketing study on 7684 patients</TI>
<SO>Human Psychopharmacology</SO>
<YR>1998</YR>
<VL>13</VL>
<PG>413-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mannens-1993" NAME="Mannens 1993" TYPE="JOURNAL_ARTICLE">
<AU>Mannens G, Huang M-L, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J</AU>
<TI>Absorption, metabolism, and excretion of risperidone in humans</TI>
<SO>Drug Metabolism and Disposition</SO>
<YR>1993</YR>
<VL>21</VL>
<NO>6</NO>
<PG>1134-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marder-1997" MODIFIED="2009-07-03 09:47:36 +0100" MODIFIED_BY="[Empty name]" NAME="Marder 1997" TYPE="JOURNAL_ARTICLE">
<AU>Marder SR, Davis JM, Chouinard G</AU>
<TI>The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>58</VL>
<NO>12</NO>
<PG>538-46</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:47:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:47:36 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9448657"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marino-2008" MODIFIED="2009-07-03 09:47:48 +0100" MODIFIED_BY="[Empty name]" NAME="Marino 2008" TYPE="JOURNAL_ARTICLE">
<AU>Marino J, Caballero J</AU>
<TI>Paliperidone extended-release for the treatment of schizophrenia</TI>
<SO>Pharmacotherapy</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>10</NO>
<PG>1283-98</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:47:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:47:48 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18823223"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>259-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Melkersson-2006" MODIFIED="2009-07-03 09:48:03 +0100" MODIFIED_BY="[Empty name]" NAME="Melkersson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Melkersson K</AU>
<TI>Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite</TI>
<SO>Human Psychopharmacology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>8</NO>
<PG>529-32</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:48:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:48:03 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17094165"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Meltzer-2008" MODIFIED="2009-07-03 09:48:16 +0100" MODIFIED_BY="[Empty name]" NAME="Meltzer 2008" NOTES="&lt;p&gt;Janssen-funded meta-analysis of the data presented in Kane 2007, Kramer 2007, and Marder 2007.&lt;/p&gt;" NOTES_MODIFIED="2009-07-03 09:48:16 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M</AU>
<TI>Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2008</YR>
<VL>69</VL>
<NO>5</NO>
<PG>817-29</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:48:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:48:16 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18466043"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nasrallah-2008" MODIFIED="2009-07-03 09:48:29 +0100" MODIFIED_BY="[Empty name]" NAME="Nasrallah 2008" TYPE="JOURNAL_ARTICLE">
<AU>Nasrallah HA</AU>
<TI>Atypical antipsychotic-induced metabolic side effects: insight from receptor-binding profiles</TI>
<SO>Molecular Psychiatry</SO>
<YR>2008</YR>
<VL>13</VL>
<NO>1</NO>
<PG>27-35</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:48:29 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:48:29 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17848919"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nussbaum-2008" MODIFIED="2009-02-20 02:41:50 +0000" MODIFIED_BY="[Empty name]" NAME="Nussbaum 2008" TYPE="COCHRANE_REVIEW">
<AU>Nussbaum AM, Stroup TS</AU>
<TI>Paliperidone for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-02-20 02:41:50 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-20 02:41:50 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006369.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" MODIFIED="2009-06-05 11:50:23 +0100" MODIFIED_BY="[Empty name]" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pandina-2007" MODIFIED="2009-07-03 09:48:51 +0100" MODIFIED_BY="[Empty name]" NAME="Pandina 2007" TYPE="JOURNAL_ARTICLE">
<AU>Pandina GJ, Canuso CM, Youssef E, Kujawa M, Mahmoud R</AU>
<TI>Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia</TI>
<SO>Human Psychopharmacology</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>5</NO>
<PG>326-7</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:48:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:48:51 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17599334"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pani-2009" MODIFIED="2009-07-03 09:49:13 +0100" MODIFIED_BY="[Empty name]" NAME="Pani 2009" TYPE="JOURNAL_ARTICLE">
<AU>Pani L, Marchese G</AU>
<TI>Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release</TI>
<SO>Expert Opinion On Drug Delivery</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>3</NO>
<PG>319-31</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:49:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:49:13 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19317589"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Patrick-2006" MODIFIED="2009-06-06 22:20:28 +0100" MODIFIED_BY="[Empty name]" NAME="Patrick 2006" TYPE="JOURNAL_ARTICLE">
<AU>Patrick D, Adriaenssen I, Morosini P, Rothman M</AU>
<TI>Reliability, validity and sensitivity to change of the personal and social performance scale in patients with acute schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>Suppl 1</NO>
<PG>S287-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patrick-2009" MODIFIED="2009-07-03 09:49:53 +0100" MODIFIED_BY="[Empty name]" NAME="Patrick 2009" TYPE="JOURNAL_ARTICLE">
<AU>Patrick DL, Burns T, Morosini P, Rothman M, Gagnon DD, Wild D, Adriaenssen I</AU>
<TI>Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2009</YR>
<VL>25</VL>
<NO>2</NO>
<PG>325-38</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:49:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:49:53 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19192977"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Peng-2008" MODIFIED="2009-07-03 09:50:08 +0100" MODIFIED_BY="[Empty name]" NAME="Peng 2008" TYPE="JOURNAL_ARTICLE">
<AU>Peng PW, Huang MC, Tsai CJ, Pan CH, Chen CC, Chiu CC</AU>
<TI>The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection</TI>
<SO>Journal of clinical psychopharmacology</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>6</NO>
<PG>726-7</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:50:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:50:08 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19011459"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-P_x0159_ikryl-2009" MODIFIED="2009-12-01 13:39:37 +0000" MODIFIED_BY="[Empty name]" NAME="P&#345;ikryl 2009" TYPE="JOURNAL_ARTICLE">
<AU>P&#345;ikryl R, Ustohal L, Kucerova HP, Ceskova E</AU>
<TI>Paliperidon mediated modification of cortical inhibition</TI>
<SO>Neuro Endocrinol Lett</SO>
<YR>2009</YR>
<VL>30</VL>
<NO>3</NO>
<PG>396-399</PG>
<IDENTIFIERS MODIFIED="2009-12-01 13:38:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
<IDENTIFIER MODIFIED="2009-12-01 13:38:59 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19855366"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rado-2007" MODIFIED="2008-05-18 13:33:07 +0100" MODIFIED_BY="[Empty name]" NAME="Rado 2007" TYPE="JOURNAL_ARTICLE">
<AU>Rado J, Dowd SM, Janicak PG</AU>
<TI>Paliperidone ER: Reformulated antipsychotic for schizophrenia Tx</TI>
<SO>Current Psychiatry</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>9</NO>
<PG>75-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roser-2009" MODIFIED="2009-07-03 09:50:20 +0100" MODIFIED_BY="[Empty name]" NAME="Roser 2009" TYPE="JOURNAL_ARTICLE">
<AU>Roser P, Haussleiter IS, Juckel G, Brne M</AU>
<TI>Paliperidone in an adult patient with asperger syndrome: case report</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2009</YR>
<VL>42</VL>
<NO>2</NO>
<PG>78-9</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:50:20 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:50:20 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19308885"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rust-1989" MODIFIED="2009-06-05 11:47:26 +0100" MODIFIED_BY="[Empty name]" NAME="Rust 1989" TYPE="BOOK">
<AU>Rust J, Golombok S</AU>
<SO>Modern Psychometrics</SO>
<YR>1989</YR>
<PB>Routledge</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneider-2008" MODIFIED="2009-07-03 09:50:34 +0100" MODIFIED_BY="[Empty name]" NAME="Schneider 2008" TYPE="JOURNAL_ARTICLE">
<AU>Schneider RA, Lizer MH</AU>
<TI>Apparent seizure and atrial fibrillation associated with paliperidone</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2008</YR>
<VL>65</VL>
<NO>22</NO>
<PG>2122-5</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:50:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:50:34 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18997140"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schooler-2007" MODIFIED="2009-06-06 22:25:40 +0100" MODIFIED_BY="[Empty name]" NAME="Schooler 2007" TYPE="CONFERENCE_PROC">
<AU>Schooler N, Bossie C, Canuso C, Turkoz I, Lindenmayer JP</AU>
<TI>A "virtual" comparison of paliperidone er and risperidone ir in patients with schizophrenia</TI>
<SO>Proceedings of the International Congress on Schizophrenia Research; 2007 Mar 28-1; Colorado Springs, Colorado</SO>
<YR>2007</YR>
<CY>Colorado Springs, Colorado</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwartzer-2009" MODIFIED="2009-07-03 09:50:47 +0100" MODIFIED_BY="[Empty name]" NAME="Schwartzer 2009" TYPE="JOURNAL_ARTICLE">
<AU>Schwartzer JJ, Morrison RL, Ricci LA, Melloni RH</AU>
<TI>Paliperidone suppresses the development of the aggressive phenotype in a developmentally sensitive animal model of escalated aggression</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>2009</YR>
<VL>203</VL>
<NO>4</NO>
<PG>653-63</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:50:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:50:47 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19066856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Simpson-2006" MODIFIED="2009-06-06 22:25:59 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Simpson G</AU>
<TI>Paliperidone: long-acting antipsychotic can be taken once daily</TI>
<SO>Current Psychiatry</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>11</NO>
<PG>118-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-2007" NAME="Simpson 2007" TYPE="JOURNAL_ARTICLE">
<AU>Simpson G</AU>
<TI>Paliperidone Extended Release</TI>
<SO>CNS Drugs</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>5</NO>
<PG>426-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spina-2007" MODIFIED="2009-07-03 09:51:03 +0100" MODIFIED_BY="[Empty name]" NAME="Spina 2007" TYPE="JOURNAL_ARTICLE">
<AU>Spina E, Cavallaro R</AU>
<TI>The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia</TI>
<SO>Expert Opinion Drug Safety</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>6</NO>
<PG>651-62</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:51:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:51:03 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17967154"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Turkoz-2008" MODIFIED="2009-07-03 09:51:17 +0100" MODIFIED_BY="[Empty name]" NAME="Turkoz 2008" TYPE="JOURNAL_ARTICLE">
<AU>Turkoz I, Bossie CA, Dirks B, Canuso CM</AU>
<TI>Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia</TI>
<SO>Neuropsychiatric disease and treatment</SO>
<YR>2008</YR>
<VL>4</VL>
<NO>5</NO>
<PG>949-58</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:51:17 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:51:17 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19183785"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2009-06-05 12:47:29 +0100" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Urichuk-2008" MODIFIED="2009-07-03 09:51:31 +0100" MODIFIED_BY="[Empty name]" NAME="Urichuk 2008" TYPE="JOURNAL_ARTICLE">
<AU>Urichuk L, Prior TI, Dursun S, Baker G</AU>
<TI>Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions</TI>
<SO>Current drug metabolism</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>5</NO>
<PG>410-8</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:51:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:51:31 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18537577"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vermeir-2005" NAME="Vermeir 2005" TYPE="JOURNAL_ARTICLE">
<AU>Vermeir M, Boom S, Naessens I, Talluri K, Eerdekens M</AU>
<TI>Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>S648-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vermeir-2008" MODIFIED="2009-07-03 09:51:43 +0100" MODIFIED_BY="[Empty name]" NAME="Vermeir 2008" TYPE="JOURNAL_ARTICLE">
<AU>Vermeir M, Naessens I, Remmerie B, Mannens G, Hendrickx J, Sterkens P, Talluri K, Boom S, Eerdekens M, van Osselaer N, Cleton A</AU>
<TI>Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans</TI>
<SO>Drug metabolism and Disposition</SO>
<YR>2008</YR>
<VL>36</VL>
<NO>4</NO>
<PG>769-79</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:51:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:51:43 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18227146"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vermeulen-2007" MODIFIED="2009-07-03 09:51:54 +0100" MODIFIED_BY="[Empty name]" NAME="Vermeulen 2007" TYPE="JOURNAL_ARTICLE">
<AU>Vermeulen A, Piotrovsky V, Ludwing EA</AU>
<TI>Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar disorder</TI>
<SO>Journal of Pharmacokinetics and Pharmacodynamics</SO>
<YR>2007</YR>
<VL>34</VL>
<NO>2</NO>
<PG>183-206</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:51:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:51:54 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17136449"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-2007" MODIFIED="2009-07-03 09:52:11 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wang L, Yu L, Zhang AP, Fang C, Du J, Gu NF, Qin SY, Feng GY, Li XW, Xing QH</AU>
<TI>Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>9</NO>
<PG>837-42</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:52:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:52:11 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17715206"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wilkinson-2000" MODIFIED="2009-07-03 09:52:22 +0100" MODIFIED_BY="[Empty name]" NAME="Wilkinson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Wilkinson G, Hesdon B, Wild D, Cookson R, Farina C, Sharma V, Fitzpatrick R, Jenkinson C</AU>
<TI>Self-report quality of life measure for people with schizophrenia: the SQLS</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>177</VL>
<PG>42-6</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:52:22 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:52:22 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10945087"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Xia-2007" MODIFIED="2009-07-03 09:52:29 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2007" TYPE="CONFERENCE_PROC">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, Pinfold V, Takriti Y</AU>
<TI>The Leeds Outcomes Stakeholders Survey (LOSS) Study</TI>
<SO>Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yang-2007" MODIFIED="2009-07-03 09:52:49 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 2007" TYPE="JOURNAL_ARTICLE">
<AU>Yang LP, Plosker GL</AU>
<TI>Paliperidone extended release</TI>
<SO>CNS Drugs</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>5</NO>
<PG>417-25</PG>
<IDENTIFIERS MODIFIED="2009-07-03 09:52:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-03 09:52:49 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17447829"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-12-01 13:14:20 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-08-12 09:35:55 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-08-12 09:35:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Canuso-2009">
<CHAR_METHODS MODIFIED="2009-08-05 15:27:02 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, 2:2:1 ratio paliperidone, quetiapine, placebo, stratified by site in blocks of five by an interactive voice response system.<BR/>Blindness: double, all medication, including placebo, identically overencapsulated.<BR/>Duration: six weeks, two weeks of monotherapy, four weeks of additive-therapy.<BR/>Design: international (India, Russia, Ukraine, USA), multicentre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 09:22:48 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DMS-IV).<BR/>N=399.<BR/>Age: &gt;18 years, mean unclear.<BR/>Sex: 262 M, 132 F.<BR/>Setting: hospital &#8805;10 days followed by outpatient.<BR/>History: acute exacerbation indicated by initial PANSS score of &#8805; 4 on two of five PANSS items (hostility, excitement, tension, uncooperativeness and poor impulse control) and total score of &#8805;17 on these five PANSS items and a score of &#8805; 5 on the CGI-S scale.<BR/>Consent: written consent required.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-05 15:31:52 +0100" MODIFIED_BY="[Empty name]">
<P>1. Paliperidone: Mean dose during monotherapy=10.4 mg SD=1.7. Mean dose during additive phase=9.8 mg SD=1.5. N=157, male=105, mean age=35.7 SD=11.6.<BR/>2. Quetiapine: Mean dose during monotherapy=690.9 mg SD=134.3. Mean dose during additive phase=599.1 mg SD=142.0. N=157, male=107, mean age=36.9 SD=10.2.<BR/>3. Placebo: N=80, male=50, age=36.1 SD=10.4.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-12 09:31:14 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change in total PANSS score at conclusion of 14-day monotherapy phase.<BR/>Global state: composite treatment response defined by PANSS total score reduction <U>&gt;</U>30% and CGI-C score <U>&lt;</U>2.<BR/>Mental state: change in PANSS.<BR/>Adverse events: various events, medication satisfaction questionnaire, AIMS, BARS and SAS scores.<BR/>Laboratory results: various mean change in serum levels.</P>
<P>Unable to use -<BR/>vital signs (no mean, SD), hematology and biochemistry studies (no mean, SD), AIMS (no mean, SD), BARS (no mean, SD), SAS (no mean, SD) and medication satisfaction questionnaire (not peer reviewed).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 09:35:55 +0100" MODIFIED_BY="[Empty name]">
<P>During monotherapy phase of the trial, subjects randomised to paliperidone 6 mg/day for three days, increased to 9 mg on day four, and, if deemed clinically necessary, to 12 mg/day on day eight. Subjects randomised to quetiapine received 50 mg/day on day one, 100 mg/day on day two, 200 mg/day on day three, 400 mg/day on day four, 600 mg/day on day five, and, if deemed clinically necessary, 800 mg/day on day eight. During monotherapy participants could receive injectable lorazepam, amobarbital sodium or midazolam for severe agitation, zaleplon, zopiclone or zolpidem for insomnia and benztropine or other unspecific treatments for movement disorders.</P>
<P>When the two week monotherapy ended, the patient was continued on last dose and additional psychotropics were provided as deemed appropriate. Study clinicians were allowed to select any psychotropic with the exception of risperidone, additional paliperidone, additional quetiapine, drugs known to interact with the cytochrome P450 isoenzymes CYP3A4, lithium, herbal or over-the-counter preparations known to have psychotropic effects and drugs known to prolong QTc. The most commonly used additional antipsychotics were haloperidol and olanzapine.</P>
<P>Patients were assessed at baseline and on days 3, 5, 7, 9, 14, 21, 28, 42 and at endpoint.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 09:07:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cleton-2007">
<CHAR_METHODS MODIFIED="2009-06-08 10:21:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised (not described).<BR/>Blindness: double (not described).<BR/>Duration: six days.<BR/>Design: parallel group, dosing on a fixed titration schedule, location and centre sites not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 09:04:14 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (not described).<BR/>N=113.<BR/>Age: 18-65 years, mean 36.9 years SD=9.5.<BR/>Sex: 73 M, 27 F.<BR/>Setting: not described.<BR/>History: oral risperidone for &#8805;1 month prior to study entry and had not experienced an acute exacerbation of psychosis for &#8805;6 months.<BR/>Consent: not described.<BR/>Exclusions: not described.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-06 09:05:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. Placebo day 1, then paliperidone: dose 12 mg/day for days 2-6. N=37.<BR/>2. Paliperidone: dose 12 mg/day. N=38.<BR/>3. Risperidone: dose 2 mg/day for day 1, 4 mg/day for days 2-6. N=38.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-06 09:05:53 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: orthostatic tolerability.<BR/>Laboratory analyses: plasma concentrations of paliperidone, risperidone active moiety (sum of risperidone and paliperidone) and prolactin. <BR/>Adverse events: various events.</P>
<P>Unable to use - <BR/>serum prolactin data (no mean, no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-06 09:07:23 +0100" MODIFIED_BY="[Empty name]">
<P>113 patients were enrolled in the study. 105 patients completed the study; five subjects discontinued due to adverse events and three subjects withdrew consent.</P>
<P>Venous blood samples taken on days one to seven at standardized intervals designed to measure peak prolactin levels. Plasma concentrations of paliperidone and risperidone determined using a validated liquid chromatography coupled to mass spectrometry/mass spectrometry technique, with limits of detection at 0.1 ng/mL. Serum prolactin levels measured with a two-site sandwich immunoassay using direct chemiluminometric technology (ADVIA Centaur Prolactin assay, Bayer Healthcare, LLC).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 09:19:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davidson-2007">
<CHAR_METHODS MODIFIED="2009-08-06 09:13:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, computer-generated, stratified by site.<BR/>Blindness: double (not described).<BR/>Duration: six weeks.<BR/>Design: international, multicentre, parallel group, fixed dosing.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 09:19:15 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N=618*.<BR/>Age: &gt;18 years, mean ~ 37 years.<BR/>Sex: 411 M, 194 F.<BR/>Setting: hospital followed by outpatient setting.<BR/>History: ill &#8805;one year, initial PANSS score 70-120.<BR/>Consent: informed consent obtained.<BR/>Exclusions: substance dependence during the six months preceding screening, risk of suicide or violence, medical conditions that could alter absorption, excretion or metabolism of medication, history of tardive dyskinesia or neuroleptic malignant syndrome, pregnancy or nursing, depot antipsychotic within 120 days of screening or paliperidone palmitate within ten months and use of antidepressant, benzodiazepine or mood stabilizer within two weeks of screening unless the dose had been stable for the preceding three months, history of allergic reaction or sensitivity to risperidone, paliperidone or olanzapine or history of non-response to anti-psychotic agents.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-06 09:16:56 +0100" MODIFIED_BY="[Empty name]">
<P>1. Paliperidone: dose 3 mg/day. N=127.<BR/>2. Paliperidone: dose 9 mg/day. N=125.<BR/>3. Paliperidone: dose 15 mg/day. N=115.<BR/>4. Olanzapine: dose 10 mg/day. N=128.<BR/>5. Placebo: N=123.</P>
<P>Discontinued use of antiparkinsonian medications, beta-blockers, antipsychotics and psychotropics for three days before receiving study medication. Antidepressant use, if stable for three months, was permitted.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-06-08 10:25:55 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: death, 30% improvement in PANSS score, relapse.<BR/>Mental state: change in PANSS.<BR/>Social functioning: change in PSP, QLS.<BR/>Adverse events: various events, BARS score, weight change.<BR/>Laboratory results: various mean change in serum levels.</P>
<P>Unable to use -<BR/>Global state: CGI-S (no mean, SD).<BR/>Adverse Events: AIMS, SAS (no mean, SD), mean duration of use of benzodiazepine (no SD), visual analogue scales for daytime drowsiness and quality of sleep (not peer reviewed).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-16 18:56:29 +0000" MODIFIED_BY="[Empty name]">
<P>*Note that 618 participants were randomised, but only 605 were included in analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 09:22:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kane-2007">
<CHAR_METHODS MODIFIED="2009-08-06 09:17:43 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, computer-generated.<BR/>Blindness: double (not described).<BR/>Duration: six weeks.<BR/>Design: international, multicentre, parallel group, fixed dosing.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 09:22:33 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N=630.<BR/>Age: &gt;18 years, mean ~ 37 years.<BR/>Sex: 328 M, 302 F.<BR/>Setting: hospital followed by outpatient.<BR/>History: ill &#8805;one year, initial PANSS score 70-120.<BR/>Consent: informed consent obtained.<BR/>Exclusions: substance dependence within six months preceding screening, history of TD or EPS, pregnancy or breast feeding, depot antipsychotic within 120 days of screening or paliperidone palmitate within 10 months and starting a mood stabilizer or antidepressant in the two weeks preceding screening.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Paliperidone: dose 6 mg/day. N=123.<BR/>2. Paliperidone: dose 9 mg/day. N=122.<BR/>3. Paliperidone: dose 12 mg/day. N=130.<BR/>4. Olanzapine: dose 10 mg/day. N=128.<BR/>5. Placebo: N=127.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-06-08 10:32:57 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: death, 30% improvement in PANSS score, relapse.<BR/>Mental state: change in PANSS score.<BR/>Social functioning: change in PSP, QLS scores.<BR/>Adverse events: various events, weight change.<BR/>Laboratory results: various mean change in serum levels.</P>
<P>Unable to use -<BR/>Global state: CGI-S (no mean, SD).<BR/>Adverse events: AIMS, SAS (no mean, SD), visual analogue scales for daytime drowsiness and quality of sleep (not peer reviewed).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-06-08 10:33:09 +0100" MODIFIED_BY="[Empty name]">
<P>After a one-week, open-label washout period, patients were randomly assigned to one of the three intervention groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 09:25:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kramer-2007">
<CHAR_METHODS MODIFIED="2009-08-06 09:22:02 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, computer-generated, voice -response system.<BR/>Blindness: double.<BR/>Duration: variable* placebo group median 29 days, paliperidone group median 45 days.<BR/>Design: international, multicentre, parallel group, flexible dosing.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 09:24:33 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N=207**.<BR/>Age: 18-65 years, mean ~ 38.5 years.<BR/>Sex: 121 M, 84 F.<BR/>Setting: hospital followed by outpatient.<BR/>History: ill &#8805;one year, initial PANSS score 70-120, physically healthy, capacity to self-administer medications or to have consistent assistance with administration and capacity to complete questionnaires.<BR/>Consent: informed consent obtained.<BR/>Exclusions: additional DSM-IV diagnosis, substance dependence during the six months preceding screening, significant risk of suicide or aggression, medical conditions that could alter response to study medication, history of allergic reaction to related medications (barbiturates, carbamazepine, lamotrigine, phenytoin, paliperidone or risperidone), history of non-response to risperidone, depot antipsychotic within 120 days of screening, electroconvulsive treatment within three months of screening, pregnancy, nursing or intention of becoming pregnant.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 14:12:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. Paliperidone: flexible dose: beginning at last dose after stabilisation phase: mean dose 10.8 mg. N=105.<BR/>2. Placebo: N=102.</P>
<P>Discontinued use of antiparkinsonian medications, antiepileptics, lithium, monoamine oxidase inhibitors and beta-blockers prescribed for psychiatric illness.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-06-08 10:35:48 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: death, relapse.<BR/>Mental state: change in PANSS score.<BR/>Social function: PSP, QLS scores.<BR/>Adverse events: various events.<BR/>Laboratory results: various mean change in serum levels.</P>
<P>Unable to use -<BR/>Global state: CGI-S (no mean, SD).<BR/>Adverse events: AIMS, SAS (no mean SD), weight change (no SD), visual analogue scales for daytime drowsiness and quality of sleep (not peer reviewed).<BR/>Behaviour: dangerous behaviour suicidal or homicidal ideation (data unusable).<BR/>Laboratory results: C-peptide serum levels (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-06 09:25:52 +0100" MODIFIED_BY="[Empty name]">
<P>*Study designed to have planned interim analysis after 43 recurrence events, and study termination if efficacy (P = 0.01) for intervention was established.<BR/>Note: the study consisted of five phases.<BR/>1. Screening.<BR/>2. Eight-week run-in phase, participants hospitalised and administered open-label paliperidone beginning at 9 mg daily, remained hospitalised until they had been clinically stable for at least two weeks.<BR/>3. Participants received open-label paliperidone, at the dose upon which they were discharged, for six weeks.<BR/>4. Remaining participants underwent randomisation to paliperidone, beginning at their most recent dose or placebo.<BR/>5. Participants could enrol in an optional fifty-two week open label extension trial.<BR/>Only data from Phase four, the randomised phase, is included in this review.<BR/>** N=530 for those entering study but only 207 were eventually randomised. 205 patients were included in the intention-to-treat population.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 09:31:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luthringer-2007">
<CHAR_METHODS MODIFIED="2009-08-06 09:27:10 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, computer-generated, permuted blocks, stratified by sex, assigned by call centre.<BR/>Blindness: double.<BR/>Duration: 14 days.<BR/>Design: multicentre (n=8), international (Poland, France and Romania).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 09:28:31 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV) and schizophrenia-related insomnia.<BR/>N=42.<BR/>Age: 18-45 years, mean ~32.6 years.<BR/>Sex: 28 M, 14 F.<BR/>Setting: hospital.<BR/>History: initial PANSS score <U>&lt;</U>90, no history of relapse or acute psychotic symptoms for <U>&gt;</U>3 months, regular sleep/wake schedule, <U>&gt;</U>1.5 hours of wakefulness per 8 hours in bed, willing to provide a sleep history. Female patients were postmenopausal for <U>&gt;</U>2 years, surgically sterile or using birth control methods.<BR/>Consent: informed consent obtained.<BR/>Exclusions: other Axis I DSM-IV diagnosis, substance dependence within three months preceding the study, suicidal or violent behavior within sixth months, medical condition altering drug metabolism, the use of other psychotropic agents (SSRI's, SNRI's, TCA's, lithium, mood stabilizers, anticonvulsants or benzodiazepines) within two weeks of screening, MAOI's or first generation depot antipsychotics within four weeks of screening and the use of Risperdal Consta within one hundred days of screening.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-06 09:29:42 +0100" MODIFIED_BY="[Empty name]">
<P>1. Paliperidone: dose 9 mg/day. N=21.<BR/>2. Placebo: N=21.</P>
<P>Prescription and over-the-counter sleep aids permitted. Benztropine and other antiparkinsonian medications permitted for movement disorders but not within five days of any PSG examination. Not allowed to smoke or use caffeine for six hours before and after PSG examinations.</P>
<P>Trial preceded by fourteen day screening period. Patients entered the hospital on the seventh day of the screening period and discontinued oral antipsychotics. On the thirteenth and fourteenth days of the screening period they received single-blind placebo treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-06 09:31:07 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: pharmacodynamic evaluations of sleep.<BR/>Global state: change in CGI-S score.<BR/>Mental state: change in PANSS score.<BR/>Adverse events: various events, weight change.<BR/>Laboratory results: various mean change in serum levels.</P>
<P>Unable to use - <BR/>Pharmacodynamic evaluations of sleep (does not directly address the use of paliperidone for schizophrenia), CGI-S (not reported), weight change (not reported) and various mean change in serum levels (not reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-01-21 02:37:03 +0000" MODIFIED_BY="[Empty name]">
<P>The study reports demographic and baseline characteristics only for patients who completed the study. The data does not constitute a last observation carried forward analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 09:34:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marder-2007">
<CHAR_METHODS MODIFIED="2009-08-06 09:32:09 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, computer-generated, stratified by site, voice -response system.<BR/>Blindness: double (not described).<BR/>Duration: six weeks.<BR/>Design: USA multicentre, parallel group, fixed dosing.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 09:33:26 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N=444*.<BR/>Age: over 18 years, mean ~ 41.5 years.<BR/>Sex: 300 M, 111 F<BR/>History: ill &#8805;one year, initial PANSS score 70-120.<BR/>Setting: hospital followed by outpatient.<BR/>Consent: informed consent obtained.<BR/>Exclusions: substance dependence during the six months preceding screening, risk of suicide or violence, medical conditions that could alter absorption, excretion or metabolism of medication, history of tardive dyskinesia or neuroleptic malignant syndrome, history of allergic reaction or sensitivity to risperidone, paliperidone or olanzapine, history of non-response to antipsychotic agents, depot antipsychotic within 120 days of screening or paliperidone palmitate within ten months, pregnancy or nursing, use of antidepressant or mood stabilizer within two weeks of screening.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-06 09:34:03 +0100" MODIFIED_BY="[Empty name]">
<P>1. Paliperidone: dose 6 mg/day. N=112.<BR/>2. Paliperidone: dose 12 mg/day. N=112.<BR/>3. Olanzapine: dose 10 mg/day. N=110.<BR/>4. Placebo: N=110.</P>
<P>Participants discontinued use of antiparkinsonian medications, beta-blockers, antipsychotics and psychotropics for three days before receiving study medication.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-06-08 10:38:57 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: death, 30% improvement in PANSS score, relapse.<BR/>Mental state: change in PANSS score.<BR/>Social function: PSP, QLS scores.<BR/>Adverse events: various events, weight change.<BR/>Laboratory results: various mean change in serum levels.</P>
<P>Unable to use -<BR/>Global state: CGI-S (no mean, SD).<BR/>Adverse events: AIMS, SAS (no mean SD), visual analogue scales for daytime drowsiness and quality of sleep (not peer reviewed).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-06-08 10:39:06 +0100" MODIFIED_BY="[Empty name]">
<P>Gender reported as percentages not as numbers.</P>
<P>*444 participants were randomised, but only 432 were included in the analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-06 09:39:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tzimos-2008">
<CHAR_METHODS MODIFIED="2009-08-06 09:35:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: screening phase &#8804;5 days, 6 weeks randomised treatment; optional 24 week open-label extension study.<BR/>Design: multicentre (N=21), international (South Africa, Czech Republic, Greece, Russia, Slovakia and Ukraine).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 09:37:07 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV), 85% with paranoid schizophrenia.<BR/>N=114.<BR/>Age: over 65 years, mean= 70 years (SD= 4.5 years).<BR/>Sex: 31 M, 83 F.<BR/>Setting: inpatient for initial 14 days of treatment, followed by outpatient.<BR/>History: ill &#8805;one year, initial PANSS score 70-120.<BR/>Exclusions: inability to self-administer medications or lack of consistent help to administer medications, diagnosis of substance dependence (excluding caffeine or nicotine) within six months of screening, subjective risk of suicidal or aggressive behavior, history of medical conditions that could affect metabolism of paliperidone, history of non-response to risperidone, depot antipsychotic within 120 days of screening, exposure to experimental treatment within 90 days of screening, electroconvulsive therapy within three months of screening, involuntary admission to a psychiatric hospital or allergic reactions to barbiturates, carbamazepine, lamotrigine, phenytoin, paliperidone or risperidone.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-06 09:39:42 +0100" MODIFIED_BY="[Empty name]">
<P>1. Paliperidone: flexible dose, one week 6 mg daily; increased to 9 mg if tolerated. Subsequent decreases by 3 mg could occur at any time at the discretion of the study clinician. Subsequent increases by 3 mg could occur on a weekly basis at the discretion of the study clinician. Modal dose 9 mg/day, mean dose 8.4 mg/day. N=76.<BR/>2. Placebo: N=38.</P>
<P>Discontinued use of antipsychotics and benzodiazepines three days before baseline assessments. Oral benzodiazepines and antidepressants (though not monoamine oxidase inhibitors) permitted if using a stable dose for at least three months before entry. Oral benztropine or biperiden for the treatment of extrapyramidal symptoms and beta-blockers for akathisia permitted. Beta-blockers permitted for hypertension.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-06 09:39:59 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: death, 30% improvement in PANSS, CGI-S, lack of efficacy (defined by at least a 20% increase in the PANSS score), PSP.<BR/>Mental state: change in PANSS score.<BR/>Adverse events: various events, weight change, AIMS, SAS.<BR/>Laboratory results: various mean changes in serum levels.</P>
<P>Unable to use - <BR/>prolactin (no SD), insulin (not reported), C-peptide (not reported), SAS (not reported), BARS (not reported), AIMS (not reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-06 09:35:58 +0100" MODIFIED_BY="[Empty name]">
<P>The researchers reported that 77% of patients were using typical antipsychotics before entering the trial. At the conclusion of the trial, the researchers found age-related increases in the incidence of somnolence and tachycardia.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-12-01 13:14:20 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-07-03 13:57:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arakawa-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-03 13:57:22 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: controlled study, unclear if randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: paliperidone ER 3 mg daily vs 9 mg vs 15 mg.<BR/>Outcomes: D(2) receptor occupancy, no clinical outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-06 09:57:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Borison-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-06 09:57:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, cross-over study.<BR/>Participants: people with schizophrenia or schizoaffective disorder.<BR/>Interventions: risperidone versus second oral dose of risperidone not sustained-release paliperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-03 13:53:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cleton-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-03 13:53:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, open-label, cross-over study.<BR/>Participants: healthy volunteers, not people with schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-03 13:56:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cleton-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-03 13:56:26 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, open-label.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-08-06 10:24:35 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-07-03 14:01:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Armenteros-2001">
<CHAR_STUDY_NAME>
<P>Risperidone treatment of adolescents with schizophrenia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-03 14:00:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: unclear.<BR/>Duration: unknown.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-03 14:01:14 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N=unknown.<BR/>Age: 12-18 years old.<BR/>Sex: unknown.<BR/>History: unknown.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-03 14:01:18 +0100" MODIFIED_BY="[Empty name]">
<P>1. Risperidone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: PANSS, negative and positive symptoms.<BR/>Adverse effects.<BR/>Cognitive function.<BR/>Serum risperidone and 9-OH-risperidone (paliperidone) levels.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Unclear.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2009-07-03 14:01:45 +0100" MODIFIED_BY="[Empty name]">
<P>This NIH grant is designed to assess the efficacy and safety of risperidone in adolescents with schizophrenia; as part of the protocol, they propose to assess the plasma levels of both risperidone and 9-OH-risperidone (paliperidone). No information beyond the summary in the CRISP database is available.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-08-06 10:24:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rossenu-2008">
<CHAR_STUDY_NAME MODIFIED="2009-03-05 01:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>Pharmacodynamics of paliperidone extended-release tablets and immediate-release risperidone in schizophrenia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-07-03 13:58:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.<BR/>Blindness: double.<BR/>Duration: six days.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-08 10:52:58 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (criteria unclear)<BR/>N=113.<BR/>Age: unclear.<BR/>Sex: unclear.<BR/>Setting: unclear.<BR/>History: unclear.<BR/>Exclusion: unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-06 10:23:44 +0100" MODIFIED_BY="[Empty name]">
<P>1. Paliperidone: dose 12 mg/day. N=unclear.<BR/>2. Risperidone: dose 2 mg/day on day one and 4 mg/day on days two to six of the trial. N=unclear.<BR/>3. Placebo: N=unclear.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-06 10:24:05 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2009-08-06 10:24:35 +0100" MODIFIED_BY="[Empty name]">
<P>The only available results are for the changes in orthostatic supine blood pressure after the first dose and the changes in serum prolactin after the first and last doses. </P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-08-06 09:40:22 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-08-06 09:26:16 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-16 18:39:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Canuso-2009">
<DESCRIPTION>
<P>Stratified by site in blocks of five by an interactive voice response system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-16 18:44:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cleton-2007">
<DESCRIPTION>
<P>Randomised - undescribed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-16 18:48:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-2007">
<DESCRIPTION>
<P>Computer-generated, stratified by site.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-16 18:53:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kane-2007">
<DESCRIPTION>
<P>Randomised - computer-generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 09:26:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kramer-2007">
<DESCRIPTION>
<P>Computer-generated, voice-response system.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-08 10:38:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luthringer-2007">
<DESCRIPTION>
<P>Computer-generated, permuted blocks, stratified by sex, assigned by call centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-08 10:39:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marder-2007">
<DESCRIPTION>
<P>Computer-generated, stratified by site, assigned by voice-response system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-16 20:02:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tzimos-2008">
<DESCRIPTION>
<P>Permuted blocks of treatment stratified by study site.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-03-16 18:45:34 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-26 20:32:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Canuso-2009">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-16 18:45:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cleton-2007">
<DESCRIPTION>
<P>Undescribed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Davidson-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kane-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kramer-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-25 18:04:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luthringer-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Marder-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-09 15:14:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tzimos-2008">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-05-13 16:06:13 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-13 16:06:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Canuso-2009">
<DESCRIPTION>
<P>Double.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-16 18:44:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cleton-2007">
<DESCRIPTION>
<P>Double - undescribed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-16 18:47:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Davidson-2007">
<DESCRIPTION>
<P>Double - not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-16 18:53:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2007">
<DESCRIPTION>
<P>Double - not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-16 19:51:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kramer-2007">
<DESCRIPTION>
<P>Double - not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-16 19:54:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Luthringer-2007">
<DESCRIPTION>
<P>Double - not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-16 20:00:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marder-2007">
<DESCRIPTION>
<P>Double - not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-16 20:02:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tzimos-2008">
<DESCRIPTION>
<P>Double - not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-08-06 09:34:26 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-05-13 15:57:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Canuso-2009">
<DESCRIPTION>
<P>All participants reported in outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-16 18:52:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cleton-2007">
<DESCRIPTION>
<P>Preliminary data only.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-16 18:48:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-2007">
<DESCRIPTION>
<P>All participants reported in outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-16 19:00:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kane-2007">
<DESCRIPTION>
<P>All participants are reported in outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-06 09:26:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kramer-2007">
<DESCRIPTION>
<P>207 patients were randomised but only 205 patients were included in the intention-to-treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-16 19:59:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Luthringer-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-06 09:34:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marder-2007">
<DESCRIPTION>
<P>444 participants were randomised but only 432 were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-03-16 20:04:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tzimos-2008">
<DESCRIPTION>
<P>All participants reported in outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-08-06 09:34:30 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-08 10:20:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Canuso-2009">
<DESCRIPTION>
<P>399 participants were randomised, but only 394 were included in analysis. Reported adverse events only when they occurred in at least five per cent of the study population.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-16 18:46:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cleton-2007">
<DESCRIPTION>
<P>Preliminary data only.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-08 10:26:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Davidson-2007">
<DESCRIPTION>
<P>618 participants were randomised, but only 605 were included in analysis. Reported adverse events only when they occurred in at least five per cent of the study population.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-08 10:33:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kane-2007">
<DESCRIPTION>
<P>Reported adverse events only when they occurred in at least five per cent of the study population.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-08 10:36:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kramer-2007">
<DESCRIPTION>
<P>Reported adverse events only when they occurred in at least five per cent of the study population.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 09:31:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Luthringer-2007">
<DESCRIPTION>
<P>Reported demographics for patients completing the study, but adverse events were reported for safety analysis set. Did not report change in CGI-S score, change in PANSS score and various mean change in serum levels.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 09:34:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marder-2007">
<DESCRIPTION>
<P>Reported adverse events only when they occurred in at least five per cent of the study population.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 14:06:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tzimos-2008">
<DESCRIPTION>
<P>Reported adverse events only when they occurred in at least five per cent of the study population.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-08-06 09:40:22 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-16 18:42:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Canuso-2009">
<DESCRIPTION>
<P>Funded by Ortho-McNeil Janssen Scientific Affairs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 09:07:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cleton-2007">
<DESCRIPTION>
<P>Funding from Johnson &amp; Johnson Pharmaceutical Services, LLC and Johnson &amp; Johnson Pharmaceutical Research &amp; Development.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-08 10:26:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Davidson-2007">
<DESCRIPTION>
<P>Sponsored by Johnson &amp; Johnson Pharmaceutical Services, LLC., and Johnson &amp; Johnson Pharmaceutical Research and Development (J &amp; J PRD).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 21:57:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kane-2007">
<DESCRIPTION>
<P>Sponsored by Johnson &amp; Johnson Pharmaceutical Research and Development.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 09:26:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kramer-2007">
<DESCRIPTION>
<P>Study was funded by Johnson &amp; Johnson Pharmaceutical Research and Development.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 09:31:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Luthringer-2007">
<DESCRIPTION>
<P>Study supported by Johnson &amp; Johnson Pharmaceutical Research and Development.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 09:34:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marder-2007">
<DESCRIPTION>
<P>Study sponsored by Johnson &amp; Johnson Pharmaceutical Research and Development.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 09:40:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tzimos-2008">
<DESCRIPTION>
<P>Study supported by Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LLC.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-08-06 10:29:54 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-08-06 10:29:54 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Suggested design for trial</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TH>
<P>Methods</P>
</TH>
<TH>
<P>Participants</P>
</TH>
<TH>
<P>Interventions</P>
</TH>
<TH>
<P>Outcomes</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<TR>
<TD>
<P>Allocation: centralised sequence generation with table of random numbers or computer generated code, stratified by severity of substance use. Sequence concealed until interventions assigned.<BR/>
<BR/>Blindness: participants, those recruiting and assigning participants and those assessing outcomes will be blind to treatment allocation.<BR/>
<BR/>Duration: minimum of one year.</P>
</TD>
<TD>
<P>Diagnosis: severe mental illness - schizophrenia, schizoaffective disorder, other psychotic disorders for which longer term antipsychotic treatment is indicated.<BR/>N&gt;1000.<BR/>Age: adults 18-55 years.<BR/>Sex: men and women.<BR/>Setting: hospital and community.</P>
</TD>
<TD>
<P>1. Paliperidone: flexible dose.<BR/>
<BR/>2. Risperidone: flexible dose.<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Discontinuation of treatment.<BR/>Death.<BR/>Efficacy: days well, CGI, PANSS.<BR/>Adverse effects: checklist.<BR/>Behavior, social functioning.<BR/>Satisfaction with treatment<BR/>Cost.<BR/>
</P>
</TD>
<TD>
<P>Size of study to detect a 10% difference in improvement with 80% certainty.<BR/>
<BR/>If scales are used to measure outcome then there should be binary cut-off points, defined before study start, of clinically important improvement.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-11-25 23:23:04 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-11-25 23:13:02 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>PALIPERIDONE - ANY DOSE OR FLEXIBLE DOSES versus PLACEBO (all short term)</NAME>
<DICH_OUTCOME CHI2="97.76445803550925" CI_END="0.748743646155047" CI_START="0.629271804158078" CI_STUDY="95" CI_TOTAL="95" DF="40" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6864133339817081" ESTIMABLE="YES" EVENTS_1="908" EVENTS_2="549" I2="59.08533550559702" I2_Q="87.99784859624872" ID="CMP-001.01" LOG_CI_END="-0.12566685001366426" LOG_CI_START="-0.20116172729095927" LOG_EFFECT_SIZE="-0.16341428865231178" METHOD="MH" MODIFIED="2009-03-20 11:26:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="9.65870513347511E-7" P_Q="3.260682834849149E-10" P_Z="2.1576279714382656E-17" Q="58.32287699530391" RANDOM="NO" SCALE="73.95769399957513" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="8989" TOTAL_2="3962" WEIGHT="800.0" Z="8.484976249218674">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="22.491861916616916" CI_END="0.7539235653457401" CI_START="0.6061617724943181" DF="6" EFFECT_SIZE="0.6760174884536714" ESTIMABLE="YES" EVENTS_1="434" EVENTS_2="269" I2="73.32368470763544" ID="CMP-001.01.01" LOG_CI_END="-0.12267268175783592" LOG_CI_START="-0.21741145582432655" LOG_EFFECT_SIZE="-0.17004206879108125" MODIFIED="2009-03-10 10:49:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="9.85815801415768E-4" P_Z="1.9827708508075065E-12" STUDIES="7" TAU2="0.0" TOTAL_1="1325" TOTAL_2="601" WEIGHT="100.0" Z="7.035690169545529">
<NAME>any reason</NAME>
<DICH_DATA CI_END="0.9055005386725347" CI_START="0.3941429787359198" EFFECT_SIZE="0.5974083022183176" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="29" LOG_CI_END="-0.04311128699272812" LOG_CI_START="-0.404346205555254" LOG_EFFECT_SIZE="-0.22372874627399109" MODIFIED="2009-01-21 03:35:06 +0000" MODIFIED_BY="[Empty name]" ORDER="411" O_E="0.0" SE="0.21219117930531337" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="80" VAR="0.04502509657497965" WEIGHT="10.127384871392064"/>
<DICH_DATA CI_END="0.7320762832085403" CI_START="0.49858097978443244" EFFECT_SIZE="0.6041517280940771" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="76" LOG_CI_END="-0.13544366258858762" LOG_CI_START="-0.3022642932855644" LOG_EFFECT_SIZE="-0.218853977937076" ORDER="1" O_E="0.0" SE="0.09799126424684407" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="123" VAR="0.00960228786869482" WEIGHT="30.007622452740105"/>
<DICH_DATA CI_END="0.6640254015267363" CI_START="0.42316480789502786" EFFECT_SIZE="0.5300869565217391" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="69" LOG_CI_END="-0.1778153068791399" LOG_CI_START="-0.37349045716499535" LOG_EFFECT_SIZE="-0.2756528820220676" ORDER="2" O_E="0.0" SE="0.1149405518855269" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="127" VAR="0.013211330467749503" WEIGHT="27.172190570335793"/>
<DICH_DATA CI_END="5.262537682271807" CI_START="1.1207443138207334" EFFECT_SIZE="2.4285714285714284" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.7211952186098283" LOG_CI_START="0.04950654411820589" LOG_EFFECT_SIZE="0.3853508813640171" MODIFIED="2009-03-10 10:49:07 +0000" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.3945532523089412" STUDY_ID="STD-Kramer-2007" TOTAL_1="105" TOTAL_2="102" VAR="0.15567226890756303" WEIGHT="2.139227392881831"/>
<DICH_DATA CI_END="9.767868569213505" CI_START="0.4095059195009289" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9897998073609312" LOG_CI_START="-0.3877398160329689" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-11-25 17:59:33 +0000" MODIFIED_BY="[Empty name]" ORDER="433" O_E="0.0" SE="0.809173593712687" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="0.6547619047619047" WEIGHT="0.527166750388737"/>
<DICH_DATA CI_END="0.9595362870906182" CI_START="0.667845698298206" EFFECT_SIZE="0.800513698630137" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="73" LOG_CI_END="-0.017938596764643964" LOG_CI_START="-0.17532386704308187" LOG_EFFECT_SIZE="-0.0966312319038629" ORDER="4" O_E="0.0" SE="0.09244888683120696" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.00854679667632931" WEIGHT="25.809073959151576"/>
<DICH_DATA CI_END="1.0058740130405417" CI_START="0.24854007237377929" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.002543588207254838" LOG_CI_START="-0.6046035795352172" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="5" O_E="0.0" SE="0.3566412517588793" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.12719298245614033" WEIGHT="4.217334003109896"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6762198170859994" CI_END="1.5673075689309797" CI_START="0.6893194885058224" DF="6" EFFECT_SIZE="1.0394112043588941" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="30" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.1951542309179991" LOG_CI_START="-0.16157944291754386" LOG_EFFECT_SIZE="0.016787394000227603" MODIFIED="2009-01-21 03:35:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.848248051004177" P_Z="0.8536475866816533" STUDIES="7" TAU2="0.0" TOTAL_1="1325" TOTAL_2="601" WEIGHT="100.0" Z="0.18446639635089954">
<NAME>adverse event</NAME>
<DICH_DATA CI_END="2.88099341199817" CI_START="0.36049429428008317" EFFECT_SIZE="1.019108280254777" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.45954226517520197" LOG_CI_START="-0.4431016046818199" LOG_EFFECT_SIZE="0.008220330246691042" MODIFIED="2009-01-21 03:35:17 +0000" MODIFIED_BY="[Empty name]" ORDER="469" O_E="0.0" SE="0.530217477313232" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="80" VAR="0.2811305732484077" WEIGHT="16.047048751232943"/>
<DICH_DATA CI_END="2.394845304021752" CI_START="0.3170642853179103" EFFECT_SIZE="0.8713896457765667" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.3792774652330225" LOG_CI_START="-0.4988526749167695" LOG_EFFECT_SIZE="-0.05978760484187345" ORDER="6" O_E="0.0" SE="0.5158179911382861" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="123" VAR="0.266068199981937" WEIGHT="18.143198405478877"/>
<DICH_DATA CI_END="1.6101084410933497" CI_START="0.3517748220987073" EFFECT_SIZE="0.7525925925925926" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.20685512682841925" LOG_CI_START="-0.4537352479226306" LOG_EFFECT_SIZE="-0.12344006054710567" ORDER="7" O_E="0.0" SE="0.38803405610385916" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="127" VAR="0.1505704286964129" WEIGHT="32.5719621384334"/>
<DICH_DATA CI_END="27.55910861153493" CI_START="0.30817619481839853" EFFECT_SIZE="2.914285714285714" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.440265166379556" LOG_CI_START="-0.5112009115562722" LOG_EFFECT_SIZE="0.4645321274116419" ORDER="8" O_E="0.0" SE="1.1463008340923844" STUDY_ID="STD-Kramer-2007" TOTAL_1="105" TOTAL_2="102" VAR="1.3140056022408964" WEIGHT="2.457495973257219"/>
<DICH_DATA CI_END="9.767868569213505" CI_START="0.4095059195009289" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9897998073609312" LOG_CI_START="-0.3877398160329689" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-11-25 18:05:51 +0000" MODIFIED_BY="[Empty name]" ORDER="434" O_E="0.0" SE="0.809173593712687" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="0.6547619047619047" WEIGHT="4.844777775849946"/>
<DICH_DATA CI_END="3.7200891612630853" CI_START="0.5082203458150649" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.5705533489626814" LOG_CI_START="-0.29394795263011847" LOG_EFFECT_SIZE="0.13830269816628146" ORDER="9" O_E="0.0" SE="0.50781234390607" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.25787337662337667" WEIGHT="16.245961404047723"/>
<DICH_DATA CI_END="3.3037098801282703" CI_START="0.21020140074087915" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.519001902149694" LOG_CI_START="-0.6773643942449437" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="10" O_E="0.0" SE="0.7027514846108879" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.493859649122807" WEIGHT="9.689555551699891"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.7812164658589" CI_END="0.48057510873468834" CI_START="0.332078879501979" DF="4" EFFECT_SIZE="0.39948572393160314" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="160" I2="30.81040947658529" ID="CMP-001.01.03" LOG_CI_END="-0.3182387271216356" LOG_CI_START="-0.4787587450201913" LOG_EFFECT_SIZE="-0.3984987360709134" MODIFIED="2009-01-21 03:35:33 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.21609387082352516" P_Z="2.2149789503520954E-22" STUDIES="5" TAU2="0.0" TOTAL_1="1199" TOTAL_2="478" WEIGHT="100.00000000000003" Z="9.731411456449269">
<NAME>lack of efficacy</NAME>
<DICH_DATA CI_END="0.5398903128098207" CI_START="0.043283028793884196" EFFECT_SIZE="0.15286624203821655" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="-0.2676944649551022" LOG_CI_START="-1.3636823564401532" LOG_EFFECT_SIZE="-0.8156884106976278" MODIFIED="2009-01-21 03:35:33 +0000" MODIFIED_BY="[Empty name]" ORDER="470" O_E="0.0" SE="0.6437887126858788" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="80" VAR="0.414463906581741" WEIGHT="5.7442935092540415"/>
<DICH_DATA CI_END="0.5658009711081823" CI_START="0.31480723987539466" EFFECT_SIZE="0.42204056917953375" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="54" LOG_CI_END="-0.24733631148036597" LOG_CI_START="-0.5019552883784812" LOG_EFFECT_SIZE="-0.3746457999294236" ORDER="11" O_E="0.0" SE="0.14956444741421576" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="123" VAR="0.022369523930319712" WEIGHT="35.0710735443078"/>
<DICH_DATA CI_END="0.480169584636532" CI_START="0.24832279878782026" EFFECT_SIZE="0.3453071895424837" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="51" LOG_CI_END="-0.3186053529063678" LOG_CI_START="-0.6049834055634304" LOG_EFFECT_SIZE="-0.4617943792348992" ORDER="12" O_E="0.0" SE="0.16821988572498192" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="127" VAR="0.028297929953325973" WEIGHT="33.035664180707236"/>
<DICH_DATA CI_END="0.766652551646666" CI_START="0.3648044395563006" EFFECT_SIZE="0.5288461538461539" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="39" LOG_CI_END="-0.11540141452606394" LOG_CI_START="-0.43793988508300913" LOG_EFFECT_SIZE="-0.2766706498045365" ORDER="13" O_E="0.0" SE="0.18946069419632836" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.03589535464535465" WEIGHT="22.680439946130406"/>
<DICH_DATA CI_END="0.9453293888529838" CI_START="0.0661145212843054" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="-0.024416840341521813" LOG_CI_START="-1.1797031423144029" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="14" O_E="0.0" SE="0.6786208925382962" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.4605263157894737" WEIGHT="3.4685288196005293"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.147337888442752" CI_END="1.682610126992598" CI_START="0.5083710394573084" DF="4" EFFECT_SIZE="0.9248731044098" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="16" I2="44.035107022602055" ID="CMP-001.01.04" LOG_CI_END="0.22598349844133456" LOG_CI_START="-0.29381919801206496" LOG_EFFECT_SIZE="-0.033917849785365196" MODIFIED="2009-01-21 03:35:39 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.12830399757587418" P_Z="0.7981201324529822" STUDIES="5" TAU2="0.0" TOTAL_1="1228" TOTAL_2="542" WEIGHT="99.99999999999997" Z="0.2557807586068001">
<NAME>loss to follow up</NAME>
<DICH_DATA CI_END="0.9653851905489572" CI_START="0.08782212463081182" EFFECT_SIZE="0.2911737943585077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="-0.01529936774251842" LOG_CI_START="-1.0563960604646507" LOG_EFFECT_SIZE="-0.5358477141035847" MODIFIED="2009-01-21 03:35:39 +0000" MODIFIED_BY="[Empty name]" ORDER="471" O_E="0.0" SE="0.6115453508167243" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="80" VAR="0.3739877161055505" WEIGHT="43.29917804668099"/>
<DICH_DATA CI_END="45.34494625527043" CI_START="0.12269162583774115" EFFECT_SIZE="2.358695652173913" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.656528891489793" LOG_CI_START="-0.9111850784838446" LOG_EFFECT_SIZE="0.37267190650297427" ORDER="15" O_E="0.0" SE="1.5082878963516566" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="123" VAR="2.2749323782809054" WEIGHT="3.4920706855819863"/>
<DICH_DATA CI_END="3.005874995972029" CI_START="0.0858532042569349" EFFECT_SIZE="0.508" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.47797091580897805" LOG_CI_START="-1.0662434912411396" LOG_EFFECT_SIZE="-0.29413628771608075" ORDER="16" O_E="0.0" SE="0.9070791866858345" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="127" VAR="0.8227926509186351" WEIGHT="13.950438279271532"/>
<DICH_DATA CI_END="3.795708695026195" CI_START="0.11049594806592708" EFFECT_SIZE="0.6476190476190476" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5792928747254361" LOG_CI_START="-0.9566536474528397" LOG_EFFECT_SIZE="-0.18868038636370174" ORDER="17" O_E="0.0" SE="0.9022225901854245" STUDY_ID="STD-Kramer-2007" TOTAL_1="105" TOTAL_2="102" VAR="0.8140056022408964" WEIGHT="14.209229018365267"/>
<DICH_DATA CI_END="6.372670295534073" CI_START="0.7662895646108763" EFFECT_SIZE="2.2098214285714284" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" LOG_CI_END="0.8043214498568868" LOG_CI_START="-0.11560708865807502" LOG_EFFECT_SIZE="0.3443571805994059" ORDER="18" O_E="0.0" SE="0.5403705772433958" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.2920003607503608" WEIGHT="25.049083970100202"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1665222844702656" CI_END="2.901068630042567" CI_START="0.2544277211357718" DF="2" EFFECT_SIZE="0.859134611338762" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="0.46255800294820826" LOG_CI_START="-0.5944355719528188" LOG_EFFECT_SIZE="-0.06593878450230531" MODIFIED="2008-06-03 18:48:49 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5580756305341782" P_Z="0.8068140357775586" STUDIES="4" TAU2="0.0" TOTAL_1="780" TOTAL_2="377" WEIGHT="99.99999999999999" Z="0.24453818051063864">
<NAME>non compliance</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20" O_E="0.0" SE="0.0" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="127" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="70.73931318952256" CI_START="0.12012803949810745" EFFECT_SIZE="2.9150943396226414" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8496608389188167" LOG_CI_START="-0.9203556105986882" LOG_EFFECT_SIZE="0.46465261416006437" ORDER="21" O_E="0.0" SE="1.6271213742491486" STUDY_ID="STD-Kramer-2007" TOTAL_1="105" TOTAL_2="102" VAR="2.647523966538438" WEIGHT="9.762937937655954"/>
<DICH_DATA CI_END="2.3935684578494163" CI_START="0.10074963478414743" EFFECT_SIZE="0.49107142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.379045853142838" LOG_CI_START="-0.9967565194947136" LOG_EFFECT_SIZE="-0.3088553331759378" ORDER="22" O_E="0.0" SE="0.808153124018878" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.6531114718614719" WEIGHT="77.45933270070633"/>
<DICH_DATA CI_END="36.44158291543759" CI_START="0.06335677169782634" EFFECT_SIZE="1.5194805194805194" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5615972331886998" LOG_CI_START="-1.1982069600413403" LOG_EFFECT_SIZE="0.18169513657367975" ORDER="23" O_E="0.0" SE="1.6211226443544078" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="2.628038628038628" WEIGHT="12.77772936163771"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.104348816073478" CI_END="1.9208722391048552" CI_START="0.9912654793727946" DF="4" EFFECT_SIZE="1.3798892495088755" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="39" I2="21.635449611043605" ID="CMP-001.01.06" LOG_CI_END="0.28349848006369327" LOG_CI_START="-0.003810017779057637" LOG_EFFECT_SIZE="0.1398442311423178" MODIFIED="2009-01-21 03:36:03 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.27675734757999204" P_Z="0.05639360097666555" STUDIES="5" TAU2="0.0" TOTAL_1="1228" TOTAL_2="542" WEIGHT="100.00000000000001" Z="1.9079815497462365">
<NAME>unspecified participant reason</NAME>
<DICH_DATA CI_END="5.4456559530510225" CI_START="0.1907174628433818" EFFECT_SIZE="1.019108280254777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.736050199910422" LOG_CI_START="-0.7196095394170399" LOG_EFFECT_SIZE="0.008220330246691042" MODIFIED="2009-01-21 03:36:03 +0000" MODIFIED_BY="[Empty name]" ORDER="472" O_E="0.0" SE="0.8550617365128718" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="80" VAR="0.7311305732484077" WEIGHT="4.740994301015285"/>
<DICH_DATA CI_END="1.9914243138286498" CI_START="0.6171127163668344" EFFECT_SIZE="1.108572626283798" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="13" LOG_CI_END="0.2991638052413564" LOG_CI_START="-0.2096355043212396" LOG_EFFECT_SIZE="0.04476415046005839" ORDER="24" O_E="0.0" SE="0.29887123303427066" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="123" VAR="0.08932401393542531" WEIGHT="34.84187094114202"/>
<DICH_DATA CI_END="3.025193655201895" CI_START="0.6066129930631848" EFFECT_SIZE="1.3546666666666667" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="7" LOG_CI_END="0.4807531808706742" LOG_CI_START="-0.21708829175827332" LOG_EFFECT_SIZE="0.1318324445562004" ORDER="25" O_E="0.0" SE="0.4099155353932446" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="127" VAR="0.16803074615673036" WEIGHT="18.711720503458363"/>
<DICH_DATA CI_END="404.9762959507941" CI_START="1.457179766834166" EFFECT_SIZE="24.29245283018868" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.607429603859008" LOG_CI_START="0.16351313236587173" LOG_EFFECT_SIZE="1.3854713681124395" ORDER="26" O_E="0.0" SE="1.435568632936709" STUDY_ID="STD-Kramer-2007" TOTAL_1="105" TOTAL_2="102" VAR="2.0608572998717714" WEIGHT="0.9074395729596958"/>
<DICH_DATA CI_END="1.9426462859754317" CI_START="0.6872547361360284" EFFECT_SIZE="1.1554621848739495" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="17" LOG_CI_END="0.2883937321318056" LOG_CI_START="-0.16288225858430436" LOG_EFFECT_SIZE="0.06275573677375065" ORDER="27" O_E="0.0" SE="0.2650817507988241" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.07026833460656991" WEIGHT="40.79797468142464"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.739246288611484" CI_END="1.2362125514799092" CI_START="0.3012928559824533" DF="5" EFFECT_SIZE="0.6102966575664145" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" I2="0.0" ID="CMP-001.01.07" LOG_CI_END="0.09209314874520275" LOG_CI_START="-0.5210111658513098" LOG_EFFECT_SIZE="-0.21445900855305353" MODIFIED="2009-01-21 03:36:26 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.5875345532413727" P_Z="0.17032520954268257" STUDIES="6" TAU2="0.0" TOTAL_1="1304" TOTAL_2="580" WEIGHT="100.00000000000001" Z="1.3711595985122866">
<NAME>unspecified reason</NAME>
<DICH_DATA CI_END="37.331874307644206" CI_START="0.06336049745937512" EFFECT_SIZE="1.5379746835443038" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5720797949365588" LOG_CI_START="-1.1981814216487796" LOG_EFFECT_SIZE="0.18694918664388957" MODIFIED="2009-01-21 03:36:26 +0000" MODIFIED_BY="[Empty name]" ORDER="473" O_E="0.0" SE="1.6272651516364105" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="80" VAR="2.64799187373027" WEIGHT="3.576859520494613"/>
<DICH_DATA CI_END="1.9695796415559725" CI_START="0.1746548480326369" EFFECT_SIZE="0.5865122615803815" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.29437354655109355" LOG_CI_START="-0.7578193548038874" LOG_EFFECT_SIZE="-0.23172290412639696" ORDER="28" O_E="0.0" SE="0.6180633186947782" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="123" VAR="0.3820022659160029" WEIGHT="32.41922801561809"/>
<DICH_DATA CI_END="67.25147815917606" CI_START="0.20851043070212172" EFFECT_SIZE="3.74468085106383" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.827701834389219" LOG_CI_START="-0.6808722146323543" LOG_EFFECT_SIZE="0.5734148098784324" ORDER="29" O_E="0.0" SE="1.473548814037084" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="127" VAR="2.1713461073500966" WEIGHT="4.036453987715089"/>
<DICH_DATA CI_END="3.795708695026195" CI_START="0.11049594806592708" EFFECT_SIZE="0.6476190476190476" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5792928747254361" LOG_CI_START="-0.9566536474528397" LOG_EFFECT_SIZE="-0.18868038636370174" ORDER="30" O_E="0.0" SE="0.9022225901854245" STUDY_ID="STD-Kramer-2007" TOTAL_1="105" TOTAL_2="102" VAR="0.8140056022408964" WEIGHT="16.466939949883017"/>
<DICH_DATA CI_END="0.9964186786312614" CI_START="0.0387228626890765" EFFECT_SIZE="0.19642857142857142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="-0.0015581398765459563" LOG_CI_START="-1.4120325438194048" LOG_EFFECT_SIZE="-0.7067953418479754" ORDER="31" O_E="0.0" SE="0.8285196468369385" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.6864448051948052" WEIGHT="36.28643054824521"/>
<DICH_DATA CI_END="7.777000992633185" CI_START="0.03214606764700353" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8908121543871789" LOG_CI_START="-1.4928721457151413" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="32" O_E="0.0" SE="1.4001879573076872" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="1.9605263157894737" WEIGHT="7.214087978043988"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03795696569737436" CI_END="1.8557729031584584" CI_START="0.6891800217216739" DF="2" EFFECT_SIZE="1.1309118487792231" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="19" I2="0.0" ID="CMP-001.01.08" LOG_CI_END="0.2685248291352477" LOG_CI_START="-0.16166732057658073" LOG_EFFECT_SIZE="0.05342875427933354" MODIFIED="2009-01-21 03:36:48 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.981200479978808" P_Z="0.6263682270774895" STUDIES="3" TAU2="0.0" TOTAL_1="600" TOTAL_2="241" WEIGHT="100.0" Z="0.48684493288165054">
<NAME>withdrawal of consent</NAME>
<DICH_DATA CI_END="3.3507416539504304" CI_START="0.44633629911441314" EFFECT_SIZE="1.2229299363057324" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.5251409445201577" LOG_CI_START="-0.35033779193152603" LOG_EFFECT_SIZE="0.08740157629431586" MODIFIED="2009-01-21 03:36:48 +0000" MODIFIED_BY="[Empty name]" ORDER="474" O_E="0.0" SE="0.5142605434813573" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="80" VAR="0.26446390658174096" WEIGHT="24.14934232045892"/>
<DICH_DATA CI_END="1.9914243138286498" CI_START="0.6171127163668344" EFFECT_SIZE="1.108572626283798" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="13" LOG_CI_END="0.2991638052413564" LOG_CI_START="-0.2096355043212396" LOG_EFFECT_SIZE="0.04476415046005839" ORDER="33" O_E="0.0" SE="0.29887123303427066" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="123" VAR="0.08932401393542531" WEIGHT="70.99002572204745"/>
<DICH_DATA CI_END="10.68307076777868" CI_START="0.09360604471666614" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0286961052968442" LOG_CI_START="-1.0286961052968442" LOG_EFFECT_SIZE="0.0" ORDER="34" O_E="0.0" SE="1.2085223687584246" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="1.4605263157894737" WEIGHT="4.860631957493641"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.005194993299764388" CI_END="1.0987236736651527" CI_START="0.029181378306655348" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.17905940683388" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="100.0" ID="CMP-001.02" LOG_CI_END="0.04088848214878756" LOG_CI_START="-1.5348941991856062" LOG_EFFECT_SIZE="-0.7470028585184094" METHOD="MH" MODIFIED="2009-05-14 13:38:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9974058739274493" P_Q="0.0" P_Z="0.06313358992063857" Q="5.754566336554751E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1326" TOTAL_2="601" WEIGHT="100.0" Z="1.8582495116709035">
<NAME>Death</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.121996882950878" CI_START="0.006995610495420411" EFFECT_SIZE="0.16981132075471697" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6151076590303495" LOG_CI_START="-2.155174379353278" LOG_EFFECT_SIZE="-0.7700333601614642" MODIFIED="2009-05-14 13:37:52 +0100" MODIFIED_BY="[Empty name]" ORDER="524" O_E="0.0" SE="1.627277382463795" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="2.64803167947822" WEIGHT="30.507626281348543"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="35" O_E="0.0" SE="0.0" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="123" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="36" O_E="0.0" SE="0.0" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="127" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.9991493707587353" CI_START="0.00944398056361641" EFFECT_SIZE="0.19433962264150945" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.601967625610085" LOG_CI_START="-2.0248449154013186" LOG_EFFECT_SIZE="-0.7114386448956168" ORDER="37" O_E="0.0" SE="1.5430026895218851" STUDY_ID="STD-Kramer-2007" TOTAL_1="105" TOTAL_2="102" VAR="2.380857299871771" WEIGHT="38.92520099693594"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-26 19:13:29 +0000" MODIFIED_BY="[Empty name]" ORDER="435" O_E="0.0" SE="0.0" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38" O_E="0.0" SE="0.0" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.049064768381955" CI_START="0.007039641299758482" EFFECT_SIZE="0.16883116883116883" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6073547237493749" LOG_CI_START="-2.1524494694806653" LOG_EFFECT_SIZE="-0.7725473728656451" MODIFIED="2008-05-18 14:07:45 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="1.6211226443544078" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="2.628038628038628" WEIGHT="30.567172721715522"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.16265829627181" CI_END="0.7671712990659381" CI_START="0.6565673899733078" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7097180126572489" ESTIMABLE="YES" EVENTS_1="608" EVENTS_2="340" I2="50.99635615241974" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.11510765308771301" LOG_CI_START="-0.18272069136961708" LOG_EFFECT_SIZE="-0.14891417222866504" METHOD="MH" MODIFIED="2011-11-25 21:44:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.08579835365257904" P_Q="1.0" P_Z="5.9536050697489746E-18" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1189" TOTAL_2="469" WEIGHT="100.0" Z="8.633435851200106">
<NAME>Global state: 1. No clinically important change</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9888065835124186" CI_START="0.6810110689220024" EFFECT_SIZE="0.8206023570493235" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="58" LOG_CI_END="-0.004888650696201302" LOG_CI_START="-0.166845829155234" LOG_EFFECT_SIZE="-0.08586723992571763" MODIFIED="2011-11-25 21:44:40 +0000" MODIFIED_BY="[Empty name]" ORDER="526" O_E="0.0" SE="0.09513444832779881" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.009050563258634622" WEIGHT="15.870096724270041"/>
<DICH_DATA CI_END="0.7517749404937826" CI_START="0.5824210439812911" EFFECT_SIZE="0.6617020067079756" ESTIMABLE="YES" EVENTS_1="194" EVENTS_2="98" LOG_CI_END="-0.12391215506096223" LOG_CI_START="-0.23476294152496405" LOG_EFFECT_SIZE="-0.17933754829296317" ORDER="40" O_E="0.0" SE="0.06511430068919728" STUDY_ID="STD-Davidson-2007" TOTAL_1="359" TOTAL_2="120" VAR="0.0042398721542431985" WEIGHT="30.273069718868587"/>
<DICH_DATA CI_END="0.7384382287364589" CI_START="0.5338337972910535" EFFECT_SIZE="0.6278561011181332" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="88" LOG_CI_END="-0.1316858280987035" LOG_CI_START="-0.2725939342720726" LOG_EFFECT_SIZE="-0.20213988118538803" ORDER="41" O_E="0.0" SE="0.0827701190726118" STUDY_ID="STD-Kane-2007" TOTAL_1="374" TOTAL_2="126" VAR="0.006850892611294335" WEIGHT="27.130370224055827"/>
<DICH_DATA CI_END="0.905695620987043" CI_START="0.616375255693136" EFFECT_SIZE="0.7471602036819428" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="69" LOG_CI_END="-0.04301773205381807" LOG_CI_START="-0.21015480430084643" LOG_EFFECT_SIZE="-0.12658626817733223" ORDER="42" O_E="0.0" SE="0.09817714357975528" STUDY_ID="STD-Marder-2007" TOTAL_1="222" TOTAL_2="105" VAR="0.009638751521479885" WEIGHT="19.30748751801148"/>
<DICH_DATA CI_END="1.1390398245362952" CI_START="0.6650729546941463" EFFECT_SIZE="0.8703703703703703" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="27" LOG_CI_END="0.056538908691917765" LOG_CI_START="-0.17713071246641982" LOG_EFFECT_SIZE="-0.060295901887251056" ORDER="43" O_E="0.0" SE="0.13725869215168698" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.018839948571191575" WEIGHT="7.41897581479407"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.183653569100792" CI_END="0.6634961753471774" CI_START="0.33721205311475294" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4730104729523521" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.17816157623647624" LOG_CI_START="-0.47209691059630315" LOG_EFFECT_SIZE="-0.3251292434163897" METHOD="MH" MODIFIED="2009-01-02 18:05:30 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5204834568629952" P_Q="1.0" P_Z="1.4514472715518707E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1322" TOTAL_2="596" WEIGHT="100.0" Z="4.335930614158747">
<NAME>Global state: 2. Relapse: recurrence of psychotic symptoms</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0762843882982567" CI_START="0.19294066815379346" EFFECT_SIZE="0.45569620253164556" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.03192704080046551" LOG_CI_START="-0.7145762218467738" LOG_EFFECT_SIZE="-0.34132459052315417" MODIFIED="2008-11-26 21:01:35 +0000" MODIFIED_BY="[Empty name]" ORDER="424" O_E="0.0" SE="0.43849971172973473" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.19228199718706046" WEIGHT="15.396600095265883"/>
<DICH_DATA CI_END="1.4607184203526717" CI_START="0.37211575905567706" EFFECT_SIZE="0.7372627372627373" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" LOG_CI_END="0.16456650595966152" LOG_CI_START="-0.4293219372722156" LOG_EFFECT_SIZE="-0.13237771565627707" ORDER="44" O_E="0.0" SE="0.348853011349611" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.12169842352769182" WEIGHT="19.068204785152982"/>
<DICH_DATA CI_END="0.8766310057698815" CI_START="0.12878394587566708" EFFECT_SIZE="0.336" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="-0.05718317274590938" LOG_CI_START="-0.8901382724744025" LOG_EFFECT_SIZE="-0.4736607226101559" ORDER="45" O_E="0.0" SE="0.4892819487747585" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="0.23939682539682539" WEIGHT="13.887632921523839"/>
<DICH_DATA CI_END="0.6648115361883196" CI_START="0.13402182451998096" EFFECT_SIZE="0.298494983277592" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="23" LOG_CI_END="-0.17730145303342187" LOG_CI_START="-0.8728244740469757" LOG_EFFECT_SIZE="-0.5250629635401988" ORDER="46" O_E="0.0" SE="0.40855366543784183" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="102" VAR="0.166916097542696" WEIGHT="26.93014270564854"/>
<DICH_DATA CI_END="20.412520736125575" CI_START="0.19595815978380854" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3098966389244104" LOG_CI_START="-0.707836647596448" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-11-26 19:15:03 +0000" MODIFIED_BY="[Empty name]" ORDER="436" O_E="0.0" SE="1.185226520443204" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="1.4047619047619047" WEIGHT="1.1596173489472406"/>
<DICH_DATA CI_END="1.045586959355515" CI_START="0.24838473539949907" EFFECT_SIZE="0.5096153846153846" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.019360158050626877" LOG_CI_START="-0.6048750974466095" LOG_EFFECT_SIZE="-0.2927574696979913" ORDER="47" O_E="0.0" SE="0.3666788790934265" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.13445340037321168" WEIGHT="20.46548921293554"/>
<DICH_DATA CI_END="2.67076769194467" CI_START="0.023401511179166532" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.42663611396888185" LOG_CI_START="-1.6307560966248067" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="48" O_E="0.0" SE="1.2085223687584246" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="1.4605263157894737" WEIGHT="3.0923129305259747"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7017244003800054" CI_END="1.0989552542860455" CI_START="0.7847040543436934" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9286305204873273" ESTIMABLE="YES" EVENTS_1="237" EVENTS_2="91" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.04098000979175904" LOG_CI_START="-0.10529410350833718" LOG_EFFECT_SIZE="-0.032157046858289066" METHOD="MH" MODIFIED="2009-05-14 15:00:59 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8727982981747793" P_Q="1.0" P_Z="0.3888191297445672" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="594" TOTAL_2="239" WEIGHT="100.0" Z="0.8617608716876357">
<NAME>Global state: 3. Use of additional benzodiazepine</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5352475767725813" CI_START="0.49302947294127497" EFFECT_SIZE="1.1180124223602483" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" LOG_CI_END="0.40402037628319143" LOG_CI_START="-0.3071271181402788" LOG_EFFECT_SIZE="0.04844662907145632" MODIFIED="2009-05-14 15:00:59 +0100" MODIFIED_BY="[Empty name]" ORDER="492" O_E="0.0" SE="0.41773155846121746" STUDY_ID="STD-Canuso-2009" TOTAL_1="138" TOTAL_2="60" VAR="0.17449965493443753" WEIGHT="7.280973748454295"/>
<DICH_DATA CI_END="1.0810530252044404" CI_START="0.7680456452300214" EFFECT_SIZE="0.9112069294463311" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="73" LOG_CI_END="0.033846996440739095" LOG_CI_START="-0.1146129689236263" LOG_EFFECT_SIZE="-0.0403829862414436" ORDER="49" O_E="0.0" SE="0.08720611854370891" STUDY_ID="STD-Davidson-2007" TOTAL_1="359" TOTAL_2="120" VAR="0.0076049071114594104" WEIGHT="81.65058945071223"/>
<DICH_DATA CI_END="7.7443737981982546" CI_START="0.014347333174563614" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8889863069264973" LOG_CI_START="-1.8432288163658224" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2008-11-26 19:15:57 +0000" MODIFIED_BY="[Empty name]" ORDER="437" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="1.1192801259269802"/>
<DICH_DATA CI_END="1.9186077510818456" CI_START="0.5212112790830381" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="0.28298619466604824" LOG_CI_START="-0.2829861946660483" LOG_EFFECT_SIZE="0.0" ORDER="50" O_E="0.0" SE="0.3324549831021844" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.11052631578947372" WEIGHT="9.94915667490649"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.45381356136002" CI_END="-6.930174340256652" CI_START="-11.046967794525763" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.988571067391208" ESTIMABLE="YES" I2="29.026113996359047" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2011-11-25 23:11:45 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.2067043975221814" P_Q="1.0" P_Z="1.1411101795196513E-17" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="714" TOTAL_2="591" UNITS="" WEIGHT="100.0" Z="8.558736677107968">
<NAME>Mental state: Average change score (PANSS total, decline=good)</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="35.69893149066594" CI_START="-51.09893149066595" EFFECT_SIZE="-7.699999999999999" ESTIMABLE="YES" MEAN_1="-31.2" MEAN_2="-23.5" MODIFIED="2011-11-25 23:11:45 +0000" MODIFIED_BY="[Empty name]" ORDER="419" SD_1="216.409565" SD_2="123.935467" SE="22.142718862688895" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="80" WEIGHT="0.2249573002176848"/>
<CONT_DATA CI_END="-8.13104966421403" CI_START="-18.868950335785968" EFFECT_SIZE="-13.5" ESTIMABLE="YES" MEAN_1="-16.3" MEAN_2="-2.8" ORDER="51" SD_1="21.8" SD_2="20.9" SE="2.739310710878141" STUDY_ID="STD-Davidson-2007" TOTAL_1="123" TOTAL_2="120" WEIGHT="14.698715771876566"/>
<CONT_DATA CI_END="-7.690948155150606" CI_START="-18.509051844849395" EFFECT_SIZE="-13.1" ESTIMABLE="YES" MEAN_1="-17.2" MEAN_2="-4.1" ORDER="52" SD_1="20.2" SD_2="23.2" SE="2.759771040445286" STUDY_ID="STD-Kane-2007" TOTAL_1="122" TOTAL_2="126" WEIGHT="14.481577645109832"/>
<CONT_DATA CI_END="-4.54948794573138" CI_START="-13.650512054268619" EFFECT_SIZE="-9.1" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="15.1" ORDER="53" SD_1="13.6" SD_2="19.1" SE="2.3217324859857005" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="101" WEIGHT="20.46150749437541"/>
<CONT_DATA CI_END="-2.3097420410849647" CI_START="-10.890257958915035" EFFECT_SIZE="-6.6" ESTIMABLE="YES" MEAN_1="-7.8" MEAN_2="-1.2" MODIFIED="2008-11-26 19:19:25 +0000" MODIFIED_BY="[Empty name]" ORDER="438" SD_1="5.82" SD_2="8.17" SE="2.1889473443165497" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="23.019259776698835"/>
<CONT_DATA CI_END="-2.2894736929371833" CI_START="-13.110526307062816" EFFECT_SIZE="-7.699999999999999" ESTIMABLE="YES" MEAN_1="-15.7" MEAN_2="-8.0" ORDER="54" SD_1="18.9" SD_2="21.5" SE="2.760523330908301" STUDY_ID="STD-Marder-2007" TOTAL_1="111" TOTAL_2="105" WEIGHT="14.4736857586839"/>
<CONT_DATA CI_END="1.0896252850425627" CI_START="-10.48962528504256" EFFECT_SIZE="-4.699999999999999" ESTIMABLE="YES" MEAN_1="-14.6" MEAN_2="-9.9" ORDER="55" SD_1="14.6" SD_2="15.0" SE="2.9539447309799503" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" WEIGHT="12.640296253037773"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="20.567646028860267" CI_END="7.810572723246343" CI_START="4.782940426134818" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="6.296756574690581" ESTIMABLE="YES" I2="80.55197957808468" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2009-01-21 01:57:20 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="3.8570037455898376E-4" P_Q="1.0" P_Z="3.564186080900093E-16" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1065" TOTAL_2="455" UNITS="" WEIGHT="100.0" Z="8.15251978754719">
<NAME>Social functioning: Average change score (PSP total, increase=good)</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paliperidone</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.215196893264245" CI_START="7.384803106735756" EFFECT_SIZE="10.8" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="-1.5" MODIFIED="2009-01-21 01:57:20 +0000" MODIFIED_BY="[Empty name]" ORDER="56" SD_1="15.77" SD_2="15.82" SE="1.7424794129906884" STUDY_ID="STD-Davidson-2007" TOTAL_1="336" TOTAL_2="109" WEIGHT="19.647838243703465"/>
<CONT_DATA CI_END="12.291170285670082" CI_START="5.908829714329917" EFFECT_SIZE="9.1" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="0.5" MODIFIED="2009-01-21 01:56:49 +0000" MODIFIED_BY="[Empty name]" ORDER="57" SD_1="15.38" SD_2="15.51" SE="1.6281780230869682" STUDY_ID="STD-Kane-2007" TOTAL_1="366" TOTAL_2="120" WEIGHT="22.503305112734026"/>
<CONT_DATA CI_END="8.180135084553623" CI_START="1.8198649154463782" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-8.0" MODIFIED="2008-05-18 19:20:34 +0100" MODIFIED_BY="[Empty name]" ORDER="58" SD_1="10.4" SD_2="12.58" SE="1.6225477149774798" STUDY_ID="STD-Kramer-2007" TOTAL_1="103" TOTAL_2="100" WEIGHT="22.65975089016293"/>
<CONT_DATA CI_END="8.151623214921921" CI_START="1.44837678507808" EFFECT_SIZE="4.800000000000001" ESTIMABLE="YES" MEAN_1="7.7" MEAN_2="2.9" MODIFIED="2009-01-21 01:56:58 +0000" MODIFIED_BY="[Empty name]" ORDER="59" SD_1="13.51" SD_2="13.04" SE="1.7100432667942354" STUDY_ID="STD-Marder-2007" TOTAL_1="184" TOTAL_2="88" WEIGHT="20.40026869894176"/>
<CONT_DATA CI_END="4.036462529420154" CI_START="-3.836462529420155" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="4.7" MODIFIED="2008-05-18 14:56:15 +0100" MODIFIED_BY="[Empty name]" ORDER="345" SD_1="10.7" SD_2="9.8" SE="2.008436155189824" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" WEIGHT="14.788837054457824"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.634453580571646" CI_END="-2.3823720630934355" CI_START="-6.222666200507086" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.302519131800261" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2008-05-18 19:53:19 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.45773098211465224" P_Q="1.0" P_Z="1.1244823639891603E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="523" TOTAL_2="473" UNITS="" WEIGHT="100.0" Z="4.391737840582357">
<NAME>Schizophrenia Quality of life: Average change score (SQLS total, decrease=good)</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9018836399469081" CI_START="-6.701883639946908" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-6.7" MEAN_2="-3.8" ORDER="60" SD_1="15.93" SD_2="13.4" SE="1.9397721947625983" STUDY_ID="STD-Davidson-2007" TOTAL_1="116" TOTAL_2="114" WEIGHT="25.507702655964895"/>
<CONT_DATA CI_END="-3.634639216670032" CI_START="-12.385360783329968" EFFECT_SIZE="-8.01" ESTIMABLE="YES" MEAN_1="-12.91" MEAN_2="-4.9" ORDER="61" SD_1="17.92" SD_2="16.64" SE="2.232367950555344" STUDY_ID="STD-Kane-2007" TOTAL_1="120" TOTAL_2="120" WEIGHT="19.259333231473157"/>
<CONT_DATA CI_END="-0.35964671841677065" CI_START="-7.840353281583228" EFFECT_SIZE="-4.1" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="6.1" ORDER="62" SD_1="12.5" SD_2="14.7" SE="1.9083785779160527" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="101" WEIGHT="26.35382996674342"/>
<CONT_DATA CI_END="1.0872892596006318" CI_START="-7.8872892596006325" EFFECT_SIZE="-3.4000000000000004" ESTIMABLE="YES" MEAN_1="-6.7" MEAN_2="-3.3" ORDER="63" SD_1="16.62" SD_2="16.31" SE="2.2894753653617093" STUDY_ID="STD-Marder-2007" TOTAL_1="107" TOTAL_2="100" WEIGHT="18.31052748131067"/>
<CONT_DATA CI_END="2.9064376825706475" CI_START="-8.906437682570647" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-9.0" MEAN_2="-6.0" MODIFIED="2008-05-18 14:57:08 +0100" MODIFIED_BY="[Empty name]" ORDER="346" SD_1="14.9" SD_2="15.3" SE="3.0135439881344115" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" WEIGHT="10.56860666450786"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="8.548354623465123" CI_END="2.149841948123317" CI_START="1.2231039769064758" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6215672161430728" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="48" I2="29.811054123444087" I2_Q="64.21649795838489" ID="CMP-001.09" LOG_CI_END="0.3324065326686242" LOG_CI_START="0.08746337827690427" LOG_EFFECT_SIZE="0.20993495547276428" METHOD="MH" MODIFIED="2009-05-13 20:59:11 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.20061649793569192" P_Q="0.06114035557983455" P_Z="7.803362206667673E-4" Q="5.589167873155797" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1458" TOTAL_2="616" WEIGHT="300.0" Z="3.3596770878896383">
<NAME>Adverse effect: 1. Anticholinergic events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4492205548935115" CI_END="1.7798849535334298" CI_START="0.9965326456943391" DF="2" EFFECT_SIZE="1.3318083427341243" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="44" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.25039193171320706" LOG_CI_START="-0.0015084695548846455" LOG_EFFECT_SIZE="0.12444173107916122" MODIFIED="2009-05-13 20:59:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.484513437183113" P_Z="0.052807709276851994" STUDIES="3" TAU2="0.0" TOTAL_1="543" TOTAL_2="224" WEIGHT="100.00000000000001" Z="1.9364900560789204">
<NAME>use of anticholinergic medication</NAME>
<DICH_DATA CI_END="1.6051657937241788" CI_START="0.8377977960508418" EFFECT_SIZE="1.1596570028583095" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="31" LOG_CI_END="0.2055198962928491" LOG_CI_START="-0.07686078644820202" LOG_EFFECT_SIZE="0.06432955492232358" MODIFIED="2009-05-13 20:59:11 +0100" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.16587181084901653" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.027513457634331922" WEIGHT="68.4875058249492"/>
<DICH_DATA CI_END="3.0330984012874254" CI_START="0.9411545888903571" EFFECT_SIZE="1.6895604395604396" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="12" LOG_CI_END="0.4818865001368805" LOG_CI_START="-0.026339035884158975" LOG_EFFECT_SIZE="0.22777373212636073" ORDER="64" O_E="0.0" SE="0.2985341956157355" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.08912266595193423" WEIGHT="29.848547014338493"/>
<DICH_DATA CI_END="20.412520736125575" CI_START="0.19595815978380854" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3098966389244104" LOG_CI_START="-0.707836647596448" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-11-26 19:24:34 +0000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="1.185226520443204" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="1.4047619047619047" WEIGHT="1.663947160712322"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2971788672557953" CI_END="17.726817604870522" CI_START="0.9587619546116157" DF="1" EFFECT_SIZE="4.122596062663582" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="1.2486307761707691" LOG_CI_START="-0.01828920787791441" LOG_EFFECT_SIZE="0.6151707841464275" MODIFIED="2009-05-13 16:33:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5856565323419507" P_Z="0.0569914930633075" STUDIES="2" TAU2="0.0" TOTAL_1="382" TOTAL_2="186" WEIGHT="100.0" Z="1.9033760560239608">
<NAME>salivation - decreased</NAME>
<DICH_DATA CI_END="21.306057383253588" CI_START="0.30081723591035975" EFFECT_SIZE="2.5316455696202533" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.3285030923650125" LOG_CI_START="-0.521697283617933" LOG_EFFECT_SIZE="0.4034029043735398" MODIFIED="2009-05-13 16:33:35 +0100" MODIFIED_BY="[Empty name]" ORDER="494" O_E="0.0" SE="1.086816859491952" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="1.1811708860759493" WEIGHT="49.44429693130524"/>
<DICH_DATA CI_END="43.10189399043252" CI_START="0.7481382019209076" EFFECT_SIZE="5.678571428571429" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.6344963544187607" LOG_CI_START="-0.12601816846229608" LOG_EFFECT_SIZE="0.7542390929782323" ORDER="65" O_E="0.0" SE="1.0341349454277697" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="1.0694350853548964" WEIGHT="50.55570306869477"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07927412058193825" CI_END="22.420476428780272" CI_START="1.3048358302401475" DF="1" EFFECT_SIZE="5.408792931452189" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="2" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="1.3506448369918662" LOG_CI_START="0.11555587373878885" LOG_EFFECT_SIZE="0.7331003553653276" MODIFIED="2009-05-13 16:40:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7782835294178503" P_Z="0.019980414388566754" STUDIES="2" TAU2="0.0" TOTAL_1="533" TOTAL_2="206" WEIGHT="100.00000000000001" Z="2.3267154615082375">
<NAME>salivation - increased</NAME>
<DICH_DATA CI_END="49.4257885266012" CI_START="0.8765948160500031" EFFECT_SIZE="6.582278481012659" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="1.6939536066659329" LOG_CI_START="-0.05720110197721711" LOG_EFFECT_SIZE="0.8183762523443577" MODIFIED="2009-05-13 16:40:43 +0100" MODIFIED_BY="[Empty name]" ORDER="496" O_E="0.0" SE="1.0286369442125955" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="1.0580939629990262" WEIGHT="47.00370528715976"/>
<DICH_DATA CI_END="33.05650198376955" CI_START="0.5771761334386751" EFFECT_SIZE="4.368" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="1.5192568949244072" LOG_CI_START="-0.23869163553104542" LOG_EFFECT_SIZE="0.6402826296966808" ORDER="66" O_E="0.0" SE="1.0326276687751024" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="1.0663199023199024" WEIGHT="52.99629471284025"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.425010355771562" CI_END="2.225340364681381" CI_START="1.3156595027739866" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7110786649653453" ESTIMABLE="YES" EVENTS_1="249" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.34739644551829857" LOG_CI_START="0.11914350690701804" LOG_EFFECT_SIZE="0.23326997621265833" METHOD="MH" MODIFIED="2009-05-14 13:26:17 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.6899320742942734" P_Q="0.5989741935823328" P_Z="6.173249082057731E-5" Q="6.43187011276511" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3560" TOTAL_2="1635" WEIGHT="900.0" Z="4.006088638621628">
<NAME>Adverse effect: 2a. Cardiovascular events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.04342432954631209" CI_END="13.354260073926675" CI_START="0.38678962575270176" DF="1" EFFECT_SIZE="2.2727272727272725" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="1.1256198298554838" LOG_CI_START="-0.4125251828278587" LOG_EFFECT_SIZE="0.3565473235138125" MODIFIED="2008-11-26 19:26:28 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8349284550728958" P_Z="0.36353341836592445" STUDIES="2" TAU2="0.0" TOTAL_1="97" TOTAL_2="59" WEIGHT="100.0" Z="0.9086528345622114">
<NAME>blood pressure - hypertension</NAME>
<DICH_DATA CI_END="69.69936418378434" CI_START="0.12912599857107263" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8432288163658224" LOG_CI_START="-0.8889863069264972" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-11-26 19:26:28 +0000" MODIFIED_BY="[Empty name]" ORDER="440" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="27.272727272727273"/>
<DICH_DATA CI_END="17.28046034716354" CI_START="0.23147531487241724" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2375553077939085" LOG_CI_START="-0.635495316465946" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="67" O_E="0.0" SE="1.1002392084403616" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="1.2105263157894737" WEIGHT="72.72727272727272"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.052603275195581E-4" CI_END="24.457329364492963" CI_START="0.8876248906852239" DF="1" EFFECT_SIZE="4.659284741632624" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="1" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="1.3884090321938694" LOG_CI_START="-0.05177052782840554" LOG_EFFECT_SIZE="0.668319252182732" MODIFIED="2008-05-18 14:29:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9860603090069484" P_Z="0.06890330436377269" STUDIES="2" TAU2="0.0" TOTAL_1="451" TOTAL_2="164" WEIGHT="100.0" Z="1.8190532636536474">
<NAME>blood pressure - hypotension</NAME>
<DICH_DATA CI_END="35.41392601611258" CI_START="0.624828097001513" EFFECT_SIZE="4.704" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.5491740756600771" LOG_CI_START="-0.20423944952391312" LOG_EFFECT_SIZE="0.672467313068082" ORDER="68" O_E="0.0" SE="1.0299637842300073" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="1.060825396825397" WEIGHT="69.28020258486825"/>
<DICH_DATA CI_END="82.53459357048892" CI_START="0.25176581773532825" EFFECT_SIZE="4.558441558441558" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9166360170080303" LOG_CI_START="-0.599003234421346" LOG_EFFECT_SIZE="0.6588163912933421" MODIFIED="2008-05-18 14:29:03 +0100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="1.4776989489047434" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="2.1835941835941837" WEIGHT="30.719797415131755"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.143434531304852" CI_END="2.09536657479784" CI_START="0.598337473406176" DF="3" EFFECT_SIZE="1.119703685009696" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="12" I2="27.596297773402032" ID="CMP-001.10.03" LOG_CI_END="0.3212600117821781" LOG_CI_START="-0.22305379678375942" LOG_EFFECT_SIZE="0.04910310749920931" MODIFIED="2008-11-26 21:02:31 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.2463866504652248" P_Z="0.7236231399016992" STUDIES="4" TAU2="0.0" TOTAL_1="479" TOTAL_2="245" WEIGHT="100.0" Z="0.35362072654745247">
<NAME>dizziness</NAME>
<DICH_DATA CI_END="24.804900394937484" CI_START="0.37207527669571916" EFFECT_SIZE="3.037974683544304" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.3945374874489682" LOG_CI_START="-0.4293691866066388" LOG_EFFECT_SIZE="0.48258415042116465" MODIFIED="2008-11-26 21:02:31 +0000" MODIFIED_BY="[Empty name]" ORDER="439" O_E="0.0" SE="1.0713718088239097" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="1.1478375527426161" WEIGHT="7.619752931756204"/>
<DICH_DATA CI_END="69.69936418378434" CI_START="0.12912599857107263" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8432288163658224" LOG_CI_START="-0.8889863069264972" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-11-26 19:28:37 +0000" MODIFIED_BY="[Empty name]" ORDER="441" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="2.8694639205031276"/>
<DICH_DATA CI_END="1.4312605873101116" CI_START="0.3310179742718188" EFFECT_SIZE="0.6883116883116883" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.15571871225573855" LOG_CI_START="-0.48014842339912417" LOG_EFFECT_SIZE="-0.16221485557169282" ORDER="70" O_E="0.0" SE="0.3735115030767516" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.13951084293065424" WEIGHT="85.7013224256934"/>
<DICH_DATA CI_END="98.19623852839231" CI_START="0.316110034271379" EFFECT_SIZE="5.571428571428571" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.992094852169328" LOG_CI_START="-0.5001617181448433" LOG_EFFECT_SIZE="0.7459665670122424" ORDER="71" O_E="0.0" SE="1.4639638462715339" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="2.143190143190143" WEIGHT="3.809460722047256"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4894218241116288" CI_END="3.0035773467763476" CI_START="0.6909419323713072" DF="2" EFFECT_SIZE="1.4405893016430233" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="9" I2="0.0" ID="CMP-001.10.04" LOG_CI_END="0.4776388201840377" LOG_CI_START="-0.16055844974647304" LOG_EFFECT_SIZE="0.15854018521878235" NO="4" P_CHI2="0.4748716592970206" P_Z="0.3301639547329429" STUDIES="3" TAU2="0.0" TOTAL_1="675" TOTAL_2="270" WEIGHT="100.0" Z="0.9737837116255814">
<NAME>ECG - abnormal</NAME>
<DICH_DATA CI_END="6.730099600376752" CI_START="0.60389240001329" EFFECT_SIZE="2.016" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="3" LOG_CI_END="0.8280214915009367" LOG_CI_START="-0.21904043595396128" LOG_EFFECT_SIZE="0.3044905277734877" ORDER="72" O_E="0.0" SE="0.615049359227139" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="0.3782857142857142" WEIGHT="35.60843668172532"/>
<DICH_DATA CI_END="2.479601416396647" CI_START="0.292603036223288" EFFECT_SIZE="0.8517857142857143" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.39438187575707756" LOG_CI_START="-0.5337211716892507" LOG_EFFECT_SIZE="-0.06966964796608652" ORDER="73" O_E="0.0" SE="0.5451723242541522" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.2972128631326745" WEIGHT="53.8198141167669"/>
<DICH_DATA CI_END="20.650001289014405" CI_START="0.3026634193638011" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.3149200831019514" LOG_CI_START="-0.5190400657578761" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="74" O_E="0.0" SE="1.0772772696894117" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="1.1605263157894736" WEIGHT="10.571749201507783"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0323210418086421" CI_END="9.963553492613059" CI_START="0.4829895303236233" DF="1" EFFECT_SIZE="2.1936936936936933" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" ID="CMP-001.10.05" LOG_CI_END="0.9984142567970975" LOG_CI_START="-0.3160622832691064" LOG_EFFECT_SIZE="0.34117598676399563" MODIFIED="2009-05-14 13:26:17 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8573249087152817" P_Z="0.30894986150202675" STUDIES="3" TAU2="0.0" TOTAL_1="459" TOTAL_2="224" WEIGHT="100.0" Z="1.0174280423653157">
<NAME>ECG - prolonged QTc LD</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-14 13:26:17 +0100" MODIFIED_BY="[Empty name]" ORDER="520" O_E="0.0" SE="0.0" STUDY_ID="STD-Canuso-2009" TOTAL_1="159" TOTAL_2="80" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.729566039101684" CI_START="0.21416623449114247" EFFECT_SIZE="1.8928571428571428" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2234846756146438" LOG_CI_START="-0.6692489990975042" LOG_EFFECT_SIZE="0.27711783825856984" ORDER="75" O_E="0.0" SE="1.1118011297087098" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="1.2361017520215631" WEIGHT="50.450450450450454"/>
<DICH_DATA CI_END="20.650001289014405" CI_START="0.3026634193638011" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.3149200831019514" LOG_CI_START="-0.5190400657578761" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2008-05-18 14:25:31 +0100" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="1.0772772696894117" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="1.1605263157894736" WEIGHT="49.549549549549546"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.670767691944671" CI_START="0.023401511179166532" DF="0" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.10.06" LOG_CI_END="0.426636113968882" LOG_CI_START="-1.6307560966248067" LOG_EFFECT_SIZE="-0.6020599913279624" NO="6" P_CHI2="1.0" P_Z="0.25134087681635964" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="38" WEIGHT="100.0" Z="1.1470986362826696">
<NAME>ECG - T-wave inversion</NAME>
<DICH_DATA CI_END="2.67076769194467" CI_START="0.023401511179166532" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.42663611396888185" LOG_CI_START="-1.6307560966248067" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="76" O_E="0.0" SE="1.2085223687584246" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="1.4605263157894737" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.380961327185917" CI_START="0.8782622919354045" DF="0" EFFECT_SIZE="1.9615384615384615" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" I2="0.0" ID="CMP-001.10.07" LOG_CI_END="0.6415694194726547" LOG_CI_START="-0.056375763218417856" LOG_EFFECT_SIZE="0.2925968281271184" NO="7" P_CHI2="1.0" P_Z="0.10031342029753126" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.0" Z="1.643336065186782">
<NAME>pulse rate - increase of 15/more beats/min</NAME>
<DICH_DATA CI_END="4.380961327185917" CI_START="0.8782622919354044" EFFECT_SIZE="1.9615384615384615" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.6415694194726547" LOG_CI_START="-0.05637576321841791" LOG_EFFECT_SIZE="0.2925968281271184" ORDER="77" O_E="0.0" SE="0.40997645519711" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="102" VAR="0.16808069381598795" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.3766173088598226" CI_END="2.7570682346719275" CI_START="1.284054375690026" DF="4" EFFECT_SIZE="1.8815487054037332" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="28" I2="0.0" ID="CMP-001.10.08" LOG_CI_END="0.4404475145913683" LOG_CI_START="0.10858341513634606" LOG_EFFECT_SIZE="0.2745154648638572" NO="8" P_CHI2="0.49688536488745716" P_Z="0.0011847153234464105" STUDIES="5" TAU2="0.0" TOTAL_1="1143" TOTAL_2="495" WEIGHT="100.00000000000003" Z="3.2425346713668963">
<NAME>pulse rate - tachycardia</NAME>
<DICH_DATA CI_END="2.6206982547049007" CI_START="0.6971246167824947" EFFECT_SIZE="1.3516483516483517" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="10" LOG_CI_END="0.41841701947365073" LOG_CI_START="-0.15668958123704194" LOG_EFFECT_SIZE="0.13086371911830436" ORDER="78" O_E="0.0" SE="0.3378204640810474" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.11412266595193424" WEIGHT="36.313416751045445"/>
<DICH_DATA CI_END="3.0704328195144908" CI_START="1.0060280179897954" EFFECT_SIZE="1.7575384615384615" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="13" LOG_CI_END="0.487199599541561" LOG_CI_START="0.0026100760369261824" LOG_EFFECT_SIZE="0.2449048377892436" ORDER="79" O_E="0.0" SE="0.2846502848634505" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="0.0810257846728435" WEIGHT="47.27500523353061"/>
<DICH_DATA CI_END="16.133450859864187" CI_START="0.7303692546399914" EFFECT_SIZE="3.4326923076923075" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.207727270619249" LOG_CI_START="-0.13645751699242367" LOG_EFFECT_SIZE="0.5356348768134128" ORDER="80" O_E="0.0" SE="0.7895807980651067" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="102" VAR="0.6234378366731308" WEIGHT="4.905585009087137"/>
<DICH_DATA CI_END="6.566360369522539" CI_START="0.5456459837165213" EFFECT_SIZE="1.8928571428571428" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.8173247136355353" LOG_CI_START="-0.2630890371183956" LOG_EFFECT_SIZE="0.27711783825856984" ORDER="81" O_E="0.0" SE="0.6346403853271788" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.40276841868823" WEIGHT="9.89350151483028"/>
<DICH_DATA CI_END="208.29633036481684" CI_START="0.769743733815374" EFFECT_SIZE="12.662337662337663" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.3186816188851007" LOG_CI_START="-0.11365383783299092" LOG_EFFECT_SIZE="1.102513890526055" ORDER="82" O_E="0.0" SE="1.4287658875309004" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="2.0413719613719614" WEIGHT="1.612491491506552"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0552885678044364E-32" CI_END="36.441582915437614" CI_START="0.06335677169782632" DF="0" EFFECT_SIZE="1.5194805194805192" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="100.0" ID="CMP-001.10.09" LOG_CI_END="1.5615972331887" LOG_CI_START="-1.1982069600413405" LOG_EFFECT_SIZE="0.1816951365736797" MODIFIED="2008-05-18 14:19:46 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Z="0.7963503173516061" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="38" WEIGHT="100.00000000000001" Z="0.25807332616137885">
<NAME>acute coronary syndrome</NAME>
<DICH_DATA CI_END="36.44158291543759" CI_START="0.06335677169782634" EFFECT_SIZE="1.5194805194805194" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5615972331886998" LOG_CI_START="-1.1982069600413403" LOG_EFFECT_SIZE="0.18169513657367975" MODIFIED="2008-05-18 14:19:46 +0100" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="1.6211226443544078" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="2.628038628038628" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="153.26082231479802" CI_END="0.058794466515990795" CI_START="-0.4633950823464564" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2023003079152328" ESTIMABLE="YES" I2="99.34751752933572" I2_Q="99.3475175293357" ID="CMP-001.11" MODIFIED="2008-05-18 19:54:01 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="-4.440892098500626E-16" P_Q="-1.3322676295501878E-15" P_Z="0.1288605167890266" Q="153.26082231479805" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="222" TOTAL_2="210" UNITS="" WEIGHT="200.0" Z="1.518610697739813">
<NAME>Adverse effect: 2b.Cardiovascular - average change in QTC LD (msec)</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.345121408349557E-30" CI_END="1.875238658013345" CI_START="1.1247613419866553" DF="0" EFFECT_SIZE="1.5000000000000002" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-001.11.01" NO="1" P_CHI2="0.0" P_Z="4.69329311125009E-15" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="105" WEIGHT="100.0" Z="7.834869659686093">
<NAME>6 mg</NAME>
<CONT_DATA CI_END="1.8752386580133449" CI_START="1.1247613419866551" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="0.5" ORDER="83" SD_1="1.3" SD_2="1.5" SE="0.1914518128767567" STUDY_ID="STD-Marder-2007" TOTAL_1="111" TOTAL_2="105" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.43647267477284" CI_START="-2.16352732522716" DF="0" EFFECT_SIZE="-1.8" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.02" NO="2" P_CHI2="1.0" P_Z="2.8783245421870647E-22" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="105" WEIGHT="100.0" Z="9.704731741878195">
<NAME>12 mg</NAME>
<CONT_DATA CI_END="-1.43647267477284" CI_START="-2.16352732522716" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="0.5" ORDER="84" SD_1="1.2" SD_2="1.5" SE="0.18547653329072225" STUDY_ID="STD-Marder-2007" TOTAL_1="111" TOTAL_2="105" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="29.327167808155366" CI_END="0.014573134458394534" CI_START="-0.041971022754284285" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.013698944147944874" ESTIMABLE="YES" I2="55.67250105758617" I2_Q="76.19254251812728" ID="CMP-001.12" MODIFIED="2009-03-17 12:33:42 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.005880871560142165" P_Q="0.005583710410904552" P_Z="0.3422747151568519" Q="12.601093595501471" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1711" TOTAL_2="1693" UNITS="" WEIGHT="400.0" Z="0.9496803376238946">
<NAME>Adverse effect: 2c. Cardiovascular - average change in serum level</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.065450581410775" CI_END="0.20532293810468188" CI_START="-0.02267103688329615" DF="2" EFFECT_SIZE="0.09132595061069286" ESTIMABLE="YES" I2="3.168828245024862" ID="CMP-001.12.01" MODIFIED="2009-03-17 12:33:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3560354866827019" P_Z="0.11637368130389115" STUDIES="4" TAU2="0.0" TOTAL_1="408" TOTAL_2="404" WEIGHT="100.0" Z="1.5701781072090182">
<NAME>LDL (mmol/L)</NAME>
<CONT_DATA CI_END="0.4048260912377296" CI_START="-0.004826091237729618" EFFECT_SIZE="0.2" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-0.2" ORDER="85" SD_1="0.81" SD_2="0.74" SE="0.10450502807876659" STUDY_ID="STD-Davidson-2007" TOTAL_1="114" TOTAL_2="106" WEIGHT="30.975348044358633"/>
<CONT_DATA CI_END="0.18104022427370778" CI_START="-0.18104022427370778" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" ORDER="86" SD_1="0.7" SD_2="0.7" SE="0.09236915866910309" STUDY_ID="STD-Kane-2007" TOTAL_1="111" TOTAL_2="119" WEIGHT="39.64939743366577"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="-0.1" ORDER="87" SD_1="0.0" SD_2="0.7" SE="0.0" STUDY_ID="STD-Kramer-2007" TOTAL_1="84" TOTAL_2="82" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.310330645957808" CI_START="-0.11033064595780803" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-0.1" ORDER="88" SD_1="0.8" SD_2="0.7" SE="0.10731352597132872" STUDY_ID="STD-Marder-2007" TOTAL_1="99" TOTAL_2="97" WEIGHT="29.3752545219756"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.300629742533514" CI_END="-0.004974260033519088" CI_START="-0.06658847209339905" DF="2" EFFECT_SIZE="-0.035781366063459066" ESTIMABLE="YES" I2="78.49607977776357" ID="CMP-001.12.02" MODIFIED="2009-03-17 12:33:42 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.009558616335537784" P_Z="0.022820347106203405" STUDIES="4" TAU2="0.0" TOTAL_1="419" TOTAL_2="416" WEIGHT="100.0" Z="2.2764289749860724">
<NAME>HDL (mmol/L)</NAME>
<CONT_DATA CI_END="0.0541121947483944" CI_START="-0.0541121947483944" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" ORDER="89" SD_1="0.18" SD_2="0.23" SE="0.02760876994435841" STUDY_ID="STD-Davidson-2007" TOTAL_1="117" TOTAL_2="109" WEIGHT="32.41242379774632"/>
<CONT_DATA CI_END="-0.048498195639530846" CI_START="-0.15150180436046917" EFFECT_SIZE="-0.1" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.1" ORDER="90" SD_1="0.2" SD_2="0.2" SE="0.026276913640612184" STUDY_ID="STD-Kane-2007" TOTAL_1="112" TOTAL_2="120" WEIGHT="35.78136606345907"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="91" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Kramer-2007" TOTAL_1="86" TOTAL_2="85" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.05462543914050784" CI_START="-0.05462543914050784" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" ORDER="92" SD_1="0.2" SD_2="0.2" SE="0.0278706341399058" STUDY_ID="STD-Marder-2007" TOTAL_1="104" TOTAL_2="102" WEIGHT="31.80621013879461"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.729720059096625" CI_END="0.23930085794104725" CI_START="-0.004857947396559759" DF="3" EFFECT_SIZE="0.11722145527224374" ESTIMABLE="YES" I2="36.571298882052666" ID="CMP-001.12.03" MODIFIED="2009-03-17 12:33:42 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.19269253651089369" P_Z="0.05984002549674666" STUDIES="5" TAU2="0.0" TOTAL_1="442" TOTAL_2="435" WEIGHT="100.0" Z="1.88197046779687">
<NAME>cholesterol (mmol/L)</NAME>
<CONT_DATA CI_END="0.31465356073527995" CI_START="-0.11465356073527994" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.2" ORDER="93" SD_1="0.85" SD_2="0.8" SE="0.10951913526393334" STUDY_ID="STD-Davidson-2007" TOTAL_1="118" TOTAL_2="109" WEIGHT="32.34510736774502"/>
<CONT_DATA CI_END="0.20600721744187664" CI_START="-0.20600721744187664" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.1" ORDER="94" SD_1="0.8" SD_2="0.8" SE="0.10510765456244874" STUDY_ID="STD-Kane-2007" TOTAL_1="112" TOTAL_2="120" WEIGHT="35.1172030762227"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="-0.2" ORDER="95" SD_1="0.0" SD_2="0.8" SE="0.0" STUDY_ID="STD-Kramer-2007" TOTAL_1="87" TOTAL_2="86" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.1486926866224443" CI_START="0.051307313377555896" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.8" ORDER="498" SD_1="0.77" SD_2="0.95" SE="0.2799503924309131" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="18" WEIGHT="4.950242198108538"/>
<CONT_DATA CI_END="0.43242703222380635" CI_START="-0.03242703222380633" EFFECT_SIZE="0.2" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-0.2" ORDER="96" SD_1="0.9" SD_2="0.8" SE="0.11858739959364616" STUDY_ID="STD-Marder-2007" TOTAL_1="104" TOTAL_2="102" WEIGHT="27.587447357923736"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6302738296129786" CI_END="0.24310358659123338" CI_START="-0.03065263847625438" DF="3" EFFECT_SIZE="0.1062254740574895" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.04" MODIFIED="2009-03-17 12:33:42 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8894682386563129" P_Z="0.1282479314575458" STUDIES="5" TAU2="0.0" TOTAL_1="442" TOTAL_2="438" WEIGHT="99.99999999999999" Z="1.5210474453470215">
<NAME>triglycerides (mmol/L)</NAME>
<CONT_DATA CI_END="0.359002487487602" CI_START="-0.15900248748760196" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.2" ORDER="97" SD_1="0.88" SD_2="1.09" SE="0.1321465544931338" STUDY_ID="STD-Davidson-2007" TOTAL_1="118" TOTAL_2="109" WEIGHT="27.929306084844512"/>
<CONT_DATA CI_END="0.3084896539933316" CI_START="-0.10848965399333163" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.3" ORDER="98" SD_1="0.9" SD_2="0.7" SE="0.10637422709696269" STUDY_ID="STD-Kane-2007" TOTAL_1="112" TOTAL_2="120" WEIGHT="43.102156420333365"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="-0.1" ORDER="99" SD_1="0.0" SD_2="0.7" SE="0.0" STUDY_ID="STD-Kramer-2007" TOTAL_1="87" TOTAL_2="86" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.8266842699117984" CI_START="-0.6266842699117983" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="-0.9" ORDER="497" SD_1="0.78" SD_2="2.76" SE="0.6258708219067939" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" WEIGHT="1.2450948114978992"/>
<CONT_DATA CI_END="0.359962334317411" CI_START="-0.15996233431741094" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.2" ORDER="100" SD_1="0.9" SD_2="1.0" SE="0.13263628126228882" STUDY_ID="STD-Marder-2007" TOTAL_1="104" TOTAL_2="102" WEIGHT="27.723442683324212"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="18.547133099906883" CI_END="1.0953636087785361" CI_START="0.7883916876195284" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9292876648712857" ESTIMABLE="YES" EVENTS_1="421" EVENTS_2="188" I2="0.0" I2_Q="52.75685225656295" ID="CMP-001.13" LOG_CI_END="0.039558308284198915" LOG_CI_START="-0.10325796333729417" LOG_EFFECT_SIZE="-0.03184982752654763" METHOD="MH" MODIFIED="2009-05-13 16:56:30 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.8549703031134732" P_Q="0.06029178002209856" P_Z="0.3820129959623745" Q="10.583545421557124" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5209" TOTAL_2="2237" WEIGHT="600.0" Z="0.8741933136483202">
<NAME>Adverse effect: 3. Central nervous system - levels of arousal</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.7577370191667687" CI_END="0.9462218446463272" CI_START="0.43874653719900236" DF="5" EFFECT_SIZE="0.6443225572340522" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="42" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="-0.024007029971823836" LOG_CI_START="-0.35778629817580576" LOG_EFFECT_SIZE="-0.19089666407381478" MODIFIED="2009-05-13 16:43:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7372747225987258" P_Z="0.02496755884142932" STUDIES="6" TAU2="0.0" TOTAL_1="1299" TOTAL_2="577" WEIGHT="99.99999999999999" Z="2.2419042882247813">
<NAME>agitation or aggression</NAME>
<DICH_DATA CI_END="2.937969952136946" CI_START="0.26723574469361705" EFFECT_SIZE="0.8860759493670886" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.46804734976334283" LOG_CI_START="-0.5731054523157121" LOG_EFFECT_SIZE="-0.052529051276184624" MODIFIED="2009-05-13 16:43:18 +0100" MODIFIED_BY="[Empty name]" ORDER="498" O_E="0.0" SE="0.6115783097307264" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.3740280289330922" WEIGHT="9.273465974215833"/>
<DICH_DATA CI_END="1.0701057087299946" CI_START="0.2675010459470057" EFFECT_SIZE="0.5350274725274725" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.02942668091001363" LOG_CI_START="-0.5726745155189215" LOG_EFFECT_SIZE="-0.27162391730445395" ORDER="101" O_E="0.0" SE="0.3536772232313469" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.125087578232636" WEIGHT="31.322443178785104"/>
<DICH_DATA CI_END="1.8239143688067465" CI_START="0.3233836029187481" EFFECT_SIZE="0.768" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" LOG_CI_END="0.2610044447228281" LOG_CI_START="-0.4902820046598041" LOG_EFFECT_SIZE="-0.114638779968488" ORDER="102" O_E="0.0" SE="0.44130937929526065" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="0.19475396825396823" WEIGHT="18.297575315796706"/>
<DICH_DATA CI_END="1.386758291045342" CI_START="0.02082394764546234" EFFECT_SIZE="0.16993464052287582" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14200077108556014" LOG_CI_START="-1.6814369367791218" LOG_EFFECT_SIZE="-0.7697180828467808" ORDER="103" O_E="0.0" SE="1.07109633576194" STUDY_ID="STD-Kramer-2007" TOTAL_1="102" TOTAL_2="104" VAR="1.1472473604826547" WEIGHT="10.374953606522531"/>
<DICH_DATA CI_END="1.6553943415197234" CI_START="0.40358596888193665" EFFECT_SIZE="0.8173701298701299" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.2189014663569936" LOG_CI_START="-0.39406394090657076" LOG_EFFECT_SIZE="-0.08758123727478863" ORDER="104" O_E="0.0" SE="0.3600589144543191" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.12964242187802266" WEIGHT="26.075264663364692"/>
<DICH_DATA CI_END="3.4135193741540677" CI_START="0.07323819571463676" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5332023721252457" LOG_CI_START="-1.135262363453208" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="105" O_E="0.0" SE="0.9800644447124248" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.9605263157894737" WEIGHT="4.656297261315123"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2929106399028738" CI_END="1.2002049147770777" CI_START="0.5311585836977996" DF="4" EFFECT_SIZE="0.7984354342588578" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="32" I2="0.0" ID="CMP-001.13.02" LOG_CI_END="0.07925540084717014" LOG_CI_START="-0.2747757957875127" LOG_EFFECT_SIZE="-0.09776019747017128" MODIFIED="2008-11-26 19:35:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9902672052648205" P_Z="0.2790628451028526" STUDIES="5" TAU2="0.0" TOTAL_1="1060" TOTAL_2="414" WEIGHT="100.0" Z="1.082427017643725">
<NAME>anxiety</NAME>
<DICH_DATA CI_END="1.598083084741114" CI_START="0.4465685336050765" EFFECT_SIZE="0.8447802197802198" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="12" LOG_CI_END="0.203599354644175" LOG_CI_START="-0.3501118817194159" LOG_EFFECT_SIZE="-0.07325626353762045" ORDER="106" O_E="0.0" SE="0.3252527211547982" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.1057893326186009" WEIGHT="39.28701617380005"/>
<DICH_DATA CI_END="1.8239143688067465" CI_START="0.3233836029187481" EFFECT_SIZE="0.768" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" LOG_CI_END="0.2610044447228281" LOG_CI_START="-0.4902820046598041" LOG_EFFECT_SIZE="-0.114638779968488" ORDER="107" O_E="0.0" SE="0.44130937929526065" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="0.19475396825396823" WEIGHT="22.950225602449695"/>
<DICH_DATA CI_END="14.954425656523698" CI_START="0.06686983659340748" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1747697380632693" LOG_CI_START="-1.1747697380632693" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-26 19:35:33 +0000" MODIFIED_BY="[Empty name]" ORDER="446" O_E="0.0" SE="1.3801311186847085" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="1.9047619047619047" WEIGHT="2.1901072432051993"/>
<DICH_DATA CI_END="1.6964893473203526" CI_START="0.3814717658038972" EFFECT_SIZE="0.8044642857142857" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.22955113694635113" LOG_CI_START="-0.4185376003285884" LOG_EFFECT_SIZE="-0.09449323169111862" ORDER="108" O_E="0.0" SE="0.38069053236628836" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.14492528143332803" WEIGHT="29.732364998664526"/>
<DICH_DATA CI_END="3.4135193741540677" CI_START="0.07323819571463676" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5332023721252457" LOG_CI_START="-1.135262363453208" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="109" O_E="0.0" SE="0.9800644447124248" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.9605263157894737" WEIGHT="5.840285981880531"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.462166320054856" CI_END="1.148380899658423" CI_START="0.6860063020745075" DF="6" EFFECT_SIZE="0.8875790299165877" ESTIMABLE="YES" EVENTS_1="160" EVENTS_2="74" I2="0.0" ID="CMP-001.13.03" LOG_CI_END="0.060085960520799536" LOG_CI_START="-0.16367189457952902" LOG_EFFECT_SIZE="-0.051792967029364756" MODIFIED="2008-11-26 21:08:53 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9619679956524596" P_Z="0.3642264524883482" STUDIES="7" TAU2="0.0" TOTAL_1="1322" TOTAL_2="596" WEIGHT="100.0" Z="0.9073411075066775">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="1.5679416555213628" CI_START="0.40990254211568317" EFFECT_SIZE="0.8016877637130801" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.19532989817204646" LOG_CI_START="-0.38731938828659634" LOG_EFFECT_SIZE="-0.09599474505727491" MODIFIED="2008-11-26 21:08:53 +0000" MODIFIED_BY="[Empty name]" ORDER="808" O_E="0.0" SE="0.3422510750262899" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.1171357983566511" WEIGHT="15.346578845548052"/>
<DICH_DATA CI_END="1.687182784629016" CI_START="0.6090989202689888" EFFECT_SIZE="1.0137362637362637" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="17" LOG_CI_END="0.22716213537843918" LOG_CI_START="-0.2153121703584305" LOG_EFFECT_SIZE="0.005924982510004358" ORDER="110" O_E="0.0" SE="0.2599115974729751" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.06755403850095384" WEIGHT="24.47775270461083"/>
<DICH_DATA CI_END="1.2084846757769006" CI_START="0.4825385936258431" EFFECT_SIZE="0.7636363636363637" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="22" LOG_CI_END="0.08224114769548775" LOG_CI_START="-0.3164679458881745" LOG_EFFECT_SIZE="-0.11711339909634337" ORDER="111" O_E="0.0" SE="0.23420369521288698" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="0.05485137085137086" WEIGHT="31.722428100795874"/>
<DICH_DATA CI_END="2.594054296558337" CI_START="0.2575088211498055" EFFECT_SIZE="0.8173076923076923" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.41397906212928126" LOG_CI_START="-0.5892078892982566" LOG_EFFECT_SIZE="-0.08761441358448763" ORDER="112" O_E="0.0" SE="0.5892769811240336" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="102" VAR="0.3472473604826546" WEIGHT="5.835358848239605"/>
<DICH_DATA CI_END="69.69936418378434" CI_START="0.12912599857107263" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8432288163658224" LOG_CI_START="-0.8889863069264972" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-11-26 19:34:20 +0000" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="0.4816041357120828"/>
<DICH_DATA CI_END="1.826985378953319" CI_START="0.52871477353241" EFFECT_SIZE="0.9828296703296703" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="13" LOG_CI_END="0.2617350717831336" LOG_CI_START="-0.27677855421761766" LOG_EFFECT_SIZE="-0.007521741217242046" ORDER="113" O_E="0.0" SE="0.3163255695982816" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.10006186598167731" WEIGHT="16.99916658416467"/>
<DICH_DATA CI_END="2.805523246219266" CI_START="0.27289918236527144" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.44801387156484623" LOG_CI_START="-0.5639977655202199" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="114" O_E="0.0" SE="0.5944606451621642" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.3533834586466166" WEIGHT="5.137110780928883"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.775562343335298" CI_END="2.1656040672491685" CI_START="1.0339285120276338" DF="5" EFFECT_SIZE="1.496355502844135" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="34" I2="13.428343375606653" ID="CMP-001.13.04" LOG_CI_END="0.33557905841733165" LOG_CI_START="0.014490511770285703" LOG_EFFECT_SIZE="0.17503478509380865" MODIFIED="2008-11-26 21:09:46 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.32867403974728726" P_Z="0.0326087524059046" STUDIES="6" TAU2="0.0" TOTAL_1="1218" TOTAL_2="494" WEIGHT="100.0" Z="2.1368677170704653">
<NAME>sleepiness</NAME>
<DICH_DATA CI_END="6.363746203627077" CI_START="1.007147218807195" EFFECT_SIZE="2.5316455696202533" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="5" LOG_CI_END="0.8037128509616306" LOG_CI_START="0.0030929577854489653" LOG_EFFECT_SIZE="0.4034029043735398" MODIFIED="2008-11-26 21:09:46 +0000" MODIFIED_BY="[Empty name]" ORDER="429" O_E="0.0" SE="0.47028808838407693" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.22117088607594937" WEIGHT="14.194293278995927"/>
<DICH_DATA CI_END="7.710531710646452" CI_START="1.0079315163375406" EFFECT_SIZE="2.7877747252747254" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="4" LOG_CI_END="0.8870843276018736" LOG_CI_START="0.0034310250786604157" LOG_EFFECT_SIZE="0.44525767634026703" ORDER="115" O_E="0.0" SE="0.5190623240565284" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.26942569625496454" WEIGHT="12.78486227064149"/>
<DICH_DATA CI_END="2.5107091436243905" CI_START="0.485446911720149" EFFECT_SIZE="1.104" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="7" LOG_CI_END="0.3997964042161608" LOG_CI_START="-0.3138582574298005" LOG_EFFECT_SIZE="0.04296907339318013" ORDER="116" O_E="0.0" SE="0.4192042808983866" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="0.17573222912353345" WEIGHT="22.405530018577288"/>
<DICH_DATA CI_END="5.103130184031393" CI_START="0.04898953994595213" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.707836647596448" LOG_CI_START="-1.3098966389244104" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-11-26 19:34:54 +0000" MODIFIED_BY="[Empty name]" ORDER="445" O_E="0.0" SE="1.185226520443204" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="1.4047619047619047" WEIGHT="4.276255443545608"/>
<DICH_DATA CI_END="1.830770251351169" CI_START="0.5616532614132626" EFFECT_SIZE="1.0140306122448979" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" LOG_CI_END="0.2626338468517234" LOG_CI_START="-0.25053171490765974" LOG_EFFECT_SIZE="0.0060510659720318105" ORDER="117" O_E="0.0" SE="0.30143599118796033" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.0908636567834681" WEIGHT="40.637385063512205"/>
<DICH_DATA CI_END="8.021070819703272" CI_START="0.38180687701661425" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.904232350833354" LOG_CI_START="-0.41815625346076496" LOG_EFFECT_SIZE="0.24303804868629444" ORDER="118" O_E="0.0" SE="0.7767776120915281" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.6033834586466165" WEIGHT="5.701673924727477"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0552885678044364E-32" CI_END="36.441582915437614" CI_START="0.06335677169782632" DF="0" EFFECT_SIZE="1.5194805194805192" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="100.0" ID="CMP-001.13.05" LOG_CI_END="1.5615972331887" LOG_CI_START="-1.1982069600413405" LOG_EFFECT_SIZE="0.1816951365736797" MODIFIED="2008-05-18 14:20:28 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.7963503173516061" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="38" WEIGHT="100.00000000000001" Z="0.25807332616137885">
<NAME>mania</NAME>
<DICH_DATA CI_END="36.44158291543759" CI_START="0.06335677169782634" EFFECT_SIZE="1.5194805194805194" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5615972331886998" LOG_CI_START="-1.1982069600413403" LOG_EFFECT_SIZE="0.18169513657367975" MODIFIED="2008-05-18 14:20:28 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="1.6211226443544078" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="2.628038628038628" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12063116359921673" CI_END="2.271237144067214" CI_START="0.35334910281779297" DF="1" EFFECT_SIZE="0.8958457496369543" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="0.0" ID="CMP-001.13.06" LOG_CI_END="0.35626248207658817" LOG_CI_START="-0.4517960070569888" LOG_EFFECT_SIZE="-0.047766762490200274" MODIFIED="2009-05-13 16:56:30 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.728351006529393" P_Z="0.8167565009003231" STUDIES="2" TAU2="0.0" TOTAL_1="234" TOTAL_2="118" WEIGHT="100.0" Z="0.23171870699422897">
<NAME>fatigue</NAME>
<DICH_DATA CI_END="2.2389157174064818" CI_START="0.3180720838489023" EFFECT_SIZE="0.8438818565400844" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.35003774514033703" LOG_CI_START="-0.49747444583258227" LOG_EFFECT_SIZE="-0.07371835034612266" MODIFIED="2009-05-13 16:56:30 +0100" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.49783285623049833" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.24783755274261604" WEIGHT="92.30846714960842"/>
<DICH_DATA CI_END="36.44158291543759" CI_START="0.06335677169782634" EFFECT_SIZE="1.5194805194805194" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5615972331886998" LOG_CI_START="-1.1982069600413403" LOG_EFFECT_SIZE="0.18169513657367975" MODIFIED="2008-05-18 14:27:52 +0100" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="1.6211226443544078" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="2.628038628038628" WEIGHT="7.691532850391586"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1214.404928152251" CI_END="24.391134198082337" CI_START="22.908176012783397" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="23.649655105432867" ESTIMABLE="YES" I2="99.17655143122523" I2_Q="99.83339364515865" ID="CMP-001.14" MODIFIED="2009-05-13 21:09:21 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="1200.4344023398864" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="812" TOTAL_2="722" UNITS="" WEIGHT="300.00000000000006" Z="62.51352561784909">
<NAME>Adverse effect: 4. Endocrine: average change in serum level</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.5653146454055695" CI_END="3.4665950775583907" CI_START="-3.5577486772860114" DF="2" EFFECT_SIZE="-0.04557679986381035" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" NO="1" P_CHI2="0.4571896461780194" P_Z="0.9797087221330849" STUDIES="3" TAU2="0.0" TOTAL_1="320" TOTAL_2="311" WEIGHT="100.00000000000001" Z="0.025434087334365398">
<NAME>insulin (mmol/L)</NAME>
<CONT_DATA CI_END="4.360905853179438" CI_START="-8.360905853179439" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="0.9" ORDER="119" SD_1="23.63" SD_2="24.23" SE="3.245419764522946" STUDY_ID="STD-Davidson-2007" TOTAL_1="113" TOTAL_2="105" WEIGHT="30.486922504158624"/>
<CONT_DATA CI_END="4.461165349111847" CI_START="-4.6611653491118465" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-0.9" ORDER="120" SD_1="14.6" SD_2="18.8" SE="2.3271679403753014" STUDY_ID="STD-Kane-2007" TOTAL_1="104" TOTAL_2="105" WEIGHT="59.29251737140263"/>
<CONT_DATA CI_END="17.085970092900293" CI_START="-4.885970092900294" EFFECT_SIZE="6.1" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="-2.7" ORDER="121" SD_1="48.4" SD_2="29.6" SE="5.60518977876952" STUDY_ID="STD-Marder-2007" TOTAL_1="103" TOTAL_2="101" WEIGHT="10.220560124438766"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="10.622333710863332" CI_END="22.891627838933065" CI_START="21.34019497840175" DF="3" EFFECT_SIZE="22.115911408667408" ESTIMABLE="YES" I2="71.75761860190914" ID="CMP-001.14.02" MODIFIED="2009-05-13 21:09:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.013953615701159272" P_Z="0.0" STUDIES="4" TAU2="0.0" TOTAL_1="303" TOTAL_2="265" WEIGHT="100.0" Z="55.879169442655765">
<NAME>prolactin (ng/ml) - men</NAME>
<CONT_DATA CI_END="22.69063064286188" CI_START="21.109369357138117" EFFECT_SIZE="21.9" ESTIMABLE="YES" MEAN_1="20.9" MEAN_2="-1.0" MODIFIED="2009-05-13 21:09:16 +0100" MODIFIED_BY="[Empty name]" ORDER="514" SD_1="1.7" SD_2="2.6" SE="0.403390393445121" STUDY_ID="STD-Canuso-2009" TOTAL_1="105" TOTAL_2="50" WEIGHT="96.26284557109938"/>
<CONT_DATA CI_END="37.133640546853805" CI_START="25.426359453146194" EFFECT_SIZE="31.28" ESTIMABLE="YES" MEAN_1="29.17" MEAN_2="-2.11" ORDER="122" SD_1="22.1" SD_2="13.19" SE="2.986606179004602" STUDY_ID="STD-Davidson-2007" TOTAL_1="74" TOTAL_2="75" WEIGHT="1.7561187500106736"/>
<CONT_DATA CI_END="34.49078207790208" CI_START="17.509217922097918" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="25.41" MEAN_2="-0.59" ORDER="123" SD_1="24.49" SD_2="21.9" SE="4.332111275960317" STUDY_ID="STD-Kane-2007" TOTAL_1="55" TOTAL_2="61" WEIGHT="0.8346619033906483"/>
<CONT_DATA CI_END="30.625024675425554" CI_START="16.13497532457445" EFFECT_SIZE="23.380000000000003" ESTIMABLE="YES" MEAN_1="23.62" MEAN_2="0.24" ORDER="124" SD_1="28.89" SD_2="11.13" SE="3.6965090851532887" STUDY_ID="STD-Marder-2007" TOTAL_1="69" TOTAL_2="79" WEIGHT="1.146373775499304"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7828774560957878" CI_END="86.13315027896093" CI_START="78.87580675249433" DF="3" EFFECT_SIZE="82.50447851572763" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.03" MODIFIED="2009-05-13 21:09:21 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6186681956069995" P_Z="0.0" STUDIES="4" TAU2="0.0" TOTAL_1="189" TOTAL_2="146" WEIGHT="100.00000000000003" Z="44.56336009570565">
<NAME>prolactin (ng/ml) - women</NAME>
<CONT_DATA CI_END="85.8759027440276" CI_START="78.32409725597239" EFFECT_SIZE="82.1" ESTIMABLE="YES" MEAN_1="76.6" MEAN_2="-5.5" MODIFIED="2009-05-13 21:09:21 +0100" MODIFIED_BY="[Empty name]" ORDER="515" SD_1="7.1" SD_2="9.1" SE="1.9265163920416122" STUDY_ID="STD-Canuso-2009" TOTAL_1="53" TOTAL_2="30" WEIGHT="92.35358767143097"/>
<CONT_DATA CI_END="115.49459225674623" CI_START="65.06540774325377" EFFECT_SIZE="90.28" ESTIMABLE="YES" MEAN_1="83.96" MEAN_2="-6.32" ORDER="125" SD_1="78.03" SD_2="28.51" SE="12.864824280260105" STUDY_ID="STD-Davidson-2007" TOTAL_1="43" TOTAL_2="34" WEIGHT="2.0710542315991436"/>
<CONT_DATA CI_END="112.84649408296178" CI_START="73.31350591703821" EFFECT_SIZE="93.08" ESTIMABLE="YES" MEAN_1="68.19" MEAN_2="-24.89" ORDER="126" SD_1="54.4" SD_2="55.15" SE="10.085131277348646" STUDY_ID="STD-Kane-2007" TOTAL_1="59" TOTAL_2="59" WEIGHT="3.3700479246630763"/>
<CONT_DATA CI_END="100.41502821716688" CI_START="51.54497178283313" EFFECT_SIZE="75.98" ESTIMABLE="YES" MEAN_1="80.97" MEAN_2="4.99" ORDER="127" SD_1="69.53" SD_2="17.45" SE="12.467080216732175" STUDY_ID="STD-Marder-2007" TOTAL_1="34" TOTAL_2="23" WEIGHT="2.20531017230682"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="11.491967970612222" CI_END="1.061203650459262" CI_START="0.5716206629443417" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7788491087460258" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="68" I2="0.0" I2_Q="1.2560505291583464" ID="CMP-001.15" LOG_CI_END="0.02579873525260882" LOG_CI_START="-0.242892080719918" LOG_EFFECT_SIZE="-0.1085466727336546" METHOD="MH" MODIFIED="2009-05-13 16:54:05 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.6470290860891555" P_Q="0.39916387215684035" P_Z="0.1132878568976641" Q="4.050881113663749" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2118" TOTAL_2="1115" WEIGHT="500.0" Z="1.5835864611120316">
<NAME>Adverse effect: 5. Gastrointestinal events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1839582750815256" CI_END="1.4014732917172723" CI_START="0.335515759977575" DF="1" EFFECT_SIZE="0.685723250705993" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="54.21157943309743" ID="CMP-001.15.01" LOG_CI_END="0.1465848256993486" LOG_CI_START="-0.4742870751655029" LOG_EFFECT_SIZE="-0.16385112473307717" MODIFIED="2009-05-13 16:48:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13945546935759734" P_Z="0.300908041629822" STUDIES="2" TAU2="0.0" TOTAL_1="382" TOTAL_2="186" WEIGHT="100.0" Z="1.0344881218037798">
<NAME>constipation</NAME>
<DICH_DATA CI_END="8.335111024845256" CI_START="0.37678230593760487" EFFECT_SIZE="1.7721518987341771" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.9209113890658256" LOG_CI_START="-0.4239095002902326" LOG_EFFECT_SIZE="0.24850094438779657" MODIFIED="2009-05-13 16:48:38 +0100" MODIFIED_BY="[Empty name]" ORDER="500" O_E="0.0" SE="0.7899544473785132" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.6240280289330922" WEIGHT="16.360213366802633"/>
<DICH_DATA CI_END="1.1022041483453977" CI_START="0.20316722681568797" EFFECT_SIZE="0.4732142857142857" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.04226204123864894" LOG_CI_START="-0.6921463473774341" LOG_EFFECT_SIZE="-0.32494215306939256" ORDER="128" O_E="0.0" SE="0.4313951228532415" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.18610175202156334" WEIGHT="83.63978663319736"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9515711123182559" CI_END="1.661676208067482" CI_START="0.5201045788627701" DF="2" EFFECT_SIZE="0.9296480002685008" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="16" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="0.22054640166873038" LOG_CI_START="-0.2839093227949026" LOG_EFFECT_SIZE="-0.031681460563086114" MODIFIED="2009-05-13 16:53:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.621396765376913" P_Z="0.80553962394801" STUDIES="3" TAU2="0.0" TOTAL_1="403" TOTAL_2="207" WEIGHT="100.0" Z="0.2461842285457159">
<NAME>dyspepsia</NAME>
<DICH_DATA CI_END="1.971884473868461" CI_START="0.13001226745508412" EFFECT_SIZE="0.5063291139240507" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.29488146748595817" LOG_CI_START="-0.8860156674109163" LOG_EFFECT_SIZE="-0.295567099962479" MODIFIED="2009-05-13 16:53:10 +0100" MODIFIED_BY="[Empty name]" ORDER="504" O_E="0.0" SE="0.6936648225735174" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.4811708860759494" WEIGHT="24.99934073468527"/>
<DICH_DATA CI_END="14.954425656523698" CI_START="0.06686983659340748" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1747697380632693" LOG_CI_START="-1.1747697380632693" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-26 19:36:39 +0000" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="1.3801311186847085" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="1.9047619047619047" WEIGHT="4.707154347195486"/>
<DICH_DATA CI_END="2.1026858199127756" CI_START="0.5500927928223288" EFFECT_SIZE="1.0754870129870129" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="11" LOG_CI_END="0.3227743859190722" LOG_CI_START="-0.2595640450302324" LOG_EFFECT_SIZE="0.03160517044441996" ORDER="129" O_E="0.0" SE="0.34206847696134507" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.11701084293065425" WEIGHT="70.29350491811925"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4415099708793236" CI_END="0.9317759277165201" CI_START="0.2547921763058276" DF="3" EFFECT_SIZE="0.487246566383257" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="24" I2="0.0" ID="CMP-001.15.03" LOG_CI_END="-0.030688513672006514" LOG_CI_START="-0.5938139116560481" LOG_EFFECT_SIZE="-0.31225121266402733" MODIFIED="2008-11-26 19:36:53 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9315401392727071" P_Z="0.02973613656620426" STUDIES="4" TAU2="0.0" TOTAL_1="321" TOTAL_2="271" WEIGHT="100.0" Z="2.1735873861892276">
<NAME>nausea</NAME>
<DICH_DATA CI_END="1.33901819101798" CI_START="0.16723578641888276" EFFECT_SIZE="0.4732142857142857" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.12678647709047408" LOG_CI_START="-0.7766707832292592" LOG_EFFECT_SIZE="-0.32494215306939256" ORDER="130" O_E="0.0" SE="0.5306952668973764" STUDY_ID="STD-Davidson-2007" TOTAL_1="112" TOTAL_2="106" VAR="0.28163746630727765" WEIGHT="39.95481300909685"/>
<DICH_DATA CI_END="3.930879612644028" CI_START="0.010175839491836992" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5944897432947772" LOG_CI_START="-1.9924297519668148" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2008-11-26 19:36:53 +0000" MODIFIED_BY="[Empty name]" ORDER="448" O_E="0.0" SE="1.5195693169746844" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.309090909090909" WEIGHT="9.72114870087401"/>
<DICH_DATA CI_END="1.5079741040228567" CI_START="0.21383771368065213" EFFECT_SIZE="0.5678571428571428" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.17839388359175096" LOG_CI_START="-0.6699156976352865" LOG_EFFECT_SIZE="-0.24576090702176775" ORDER="131" O_E="0.0" SE="0.49830124721291263" STUDY_ID="STD-Marder-2007" TOTAL_1="112" TOTAL_2="106" VAR="0.24830413297394427" WEIGHT="39.95481300909685"/>
<DICH_DATA CI_END="3.4135193741540677" CI_START="0.07323819571463676" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5332023721252457" LOG_CI_START="-1.135262363453208" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="132" O_E="0.0" SE="0.9800644447124248" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.9605263157894737" WEIGHT="10.369225280932277"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.711569471368653" CI_END="2.085560987967466" CI_START="0.6077978658791707" DF="4" EFFECT_SIZE="1.1258772213911608" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="14" I2="15.102599583699892" ID="CMP-001.15.04" LOG_CI_END="0.31922289442181856" LOG_CI_START="-0.2162408291631622" LOG_EFFECT_SIZE="0.05149103262932817" MODIFIED="2009-05-13 16:53:25 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.31819259460460236" P_Z="0.7062134167907819" STUDIES="5" TAU2="0.0" TOTAL_1="854" TOTAL_2="371" WEIGHT="100.0" Z="0.376946429926521">
<NAME>vomiting</NAME>
<DICH_DATA CI_END="13.247124755076138" CI_START="0.6967013860362086" EFFECT_SIZE="3.037974683544304" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.122121626309944" LOG_CI_START="-0.1569533254676148" LOG_EFFECT_SIZE="0.48258415042116465" MODIFIED="2009-05-13 16:53:25 +0100" MODIFIED_BY="[Empty name]" ORDER="505" O_E="0.0" SE="0.7513349581972629" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.5645042194092827" WEIGHT="14.11040989235444"/>
<DICH_DATA CI_END="7.564762500528258" CI_START="0.37309829618615364" EFFECT_SIZE="1.68" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="0.8787952976825161" LOG_CI_START="-0.4281767342307904" LOG_EFFECT_SIZE="0.22530928172586284" ORDER="133" O_E="0.0" SE="0.7677218411617748" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="0.5893968253968254" WEIGHT="15.909372178334898"/>
<DICH_DATA CI_END="14.954425656523698" CI_START="0.06686983659340748" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1747697380632693" LOG_CI_START="-1.1747697380632693" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-11-26 19:37:01 +0000" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="1.3801311186847085" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="1.9047619047619047" WEIGHT="5.313730307563856"/>
<DICH_DATA CI_END="1.7268585337916704" CI_START="0.2646444878433574" EFFECT_SIZE="0.6760204081632653" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.2372567611284781" LOG_CI_START="-0.577337147295777" LOG_EFFECT_SIZE="-0.17004019308364943" ORDER="134" O_E="0.0" SE="0.47849649411328626" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.2289588948787062" WEIGHT="50.49654013490986"/>
<DICH_DATA CI_END="2.67076769194467" CI_START="0.023401511179166532" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.42663611396888185" LOG_CI_START="-1.6307560966248067" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="135" O_E="0.0" SE="1.2085223687584246" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="1.4605263157894737" WEIGHT="14.169947486836948"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5284395045499437" CI_START="0.07265794730971716" DF="0" EFFECT_SIZE="0.5063291139240507" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.15.05" LOG_CI_END="0.547582675811427" LOG_CI_START="-1.138716875736385" LOG_EFFECT_SIZE="-0.295567099962479" MODIFIED="2009-05-13 16:54:05 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.492040151429463" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="80" WEIGHT="100.0" Z="0.6870675739783992">
<NAME>diarrhea</NAME>
<DICH_DATA CI_END="3.5284395045499424" CI_START="0.07265794730971716" EFFECT_SIZE="0.5063291139240507" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5475826758114268" LOG_CI_START="-1.138716875736385" LOG_EFFECT_SIZE="-0.295567099962479" MODIFIED="2009-05-13 16:54:05 +0100" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.9905407038965887" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.9811708860759494" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="13.174438146202341" CI_END="1.4930121926978246" CI_START="0.6488522114660898" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0709322020819572" ESTIMABLE="YES" I2="69.63817389697914" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2011-11-25 23:13:02 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.010454208900089412" P_Q="1.0" P_Z="6.593695157132087E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="566" TOTAL_2="441" UNITS="" WEIGHT="100.00000000000001" Z="4.972963875643859">
<NAME>Adverse effect: 6a. Metabolic - average change in weight (kg)</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.714897012396062" CI_START="-14.514897012396062" EFFECT_SIZE="0.10000000000000003" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.3" MODIFIED="2011-11-25 23:13:02 +0000" MODIFIED_BY="[Empty name]" ORDER="516" SD_1="70.66" SD_2="43.82" SE="7.456717127292391" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" WEIGHT="0.08340613751236674"/>
<CONT_DATA CI_END="3.2740619921524234" CI_START="1.3259380078475762" EFFECT_SIZE="2.3" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="-0.8" ORDER="136" SD_1="3.14" SD_2="4.24" SE="0.4969795362750031" STUDY_ID="STD-Davidson-2007" TOTAL_1="118" TOTAL_2="110" WEIGHT="18.776573143318892"/>
<CONT_DATA CI_END="1.9521441202684418" CI_START="0.6478558797315579" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="-0.7" ORDER="137" SD_1="2.7" SD_2="2.4" SE="0.332732706015249" STUDY_ID="STD-Kane-2007" TOTAL_1="117" TOTAL_2="119" WEIGHT="41.889228556991306"/>
<CONT_DATA CI_END="1.6639490130685513" CI_START="-0.4639490130685512" EFFECT_SIZE="0.6" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.4" ORDER="138" SD_1="3.9" SD_2="3.6" SE="0.5428411039492792" STUDY_ID="STD-Marder-2007" TOTAL_1="97" TOTAL_2="94" WEIGHT="15.737940401203913"/>
<CONT_DATA CI_END="0.8704465560108314" CI_START="-0.8704465560108314" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" MODIFIED="2008-05-18 14:34:08 +0100" MODIFIED_BY="[Empty name]" ORDER="139" SD_1="2.1" SD_2="2.3" SE="0.4441135464104457" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" WEIGHT="23.512851760973536"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.980592100869764" CI_END="0.6272877124613279" CI_START="0.2962982559240528" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4617929841926903" ESTIMABLE="YES" I2="81.78604594699787" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2008-05-18 19:54:20 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.004126643447852962" P_Q="1.0" P_Z="4.524745659091814E-8" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="308" TOTAL_2="265" UNITS="" WEIGHT="100.00000000000003" Z="5.469041985807291">
<NAME>Adverse effect: 6b. Metabolic - average change in BMI</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1292252666778528" CI_START="0.4707747333221473" EFFECT_SIZE="0.8" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="-0.3" ORDER="140" SD_1="1.08" SD_2="1.42" SE="0.16797516141864832" STUDY_ID="STD-Davidson-2007" TOTAL_1="118" TOTAL_2="110" WEIGHT="25.2686483756435"/>
<CONT_DATA CI_END="0.7296572659997201" CI_START="0.27034273400027986" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-0.3" ORDER="141" SD_1="0.9" SD_2="0.9" SE="0.11717422759358201" STUDY_ID="STD-Kane-2007" TOTAL_1="117" TOTAL_2="119" WEIGHT="51.92875943750846"/>
<CONT_DATA CI_END="0.34657086800704323" CI_START="-0.34657086800704323" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" MODIFIED="2008-05-18 14:34:43 +0100" MODIFIED_BY="[Empty name]" ORDER="142" SD_1="0.8" SD_2="0.9" SE="0.17682512063525146" STUDY_ID="STD-Tzimos-2008" TOTAL_1="73" TOTAL_2="36" WEIGHT="22.802592186848056"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8373631134966556" CI_END="0.1336263595525652" CI_START="-0.235283176109653" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.05082840827854391" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2009-01-21 03:46:50 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.65791368623651" P_Q="1.0" P_Z="0.5891361875938242" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="328" TOTAL_2="322" UNITS="" WEIGHT="100.0" Z="0.5400882329518291">
<NAME>Adverse effect: 6c. Metabolic - average change in serum level</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8373631134966556" CI_END="0.1336263595525652" CI_START="-0.235283176109653" DF="2" EFFECT_SIZE="-0.05082840827854391" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.01" NO="1" P_CHI2="0.65791368623651" P_Z="0.5891361875938242" STUDIES="3" TAU2="0.0" TOTAL_1="328" TOTAL_2="322" WEIGHT="100.0" Z="0.5400882329518291">
<NAME>glucose (mmol/L)</NAME>
<CONT_DATA CI_END="0.47200412002220526" CI_START="-0.2720041200222053" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.0" ORDER="143" SD_1="1.22" SD_2="1.59" SE="0.18980150806674323" STUDY_ID="STD-Davidson-2007" TOTAL_1="116" TOTAL_2="109" WEIGHT="24.585795860728048"/>
<CONT_DATA CI_END="0.150604779272303" CI_START="-0.35060477927230305" EFFECT_SIZE="-0.1" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.1" ORDER="144" SD_1="0.96" SD_2="1.0" SE="0.12786193075436156" STUDY_ID="STD-Kane-2007" TOTAL_1="114" TOTAL_2="121" WEIGHT="54.17526852462596"/>
<CONT_DATA CI_END="0.3002427844890605" CI_START="-0.5002427844890605" EFFECT_SIZE="-0.1" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.1" ORDER="145" SD_1="1.3" SD_2="1.5" SE="0.2042092546833128" STUDY_ID="STD-Marder-2007" TOTAL_1="98" TOTAL_2="92" WEIGHT="21.238935614645985"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="15.591271522875761" CI_END="2.5380466995057445" CI_START="1.455185925635687" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9218037974067141" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.4044996087559536" LOG_CI_START="0.1629184856373976" LOG_EFFECT_SIZE="0.28370904719667556" METHOD="MH" MODIFIED="2009-01-02 18:33:24 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.7921584329000468" P_Q="0.664611824078825" P_Z="4.1544647940820264E-6" Q="4.96191008874418" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3664" TOTAL_2="1617" WEIGHT="800.0" Z="4.6035013614931515">
<NAME>Adverse effect: 7a. Movement disorder - various events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.217962568830391" CI_START="0.1916456829287203" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.19.01" LOG_CI_END="0.7175009593543286" LOG_CI_START="-0.7175009593543286" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="38" WEIGHT="100.0" Z="0.0">
<NAME>asthenia</NAME>
<DICH_DATA CI_END="5.217962568830391" CI_START="0.1916456829287203" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.7175009593543286" LOG_CI_START="-0.7175009593543286" LOG_EFFECT_SIZE="0.0" ORDER="146" O_E="0.0" SE="0.8429272304235246" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.7105263157894737" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.11344574647779" CI_END="3.951136042594254" CI_START="1.3092370511248552" DF="5" EFFECT_SIZE="2.2744172222789802" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="15" I2="45.13600959403939" ID="CMP-001.19.02" LOG_CI_END="0.5967219832453119" LOG_CI_START="0.11701828724961127" LOG_EFFECT_SIZE="0.35687013524746164" MODIFIED="2008-11-26 19:38:42 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.10462402407546223" P_Z="0.003543391385661174" STUDIES="6" TAU2="0.0" TOTAL_1="1164" TOTAL_2="516" WEIGHT="100.0" Z="2.916186046018006">
<NAME>extrapyramidal disorder</NAME>
<DICH_DATA CI_END="10.877500115572152" CI_START="1.0497318128605744" EFFECT_SIZE="3.379120879120879" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="3" LOG_CI_END="1.036529096579082" LOG_CI_START="0.021078359001601776" LOG_EFFECT_SIZE="0.5288037277903419" ORDER="147" O_E="0.0" SE="0.5964807898152302" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.3557893326186009" WEIGHT="22.119552901136544"/>
<DICH_DATA CI_END="63.72198035147011" CI_START="1.1976667325631747" EFFECT_SIZE="8.736" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="1" LOG_CI_END="1.8042892643411335" LOG_CI_START="0.0783359863801908" LOG_EFFECT_SIZE="0.9413126253606621" ORDER="148" O_E="0.0" SE="1.0138334990807731" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="1.027858363858364" WEIGHT="7.383736827754858"/>
<DICH_DATA CI_END="8.606506245176842" CI_START="0.6084996703456342" EFFECT_SIZE="2.2884615384615383" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9348268882281152" LOG_CI_START="-0.21573965271265205" LOG_EFFECT_SIZE="0.3595436177577316" ORDER="149" O_E="0.0" SE="0.6758484815448386" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="102" VAR="0.45677117000646406" WEIGHT="14.940668880518023"/>
<DICH_DATA CI_END="98.2719903161007" CI_START="0.25439598729592483" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9924297519668148" LOG_CI_START="-0.5944897432947772" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2008-11-26 19:38:42 +0000" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="1.5195693169746844" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.309090909090909" WEIGHT="2.4661681004701226"/>
<DICH_DATA CI_END="3.379161314956866" CI_START="0.33548399450933986" EFFECT_SIZE="1.0647321428571428" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.5288089246909554" LOG_CI_START="-0.4743281946070158" LOG_EFFECT_SIZE="0.027240365041969892" ORDER="150" O_E="0.0" SE="0.5892477094844532" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.34721286313267447" WEIGHT="26.78408021843915"/>
<DICH_DATA CI_END="1.8906587777059676" CI_START="0.1322290425686108" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.2766131553224594" LOG_CI_START="-0.8786731466504217" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="151" O_E="0.0" SE="0.6786208925382962" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.4605263157894737" WEIGHT="26.305793071681308"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5464560152976692" CI_END="2.885010571010199" CI_START="0.969798498674928" DF="3" EFFECT_SIZE="1.6726861392463883" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="16" I2="0.0" ID="CMP-001.19.03" LOG_CI_END="0.4601474087995446" LOG_CI_START="-0.01331849254231235" LOG_EFFECT_SIZE="0.22341445812861616" MODIFIED="2008-11-26 19:42:06 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6715905848247501" P_Z="0.06435719483138612" STUDIES="4" TAU2="0.0" TOTAL_1="984" TOTAL_2="376" WEIGHT="100.0" Z="1.8496972657021553">
<NAME>hyperkinesia</NAME>
<DICH_DATA CI_END="4.9515234933492955" CI_START="0.7757550273172258" EFFECT_SIZE="1.9598901098901098" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="5" LOG_CI_END="0.6947388439752598" LOG_CI_START="-0.11027540126870118" LOG_EFFECT_SIZE="0.2922317213532792" ORDER="152" O_E="0.0" SE="0.472869352541084" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.22360542457262395" WEIGHT="33.592150906492265"/>
<DICH_DATA CI_END="5.917624635411007" CI_START="0.7452314520949173" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="4" LOG_CI_END="0.77214741369047" LOG_CI_START="-0.12770882422263144" LOG_EFFECT_SIZE="0.3222192947339193" ORDER="153" O_E="0.0" SE="0.5285800085103725" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="0.2793968253968254" WEIGHT="26.912182489079644"/>
<DICH_DATA CI_END="5.103130184031393" CI_START="0.04898953994595213" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.707836647596448" LOG_CI_START="-1.3098966389244104" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-11-26 19:42:06 +0000" MODIFIED_BY="[Empty name]" ORDER="455" O_E="0.0" SE="1.185226520443204" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="1.4047619047619047" WEIGHT="8.9886689513526"/>
<DICH_DATA CI_END="3.582439941575593" CI_START="0.4900640425608526" EFFECT_SIZE="1.325" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.5541789183266194" LOG_CI_START="-0.3097471617809661" LOG_EFFECT_SIZE="0.12221587827282664" ORDER="154" O_E="0.0" SE="0.5074744559582628" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.2575303234501348" WEIGHT="30.506997653075494"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0830958583850188" CI_END="7.215094582292754" CI_START="1.4591679354082223" DF="4" EFFECT_SIZE="3.244693308375873" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="6" I2="0.0" ID="CMP-001.19.04" LOG_CI_END="0.858242028610191" LOG_CI_START="0.16410527765355998" LOG_EFFECT_SIZE="0.5111736531318756" MODIFIED="2008-11-26 21:11:01 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8969448861815242" P_Z="0.00389306408000462" STUDIES="5" TAU2="0.0" TOTAL_1="854" TOTAL_2="371" WEIGHT="100.0" Z="2.8866990505933976">
<NAME>hypertonia</NAME>
<DICH_DATA CI_END="10.515332355834648" CI_START="0.9779293682610609" EFFECT_SIZE="3.2067510548523206" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="3" LOG_CI_END="1.0218230038909966" LOG_CI_START="-0.009692511349621685" LOG_EFFECT_SIZE="0.5060652462706875" MODIFIED="2008-11-26 21:11:01 +0000" MODIFIED_BY="[Empty name]" ORDER="436" O_E="0.0" SE="0.6059173197364894" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.3671357983566511" WEIGHT="43.72497351920766"/>
<DICH_DATA CI_END="163.02449047824274" CI_START="0.5885385247879716" EFFECT_SIZE="9.795212765957446" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.2122528515242856" LOG_CI_START="-0.23022510366978177" LOG_EFFECT_SIZE="0.9910138739272518" ORDER="155" O_E="0.0" SE="1.4347236413418658" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="2.058431927025263" WEIGHT="8.205745338699565"/>
<DICH_DATA CI_END="20.412520736125575" CI_START="0.19595815978380854" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3098966389244104" LOG_CI_START="-0.707836647596448" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-11-26 19:42:40 +0000" MODIFIED_BY="[Empty name]" ORDER="454" O_E="0.0" SE="1.185226520443204" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="1.4047619047619047" WEIGHT="10.977366769590109"/>
<DICH_DATA CI_END="9.684452445791047" CI_START="0.46823691576940313" EFFECT_SIZE="2.1294642857142856" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.9860750709514738" LOG_CI_START="-0.32953434953957167" LOG_EFFECT_SIZE="0.3282703607059511" ORDER="156" O_E="0.0" SE="0.7727954859681018" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.5972128631326745" WEIGHT="29.80521401682648"/>
<DICH_DATA CI_END="51.47122985627398" CI_START="0.12460148748943188" EFFECT_SIZE="2.5324675324675323" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7115645454293444" LOG_CI_START="-0.904476773049272" LOG_EFFECT_SIZE="0.4035438861900361" ORDER="157" O_E="0.0" SE="1.5366756200877143" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="2.3613719613719613" WEIGHT="7.286700355676193"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.17881710084572772" CI_END="2.4670017789015835" CI_START="0.7464207199691779" DF="1" EFFECT_SIZE="1.3569897729802398" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="12" I2="0.0" ID="CMP-001.19.05" LOG_CI_END="0.39216946265019936" LOG_CI_START="-0.12701631346924414" LOG_EFFECT_SIZE="0.13257657459047764" MODIFIED="2008-11-26 21:10:42 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6723917877420802" P_Z="0.31684017435663936" STUDIES="2" TAU2="0.0" TOTAL_1="234" TOTAL_2="118" WEIGHT="99.99999999999997" Z="1.000972381536294">
<NAME>tremor</NAME>
<DICH_DATA CI_END="2.40654240370249" CI_START="0.7109403721917965" EFFECT_SIZE="1.3080168776371308" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" LOG_CI_END="0.3813935184263251" LOG_CI_START="-0.14816682277798743" LOG_EFFECT_SIZE="0.11661334782416882" MODIFIED="2008-11-26 21:10:42 +0000" MODIFIED_BY="[Empty name]" ORDER="437" O_E="0.0" SE="0.31106636578937896" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.09676228392541172" WEIGHT="96.00041903281985"/>
<DICH_DATA CI_END="51.47122985627398" CI_START="0.12460148748943188" EFFECT_SIZE="2.5324675324675323" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7115645454293444" LOG_CI_START="-0.904476773049272" LOG_EFFECT_SIZE="0.4035438861900361" ORDER="158" O_E="0.0" SE="1.5366756200877143" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="2.3613719613719613" WEIGHT="3.999580967180127"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10231248464459566" CI_END="3.522259317703368" CI_START="0.5823408184438165" DF="1" EFFECT_SIZE="1.4321855235418133" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" I2="0.0" ID="CMP-001.19.06" LOG_CI_END="0.5468213266743689" LOG_CI_START="-0.2348227675021222" LOG_EFFECT_SIZE="0.1559992795861233" MODIFIED="2008-11-26 21:11:28 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7490720427075568" P_Z="0.4340189271124192" STUDIES="2" TAU2="0.0" TOTAL_1="234" TOTAL_2="118" WEIGHT="100.0" Z="0.7823329617173794">
<NAME>akasthia (no BARS data)</NAME>
<DICH_DATA CI_END="4.030048291331668" CI_START="0.572529750928024" EFFECT_SIZE="1.518987341772152" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.6053102502436432" LOG_CI_START="-0.24220194072927625" LOG_EFFECT_SIZE="0.18155415475718342" MODIFIED="2008-11-26 21:11:28 +0000" MODIFIED_BY="[Empty name]" ORDER="435" O_E="0.0" SE="0.49783285623049833" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.24783755274261604" WEIGHT="83.27477160927619"/>
<DICH_DATA CI_END="10.68307076777868" CI_START="0.09360604471666614" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.0286961052968442" LOG_CI_START="-1.0286961052968442" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 14:40:43 +0100" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="1.2085223687584246" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="1.4605263157894737" WEIGHT="16.72522839072382"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.69936418378434" CI_START="0.12912599857107263" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.19.07" LOG_CI_END="1.8432288163658224" LOG_CI_START="-0.8889863069264972" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-11-26 19:40:40 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.49364108067680157" STUDIES="2" TAU2="0.0" TOTAL_1="97" TOTAL_2="59" WEIGHT="100.0" Z="0.6845291701498639">
<NAME>tardive dyskinesia</NAME>
<DICH_DATA CI_END="69.69936418378434" CI_START="0.12912599857107263" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8432288163658224" LOG_CI_START="-0.8889863069264972" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-11-26 19:40:40 +0000" MODIFIED_BY="[Empty name]" ORDER="453" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 14:41:28 +0100" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="0.0" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="98.2719903161007" CI_START="0.25439598729592483" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.19.08" LOG_CI_END="1.9924297519668148" LOG_CI_START="-0.5944897432947772" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2008-11-26 19:39:50 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.28953566170301226" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0" Z="1.0591408331660286">
<NAME>oculogyric crisis</NAME>
<DICH_DATA CI_END="98.2719903161007" CI_START="0.25439598729592483" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9924297519668148" LOG_CI_START="-0.5944897432947772" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2008-11-26 19:39:50 +0000" MODIFIED_BY="[Empty name]" ORDER="452" O_E="0.0" SE="1.5195693169746844" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.309090909090909" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.271478575642176" CI_END="1.1767050390769074" CI_START="0.9086841100242316" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0340469869375513" ESTIMABLE="YES" EVENTS_1="357" EVENTS_2="116" I2="44.99055510664497" I2_Q="44.50544356638998" ID="CMP-001.20" LOG_CI_END="0.0706676132638824" LOG_CI_START="-0.04158706630109802" LOG_EFFECT_SIZE="0.014540273481392217" METHOD="MH" MODIFIED="2008-05-18 19:54:29 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.12221871561735476" P_Q="0.12530049351718187" P_Z="0.6116317350531917" Q="7.207914175844135" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1820" TOTAL_2="615" WEIGHT="500.0" Z="0.5077456451585133">
<NAME>Adverse effect: 7b. Movement disorder - akathisia (BARS)</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1946988755607202" CI_START="0.9440571422977218" DF="0" EFFECT_SIZE="1.0620094191522762" ESTIMABLE="YES" EVENTS_1="286" EVENTS_2="91" I2="0.0" ID="CMP-001.20.01" LOG_CI_END="0.07725845493928246" LOG_CI_START="-0.025001717742699874" LOG_EFFECT_SIZE="0.026128368598291308" NO="1" P_CHI2="1.0" P_Z="0.3165484866309072" STUDIES="1" TAU2="0.0" TOTAL_1="364" TOTAL_2="123" WEIGHT="100.0" Z="1.0015758840286273">
<NAME>absent</NAME>
<DICH_DATA CI_END="1.1946988755607202" CI_START="0.9440571422977218" EFFECT_SIZE="1.0620094191522762" ESTIMABLE="YES" EVENTS_1="286" EVENTS_2="91" LOG_CI_END="0.07725845493928246" LOG_CI_START="-0.025001717742699874" LOG_EFFECT_SIZE="0.026128368598291308" ORDER="159" O_E="0.0" SE="0.06006813162941502" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.003608180437448729" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2338238841052966" CI_START="0.4522157264651335" DF="0" EFFECT_SIZE="0.7469635627530364" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="19" I2="0.0" ID="CMP-001.20.02" LOG_CI_END="0.0912531729712919" LOG_CI_START="-0.344654338500465" LOG_EFFECT_SIZE="-0.12670058276458657" NO="2" P_CHI2="1.0" P_Z="0.2545515442440953" STUDIES="1" TAU2="0.0" TOTAL_1="364" TOTAL_2="123" WEIGHT="100.0" Z="1.139363615003526">
<NAME>questionable</NAME>
<DICH_DATA CI_END="1.2338238841052964" CI_START="0.4522157264651335" EFFECT_SIZE="0.7469635627530364" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="19" LOG_CI_END="0.09125317297129183" LOG_CI_START="-0.344654338500465" LOG_EFFECT_SIZE="-0.12670058276458657" ORDER="160" O_E="0.0" SE="0.25605423001549193" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.06556376870882646" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.94827533288975" CI_START="0.7498535077322297" DF="0" EFFECT_SIZE="2.1119505494505493" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="4" I2="0.0" ID="CMP-001.20.03" LOG_CI_END="0.7743910628739944" LOG_CI_START="-0.12502357260516025" LOG_EFFECT_SIZE="0.3246837451344171" NO="3" P_CHI2="1.0" P_Z="0.15704724773353965" STUDIES="1" TAU2="0.0" TOTAL_1="364" TOTAL_2="123" WEIGHT="100.0" Z="1.4150724743099612">
<NAME>mild</NAME>
<DICH_DATA CI_END="5.94827533288975" CI_START="0.7498535077322297" EFFECT_SIZE="2.1119505494505493" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="4" LOG_CI_END="0.7743910628739944" LOG_CI_START="-0.12502357260516025" LOG_EFFECT_SIZE="0.3246837451344171" ORDER="161" O_E="0.0" SE="0.5283206090547048" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.27912266595193425" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="56.3870383621085" CI_START="0.16579192560081596" DF="0" EFFECT_SIZE="3.0575342465753423" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-001.20.04" LOG_CI_END="1.7511792845728988" LOG_CI_START="-0.7804366242827283" LOG_EFFECT_SIZE="0.4853713301450852" NO="4" P_CHI2="1.0" P_Z="0.4523253593662001" STUDIES="1" TAU2="0.0" TOTAL_1="364" TOTAL_2="123" WEIGHT="100.0" Z="0.751543962798599">
<NAME>moderate</NAME>
<DICH_DATA CI_END="56.3870383621085" CI_START="0.16579192560081596" EFFECT_SIZE="3.0575342465753423" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.7511792845728988" LOG_CI_START="-0.7804366242827283" LOG_EFFECT_SIZE="0.4853713301450852" ORDER="162" O_E="0.0" SE="1.487083716562653" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="2.2114179800657925" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4056041893254918" CI_START="0.003284389007022176" DF="0" EFFECT_SIZE="0.06794520547945206" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.20.05" LOG_CI_END="0.14786304287983437" LOG_CI_START="-2.483545410140351" LOG_EFFECT_SIZE="-1.1678411836302585" NO="5" P_CHI2="1.0" P_Z="0.08191224123274167" STUDIES="1" TAU2="0.0" TOTAL_1="364" TOTAL_2="123" WEIGHT="100.0" Z="1.7396969725097833">
<NAME>marked</NAME>
<DICH_DATA CI_END="1.4056041893254918" CI_START="0.003284389007022176" EFFECT_SIZE="0.06794520547945206" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.14786304287983437" LOG_CI_START="-2.483545410140351" LOG_EFFECT_SIZE="-1.1678411836302585" ORDER="163" O_E="0.0" SE="1.5457023509859749" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="2.38919575784357" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.924742398659509" CI_END="0.15650059093493224" CI_START="-0.11190363997634745" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0222984754792924" ESTIMABLE="YES" I2="56.67708880288832" I2_Q="0.0" ID="CMP-001.21" MODIFIED="2009-01-21 02:01:57 +0000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.07433563737583837" P_Q="1.0" P_Z="0.7446819052346851" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1052" TOTAL_2="444" UNITS="" WEIGHT="100.00000000000001" Z="0.3256596120052142">
<NAME>Adverse effect: 7c. Movement disorder - Average change score (BARS total, decline=good)</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1330573776173819" CI_START="-0.5330573776173819" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.2" MODIFIED="2009-01-21 02:01:57 +0000" MODIFIED_BY="[Empty name]" ORDER="492" SD_1="1.31" SD_2="1.67" SE="0.16993035598842426" STUDY_ID="STD-Davidson-2007" TOTAL_1="355" TOTAL_2="116" WEIGHT="16.236058484742088"/>
<CONT_DATA CI_END="0.3903423425242509" CI_START="0.009657657475749148" EFFECT_SIZE="0.2" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-0.2" MODIFIED="2009-01-21 01:59:42 +0000" MODIFIED_BY="[Empty name]" ORDER="490" SD_1="0.94" SD_2="0.94" SE="0.09711522457843459" STUDY_ID="STD-Kane-2007" TOTAL_1="374" TOTAL_2="125" WEIGHT="49.71047395615118"/>
<CONT_DATA CI_END="0.17709393436965273" CI_START="-0.3770939343696528" EFFECT_SIZE="-0.1" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.0" MODIFIED="2008-11-28 13:48:51 +0000" MODIFIED_BY="[Empty name]" ORDER="474" SD_1="0.9" SD_2="1.11" SE="0.1413770541475937" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="101" WEIGHT="23.456579654687694"/>
<CONT_DATA CI_END="0.21225904378346028" CI_START="-0.6122590437834603" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.1" MODIFIED="2009-01-21 02:01:01 +0000" MODIFIED_BY="[Empty name]" ORDER="491" SD_1="1.53" SD_2="1.85" SE="0.21034011187721152" STUDY_ID="STD-Marder-2007" TOTAL_1="219" TOTAL_2="102" WEIGHT="10.596887904419045"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.948117410229731" CI_END="0.14796584953559466" CI_START="-0.16152727427226277" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.006780712368334046" ESTIMABLE="YES" I2="49.56387385964305" I2_Q="0.0" ID="CMP-001.22" MODIFIED="2009-01-21 01:58:25 +0000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.11416193756616999" P_Q="1.0" P_Z="0.931560180479803" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1050" TOTAL_2="442" UNITS="" WEIGHT="100.0" Z="0.08588205041809474">
<NAME>Adverse effect: 7d. Movement disorder - Average change score (AIMS total, decline=good)</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.27316943636323565" CI_START="-0.27316943636323565" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" MODIFIED="2009-01-21 01:58:25 +0000" MODIFIED_BY="[Empty name]" ORDER="489" SD_1="1.48" SD_2="1.24" SE="0.13937472245304572" STUDY_ID="STD-Davidson-2007" TOTAL_1="355" TOTAL_2="116" WEIGHT="32.09059758355492"/>
<CONT_DATA CI_END="0.4535806223004849" CI_START="-0.053580622300484965" EFFECT_SIZE="0.19999999999999998" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.3" MODIFIED="2009-01-21 01:56:26 +0000" MODIFIED_BY="[Empty name]" ORDER="487" SD_1="1.04" SD_2="1.31" SE="0.1293802459130354" STUDY_ID="STD-Kane-2007" TOTAL_1="373" TOTAL_2="124" WEIGHT="37.24001875793526"/>
<CONT_DATA CI_END="0.04670070993394809" CI_START="-0.6467007099339481" EFFECT_SIZE="-0.3" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.3" MODIFIED="2008-11-28 13:40:42 +0000" MODIFIED_BY="[Empty name]" ORDER="473" SD_1="0.72" SD_2="1.63" SE="0.17689136773363134" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="101" WEIGHT="19.921982567184923"/>
<CONT_DATA CI_END="0.27202965122933415" CI_START="-0.6720296512293342" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.1" MODIFIED="2009-01-21 01:55:59 +0000" MODIFIED_BY="[Empty name]" ORDER="488" SD_1="1.45" SD_2="2.21" SE="0.2408358801246573" STUDY_ID="STD-Marder-2007" TOTAL_1="218" TOTAL_2="101" WEIGHT="10.747401091324894"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="18.785696024504162" CI_END="1.3490854107372319" CI_START="0.8316592736318266" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0592352867805248" ESTIMABLE="YES" EVENTS_1="197" EVENTS_2="80" I2="14.828814545228909" I2_Q="50.99757444866789" ID="CMP-001.23" LOG_CI_END="0.1300394457709824" LOG_CI_START="-0.08005456540374854" LOG_EFFECT_SIZE="0.024992440183616925" METHOD="MH" MODIFIED="2009-01-02 18:35:40 +0000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.27993287763601715" P_Q="0.056735680811381695" P_Z="0.6409948942352492" Q="12.244291853909857" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2574" TOTAL_2="1184" WEIGHT="700.0" Z="0.4663082243207929">
<NAME>Adverse effect: 8. Other events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.043358923815688684" CI_END="1.2015024351233545" CI_START="0.17165804343977686" DF="1" EFFECT_SIZE="0.454144863673919" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-001.23.01" LOG_CI_END="0.07972465533930627" LOG_CI_START="-0.7653358418760534" LOG_EFFECT_SIZE="-0.34280559326837357" MODIFIED="2008-11-26 19:45:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8350510290268792" P_Z="0.11180092223928155" STUDIES="2" TAU2="0.0" TOTAL_1="245" TOTAL_2="127" WEIGHT="100.0" Z="1.590150335316577">
<NAME>pain - body pain</NAME>
<DICH_DATA CI_END="7.7443737981982546" CI_START="0.014347333174563614" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8889863069264973" LOG_CI_START="-1.8432288163658224" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2008-11-26 19:45:32 +0000" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="13.632608096942992"/>
<DICH_DATA CI_END="1.3147407093728138" CI_START="0.1703238962691787" EFFECT_SIZE="0.4732142857142857" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.1188401105504301" LOG_CI_START="-0.7687244166892153" LOG_EFFECT_SIZE="-0.32494215306939256" ORDER="164" O_E="0.0" SE="0.5213597968158353" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.27181603773584906" WEIGHT="86.36739190305701"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.0778907843672325" CI_END="1.5820429778684753" CI_START="0.9017574848966725" DF="5" EFFECT_SIZE="1.1944116110960736" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="56" I2="17.734619173145465" ID="CMP-001.23.02" LOG_CI_END="0.19921827739022446" LOG_CI_START="-0.04491024420135786" LOG_EFFECT_SIZE="0.07715401659443329" MODIFIED="2008-11-26 21:12:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2987134976757926" P_Z="0.21540173147538166" STUDIES="6" TAU2="0.0" TOTAL_1="1218" TOTAL_2="494" WEIGHT="100.0" Z="1.2388482329047867">
<NAME>pain - headache</NAME>
<DICH_DATA CI_END="1.67301062595444" CI_START="0.4796628329798335" EFFECT_SIZE="0.8958130477117819" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="13" LOG_CI_END="0.22349869934776392" LOG_CI_START="-0.3190639318512098" LOG_EFFECT_SIZE="-0.047782616251722906" MODIFIED="2008-11-26 21:12:14 +0000" MODIFIED_BY="[Empty name]" ORDER="431" O_E="0.0" SE="0.31870397529461647" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.10157222386859151" WEIGHT="21.80628323535901"/>
<DICH_DATA CI_END="3.0330984012874254" CI_START="0.9411545888903571" EFFECT_SIZE="1.6895604395604396" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="12" LOG_CI_END="0.4818865001368805" LOG_CI_START="-0.026339035884158975" LOG_EFFECT_SIZE="0.22777373212636073" ORDER="165" O_E="0.0" SE="0.2985341956157355" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.08912266595193423" WEIGHT="22.66270966346775"/>
<DICH_DATA CI_END="1.3362332557547882" CI_START="0.305002557184365" EFFECT_SIZE="0.6384" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.12588227613723782" LOG_CI_START="-0.5156965194518919" LOG_EFFECT_SIZE="-0.19490712165732701" ORDER="166" O_E="0.0" SE="0.37686656039531263" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="0.1420284043441938" WEIGHT="18.91262051122479"/>
<DICH_DATA CI_END="98.2719903161007" CI_START="0.25439598729592483" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9924297519668148" LOG_CI_START="-0.5944897432947772" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2008-11-26 19:38:19 +0000" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="1.5195693169746844" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.309090909090909" WEIGHT="0.631681525074908"/>
<DICH_DATA CI_END="1.985514851555439" CI_START="0.7920166322610125" EFFECT_SIZE="1.254017857142857" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="20" LOG_CI_END="0.297873139913854" LOG_CI_START="-0.1012656981790235" LOG_EFFECT_SIZE="0.09830372086741526" ORDER="167" O_E="0.0" SE="0.23445612926486958" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.05496967654986523" WEIGHT="34.30222099800713"/>
<DICH_DATA CI_END="17.28046034716354" CI_START="0.23147531487241724" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2375553077939085" LOG_CI_START="-0.635495316465946" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="168" O_E="0.0" SE="1.1002392084403616" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="1.2105263157894737" WEIGHT="1.6844840668664214"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.034044757359079816" CI_END="22.121779610562395" CI_START="0.6946507856584234" DF="1" EFFECT_SIZE="3.9200652528548123" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" ID="CMP-001.23.03" LOG_CI_END="1.3448200613288164" LOG_CI_START="-0.1582334687578464" LOG_EFFECT_SIZE="0.5932932962854851" MODIFIED="2008-11-26 19:44:49 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8536117003492928" P_Z="0.12179216308989084" STUDIES="2" TAU2="0.0" TOTAL_1="245" TOTAL_2="127" WEIGHT="100.0" Z="1.547294849733736">
<NAME>pain - musculoskeletal</NAME>
<DICH_DATA CI_END="69.69936418378434" CI_START="0.12912599857107263" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8432288163658224" LOG_CI_START="-0.8889863069264972" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-11-26 19:44:49 +0000" MODIFIED_BY="[Empty name]" ORDER="456" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="26.916802610114193"/>
<DICH_DATA CI_END="33.18305329527465" CI_START="0.5466185530043911" EFFECT_SIZE="4.258928571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.5209163445660123" LOG_CI_START="-0.2623156318261475" LOG_EFFECT_SIZE="0.6293003563699323" ORDER="169" O_E="0.0" SE="1.0474792900734" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="1.0972128631326743" WEIGHT="73.08319738988581"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.185855433736144" CI_START="0.2912628128414789" DF="0" EFFECT_SIZE="1.1041666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-001.23.04" LOG_CI_END="0.6217842250980246" LOG_CI_START="-0.5357149606476208" LOG_EFFECT_SIZE="0.04303463222520185" NO="4" P_CHI2="1.0" P_Z="0.8841275112019231" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="106" WEIGHT="100.0" Z="0.14573890036041395">
<NAME>pain - toothache</NAME>
<DICH_DATA CI_END="4.185855433736144" CI_START="0.2912628128414789" EFFECT_SIZE="1.1041666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.6217842250980246" LOG_CI_START="-0.5357149606476208" LOG_EFFECT_SIZE="0.04303463222520185" ORDER="170" O_E="0.0" SE="0.6799207514203692" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.4622922282120395" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9070528558192548" CI_END="0.6327000371533071" CI_START="0.013327160123077553" DF="1" EFFECT_SIZE="0.09182643794147326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" I2="0.0" ID="CMP-001.23.05" LOG_CI_END="-0.19880214003828153" LOG_CI_START="-1.875262384290082" LOG_EFFECT_SIZE="-1.0370322621641817" MODIFIED="2008-11-26 19:46:29 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3408977209870595" P_Z="0.015316546280617026" STUDIES="2" TAU2="0.0" TOTAL_1="245" TOTAL_2="127" WEIGHT="99.99999999999999" Z="2.4248065429729477">
<NAME>rash</NAME>
<DICH_DATA CI_END="7.7443737981982546" CI_START="0.014347333174563614" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8889863069264973" LOG_CI_START="-1.8432288163658224" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2008-11-26 19:46:29 +0000" MODIFIED_BY="[Empty name]" ORDER="458" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="16.750756811301713"/>
<DICH_DATA CI_END="0.7747058881789676" CI_START="0.0024125720490616735" EFFECT_SIZE="0.04323232323232323" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.11086314315046211" LOG_CI_START="-2.6175197080182935" LOG_EFFECT_SIZE="-1.364191425584378" ORDER="171" O_E="0.0" SE="1.4724224743534764" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="2.168027942981214" WEIGHT="83.24924318869827"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7423526202643314" CI_END="2.699864977222286" CI_START="0.40274527176461733" DF="2" EFFECT_SIZE="1.0427645247030424" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" ID="CMP-001.23.06" LOG_CI_END="0.4313420452280318" LOG_CI_START="-0.3949695495023869" LOG_EFFECT_SIZE="0.018186247862822445" MODIFIED="2008-11-26 19:46:49 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.41845938685698136" P_Z="0.9312490151283868" STUDIES="3" TAU2="0.0" TOTAL_1="321" TOTAL_2="165" WEIGHT="100.0" Z="0.08627348581906173">
<NAME>upper respiratory infection</NAME>
<DICH_DATA CI_END="69.69936418378434" CI_START="0.12912599857107263" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8432288163658224" LOG_CI_START="-0.8889863069264972" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-11-26 19:46:49 +0000" MODIFIED_BY="[Empty name]" ORDER="459" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="6.311790583098647"/>
<DICH_DATA CI_END="3.6853254765219687" CI_START="0.3797693067252121" EFFECT_SIZE="1.1830357142857142" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.5664758494312663" LOG_CI_START="-0.42048013822597624" LOG_EFFECT_SIZE="0.072997855602645" ORDER="172" O_E="0.0" SE="0.5797428326607956" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.33610175202156334" WEIGHT="68.54987106007744"/>
<DICH_DATA CI_END="4.049064768381955" CI_START="0.007039641299758482" EFFECT_SIZE="0.16883116883116883" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6073547237493749" LOG_CI_START="-2.1524494694806653" LOG_EFFECT_SIZE="-0.7725473728656451" MODIFIED="2008-05-18 14:29:55 +0100" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="1.6211226443544078" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="2.628038628038628" WEIGHT="25.138338356823922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.777000992633185" CI_START="0.03214606764700353" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.23.07" LOG_CI_END="0.8908121543871789" LOG_CI_START="-1.4928721457151413" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-05-18 14:30:29 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.620572827836049" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="38" WEIGHT="100.0" Z="0.4950386674462936">
<NAME>pneumonia</NAME>
<DICH_DATA CI_END="7.777000992633185" CI_START="0.03214606764700353" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8908121543871789" LOG_CI_START="-1.4928721457151413" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-05-18 14:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="1.4001879573076872" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="1.9605263157894737" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.803013373511589" CI_END="2.05361983332281" CI_START="0.5578005343567947" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0702851210743682" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="0.3125200499860694" LOG_CI_START="-0.2535210740282046" LOG_EFFECT_SIZE="0.02949948797893237" METHOD="MH" MODIFIED="2009-06-08 11:11:32 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="0.9995762785066004" P_Q="0.9711929042942307" P_Z="0.8381278135324394" Q="1.3083927214320663" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5946" TOTAL_2="2598" WEIGHT="700.0" Z="0.20428881064698656">
<NAME>Adverse effect: 9.Potentially prolactin-related events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.899841774459418" CI_START="0.04061970398931037" DF="0" EFFECT_SIZE="0.9852941176470589" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.24.01" LOG_CI_END="1.3783950257721278" LOG_CI_START="-1.391263245782948" LOG_EFFECT_SIZE="-0.006434110005409862" MODIFIED="2008-05-18 19:06:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9927343505562831" STUDIES="4" TAU2="0.0" TOTAL_1="695" TOTAL_2="337" WEIGHT="100.0" Z="0.009106267016899292">
<NAME>gynaecomastia - men</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 18:54:23 +0100" MODIFIED_BY="[Empty name]" ORDER="368" O_E="0.0" SE="0.0" STUDY_ID="STD-Davidson-2007" TOTAL_1="234" TOTAL_2="86" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="23.899841774459418" CI_START="0.04061970398931037" EFFECT_SIZE="0.9852941176470589" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3783950257721278" LOG_CI_START="-1.391263245782948" LOG_EFFECT_SIZE="-0.006434110005409862" MODIFIED="2008-05-18 18:38:53 +0100" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="1.626910978741008" STUDY_ID="STD-Kane-2007" TOTAL_1="203" TOTAL_2="66" VAR="2.6468393327480246" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 19:06:54 +0100" MODIFIED_BY="[Empty name]" ORDER="369" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="102" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 18:53:16 +0100" MODIFIED_BY="[Empty name]" ORDER="359" O_E="0.0" SE="0.0" STUDY_ID="STD-Marder-2007" TOTAL_1="154" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.015637808499659" CI_END="3.0334354817809337" CI_START="0.162197323060048" DF="3" EFFECT_SIZE="0.7014378909213804" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.24.02" LOG_CI_END="0.48193476235753574" LOG_CI_START="-0.7899563177564486" LOG_EFFECT_SIZE="-0.15401077769945645" MODIFIED="2009-05-14 13:23:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7974681583515375" P_Z="0.6350319491699399" STUDIES="5" TAU2="0.0" TOTAL_1="800" TOTAL_2="387" WEIGHT="100.0" Z="0.4746563321992753">
<NAME>impotence - men</NAME>
<DICH_DATA CI_END="34.81786115780804" CI_START="0.0598368939719356" EFFECT_SIZE="1.4433962264150944" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5418020891279072" LOG_CI_START="-1.22303095802225" LOG_EFFECT_SIZE="0.15938556555282857" MODIFIED="2009-05-14 13:23:28 +0100" MODIFIED_BY="[Empty name]" ORDER="518" O_E="0.0" SE="1.624076618040313" STUDY_ID="STD-Canuso-2009" TOTAL_1="105" TOTAL_2="50" VAR="2.6376248612652606" WEIGHT="16.453865966310865"/>
<DICH_DATA CI_END="27.00648824799164" CI_START="0.045674854774667" EFFECT_SIZE="1.1106382978723404" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.431468114965898" LOG_CI_START="-1.3403228248328087" LOG_EFFECT_SIZE="0.04557264506654467" MODIFIED="2008-05-18 18:54:37 +0100" MODIFIED_BY="[Empty name]" ORDER="370" O_E="0.0" SE="1.628163718624195" STUDY_ID="STD-Davidson-2007" TOTAL_1="234" TOTAL_2="86" VAR="2.650917094644167" WEIGHT="17.78581345444273"/>
<DICH_DATA CI_END="23.899841774459418" CI_START="0.04061970398931037" EFFECT_SIZE="0.9852941176470589" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3783950257721278" LOG_CI_START="-1.391263245782948" LOG_EFFECT_SIZE="-0.006434110005409862" MODIFIED="2008-05-18 18:39:14 +0100" MODIFIED_BY="[Empty name]" ORDER="348" O_E="0.0" SE="1.626910978741008" STUDY_ID="STD-Kane-2007" TOTAL_1="203" TOTAL_2="66" VAR="2.6468393327480246" WEIGHT="18.34520710050144"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 19:07:45 +0100" MODIFIED_BY="[Empty name]" ORDER="371" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="102" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.385713111453443" CI_START="0.007440676913495618" EFFECT_SIZE="0.18064516129032257" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6420402191819685" LOG_CI_START="-2.128387552838113" LOG_EFFECT_SIZE="-0.7431736668280723" MODIFIED="2008-05-18 18:53:03 +0100" MODIFIED_BY="[Empty name]" ORDER="360" O_E="0.0" SE="1.6273629871232413" STUDY_ID="STD-Marder-2007" TOTAL_1="154" TOTAL_2="83" VAR="2.648310291858679" WEIGHT="47.415113478744956"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.19712863935975544" CI_END="6.71420217609467" CI_START="0.3058903554940129" DF="3" EFFECT_SIZE="1.4331118904343352" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-001.24.03" LOG_CI_END="0.8269944144574675" LOG_CI_START="-0.5144342157964958" LOG_EFFECT_SIZE="0.15628009933048584" MODIFIED="2008-05-18 19:08:16 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9780515065580474" P_Z="0.6478994054441758" STUDIES="4" TAU2="0.0" TOTAL_1="418" TOTAL_2="158" WEIGHT="100.0" Z="0.45668231507792445">
<NAME>lactation nonpuerperal - women</NAME>
<DICH_DATA CI_END="29.566378668021578" CI_START="0.07114861916394868" EFFECT_SIZE="1.450381679389313" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.4707981347795434" LOG_CI_START="-1.147833524185414" LOG_EFFECT_SIZE="0.1614823052970647" MODIFIED="2008-05-18 18:54:57 +0100" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="1.5381971989117833" STUDY_ID="STD-Davidson-2007" TOTAL_1="130" TOTAL_2="37" VAR="2.3660506227400564" WEIGHT="27.601599698046478"/>
<DICH_DATA CI_END="25.62242038041785" CI_START="0.04367066657794103" EFFECT_SIZE="1.0578034682080926" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.4086201522708865" LOG_CI_START="-1.3598101790676185" LOG_EFFECT_SIZE="0.02440498660163409" MODIFIED="2008-05-18 18:39:29 +0100" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="1.6261896805793925" STUDY_ID="STD-Kane-2007" TOTAL_1="172" TOTAL_2="60" VAR="2.644492877222907" WEIGHT="26.325698779010406"/>
<DICH_DATA CI_END="59.40350620298724" CI_START="0.10431912323229653" EFFECT_SIZE="2.4893617021276597" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.773812079319083" LOG_CI_START="-0.9816360716981948" LOG_EFFECT_SIZE="0.3960880038104442" MODIFIED="2008-05-18 19:08:16 +0100" MODIFIED_BY="[Empty name]" ORDER="362" O_E="0.0" SE="1.6185638835958747" STUDY_ID="STD-Kramer-2007" TOTAL_1="46" TOTAL_2="38" VAR="2.61974904528096" WEIGHT="19.460279282938327"/>
<DICH_DATA CI_END="24.069855472633286" CI_START="0.04272428592653386" EFFECT_SIZE="1.0140845070422535" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3814734825630943" LOG_CI_START="-1.369325187138708" LOG_EFFECT_SIZE="0.006074147712193166" MODIFIED="2008-05-18 18:52:50 +0100" MODIFIED_BY="[Empty name]" ORDER="363" O_E="0.0" SE="1.6158327552558607" STUDY_ID="STD-Marder-2007" TOTAL_1="70" TOTAL_2="23" VAR="2.6109154929577465" WEIGHT="26.612422240004797"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3256113935806675" CI_END="6.919726593481952" CI_START="0.308585122013421" DF="2" EFFECT_SIZE="1.4612750169455244" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.24.04" LOG_CI_END="0.8400889353111175" LOG_CI_START="-0.5106250166501706" LOG_EFFECT_SIZE="0.1647319593304735" MODIFIED="2009-06-08 11:11:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5154032763062766" P_Z="0.6325995444012031" STUDIES="5" TAU2="0.0" TOTAL_1="673" TOTAL_2="265" WEIGHT="100.0" Z="0.47807118142464927">
<NAME>amenorrhoea/dysmenorrhoea - women</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 18:56:11 +0100" MODIFIED_BY="[Empty name]" ORDER="365" O_E="0.0" SE="0.0" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="36.2095965756488" CI_START="0.08583882935681697" EFFECT_SIZE="1.7630057803468209" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.5588236862103948" LOG_CI_START="-1.066316213774414" LOG_EFFECT_SIZE="0.24625373621799043" MODIFIED="2008-05-18 18:39:47 +0100" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="1.5420201719031565" STUDY_ID="STD-Kane-2007" TOTAL_1="172" TOTAL_2="60" VAR="2.37782621055624" WEIGHT="26.53847525953409"/>
<DICH_DATA CI_END="83.88020721587765" CI_START="0.20521732022189615" EFFECT_SIZE="4.148936170212766" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9236594946664711" LOG_CI_START="-0.6877859878128701" LOG_EFFECT_SIZE="0.6179367534268005" MODIFIED="2008-05-18 19:09:09 +0100" MODIFIED_BY="[Empty name]" ORDER="366" O_E="0.0" SE="1.5339760032719851" STUDY_ID="STD-Kramer-2007" TOTAL_1="46" TOTAL_2="38" VAR="2.3530823786142934" WEIGHT="19.617566265919873"/>
<DICH_DATA CI_END="7.7443737981982546" CI_START="0.014347333174563614" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8889863069264973" LOG_CI_START="-1.8432288163658224" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2008-11-26 19:32:50 +0000" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="53.843958474546035"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 18:52:40 +0100" MODIFIED_BY="[Empty name]" ORDER="367" O_E="0.0" SE="0.0" STUDY_ID="STD-Marder-2007" TOTAL_1="70" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.302889967113081E-6" CI_END="9.725421182919685" CI_START="0.10618925725539599" DF="1" EFFECT_SIZE="1.0162358249491779" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.24.05" LOG_CI_END="0.9879084185794413" LOG_CI_START="-0.9739194168768646" LOG_EFFECT_SIZE="0.006994500851288352" MODIFIED="2008-05-18 19:09:38 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9979968684651517" P_Z="0.9888493586913287" STUDIES="4" TAU2="0.0" TOTAL_1="1067" TOTAL_2="457" WEIGHT="99.99999999999999" Z="0.013975711334701622">
<NAME>anorgasmia</NAME>
<DICH_DATA CI_END="24.85636676680716" CI_START="0.04178905038556213" EFFECT_SIZE="1.0191780821917809" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3954376485034892" LOG_CI_START="-1.3789374976526434" LOG_EFFECT_SIZE="0.008250075425422816" MODIFIED="2008-05-18 18:56:36 +0100" MODIFIED_BY="[Empty name]" ORDER="372" O_E="0.0" SE="1.6296816942305747" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="2.6558624245102367" WEIGHT="49.96339727697511"/>
<DICH_DATA CI_END="24.71697875796543" CI_START="0.04154118463037236" EFFECT_SIZE="1.0132978723404256" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.392995384340215" LOG_CI_START="-1.3815211228442985" LOG_EFFECT_SIZE="0.005737130747958266" MODIFIED="2008-05-18 18:40:09 +0100" MODIFIED_BY="[Empty name]" ORDER="351" O_E="0.0" SE="1.629764730398394" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="2.65613307645055" WEIGHT="50.03660272302488"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 19:09:38 +0100" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="102" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 18:52:32 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.0" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.096117282048458" CI_END="3.114397287137198" CI_START="0.11798872087821001" DF="2" EFFECT_SIZE="0.6061878852434163" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.24.06" LOG_CI_END="0.49337401240871254" LOG_CI_START="-0.9281595070538797" LOG_EFFECT_SIZE="-0.21739274732258362" MODIFIED="2009-05-14 13:24:24 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5780710892211303" P_Z="0.5488608205751662" STUDIES="5" TAU2="0.0" TOTAL_1="1226" TOTAL_2="537" WEIGHT="100.0" Z="0.5994680384512628">
<NAME>abnormal sexual function</NAME>
<DICH_DATA CI_END="36.866982332467785" CI_START="0.06256551029045404" EFFECT_SIZE="1.51875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5666375908203183" LOG_CI_START="-1.2036650089355434" LOG_EFFECT_SIZE="0.1814862909423874" MODIFIED="2009-05-14 13:24:24 +0100" MODIFIED_BY="[Empty name]" ORDER="519" O_E="0.0" SE="1.6272894603156258" STUDY_ID="STD-Canuso-2009" TOTAL_1="159" TOTAL_2="80" VAR="2.6480709876543207" WEIGHT="19.27394952168767"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 18:56:45 +0100" MODIFIED_BY="[Empty name]" ORDER="375" O_E="0.0" SE="0.0" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="24.71697875796543" CI_START="0.04154118463037236" EFFECT_SIZE="1.0132978723404256" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.392995384340215" LOG_CI_START="-1.3815211228442985" LOG_EFFECT_SIZE="0.005737130747958266" MODIFIED="2008-05-18 18:40:26 +0100" MODIFIED_BY="[Empty name]" ORDER="352" O_E="0.0" SE="1.629764730398394" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="2.65613307645055" WEIGHT="21.701394257669605"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 19:09:47 +0100" MODIFIED_BY="[Empty name]" ORDER="376" O_E="0.0" SE="0.0" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="102" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.85911346997617" CI_START="0.006511371305560777" EFFECT_SIZE="0.15851851851851853" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5864875483718687" LOG_CI_START="-2.186327538663499" LOG_EFFECT_SIZE="-0.7999199951458152" MODIFIED="2008-05-18 18:52:14 +0100" MODIFIED_BY="[Empty name]" ORDER="377" O_E="0.0" SE="1.6287653077806203" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="2.652876427829699" WEIGHT="59.024656220642726"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.22226348937546464" CI_END="10.084608824345977" CI_START="0.2751527533308869" DF="2" EFFECT_SIZE="1.6657754603438468" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.24.07" LOG_CI_END="1.0036590568648152" LOG_CI_START="-0.5604261370398924" LOG_EFFECT_SIZE="0.2216164599124614" MODIFIED="2008-05-18 19:09:59 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8948208556481059" P_Z="0.5786090092451976" STUDIES="4" TAU2="0.0" TOTAL_1="1067" TOTAL_2="457" WEIGHT="100.0" Z="0.5554176735415765">
<NAME>decreased libido</NAME>
<DICH_DATA CI_END="24.85636676680716" CI_START="0.04178905038556213" EFFECT_SIZE="1.0191780821917809" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3954376485034892" LOG_CI_START="-1.3789374976526434" LOG_EFFECT_SIZE="0.008250075425422816" MODIFIED="2008-05-18 18:56:58 +0100" MODIFIED_BY="[Empty name]" ORDER="378" O_E="0.0" SE="1.6296816942305747" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="2.6558624245102367" WEIGHT="38.695933720188684"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 18:52:01 +0100" MODIFIED_BY="[Empty name]" ORDER="379" O_E="0.0" SE="0.0" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="71.40915662097004" CI_START="0.12127867871670234" EFFECT_SIZE="2.942857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8537539038628683" LOG_CI_START="-0.9162155431530754" LOG_EFFECT_SIZE="0.4687691803548966" MODIFIED="2008-05-18 19:09:59 +0100" MODIFIED_BY="[Empty name]" ORDER="380" O_E="0.0" SE="1.6270937647470656" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="102" VAR="2.6474341192787794" WEIGHT="26.170214921800422"/>
<DICH_DATA CI_END="34.73202122978552" CI_START="0.05860234175004696" EFFECT_SIZE="1.4266666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5407300578111933" LOG_CI_START="-1.2320850292241743" LOG_EFFECT_SIZE="0.15432251429350963" MODIFIED="2008-05-18 18:51:51 +0100" MODIFIED_BY="[Empty name]" ORDER="381" O_E="0.0" SE="1.6287653077806203" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="2.652876427829699" WEIGHT="35.133851358010894"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.344879332631163" CI_END="1.1759008465924534" CI_START="0.5613931879688705" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8124916768828042" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="0.07037070303840248" LOG_CI_START="-0.2507328614655252" LOG_EFFECT_SIZE="-0.09018107921356137" METHOD="MH" MODIFIED="2009-03-20 11:29:42 +0000" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.9108895932382832" P_Q="0.5877549374727116" P_Z="0.27093962939104943" Q="0.2938641655541769" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2155" TOTAL_2="1025" WEIGHT="200.0" Z="1.1009013096357083">
<NAME>Adverse effect: 10. Psychiatric event, serious</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3529939541367115" CI_END="1.7731243943205002" CI_START="0.21901010670522494" DF="4" EFFECT_SIZE="0.6231630306763793" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" ID="CMP-001.25.01" LOG_CI_END="0.24873920478980582" LOG_CI_START="-0.6595358432191" LOG_EFFECT_SIZE="-0.20539831921464705" MODIFIED="2009-03-20 11:29:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6711381961218836" P_Z="0.37537141883217706" STUDIES="5" TAU2="0.0" TOTAL_1="1088" TOTAL_2="478" WEIGHT="100.0" Z="0.8864568261085212">
<NAME>Suicide attempt</NAME>
<DICH_DATA CI_END="45.716981012027304" CI_START="0.12370184525914513" EFFECT_SIZE="2.378082191780822" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.6600775433963038" LOG_CI_START="-0.9076238219562694" LOG_EFFECT_SIZE="0.3762268607200172" MODIFIED="2008-05-18 19:49:42 +0100" MODIFIED_BY="[Empty name]" ORDER="403" O_E="0.0" SE="1.5082804923348494" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="2.2749100435578558" WEIGHT="8.166679439571114"/>
<DICH_DATA CI_END="5.332425899883695" CI_START="0.02117160221625628" EFFECT_SIZE="0.336" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.7269248291481487" LOG_CI_START="-1.6742462743684605" LOG_EFFECT_SIZE="-0.4736607226101559" MODIFIED="2008-05-18 19:48:59 +0100" MODIFIED_BY="[Empty name]" ORDER="404" O_E="0.0" SE="1.4104597921943134" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="1.9893968253968255" WEIGHT="16.37891168054415"/>
<DICH_DATA CI_END="2.15654157819904" CI_START="0.02787762979357244" EFFECT_SIZE="0.24519230769230768" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3337578357758902" LOG_CI_START="-1.5547441535055406" LOG_EFFECT_SIZE="-0.6104931588648252" MODIFIED="2008-05-18 19:50:04 +0100" MODIFIED_BY="[Empty name]" ORDER="405" O_E="0.0" SE="1.1093154167395258" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="102" VAR="1.230580693815988" WEIGHT="44.18934960274809"/>
<DICH_DATA CI_END="7.7443737981982546" CI_START="0.014347333174563614" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8889863069264973" LOG_CI_START="-1.8432288163658224" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2008-11-26 19:30:17 +0000" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="16.411669503905237"/>
<DICH_DATA CI_END="13.487328376368598" CI_START="0.14942809914585678" EFFECT_SIZE="1.4196428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1299259314132801" LOG_CI_START="-0.8255677281127405" LOG_EFFECT_SIZE="0.1521791016502699" MODIFIED="2008-05-18 19:49:14 +0100" MODIFIED_BY="[Empty name]" ORDER="406" O_E="0.0" SE="1.1486666554553138" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="1.3194350853548964" WEIGHT="14.853389773231408"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6940308239143109" CI_END="1.2605426088641245" CI_START="0.5717540800022907" DF="3" EFFECT_SIZE="0.8489525190697033" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="49" I2="0.0" ID="CMP-001.25.02" LOG_CI_END="0.10055753028363994" LOG_CI_START="-0.2427907276111854" LOG_EFFECT_SIZE="-0.0711165986637727" MODIFIED="2008-05-18 19:57:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.874607072375297" P_Z="0.4168364977357357" STUDIES="4" TAU2="0.0" TOTAL_1="1067" TOTAL_2="547" WEIGHT="100.0" Z="0.8119218250216411">
<NAME>Treatment-emergent psychiatric disorder</NAME>
<DICH_DATA CI_END="2.326251041871158" CI_START="0.4417671153786324" EFFECT_SIZE="1.0137362637362637" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="7" LOG_CI_END="0.36665658064878304" LOG_CI_START="-0.35480661562877425" LOG_EFFECT_SIZE="0.005924982510004358" MODIFIED="2008-05-18 19:57:15 +0100" MODIFIED_BY="[Empty name]" ORDER="408" O_E="0.0" SE="0.42379105279385587" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="123" VAR="0.17959885642812473" WEIGHT="22.048158795949302"/>
<DICH_DATA CI_END="4.275936816051702" CI_START="0.16501647015718396" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.6310312791740584" LOG_CI_START="-0.7824727070502951" LOG_EFFECT_SIZE="-0.07572071393811836" MODIFIED="2008-05-18 19:56:30 +0100" MODIFIED_BY="[Empty name]" ORDER="409" O_E="0.0" SE="0.8302992384657626" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="126" VAR="0.6893968253968253" WEIGHT="6.308489771023481"/>
<DICH_DATA CI_END="1.5770569953843385" CI_START="0.5059965084715595" EFFECT_SIZE="0.8933002481389578" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="31" LOG_CI_END="0.19784738916505998" LOG_CI_START="-0.2958524799127043" LOG_EFFECT_SIZE="-0.04900254537382219" MODIFIED="2008-05-18 19:57:36 +0100" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="0.29000174695004466" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="192" VAR="0.08410101323407775" WEIGHT="45.89920757617851"/>
<DICH_DATA CI_END="1.4510364293699813" CI_START="0.27435624562667116" EFFECT_SIZE="0.6309523809523809" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.16167831586692982" LOG_CI_START="-0.561685148789115" LOG_EFFECT_SIZE="-0.20000341646109263" MODIFIED="2008-05-18 19:56:53 +0100" MODIFIED_BY="[Empty name]" ORDER="411" O_E="0.0" SE="0.42490727984585974" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="106" VAR="0.18054619646600775" WEIGHT="25.744143856848698"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="145.1943249454119" CI_START="-68.59432494541191" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="38.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.26" MODIFIED="2008-11-28 13:48:57 +0000" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.4825228018939147" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="75" TOTAL_2="36" UNITS="" WEIGHT="100.00000000000001" Z="0.7022507569622485">
<NAME>Adverse effect: 11. Renal: average change in serum level</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="145.1943249454119" CI_START="-68.59432494541191" DF="0" EFFECT_SIZE="38.3" ESTIMABLE="YES" I2="0.0" ID="CMP-001.26.01" NO="1" P_CHI2="1.0" P_Z="0.4825228018939147" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="36" WEIGHT="100.00000000000001" Z="0.7022507569622485">
<NAME>creatine kinase (U/L)</NAME>
<CONT_DATA CI_END="145.1943249454119" CI_START="-68.59432494541191" EFFECT_SIZE="38.3" ESTIMABLE="YES" MEAN_1="34.4" MEAN_2="-3.9" ORDER="174" SD_1="113.12" SD_2="317.71" SE="54.53892305602588" STUDY_ID="STD-Tzimos-2008" TOTAL_1="75" TOTAL_2="36" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-11-25 20:55:43 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>SENSITIVITY ANALYSIS: 1. INCREASING DOSES OF PALPERIDONE versus PLACEBO (primary outcomes only)</NAME>
<DICH_OUTCOME CHI2="33.80238627245885" CI_END="0.7112795111176302" CI_START="0.592424707476669" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.649137548065131" ESTIMABLE="YES" EVENTS_1="434" EVENTS_2="632" I2="67.45791876544982" I2_Q="50.66109055218596" ID="CMP-002.01" LOG_CI_END="-0.1479597012651914" LOG_CI_START="-0.22736683722540998" LOG_EFFECT_SIZE="-0.18766326924530063" METHOD="MH" MODIFIED="2008-11-26 20:51:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.896046310908341E-4" P_Q="0.07152656591215523" P_Z="1.969419125812831E-20" Q="10.133989696891293" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1326" TOTAL_2="1211" WEIGHT="600.0" Z="9.263984766459773">
<NAME>Leaving the study early: any reason</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.921206794546165" CI_START="0.5727540584519857" DF="0" EFFECT_SIZE="0.7263779527559056" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="76" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.035642867469612545" LOG_CI_START="-0.24203182478010515" LOG_EFFECT_SIZE="-0.13883734612485887" NO="1" P_CHI2="1.0" P_Z="0.008366109353186612" STUDIES="1" TAU2="0.0" TOTAL_1="127" TOTAL_2="123" WEIGHT="100.00000000000001" Z="2.6369259446809648">
<NAME>3 mg</NAME>
<DICH_DATA CI_END="0.921206794546165" CI_START="0.5727540584519857" EFFECT_SIZE="0.7263779527559056" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="76" LOG_CI_END="-0.035642867469612545" LOG_CI_START="-0.24203182478010515" LOG_EFFECT_SIZE="-0.13883734612485887" ORDER="175" O_E="0.0" SE="0.12123389516599888" STUDY_ID="STD-Davidson-2007" TOTAL_1="127" TOTAL_2="123" VAR="0.014697657337120406" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8156323070999205" CI_END="0.8768565772776723" CI_START="0.6172363110113843" DF="1" EFFECT_SIZE="0.7356818055687794" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="142" I2="44.92276899405456" ID="CMP-002.01.02" LOG_CI_END="-0.05707143604175974" LOG_CI_START="-0.20954853301716003" LOG_EFFECT_SIZE="-0.13330998452945989" NO="2" P_CHI2="0.17783421136585986" P_Z="6.098982090838737E-4" STUDIES="2" TAU2="0.0" TOTAL_1="235" TOTAL_2="237" WEIGHT="100.0" Z="3.4271739643559305">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.8590851432572306" CI_START="0.48194750928150326" EFFECT_SIZE="0.6434546954165193" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="69" LOG_CI_END="-0.06596379144892886" LOG_CI_START="-0.3170002598332909" LOG_EFFECT_SIZE="-0.1914820256411099" ORDER="176" O_E="0.0" SE="0.14746006417953395" STUDY_ID="STD-Kane-2007" TOTAL_1="123" TOTAL_2="127" VAR="0.021744470527832273" WEIGHT="47.9648503072976"/>
<DICH_DATA CI_END="1.0179060689255774" CI_START="0.661691523245911" EFFECT_SIZE="0.8206947162426614" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="73" LOG_CI_END="0.00770770370855864" LOG_CI_START="-0.17934442895184952" LOG_EFFECT_SIZE="-0.08581836262164544" ORDER="177" O_E="0.0" SE="0.10987534864771352" STUDY_ID="STD-Marder-2007" TOTAL_1="112" TOTAL_2="110" VAR="0.012072592240456603" WEIGHT="52.0351496927024"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.594549019240035" CI_END="0.7310267386331284" CI_START="0.48806111485357795" DF="2" EFFECT_SIZE="0.5973154317821194" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="147" I2="22.91531263549545" ID="CMP-002.01.03" LOG_CI_END="-0.13606673764070915" LOG_CI_START="-0.311525792378803" LOG_EFFECT_SIZE="-0.22379626500975608" MODIFIED="2008-11-26 19:49:31 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.27327572323738425" P_Z="5.738123552855695E-7" STUDIES="3" TAU2="0.0" TOTAL_1="268" TOTAL_2="271" WEIGHT="100.0" Z="4.9998288198742">
<NAME>9 mg</NAME>
<DICH_DATA CI_END="0.7933076559942697" CI_START="0.46678520522306044" EFFECT_SIZE="0.6085263157894737" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="76" LOG_CI_END="-0.10055835443685203" LOG_CI_START="-0.33088291739061276" LOG_EFFECT_SIZE="-0.21572063591373236" ORDER="178" O_E="0.0" SE="0.13529378840401338" STUDY_ID="STD-Davidson-2007" TOTAL_1="125" TOTAL_2="123" VAR="0.018304409180709948" WEIGHT="52.393001331586234"/>
<DICH_DATA CI_END="0.7458916850253953" CI_START="0.39547481797155626" EFFECT_SIZE="0.5431218816821097" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="69" LOG_CI_END="-0.12732423420443972" LOG_CI_START="-0.4028811651730792" LOG_EFFECT_SIZE="-0.26510269968875944" ORDER="179" O_E="0.0" SE="0.1618635052797859" STUDY_ID="STD-Kane-2007" TOTAL_1="122" TOTAL_2="127" VAR="0.026199794341459276" WEIGHT="46.239265581020774"/>
<DICH_DATA CI_END="9.767868569213505" CI_START="0.4095059195009289" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9897998073609312" LOG_CI_START="-0.3877398160329689" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2008-11-26 19:49:31 +0000" MODIFIED_BY="[Empty name]" ORDER="460" O_E="0.0" SE="0.809173593712687" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="0.6547619047619047" WEIGHT="1.367733087392988"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.639196659635399" CI_END="0.7292495403354692" CI_START="0.49435916653416667" DF="1" EFFECT_SIZE="0.6004258446766484" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="142" I2="89.62569148332092" ID="CMP-002.01.04" LOG_CI_END="-0.13712383595299993" LOG_CI_START="-0.3059574086337658" LOG_EFFECT_SIZE="-0.22154062229338287" NO="4" P_CHI2="0.0019047060095557233" P_Z="2.694302847073535E-7" STUDIES="2" TAU2="0.0" TOTAL_1="242" TOTAL_2="237" WEIGHT="100.0" Z="5.143664662343412">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.587480467249101" CI_START="0.2869624820123278" EFFECT_SIZE="0.41059085841694537" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="69" LOG_CI_END="-0.23100656838720918" LOG_CI_START="-0.5421748799911491" LOG_EFFECT_SIZE="-0.3865907241891791" ORDER="180" O_E="0.0" SE="0.1827818065441385" STUDY_ID="STD-Kane-2007" TOTAL_1="130" TOTAL_2="127" VAR="0.033409188803538874" WEIGHT="48.657421298880024"/>
<DICH_DATA CI_END="0.9750673231342478" CI_START="0.6244892825521328" EFFECT_SIZE="0.7803326810176126" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="73" LOG_CI_END="-0.010965397577032682" LOG_CI_START="-0.2044750105619177" LOG_EFFECT_SIZE="-0.10772020406947518" ORDER="181" O_E="0.0" SE="0.11366850455535434" STUDY_ID="STD-Marder-2007" TOTAL_1="112" TOTAL_2="110" VAR="0.01292052892785061" WEIGHT="51.34257870111998"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6394788599687371" CI_START="0.3372788009994532" DF="0" EFFECT_SIZE="0.46441647597254004" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="76" I2="0.0" ID="CMP-002.01.05" LOG_CI_END="-0.19417380794948177" LOG_CI_START="-0.4720109546847535" LOG_EFFECT_SIZE="-0.3330923813171176" NO="5" P_CHI2="1.0" P_Z="2.607878668668828E-6" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="123" WEIGHT="100.0" Z="4.699508892727575">
<NAME>15 mg</NAME>
<DICH_DATA CI_END="0.6394788599687371" CI_START="0.3372788009994532" EFFECT_SIZE="0.46441647597254004" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="76" LOG_CI_END="-0.19417380794948177" LOG_CI_START="-0.4720109546847535" LOG_EFFECT_SIZE="-0.3330923813171176" ORDER="182" O_E="0.0" SE="0.1632029153083558" STUDY_ID="STD-Davidson-2007" TOTAL_1="115" TOTAL_2="123" VAR="0.026635191565146356" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.695941765063694" CI_END="1.1044965682405519" CI_START="0.5904006545944496" DF="2" EFFECT_SIZE="0.8075243011120748" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="49" I2="82.90005165745532" ID="CMP-002.01.06" LOG_CI_END="0.043164370821752576" LOG_CI_START="-0.2288531696697714" LOG_EFFECT_SIZE="-0.09284439942400942" MODIFIED="2008-11-26 20:51:38 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0028857642299251474" P_Z="0.1809157448762057" STUDIES="3" TAU2="0.0" TOTAL_1="339" TOTAL_2="220" WEIGHT="100.0" Z="1.3379407718229845">
<NAME>Flexible dosing</NAME>
<DICH_DATA CI_END="0.8999370201902045" CI_START="0.391575508751575" EFFECT_SIZE="0.5936272370144042" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="29" LOG_CI_END="-0.045787882495026" LOG_CI_START="-0.40718447914333383" LOG_EFFECT_SIZE="-0.22648618081917998" MODIFIED="2008-11-26 20:51:38 +0000" MODIFIED_BY="[Empty name]" ORDER="418" O_E="0.0" SE="0.21228614981322114" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.045065409402521364" WEIGHT="61.48852334034782"/>
<DICH_DATA CI_END="5.262537682271807" CI_START="1.1207443138207334" EFFECT_SIZE="2.4285714285714284" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.7211952186098283" LOG_CI_START="0.04950654411820589" LOG_EFFECT_SIZE="0.3853508813640171" ORDER="183" O_E="0.0" SE="0.3945532523089412" STUDY_ID="STD-Kramer-2007" TOTAL_1="105" TOTAL_2="102" VAR="0.15567226890756303" WEIGHT="12.960593106613716"/>
<DICH_DATA CI_END="1.0058740130405417" CI_START="0.24854007237377929" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.002543588207254838" LOG_CI_START="-0.6046035795352172" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="184" O_E="0.0" SE="0.3566412517588793" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.12719298245614033" WEIGHT="25.550883553038467"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="62.150836492193854" CI_END="0.7424349918728943" CI_START="0.6335306787000581" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6858245725343375" ESTIMABLE="YES" EVENTS_1="690" EVENTS_2="830" I2="83.9101119720955" I2_Q="31.812552711835536" ID="CMP-002.02" LOG_CI_END="-0.12934156747456282" LOG_CI_START="-0.19823234957683852" LOG_EFFECT_SIZE="-0.16378695852570072" METHOD="MH" MODIFIED="2011-11-25 20:55:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.416550321486909E-9" P_Q="0.1970475889251182" P_Z="1.1680293939043487E-20" Q="7.332727941654252" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.06167684619722436" TOTALS="SUB" TOTAL_1="1293" TOTAL_2="1167" WEIGHT="600.0" Z="9.319578905960032">
<NAME>Global state: 1. No clinically important change</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.870522240993628" CI_START="0.6234242419780893" DF="0" EFFECT_SIZE="0.7366849178695869" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="98" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-0.06022012860476279" LOG_CI_START="-0.20521631410182062" LOG_EFFECT_SIZE="-0.13271822135329175" NO="1" P_CHI2="1.0" P_Z="3.332282175303839E-4" STUDIES="1" TAU2="0.0" TOTAL_1="123" TOTAL_2="120" WEIGHT="100.0" Z="3.5879969263045868">
<NAME>3 mg</NAME>
<DICH_DATA CI_END="0.870522240993628" CI_START="0.6234242419780893" EFFECT_SIZE="0.7366849178695869" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="98" LOG_CI_END="-0.06022012860476279" LOG_CI_START="-0.20521631410182062" LOG_EFFECT_SIZE="-0.13271822135329175" ORDER="185" O_E="0.0" SE="0.08517147710366559" STUDY_ID="STD-Davidson-2007" TOTAL_1="123" TOTAL_2="120" VAR="0.007254180512020231" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.18601716178624" CI_END="0.8222138651909652" CI_START="0.5754325903529427" DF="1" EFFECT_SIZE="0.6878434809394811" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="157" I2="15.684188035363908" ID="CMP-002.02.02" LOG_CI_END="-0.0850152038811923" LOG_CI_START="-0.24000554493156478" LOG_EFFECT_SIZE="-0.16251037440637853" NO="2" P_CHI2="0.2761344747466311" P_Z="3.9545287826938913E-5" STUDIES="2" TAU2="0.002600270558048596" TOTAL_1="234" TOTAL_2="231" WEIGHT="100.00000000000001" Z="4.110120395787804">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="0.7914553871111778" CI_START="0.49925980549367033" EFFECT_SIZE="0.6286031042128604" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="88" LOG_CI_END="-0.10157356049524158" LOG_CI_START="-0.3016733968028287" LOG_EFFECT_SIZE="-0.20162347864903513" ORDER="186" O_E="0.0" SE="0.11753963435724113" STUDY_ID="STD-Kane-2007" TOTAL_1="123" TOTAL_2="126" VAR="0.013815565644833938" WEIGHT="50.49187074652634"/>
<DICH_DATA CI_END="0.9519278738691563" CI_START="0.5972494992302232" EFFECT_SIZE="0.754014884449667" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="69" LOG_CI_END="-0.021395956203006442" LOG_CI_START="-0.22384420571645527" LOG_EFFECT_SIZE="-0.12262008095973086" ORDER="187" O_E="0.0" SE="0.11891910389919719" STUDY_ID="STD-Marder-2007" TOTAL_1="111" TOTAL_2="105" VAR="0.014141753272188057" WEIGHT="49.508129253473676"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1445958355072881" CI_END="0.7840142157949292" CI_START="0.593990042469742" DF="1" EFFECT_SIZE="0.682419692958015" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="186" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="-0.10567606258938674" LOG_CI_START="-0.22622083538360743" LOG_EFFECT_SIZE="-0.1659484489864971" NO="3" P_CHI2="0.7037543450153112" P_Z="6.799707609545899E-8" STUDIES="2" TAU2="0.0" TOTAL_1="245" TOTAL_2="246" WEIGHT="100.0" Z="5.39638469200235">
<NAME>9 mg</NAME>
<DICH_DATA CI_END="0.8005059207391493" CI_START="0.5557572985289149" EFFECT_SIZE="0.6669985067197611" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="98" LOG_CI_END="-0.09663545158374186" LOG_CI_START="-0.2551148251831411" LOG_EFFECT_SIZE="-0.1758751383834415" ORDER="188" O_E="0.0" SE="0.09309156853783845" STUDY_ID="STD-Davidson-2007" TOTAL_1="123" TOTAL_2="120" VAR="0.008666040132835074" WEIGHT="57.85638221627362"/>
<DICH_DATA CI_END="0.872013083956306" CI_START="0.5686376143263558" EFFECT_SIZE="0.7041728763040238" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="88" LOG_CI_END="-0.059476998728676476" LOG_CI_START="-0.2451644159187442" LOG_EFFECT_SIZE="-0.15232070732371034" ORDER="189" O_E="0.0" SE="0.10907370802498502" STUDY_ID="STD-Kane-2007" TOTAL_1="122" TOTAL_2="126" VAR="0.011897073782319682" WEIGHT="42.143617783726384"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7718537142398727" CI_END="0.8526406443849158" CI_START="0.48384353860744633" DF="1" EFFECT_SIZE="0.6422964008460043" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="157" I2="63.923060049572975" ID="CMP-002.02.04" LOG_CI_END="-0.06923396888409392" LOG_CI_START="-0.31529505427468674" LOG_EFFECT_SIZE="-0.1922645115793903" NO="4" P_CHI2="0.09593509074478423" P_Z="0.0021919574303489054" STUDIES="2" TAU2="0.026713923105277006" TOTAL_1="240" TOTAL_2="231" WEIGHT="100.0" Z="3.062910314344211">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="0.7093149470518924" CI_START="0.4342074017192294" EFFECT_SIZE="0.554968287526427" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="88" LOG_CI_END="-0.14916088837681551" LOG_CI_START="-0.36230277761485635" LOG_EFFECT_SIZE="-0.2557318329958359" ORDER="190" O_E="0.0" SE="0.12520060080779286" STUDY_ID="STD-Kane-2007" TOTAL_1="129" TOTAL_2="126" VAR="0.015675190442632304" WEIGHT="49.28408979668138"/>
<DICH_DATA CI_END="0.9372016529634576" CI_START="0.5847751820799059" EFFECT_SIZE="0.7403055229142186" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="69" LOG_CI_END="-0.02816695409953563" LOG_CI_START="-0.23301106716247666" LOG_EFFECT_SIZE="-0.13058901063100617" ORDER="191" O_E="0.0" SE="0.12032644600788471" STUDY_ID="STD-Marder-2007" TOTAL_1="111" TOTAL_2="105" VAR="0.014478453608888393" WEIGHT="50.71591020331863"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.711156602157756" CI_START="0.4638098276994072" DF="0" EFFECT_SIZE="0.574318222864367" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="98" I2="0.0" ID="CMP-002.02.05" LOG_CI_END="-0.14803475375111255" LOG_CI_START="-0.33366005330388887" LOG_EFFECT_SIZE="-0.24084740352750073" NO="5" P_CHI2="1.0" P_Z="3.6554666090828385E-7" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="120" WEIGHT="100.0" Z="5.086076497343771">
<NAME>15 mg</NAME>
<DICH_DATA CI_END="0.711156602157756" CI_START="0.4638098276994072" EFFECT_SIZE="0.574318222864367" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="98" LOG_CI_END="-0.14803475375111255" LOG_CI_START="-0.33366005330388887" LOG_EFFECT_SIZE="-0.24084740352750073" ORDER="192" O_E="0.0" SE="0.10903721981735283" STUDY_ID="STD-Davidson-2007" TOTAL_1="113" TOTAL_2="120" VAR="0.011889115305497721" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="22.056957396938145" CI_END="1.6151274800748834" CI_START="0.6829668616402111" DF="2" EFFECT_SIZE="1.0502754620648842" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="134" I2="90.93256624652305" ID="CMP-002.02.06" LOG_CI_END="0.2082068063625484" LOG_CI_START="-0.16560036828910246" LOG_EFFECT_SIZE="0.021303219036723026" MODIFIED="2011-11-25 20:55:43 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.6232945003746835E-5" P_Z="0.8232271996570478" STUDIES="3" TAU2="0.1310821705654467" TOTAL_1="338" TOTAL_2="219" WEIGHT="100.0" Z="0.22339615126785659">
<NAME>Flexible dosing</NAME>
<DICH_DATA CI_END="0.9981701311454257" CI_START="0.6890527232500765" EFFECT_SIZE="0.8293321693583589" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="58" LOG_CI_END="-7.954299345359268E-4" LOG_CI_START="-0.16174754653860113" LOG_EFFECT_SIZE="-0.08127148823656853" MODIFIED="2011-11-25 20:55:43 +0000" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="0.09454407001905449" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.008938581175767877" WEIGHT="34.43325386895878"/>
<DICH_DATA CI_END="2.0114594453859524" CI_START="1.2812759248101333" EFFECT_SIZE="1.6053767660910518" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="49" LOG_CI_END="0.3035112808433246" LOG_CI_START="0.10764266582467207" LOG_EFFECT_SIZE="0.20557697333399833" ORDER="193" O_E="0.0" SE="0.11505419402723778" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="101" VAR="0.013237467563257279" WEIGHT="33.40758163021449"/>
<DICH_DATA CI_END="1.1390398245362952" CI_START="0.6650729546941463" EFFECT_SIZE="0.8703703703703703" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="27" LOG_CI_END="0.056538908691917765" LOG_CI_START="-0.17713071246641982" LOG_EFFECT_SIZE="-0.060295901887251056" ORDER="194" O_E="0.0" SE="0.13725869215168698" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="0.018839948571191575" WEIGHT="32.159164500826726"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.6945104882192075" CI_END="0.6362707348025443" CI_START="0.3341902086582589" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4611241152084826" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="120" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.19635805162791725" LOG_CI_START="-0.47600627852396143" LOG_EFFECT_SIZE="-0.33618216507593934" METHOD="MH" MODIFIED="2008-11-26 21:13:32 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7403796409237611" P_Q="0.8760653975095223" P_Z="2.4483527761147975E-6" Q="1.80002309209797" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1322" TOTAL_2="1200" WEIGHT="600.0" Z="4.712384148521567">
<NAME>Global state: 2. Recurrence of psychotic symptoms</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.691909657903799" CI_START="0.29323797727636136" DF="0" EFFECT_SIZE="0.7043664996420902" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.22837716950598744" LOG_CI_START="-0.5327797848716682" LOG_EFFECT_SIZE="-0.15220130768284038" NO="1" P_CHI2="1.0" P_Z="0.43313948378519096" STUDIES="1" TAU2="0.0" TOTAL_1="127" TOTAL_2="123" WEIGHT="100.0" Z="0.7838306665730275">
<NAME>3 mg</NAME>
<DICH_DATA CI_END="1.691909657903799" CI_START="0.29323797727636136" EFFECT_SIZE="0.7043664996420902" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.22837716950598744" LOG_CI_START="-0.5327797848716682" LOG_EFFECT_SIZE="-0.15220130768284038" ORDER="195" O_E="0.0" SE="0.44710736278912516" STUDY_ID="STD-Davidson-2007" TOTAL_1="127" TOTAL_2="123" VAR="0.1999049938602464" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.553281136427653E-5" CI_END="1.0322260913872614" CI_START="0.2525147232987591" DF="1" EFFECT_SIZE="0.5105411695920457" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.013774832453659307" LOG_CI_START="-0.5977132945315013" LOG_EFFECT_SIZE="-0.29196923103892103" NO="2" P_CHI2="0.9946160750332024" P_Z="0.061253546513014685" STUDIES="2" TAU2="0.0" TOTAL_1="235" TOTAL_2="232" WEIGHT="100.0" Z="1.8716607965931167">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="1.657292763604279" CI_START="0.15829662007337764" EFFECT_SIZE="0.5121951219512195" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.21939923406021397" LOG_CI_START="-0.8005283580318465" LOG_EFFECT_SIZE="-0.2905645619858162" ORDER="196" O_E="0.0" SE="0.5991105163178819" STUDY_ID="STD-Kane-2007" TOTAL_1="123" TOTAL_2="126" VAR="0.35893341076267904" WEIGHT="35.9449079728225"/>
<DICH_DATA CI_END="1.2281692595526794" CI_START="0.2114593230669822" EFFECT_SIZE="0.5096153846153846" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.08925822301381084" LOG_CI_START="-0.6747731624097936" LOG_EFFECT_SIZE="-0.2927574696979913" ORDER="197" O_E="0.0" SE="0.4487958178141786" STUDY_ID="STD-Marder-2007" TOTAL_1="112" TOTAL_2="106" VAR="0.2014176860874974" WEIGHT="64.0550920271775"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.161815593986113" CI_END="2.251658573081696" CI_START="0.09729376448579823" DF="2" EFFECT_SIZE="0.46805164128741067" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="21" I2="51.9440505031018" ID="CMP-002.03.03" LOG_CI_END="0.3525025375700188" LOG_CI_START="-1.0119149925804318" LOG_EFFECT_SIZE="-0.3297062275052065" MODIFIED="2008-11-26 19:50:33 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.12481689976837884" P_Z="0.3435188229512546" STUDIES="3" TAU2="1.0399981268702672" TOTAL_1="267" TOTAL_2="270" WEIGHT="99.99999999999999" Z="0.947235457048867">
<NAME>9 mg</NAME>
<DICH_DATA CI_END="2.202398366062113" CI_START="0.44675659922578304" EFFECT_SIZE="0.9919354838709677" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.34289587618654915" LOG_CI_START="-0.34992902363222345" LOG_EFFECT_SIZE="-0.003516573722837135" ORDER="198" O_E="0.0" SE="0.406968775692112" STUDY_ID="STD-Davidson-2007" TOTAL_1="124" TOTAL_2="123" VAR="0.16562358438833658" WEIGHT="53.279326335562935"/>
<DICH_DATA CI_END="1.0409751068190185" CI_START="0.0035437170006087666" EFFECT_SIZE="0.060736489717838356" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.017440344207558814" LOG_CI_START="-2.450540967930989" LOG_EFFECT_SIZE="-1.216550311861715" ORDER="199" O_E="0.0" SE="1.4497044394547065" STUDY_ID="STD-Kane-2007" TOTAL_1="122" TOTAL_2="126" VAR="2.101642961774685" WEIGHT="20.446228827205914"/>
<DICH_DATA CI_END="5.103130184031393" CI_START="0.04898953994595213" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.707836647596448" LOG_CI_START="-1.3098966389244104" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2008-11-26 19:50:33 +0000" MODIFIED_BY="[Empty name]" ORDER="461" O_E="0.0" SE="1.185226520443204" STUDY_ID="STD-Luthringer-2007" TOTAL_1="21" TOTAL_2="21" VAR="1.4047619047619047" WEIGHT="26.274444837231147"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.01845038555473006" CI_END="0.9427560084526403" CI_START="0.21925246880736735" DF="1" EFFECT_SIZE="0.45464445706092216" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" I2="0.0" ID="CMP-002.03.04" LOG_CI_END="-0.025600691031054914" LOG_CI_START="-0.659055507729858" LOG_EFFECT_SIZE="-0.3423280993804564" NO="4" P_CHI2="0.8919539443986834" P_Z="0.03414243383936975" STUDIES="2" TAU2="0.0" TOTAL_1="242" TOTAL_2="232" WEIGHT="100.0" Z="2.118385488576271">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="1.5691768321443305" CI_START="0.1496657777472946" EFFECT_SIZE="0.4846153846153846" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.19567188743471509" LOG_CI_START="-0.8248774931412253" LOG_EFFECT_SIZE="-0.3146028028532551" ORDER="200" O_E="0.0" SE="0.5994757579512155" STUDY_ID="STD-Kane-2007" TOTAL_1="130" TOTAL_2="126" VAR="0.3593711843711844" WEIGHT="38.52682663950153"/>
<DICH_DATA CI_END="1.1072862216833044" CI_START="0.17231837300732214" EFFECT_SIZE="0.4368131868131868" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" LOG_CI_END="0.044259895883765256" LOG_CI_START="-0.7636684145409743" LOG_EFFECT_SIZE="-0.3597042593286045" ORDER="201" O_E="0.0" SE="0.47458108885312866" STUDY_ID="STD-Marder-2007" TOTAL_1="112" TOTAL_2="106" VAR="0.22522720989702122" WEIGHT="61.47317336049848"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3800923553532316" CI_START="0.1773780287030503" DF="0" EFFECT_SIZE="0.4947707160096541" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="0.0" ID="CMP-002.03.05" LOG_CI_END="0.13990815022601752" LOG_CI_START="-0.7511001759584734" LOG_EFFECT_SIZE="-0.305596012866228" NO="5" P_CHI2="1.0" P_Z="0.17880356240951442" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="123" WEIGHT="100.0" Z="1.3444479954563895">
<NAME>15 mg</NAME>
<DICH_DATA CI_END="1.3800923553532314" CI_START="0.17737802870305028" EFFECT_SIZE="0.49477071600965405" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.13990815022601744" LOG_CI_START="-0.7511001759584736" LOG_EFFECT_SIZE="-0.30559601286622806" ORDER="202" O_E="0.0" SE="0.5233827013631173" STUDY_ID="STD-Davidson-2007" TOTAL_1="113" TOTAL_2="123" VAR="0.273929452086154" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5933534959603266" CI_END="0.6279907397629083" CI_START="0.2013545444712271" DF="2" EFFECT_SIZE="0.3555963854387574" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="35" I2="0.0" ID="CMP-002.03.06" LOG_CI_END="-0.20204676024293333" LOG_CI_START="-0.6960385641369822" LOG_EFFECT_SIZE="-0.4490426621899578" MODIFIED="2008-11-26 21:13:32 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7432842726427595" P_Z="3.66295500457328E-4" STUDIES="3" TAU2="0.0" TOTAL_1="338" TOTAL_2="220" WEIGHT="100.0" Z="3.563247157044202">
<NAME>Flexible dosing</NAME>
<DICH_DATA CI_END="1.0762843882982567" CI_START="0.19294066815379346" EFFECT_SIZE="0.45569620253164556" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.03192704080046551" LOG_CI_START="-0.7145762218467738" LOG_EFFECT_SIZE="-0.34132459052315417" MODIFIED="2008-11-26 21:13:32 +0000" MODIFIED_BY="[Empty name]" ORDER="809" O_E="0.0" SE="0.43849971172973473" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="80" VAR="0.19228199718706046" WEIGHT="43.790113045604976"/>
<DICH_DATA CI_END="0.6648115361883196" CI_START="0.13402182451998096" EFFECT_SIZE="0.298494983277592" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="23" LOG_CI_END="-0.17730145303342187" LOG_CI_START="-0.8728244740469757" LOG_EFFECT_SIZE="-0.5250629635401988" ORDER="203" O_E="0.0" SE="0.40855366543784183" STUDY_ID="STD-Kramer-2007" TOTAL_1="104" TOTAL_2="102" VAR="0.166916097542696" WEIGHT="50.4448074057224"/>
<DICH_DATA CI_END="2.67076769194467" CI_START="0.023401511179166532" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.42663611396888185" LOG_CI_START="-1.6307560966248067" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="204" O_E="0.0" SE="1.2085223687584246" STUDY_ID="STD-Tzimos-2008" TOTAL_1="76" TOTAL_2="38" VAR="1.4605263157894737" WEIGHT="5.765079548672627"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-08-06 10:48:11 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>PALIPERIDONE - ANY DOSE OR FLEXIBLE DOSES versus OLANZAPINE (fixed dose 10 mg/day, all short term)</NAME>
<DICH_OUTCOME CHI2="16.023975165121602" CI_END="1.1869923578371793" CI_START="0.9375326163534292" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="1.054914238615925" ESTIMABLE="YES" EVENTS_1="771" EVENTS_2="286" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.07444792286375133" LOG_CI_START="-0.028013614420603676" LOG_EFFECT_SIZE="0.023217154221573832" METHOD="MH" NO="1" P_CHI2="0.7683025765348064" P_Q="0.6069480423620411" P_Z="0.37441620952715504" Q="5.435721589218178" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="7129" TOTAL_2="2690" WEIGHT="800.0" Z="0.8882315706724222">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4465764178694853" CI_END="1.2104571460847489" CI_START="0.892599316048892" DF="2" EFFECT_SIZE="1.0394485175811934" ESTIMABLE="YES" EVENTS_1="364" EVENTS_2="138" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.08294941868616562" LOG_CI_START="-0.04934345027199162" LOG_EFFECT_SIZE="0.01680298420708699" NO="1" P_CHI2="0.48515441945649407" P_Z="0.618565887081101" STUDIES="3" TAU2="0.0" TOTAL_1="966" TOTAL_2="366" WEIGHT="100.0" Z="0.4978838865321189">
<NAME>any reason</NAME>
<DICH_DATA CI_END="1.5950460473265742" CI_START="0.8946140967925291" EFFECT_SIZE="1.1945504087193461" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="40" LOG_CI_END="0.2027732252058473" LOG_CI_START="-0.04836426275740047" LOG_EFFECT_SIZE="0.07720448122422344" ORDER="205" O_E="0.0" SE="0.14751940358022644" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="128" VAR="0.021761974432665726" WEIGHT="30.192142104263294"/>
<DICH_DATA CI_END="1.3233157583149615" CI_START="0.7111713252814273" EFFECT_SIZE="0.9701052631578947" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="38" LOG_CI_END="0.1216634841964627" LOG_CI_START="-0.14802576261588457" LOG_EFFECT_SIZE="-0.01318113920971096" ORDER="206" O_E="0.0" SE="0.15841679856087487" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.025095882066276803" WEIGHT="28.841639856765024"/>
<DICH_DATA CI_END="1.2019334567693218" CI_START="0.7892240870132473" EFFECT_SIZE="0.9739583333333334" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="60" LOG_CI_END="0.07988042427415713" LOG_CI_START="-0.10279966860825844" LOG_EFFECT_SIZE="-0.011459622167050623" ORDER="207" O_E="0.0" SE="0.10730719084017473" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.01151483320600968" WEIGHT="40.96621803897168"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08956504691509276" CI_END="1.3536126071584729" CI_START="0.5060424367575208" DF="2" EFFECT_SIZE="0.8276384610155417" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="22" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.13149439060766985" LOG_CI_START="-0.2958130616644956" LOG_EFFECT_SIZE="-0.08215933552841288" NO="2" P_CHI2="0.956205412915115" P_Z="0.451033533697497" STUDIES="3" TAU2="0.0" TOTAL_1="966" TOTAL_2="366" WEIGHT="100.0" Z="0.753693097432182">
<NAME>adverse event</NAME>
<DICH_DATA CI_END="2.493700436047807" CI_START="0.3297541162884155" EFFECT_SIZE="0.9068119891008174" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.3968442812253687" LOG_CI_START="-0.4818097744921748" LOG_EFFECT_SIZE="-0.042482746633403026" ORDER="208" O_E="0.0" SE="0.5161257417362072" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="128" VAR="0.26638578128275" WEIGHT="23.489111088839"/>
<DICH_DATA CI_END="1.6230385675548162" CI_START="0.35448963101494274" EFFECT_SIZE="0.7585185185185185" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.21032883989846107" LOG_CI_START="-0.4503964636088495" LOG_EFFECT_SIZE="-0.12003381185519418" ORDER="209" O_E="0.0" SE="0.38811331392319487" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.15063194444444442" WEIGHT="42.51493351909432"/>
<DICH_DATA CI_END="1.986954686092298" CI_START="0.3716870826467827" EFFECT_SIZE="0.859375" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.29818796282975973" LOG_CI_START="-0.42982253180904634" LOG_EFFECT_SIZE="-0.06581728448964333" ORDER="210" O_E="0.0" SE="0.427636968260903" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.1828733766233766" WEIGHT="33.99595539206667"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7944491941495975" CI_END="1.3951792310824158" CI_START="0.8052697733118752" DF="2" EFFECT_SIZE="1.059950783358913" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="59" I2="28.4295451072376" ID="CMP-003.01.03" LOG_CI_END="0.14463000264193449" LOG_CI_START="-0.09405860232347911" LOG_EFFECT_SIZE="0.025285700159227684" NO="3" P_CHI2="0.24728259794734853" P_Z="0.6779506819213812" STUDIES="3" TAU2="0.0" TOTAL_1="966" TOTAL_2="366" WEIGHT="100.0" Z="0.4152612282697465">
<NAME>lack of efficacy</NAME>
<DICH_DATA CI_END="2.458755213112145" CI_START="0.8936148498630777" EFFECT_SIZE="1.4822888283378746" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="16" LOG_CI_END="0.3907152937300115" LOG_CI_START="-0.04884962283783044" LOG_EFFECT_SIZE="0.17093283544609053" ORDER="211" O_E="0.0" SE="0.25820260787337956" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="128" VAR="0.0666685867126142" WEIGHT="28.161576953532407"/>
<DICH_DATA CI_END="1.5181650349100928" CI_START="0.574827986424169" EFFECT_SIZE="0.9341754385964912" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="19" LOG_CI_END="0.18131898490262385" LOG_CI_START="-0.24046209569838436" LOG_EFFECT_SIZE="-0.029571555397880294" ORDER="212" O_E="0.0" SE="0.2477562945950536" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.061383181511470986" WEIGHT="33.62737800648073"/>
<DICH_DATA CI_END="1.3431948667820908" CI_START="0.5498274367250188" EFFECT_SIZE="0.859375" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="24" LOG_CI_END="0.1281390234125473" LOG_CI_START="-0.2597735923918339" LOG_EFFECT_SIZE="-0.06581728448964333" ORDER="213" O_E="0.0" SE="0.22786179072191032" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.05192099567099566" WEIGHT="38.21104503998686"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.9244228956256606" CI_END="1.912895895784926" CI_START="0.4866768969867442" DF="2" EFFECT_SIZE="0.9648638447051927" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="11" I2="31.610438319588063" ID="CMP-003.01.04" LOG_CI_END="0.2816913353611198" LOG_CI_START="-0.31275926963756756" LOG_EFFECT_SIZE="-0.015533967138223885" NO="4" P_CHI2="0.2317233157964076" P_Z="0.9184120920531849" STUDIES="3" TAU2="0.0" TOTAL_1="966" TOTAL_2="366" WEIGHT="100.0" Z="0.10243413286799424">
<NAME>loss to follow up</NAME>
<DICH_DATA CI_END="1.7062104114607268" CI_START="0.07129436792774574" EFFECT_SIZE="0.34877384196185285" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.23203258773509433" LOG_CI_START="-1.1469447769435364" LOG_EFFECT_SIZE="-0.457456094604221" ORDER="214" O_E="0.0" SE="0.8100181300602719" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="128" VAR="0.6561293710263396" WEIGHT="28.73977377831149"/>
<DICH_DATA CI_END="3.0297446488763464" CI_START="0.08652346332131405" EFFECT_SIZE="0.512" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.48140602709731456" LOG_CI_START="-1.062866105145653" LOG_EFFECT_SIZE="-0.2907300390241692" ORDER="215" O_E="0.0" SE="0.9071130947498589" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.8228541666666666" WEIGHT="19.266130763463075"/>
<DICH_DATA CI_END="3.606579585662842" CI_START="0.601778022661815" EFFECT_SIZE="1.4732142857142858" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.557095520120388" LOG_CI_START="-0.2205636770329386" LOG_EFFECT_SIZE="0.1682659215437247" ORDER="216" O_E="0.0" SE="0.4568008618829735" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.2086670274170274" WEIGHT="51.994095458225424"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3213691005716979" CI_END="1.9407299818354387" CI_START="0.18008111346041747" DF="2" EFFECT_SIZE="0.5911757911610908" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-003.01.05" LOG_CI_END="0.287965115215079" LOG_CI_START="-0.7445318327108897" LOG_EFFECT_SIZE="-0.22828335874790534" NO="5" P_CHI2="0.5164976813739173" P_Z="0.38611213764056884" STUDIES="3" TAU2="0.0" TOTAL_1="966" TOTAL_2="366" WEIGHT="100.0" Z="0.8666895574161295">
<NAME>non compliance</NAME>
<DICH_DATA CI_END="9.969112307013601" CI_START="0.10981807625552215" EFFECT_SIZE="1.0463215258855585" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.9986564885694991" LOG_CI_START="-0.9593261683386161" LOG_EFFECT_SIZE="0.019665160115441428" ORDER="217" O_E="0.0" SE="1.1501287048382918" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="128" VAR="1.3227960376930064" WEIGHT="23.172355019137946"/>
<DICH_DATA CI_END="2.7897850560076667" CI_START="0.00468803103141276" EFFECT_SIZE="0.11436170212765957" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.44557074356541965" LOG_CI_START="-2.329009522261569" LOG_EFFECT_SIZE="-0.9417193893480745" ORDER="218" O_E="0.0" SE="1.6298021825405944" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="2.6562551542140853" WEIGHT="34.905754845242036"/>
<DICH_DATA CI_END="4.344376190889121" CI_START="0.12489482012309731" EFFECT_SIZE="0.7366071428571429" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6379274249034046" LOG_CI_START="-0.9034555731439174" LOG_EFFECT_SIZE="-0.1327640741202565" ORDER="219" O_E="0.0" SE="0.9054160030218918" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.8197781385281385" WEIGHT="41.92189013562002"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8818978212546269" CI_END="1.951555830521397" CI_START="0.9329299466905483" DF="2" EFFECT_SIZE="1.349320153607718" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="33" I2="0.0" ID="CMP-003.01.06" LOG_CI_END="0.2903809801832583" LOG_CI_START="-0.030150966015514105" LOG_EFFECT_SIZE="0.1301150070838721" NO="6" P_CHI2="0.6434256019190177" P_Z="0.11155683638018608" STUDIES="3" TAU2="0.0" TOTAL_1="966" TOTAL_2="366" WEIGHT="100.0" Z="1.5912343886897105">
<NAME>unspecified participant reason</NAME>
<DICH_DATA CI_END="2.5623121065123207" CI_START="0.7254497294453777" EFFECT_SIZE="1.3633886549417884" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="11" LOG_CI_END="0.40863202856265857" LOG_CI_START="-0.13939267692837762" LOG_EFFECT_SIZE="0.1346196758171405" ORDER="220" O_E="0.0" SE="0.32191242477147775" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="128" VAR="0.10362760922225231" WEIGHT="35.02585415347967"/>
<DICH_DATA CI_END="4.845493071814469" CI_START="0.7540419031926491" EFFECT_SIZE="1.9114666666666666" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="5" LOG_CI_END="0.6853379769435641" LOG_CI_START="-0.12260451909086427" LOG_EFFECT_SIZE="0.28136672892634995" ORDER="221" O_E="0.0" SE="0.4745894215504798" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.22523511904761903" WEIGHT="16.009157286254396"/>
<DICH_DATA CI_END="1.9426462859754317" CI_START="0.6872547361360284" EFFECT_SIZE="1.1554621848739495" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="17" LOG_CI_END="0.2883937321318056" LOG_CI_START="-0.16288225858430436" LOG_EFFECT_SIZE="0.06275573677375065" ORDER="222" O_E="0.0" SE="0.2650817507988241" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.07026833460656991" WEIGHT="48.96498856026593"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.369837392261144" CI_END="1.5680700694772425" CI_START="0.2725040479788254" DF="2" EFFECT_SIZE="0.6536860419551472" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="0.0" ID="CMP-003.01.07" LOG_CI_END="0.19536546530467197" LOG_CI_START="-0.5646270420045526" LOG_EFFECT_SIZE="-0.18463078834994032" NO="7" P_CHI2="0.5041312651738283" P_Z="0.34094585256074894" STUDIES="3" TAU2="0.0" TOTAL_1="966" TOTAL_2="366" WEIGHT="100.0" Z="0.9522980611593937">
<NAME>unspecified reason</NAME>
<DICH_DATA CI_END="2.0506759920957065" CI_START="0.18166315863584276" EFFECT_SIZE="0.6103542234332425" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.3118970470281163" LOG_CI_START="-0.7407331388639693" LOG_EFFECT_SIZE="-0.21441804591792651" ORDER="223" O_E="0.0" SE="0.6183201817964669" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="128" VAR="0.3823198472168159" WEIGHT="51.81852070095885"/>
<DICH_DATA CI_END="14.471481720123164" CI_START="0.2012724866356202" EFFECT_SIZE="1.7066666666666668" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.160513000360799" LOG_CI_START="-0.6962155878484625" LOG_EFFECT_SIZE="0.23214870625616835" ORDER="224" O_E="0.0" SE="1.0906515636688618" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="1.1895208333333334" WEIGHT="13.026490789751255"/>
<DICH_DATA CI_END="1.9308338626173869" CI_START="0.0555088089435988" EFFECT_SIZE="0.3273809523809524" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.28574490679204206" LOG_CI_START="-1.25563809125528" LOG_EFFECT_SIZE="-0.484946592231619" ORDER="225" O_E="0.0" SE="0.9054160030218918" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.8197781385281385" WEIGHT="35.1549885092899"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.56231210651232" CI_START="0.7254497294453778" DF="0" EFFECT_SIZE="1.3633886549417884" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="11" I2="0.0" ID="CMP-003.01.08" LOG_CI_END="0.4086320285626585" LOG_CI_START="-0.13939267692837756" LOG_EFFECT_SIZE="0.1346196758171405" NO="8" P_CHI2="1.0" P_Z="0.3355918206680202" STUDIES="1" TAU2="0.0" TOTAL_1="367" TOTAL_2="128" WEIGHT="100.0" Z="0.9629117576939925">
<NAME>withdrawal of consent</NAME>
<DICH_DATA CI_END="2.5623121065123207" CI_START="0.7254497294453777" EFFECT_SIZE="1.3633886549417884" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="11" LOG_CI_END="0.40863202856265857" LOG_CI_START="-0.13939267692837762" LOG_EFFECT_SIZE="0.1346196758171405" ORDER="226" O_E="0.0" SE="0.32191242477147775" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="128" VAR="0.10362760922225231" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7897850560076667" CI_START="0.00468803103141276" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.11436170212765956" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.44557074356541965" LOG_CI_START="-2.329009522261569" LOG_EFFECT_SIZE="-0.9417193893480745" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.18336626902724443" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="966" TOTAL_2="366" WEIGHT="100.0" Z="1.3304614823353405">
<NAME>Death</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="227" O_E="0.0" SE="0.0" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="128" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.7897850560076667" CI_START="0.00468803103141276" EFFECT_SIZE="0.11436170212765957" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.44557074356541965" LOG_CI_START="-2.329009522261569" LOG_EFFECT_SIZE="-0.9417193893480745" ORDER="228" O_E="0.0" SE="1.6298021825405944" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="2.6562551542140853" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="229" O_E="0.0" SE="0.0" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="110" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1279119489110185" CI_START="0.7252717076283351" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.904457088667615" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.05227519752440765" LOG_CI_START="-0.1394992637495443" LOG_EFFECT_SIZE="-0.04361203311256832" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.3726914913063145" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="222" TOTAL_2="105" WEIGHT="100.0" Z="0.8914431423806309">
<NAME>Global state: 1. No clinically important change</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1279119489110185" CI_START="0.7252717076283351" EFFECT_SIZE="0.904457088667615" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="57" LOG_CI_END="0.05227519752440765" LOG_CI_START="-0.1394992637495443" LOG_EFFECT_SIZE="-0.04361203311256832" ORDER="230" O_E="0.0" SE="0.11264926785121279" STUDY_ID="STD-Marder-2007" TOTAL_1="222" TOTAL_2="105" VAR="0.012689857547414283" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.26931141463616" CI_END="1.764510213824472" CI_START="0.643501591135226" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.06558206167822" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="20" I2="53.154038069381635" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.2466241766063133" LOG_CI_START="-0.19145037491282793" LOG_EFFECT_SIZE="0.0275869008467427" METHOD="MH" NO="4" P_CHI2="0.11828537255934113" P_Q="1.0" P_Z="0.8050243820021024" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="963" TOTAL_2="364" WEIGHT="100.0" Z="0.24684991135501153">
<NAME>Global state: 2. Relapse: recurrence of psychotic symptoms</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.598304378477499" CI_START="0.850084881626839" EFFECT_SIZE="1.9771062271062272" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="6" LOG_CI_END="0.6625977154147797" LOG_CI_START="-0.07053770748375497" LOG_EFFECT_SIZE="0.2960300039655124" ORDER="231" O_E="0.0" SE="0.4306473764894717" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="127" VAR="0.18545716287726477" WEIGHT="31.419769914112834"/>
<DICH_DATA CI_END="2.2290838339469703" CI_START="0.20906965035612235" EFFECT_SIZE="0.6826666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.3481264022334491" LOG_CI_START="-0.6797090070651877" LOG_EFFECT_SIZE="-0.1657913024158693" ORDER="232" O_E="0.0" SE="0.6037556072893513" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.36452083333333335" WEIGHT="21.064692924635434"/>
<DICH_DATA CI_END="1.3966236387781117" CI_START="0.2865261572907453" EFFECT_SIZE="0.6325892857142857" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.14507938848833676" LOG_CI_START="-0.5428357246617415" LOG_EFFECT_SIZE="-0.1988781680867024" ORDER="233" O_E="0.0" SE="0.40408474269908495" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.1632844792821857" WEIGHT="47.51553716125173"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2170932334887625" CI_START="0.8441454170587244" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0136092319936332" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.08532384794148021" LOG_CI_START="-0.07358273301148209" LOG_EFFECT_SIZE="0.005870557464999067" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.8848564127331053" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="359" TOTAL_2="128" WEIGHT="100.0" Z="0.14481566630619064">
<NAME>Global state: 3. Use of additional benzodiazepine</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2170932334887625" CI_START="0.8441454170587244" EFFECT_SIZE="1.0136092319936332" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="70" LOG_CI_END="0.08532384794148021" LOG_CI_START="-0.07358273301148209" LOG_EFFECT_SIZE="0.005870557464999067" ORDER="234" O_E="0.0" SE="0.09334251225203191" STUDY_ID="STD-Davidson-2007" TOTAL_1="359" TOTAL_2="128" VAR="0.008712824593520727" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.07780978071520281" CI_END="5.353437951795721" CI_START="-0.5198424849441023" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.4167977334258093" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" NO="6" P_CHI2="0.9618421859815133" P_Q="1.0" P_Z="0.10674185608198397" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="356" TOTAL_2="359" UNITS="" WEIGHT="99.99999999999999" Z="1.6130122055135423">
<NAME>Mental state: Average change score (PANSS total, decline=good)</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.035083759282209" CI_START="-3.4350837592822074" EFFECT_SIZE="1.8000000000000007" ESTIMABLE="YES" MEAN_1="-16.3" MEAN_2="-18.1" ORDER="235" SD_1="21.8" SD_2="20.3" SE="2.671010182113488" STUDY_ID="STD-Davidson-2007" TOTAL_1="123" TOTAL_2="126" WEIGHT="31.466918508243378"/>
<CONT_DATA CI_END="7.566438093420238" CI_START="-2.16643809342024" EFFECT_SIZE="2.6999999999999993" ESTIMABLE="YES" MEAN_1="-17.2" MEAN_2="-19.9" ORDER="236" SD_1="20.2" SD_2="19.0" SE="2.482922202553762" STUDY_ID="STD-Kane-2007" TOTAL_1="122" TOTAL_2="128" WEIGHT="36.41489638711437"/>
<CONT_DATA CI_END="7.881735537770363" CI_START="-2.4817355377703647" EFFECT_SIZE="2.6999999999999993" ESTIMABLE="YES" MEAN_1="-15.7" MEAN_2="-18.4" ORDER="237" SD_1="18.9" SD_2="19.9" SE="2.643791201595148" STUDY_ID="STD-Marder-2007" TOTAL_1="111" TOTAL_2="105" WEIGHT="32.118185104642244"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6604006241252744" CI_END="1.7634716901708665" CI_START="-2.499792301092434" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3681603054607836" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" NO="7" P_CHI2="0.43596219441484707" P_Q="1.0" P_Z="0.7349781181839692" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="345" TOTAL_2="351" UNITS="" WEIGHT="100.0" Z="0.3385110285073294">
<NAME>Social functioning: Average change score (PSP total, increase=good)</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.5419688255086017" CI_START="-3.941968825508602" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="7.8" ORDER="238" SD_1="14.2" SD_2="15.0" SE="1.9092028501670308" STUDY_ID="STD-Davidson-2007" TOTAL_1="116" TOTAL_2="118" WEIGHT="32.450704565174625"/>
<CONT_DATA CI_END="1.5242450413018864" CI_START="-5.924245041301889" EFFECT_SIZE="-2.200000000000001" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="10.3" ORDER="239" SD_1="14.5" SD_2="15.3" SE="1.9001599369571365" STUDY_ID="STD-Kane-2007" TOTAL_1="118" TOTAL_2="128" WEIGHT="32.76030710436291"/>
<CONT_DATA CI_END="4.814026482004879" CI_START="-2.4140264820048767" EFFECT_SIZE="1.200000000000001" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="7.6" ORDER="240" SD_1="13.9" SD_2="13.2" SE="1.8439249448009543" STUDY_ID="STD-Marder-2007" TOTAL_1="111" TOTAL_2="105" WEIGHT="34.788988330462466"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.3182199577940352" CI_END="4.622733189537037" CI_START="0.9503448892636234" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.095994003117817" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="7" I2="39.726720186156456" I2_Q="33.05060767715444" ID="CMP-003.08" LOG_CI_END="0.6648988279707065" LOG_CI_START="-0.022118756477639938" LOG_EFFECT_SIZE="0.32139003574653324" METHOD="MH" NO="8" P_CHI2="0.1903084809619665" P_Q="0.2245481213151468" P_Z="0.06668953602603883" Q="2.9873310729327223" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="823" TOTAL_2="346" WEIGHT="300.0" Z="1.8337606178131414">
<NAME>Adverse effect: 1. Anticholinergic events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7778564436318485" CI_START="0.3409629205604453" DF="0" EFFECT_SIZE="0.9732142857142857" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="0.443709798151244" LOG_CI_START="-0.4672928476103601" LOG_EFFECT_SIZE="-0.011791524729557983" NO="1" P_CHI2="1.0" P_Z="0.9595347549260078" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="109" WEIGHT="100.0" Z="0.050737424090412236">
<NAME>constipation</NAME>
<DICH_DATA CI_END="2.7778564436318494" CI_START="0.34096292056044525" EFFECT_SIZE="0.9732142857142857" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.4437097981512442" LOG_CI_START="-0.46729284761036016" LOG_EFFECT_SIZE="-0.011791524729557983" ORDER="241" O_E="0.0" SE="0.5351274636561918" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.28636140235910884" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.81742234637471" CI_START="0.6650568408301167" DF="0" EFFECT_SIZE="2.919642857142857" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="1.1078006949719554" LOG_CI_START="-0.1771412349917464" LOG_EFFECT_SIZE="0.46532972999010447" NO="2" P_CHI2="1.0" P_Z="0.15573426288538209" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="109" WEIGHT="100.0" Z="1.4195653366874201">
<NAME>salivation - decreased</NAME>
<DICH_DATA CI_END="12.81742234637471" CI_START="0.6650568408301167" EFFECT_SIZE="2.919642857142857" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.1078006949719554" LOG_CI_START="-0.1771412349917464" LOG_EFFECT_SIZE="0.46532972999010447" ORDER="242" O_E="0.0" SE="0.7547812502258135" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.5696947356924422" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="154.7231341021311" CI_START="0.5545950705410683" DF="0" EFFECT_SIZE="9.263297872340425" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" I2="0.0" ID="CMP-003.08.03" LOG_CI_END="2.189555253982176" LOG_CI_START="-0.25602399492102607" LOG_EFFECT_SIZE="0.9667656295305752" NO="3" P_CHI2="1.0" P_Z="0.12123931804015035" STUDIES="1" TAU2="0.0" TOTAL_1="375" TOTAL_2="128" WEIGHT="99.99999999999999" Z="1.5495926506744075">
<NAME>salivation - increased</NAME>
<DICH_DATA CI_END="154.7231341021311" CI_START="0.5545950705410683" EFFECT_SIZE="9.263297872340425" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.189555253982176" LOG_CI_START="-0.25602399492102607" LOG_EFFECT_SIZE="0.9667656295305752" ORDER="243" O_E="0.0" SE="1.436545356618263" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="2.0636625616214928" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.4015066398158" CI_END="1.453609930418521" CI_START="0.8212462808823905" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0925986221892836" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="58" I2="32.70205709233713" I2_Q="50.43948398308626" ID="CMP-003.09" LOG_CI_END="0.16244788121744855" LOG_CI_START="-0.0855265841851767" LOG_EFFECT_SIZE="0.03846064851613593" METHOD="MH" MODIFIED="2009-03-17 12:33:08 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.16693907891360482" P_Q="0.08901388913723929" P_Z="0.5432021960660172" Q="8.070940985834172" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2415" TOTAL_2="947" WEIGHT="500.0" Z="0.6079778076447242">
<NAME>Adverse effect: 2a. Cardiovascular events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.028879737854408" CI_START="0.31264729064583846" DF="0" EFFECT_SIZE="0.7964444444444444" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="0.30725630492682643" LOG_CI_START="-0.5049453304973387" LOG_EFFECT_SIZE="-0.09884451278525612" MODIFIED="2009-03-17 12:33:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6333242573710784" STUDIES="1" TAU2="0.0" TOTAL_1="375" TOTAL_2="128" WEIGHT="100.0" Z="0.4770531766470434">
<NAME>blood pressure - hypotension</NAME>
<DICH_DATA CI_END="2.028879737854408" CI_START="0.31264729064583846" EFFECT_SIZE="0.7964444444444444" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.30725630492682643" LOG_CI_START="-0.5049453304973387" LOG_EFFECT_SIZE="-0.09884451278525612" ORDER="244" O_E="0.0" SE="0.4770912611110912" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.2276160714285714" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8452119985528598" CI_START="0.13208705540836807" DF="0" EFFECT_SIZE="0.3341280653950954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-003.09.02" LOG_CI_END="-0.07303434637089452" LOG_CI_START="-0.8791397413572744" LOG_EFFECT_SIZE="-0.4760870438640844" MODIFIED="2009-03-17 12:33:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.020606623900877755" STUDIES="1" TAU2="0.0" TOTAL_1="367" TOTAL_2="109" WEIGHT="100.0" Z="2.315115282153676">
<NAME>dizziness</NAME>
<DICH_DATA CI_END="0.8452119985528597" CI_START="0.13208705540836813" EFFECT_SIZE="0.3341280653950954" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="-0.07303434637089458" LOG_CI_START="-0.8791397413572742" LOG_EFFECT_SIZE="-0.4760870438640844" ORDER="245" O_E="0.0" SE="0.47351029930105915" STUDY_ID="STD-Davidson-2007" TOTAL_1="367" TOTAL_2="109" VAR="0.2242120035441786" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6865310367058717" CI_END="3.0188418294297636" CI_START="0.6142546560234998" DF="1" EFFECT_SIZE="1.3617406689695848" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="8" I2="62.7772772271351" ID="CMP-003.09.03" LOG_CI_END="0.4798403589968051" LOG_CI_START="-0.2116515429021755" LOG_EFFECT_SIZE="0.1340944080473148" MODIFIED="2009-03-17 12:33:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.10119997981357454" P_Z="0.4471624699846386" STUDIES="2" TAU2="0.0" TOTAL_1="599" TOTAL_2="237" WEIGHT="100.0" Z="0.7601541235094614">
<NAME>ECG - abnormal</NAME>
<DICH_DATA CI_END="13.057416497990069" CI_START="0.7227451158851119" EFFECT_SIZE="3.072" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="2" LOG_CI_END="1.1158572572103067" LOG_CI_START="-0.14101483449135768" LOG_EFFECT_SIZE="0.4874212113594744" ORDER="246" O_E="0.0" SE="0.7382928882827525" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.5450763888888889" WEIGHT="26.977193334931986"/>
<DICH_DATA CI_END="1.9986662620123627" CI_START="0.26656258773921615" EFFECT_SIZE="0.7299107142857143" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.3007402815283861" LOG_CI_START="-0.5742008042041019" LOG_EFFECT_SIZE="-0.13673026133785793" ORDER="247" O_E="0.0" SE="0.5139447247874878" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.2641391801368866" WEIGHT="73.02280666506802"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.304493261316114" CI_START="0.1237705854059545" DF="0" EFFECT_SIZE="0.7299107142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-003.09.04" LOG_CI_END="0.6339220322664294" LOG_CI_START="-0.9073825549421453" LOG_EFFECT_SIZE="-0.13673026133785793" MODIFIED="2009-03-17 12:33:08 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.7280356888348112" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="109" WEIGHT="100.0" Z="0.34773968759062174">
<NAME>ECG - prolonged QTC LD</NAME>
<DICH_DATA CI_END="4.3044932613161135" CI_START="0.1237705854059545" EFFECT_SIZE="0.7299107142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6339220322664293" LOG_CI_START="-0.9073825549421453" LOG_EFFECT_SIZE="-0.13673026133785793" ORDER="248" O_E="0.0" SE="0.9053699441070716" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.819694735692442" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.050312690553956256" CI_END="1.8670976789198972" CI_START="0.9056983313028645" DF="2" EFFECT_SIZE="1.3003950369703825" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="34" I2="0.0" ID="CMP-003.09.05" LOG_CI_END="0.27116703905579104" LOG_CI_START="-0.04301643241913178" LOG_EFFECT_SIZE="0.11407530331832966" MODIFIED="2009-03-17 12:33:08 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9751574552042317" P_Z="0.15465876472545936" STUDIES="3" TAU2="0.0" TOTAL_1="850" TOTAL_2="364" WEIGHT="100.0" Z="1.4232670164334498">
<NAME>pulse rate - tachycardia</NAME>
<DICH_DATA CI_END="2.3858289815795266" CI_START="0.6706573776687578" EFFECT_SIZE="1.2649402390438247" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="12" LOG_CI_END="0.3776393098212437" LOG_CI_START="-0.1734992935273311" LOG_EFFECT_SIZE="0.10207000814695633" ORDER="249" O_E="0.0" SE="0.32374154378703895" STUDY_ID="STD-Davidson-2007" TOTAL_1="251" TOTAL_2="127" VAR="0.10480858717361526" WEIGHT="33.09291639622683"/>
<DICH_DATA CI_END="2.0822717406765414" CI_START="0.7985328997181873" EFFECT_SIZE="1.2894814814814815" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="18" LOG_CI_END="0.31853740518189794" LOG_CI_START="-0.09770718613573846" LOG_EFFECT_SIZE="0.11041510952307976" ORDER="250" O_E="0.0" SE="0.24450413338393703" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.05978227124183007" WEIGHT="55.73238931944374"/>
<DICH_DATA CI_END="4.421629169791077" CI_START="0.48196683201658475" EFFECT_SIZE="1.4598214285714286" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.6455823166536708" LOG_CI_START="-0.3169828480014242" LOG_EFFECT_SIZE="0.16429973432612327" ORDER="251" O_E="0.0" SE="0.5654155424928131" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.3196947356924421" WEIGHT="11.174694284329423"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="289.66702669861945" CI_END="-0.48859930263811097" CI_START="-1.0294416734985208" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7590204880683159" ESTIMABLE="YES" I2="99.65477603322782" I2_Q="99.65477603322782" ID="CMP-003.10" NO="10" P_CHI2="9.992007221626409E-16" P_Q="9.992007221626409E-16" P_Z="3.77121699639973E-8" Q="289.66702669861945" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="11.006870012870012" TOTALS="SUB" TOTAL_1="222" TOTAL_2="210" UNITS="" WEIGHT="200.0" Z="5.501243616602194">
<NAME>Adverse effect: 2b.Cardiovascular - Average change in QTC LD (msec) from baseline to end of trial</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.345121408349557E-30" CI_END="1.875238658013345" CI_START="1.1247613419866553" DF="0" EFFECT_SIZE="1.5000000000000002" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-003.10.01" NO="1" P_CHI2="0.0" P_Z="4.69329311125009E-15" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="105" WEIGHT="100.0" Z="7.834869659686093">
<NAME>6 mg</NAME>
<CONT_DATA CI_END="1.8752386580133449" CI_START="1.1247613419866551" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="0.5" ORDER="252" SD_1="1.3" SD_2="1.5" SE="0.1914518128767567" STUDY_ID="STD-Marder-2007" TOTAL_1="111" TOTAL_2="105" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.809941670619343" CI_START="-3.5900583293806574" DF="0" EFFECT_SIZE="-3.2" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.02" NO="2" P_CHI2="1.0" P_Z="3.560903615531258E-58" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="105" WEIGHT="100.0" Z="16.07935090243248">
<NAME>12 mg</NAME>
<CONT_DATA CI_END="-2.809941670619343" CI_START="-3.5900583293806574" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="1.9" ORDER="253" SD_1="1.3" SD_2="1.6" SE="0.19901300863556035" STUDY_ID="STD-Marder-2007" TOTAL_1="111" TOTAL_2="105" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="41.56596311190146" CI_END="-0.0036606172304083535" CI_START="-0.06569946589348977" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.03468004156194906" ESTIMABLE="YES" I2="80.75348337662027" I2_Q="94.8341386681289" ID="CMP-003.11" NO="11" P_CHI2="1.6333855544781173E-6" P_Q="3.917363211591862E-9" P_Z="0.02843296265198135" Q="38.7157120858215" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1001" TOTAL_2="1056" UNITS="" WEIGHT="300.0" Z="2.1912602799226826">
<NAME>Adverse effect: 2c. Cardiovascular - average change in serum level</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.032886905782686666" CI_START="-0.032886905782686666" DF="2" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.11.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="3" TAU2="0.0" TOTAL_1="333" TOTAL_2="350" WEIGHT="100.0" Z="0.0">
<NAME>HDL (mmol/L)</NAME>
<CONT_DATA CI_END="0.0701497761998241" CI_START="-0.0701497761998241" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" ORDER="254" SD_1="0.18" SD_2="0.35" SE="0.035791359817403064" STUDY_ID="STD-Davidson-2007" TOTAL_1="117" TOTAL_2="122" WEIGHT="21.97826717802258"/>
<CONT_DATA CI_END="0.051099215684385725" CI_START="-0.051099215684385725" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" ORDER="255" SD_1="0.2" SD_2="0.2" SE="0.026071507480468936" STUDY_ID="STD-Kane-2007" TOTAL_1="112" TOTAL_2="124" WEIGHT="41.42071198133113"/>
<CONT_DATA CI_END="0.054359620340937505" CI_START="-0.054359620340937505" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" ORDER="256" SD_1="0.2" SD_2="0.2" SE="0.02773500981126146" STUDY_ID="STD-Marder-2007" TOTAL_1="104" TOTAL_2="104" WEIGHT="36.60102084064629"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5509325692400098" CI_END="-0.18846692567667003" CI_START="-0.43568973290852886" DF="2" EFFECT_SIZE="-0.31207832929259943" ESTIMABLE="YES" I2="0.0" ID="CMP-003.11.02" NO="2" P_CHI2="0.4604891514013226" P_Z="7.487697607423571E-7" STUDIES="3" TAU2="0.0" TOTAL_1="334" TOTAL_2="353" WEIGHT="100.0" Z="4.948267456531846">
<NAME>cholesterol (mmol/L)</NAME>
<CONT_DATA CI_END="-0.19844827912411733" CI_START="-0.6015517208758827" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.3" ORDER="257" SD_1="0.85" SD_2="0.74" SE="0.10283440025719703" STUDY_ID="STD-Davidson-2007" TOTAL_1="118" TOTAL_2="123" WEIGHT="37.613526633163545"/>
<CONT_DATA CI_END="-0.09637444892950692" CI_START="-0.5036255510704932" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.2" ORDER="258" SD_1="0.8" SD_2="0.8" SE="0.10389249632986396" STUDY_ID="STD-Kane-2007" TOTAL_1="112" TOTAL_2="126" WEIGHT="36.85127602627231"/>
<CONT_DATA CI_END="0.04461829153421876" CI_START="-0.4446182915342188" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.2" ORDER="259" SD_1="0.9" SD_2="0.9" SE="0.12480754415067656" STUDY_ID="STD-Marder-2007" TOTAL_1="104" TOTAL_2="104" WEIGHT="25.535197340564153"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2993184568399516" CI_END="-0.17470375894133855" CI_START="-0.45973895048394914" DF="2" EFFECT_SIZE="-0.31722135471264384" ESTIMABLE="YES" I2="0.0" ID="CMP-003.11.03" NO="3" P_CHI2="0.5222237371539636" P_Z="1.2854573643108883E-5" STUDIES="3" TAU2="0.0" TOTAL_1="334" TOTAL_2="353" WEIGHT="100.0" Z="4.362566088762002">
<NAME>triglycerides (mmol/L)</NAME>
<CONT_DATA CI_END="-0.18622139748448313" CI_START="-0.613778602515517" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.3" ORDER="260" SD_1="0.88" SD_2="0.81" SE="0.10907271980596338" STUDY_ID="STD-Davidson-2007" TOTAL_1="118" TOTAL_2="123" WEIGHT="44.44352600842534"/>
<CONT_DATA CI_END="-0.03226063887931979" CI_START="-0.5677393611206802" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="0.1" ORDER="261" SD_1="0.9" SD_2="1.2" SE="0.13660422499218056" STUDY_ID="STD-Kane-2007" TOTAL_1="112" TOTAL_2="126" WEIGHT="28.33430269579317"/>
<CONT_DATA CI_END="0.07315371161888751" CI_START="-0.47315371161888753" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.1" ORDER="262" SD_1="0.9" SD_2="1.1" SE="0.1393666994768726" STUDY_ID="STD-Marder-2007" TOTAL_1="104" TOTAL_2="104" WEIGHT="27.222171295781486"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="20.985153282180004" CI_END="0.9536785893207315" CI_START="0.6683147040544586" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7983466817022278" ESTIMABLE="YES" EVENTS_1="331" EVENTS_2="160" I2="47.58198878947009" I2_Q="81.86246572687544" ID="CMP-003.12" LOG_CI_END="-0.02059796743816439" LOG_CI_START="-0.17501898355764403" LOG_EFFECT_SIZE="-0.09780847549790421" METHOD="MH" NO="12" P_CHI2="0.033525237966382626" P_Q="8.785016588673811E-4" P_Z="0.013034079402623598" Q="16.540285767758814" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3842" TOTAL_2="1456" WEIGHT="400.0" Z="2.482836781883839">
<NAME>Adverse effect: 3. Central nervous system - levels of arousal</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4041358533232535" CI_END="1.3520482071323516" CI_START="0.5402635400043271" DF="2" EFFECT_SIZE="0.8546709019510539" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="25" I2="16.810025638302168" ID="CMP-003.12.01" LOG_CI_END="0.13099217660437987" LOG_CI_START="-0.26739434008474444" LOG_EFFECT_SIZE="-0.06820108174018229" NO="1" P_CHI2="0.3005720712359199" P_Z="0.5021789988036285" STUDIES="3" TAU2="0.0" TOTAL_1="963" TOTAL_2="364" WEIGHT="99.99999999999999" Z="0.6710652008423194">
<NAME>agitation or aggression</NAME>
<DICH_DATA CI_END="1.2313890142989656" CI_START="0.29493833990359625" EFFECT_SIZE="0.6026473526473527" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.09039527476251091" LOG_CI_START="-0.5302687685595012" LOG_EFFECT_SIZE="-0.21993674689849518" ORDER="263" O_E="0.0" SE="0.36458113138391446" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="127" VAR="0.13291940136117508" WEIGHT="45.83718385142578"/>
<DICH_DATA CI_END="6.145779452866205" CI_START="0.5392347709065748" EFFECT_SIZE="1.8204444444444445" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="0.788576971129958" LOG_CI_START="-0.26822211141713415" LOG_EFFECT_SIZE="0.2601774298564119" ORDER="264" O_E="0.0" SE="0.6207690123279888" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.38535416666666666" WEIGHT="12.571580720438268"/>
<DICH_DATA CI_END="1.7034479197798873" CI_START="0.4147151783155385" EFFECT_SIZE="0.8405032467532467" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.23132886024145724" LOG_CI_START="-0.3822500694393278" LOG_EFFECT_SIZE="-0.07546060459893526" ORDER="265" O_E="0.0" SE="0.3604193005591794" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.1299020722155681" WEIGHT="41.59123542813594"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2959530933281784" CI_END="1.734635522138852" CI_START="0.6818451704469499" DF="2" EFFECT_SIZE="1.087544414383201" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="22" I2="0.0" ID="CMP-003.12.02" LOG_CI_END="0.23920823569602223" LOG_CI_START="-0.16631423128834696" LOG_EFFECT_SIZE="0.03644700220383762" NO="2" P_CHI2="0.5231032125022217" P_Z="0.7246057845577738" STUDIES="3" TAU2="0.0" TOTAL_1="963" TOTAL_2="364" WEIGHT="99.99999999999999" Z="0.35231000736009616">
<NAME>anxiety</NAME>
<DICH_DATA CI_END="2.079705747092184" CI_START="0.5267994248039106" EFFECT_SIZE="1.0467032967032968" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="10" LOG_CI_END="0.31800189195590894" LOG_CI_START="-0.2783547079027823" LOG_EFFECT_SIZE="0.019823592026563336" ORDER="266" O_E="0.0" SE="0.350302818769774" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="127" VAR="0.1227120648380491" WEIGHT="46.34706705521455"/>
<DICH_DATA CI_END="1.8533756122740763" CI_START="0.32842623756738426" EFFECT_SIZE="0.7801904761904762" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" LOG_CI_END="0.2679634440393197" LOG_CI_START="-0.4835621549156847" LOG_EFFECT_SIZE="-0.10779935543818252" ORDER="267" O_E="0.0" SE="0.44144985693788164" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.19487797619047617" WEIGHT="32.62598914796368"/>
<DICH_DATA CI_END="4.366562164558945" CI_START="0.6268666217375527" EFFECT_SIZE="1.6544642857142857" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="0.6401396473715657" LOG_CI_START="-0.20282485407413384" LOG_EFFECT_SIZE="0.21865739664871595" ORDER="268" O_E="0.0" SE="0.4951615208907832" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.24518493177087353" WEIGHT="21.026943796821758"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9391315503075253" CI_END="1.5312459073419449" CI_START="0.8032996588437215" DF="2" EFFECT_SIZE="1.1090758833252254" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="43" I2="0.0" ID="CMP-003.12.03" LOG_CI_END="0.1850449409437522" LOG_CI_START="-0.09512241747867267" LOG_EFFECT_SIZE="0.044961261732539774" NO="3" P_CHI2="0.6252737573876939" P_Z="0.5293031697722501" STUDIES="3" TAU2="0.0" TOTAL_1="963" TOTAL_2="364" WEIGHT="100.00000000000003" Z="0.629070097183766">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="1.8781836729737973" CI_START="0.6585170145246381" EFFECT_SIZE="1.1121222527472527" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="16" LOG_CI_END="0.27373806091118325" LOG_CI_START="-0.1814329994133584" LOG_EFFECT_SIZE="0.04615253074891246" ORDER="269" O_E="0.0" SE="0.2673697339677224" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="127" VAR="0.07148657464197065" WEIGHT="37.853806814177126"/>
<DICH_DATA CI_END="1.5632136798627108" CI_START="0.5750876687029223" EFFECT_SIZE="0.9481481481481482" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="18" LOG_CI_END="0.1940183469522905" LOG_CI_START="-0.24026594464656603" LOG_EFFECT_SIZE="-0.023123798847137732" ORDER="270" O_E="0.0" SE="0.2551007426270823" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.06507638888888889" WEIGHT="42.825799063410244"/>
<DICH_DATA CI_END="2.9955910765350175" CI_START="0.7114050445701463" EFFECT_SIZE="1.4598214285714286" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="9" LOG_CI_END="0.4764825282112417" LOG_CI_START="-0.1478830595589951" LOG_EFFECT_SIZE="0.16429973432612327" ORDER="271" O_E="0.0" SE="0.36675543691574214" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.1345095505072569" WEIGHT="19.32039412241265"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.28894363419956476" CI_END="0.6547478008666698" CI_START="0.366352764656637" DF="2" EFFECT_SIZE="0.48976388903262125" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="70" I2="0.0" ID="CMP-003.12.04" LOG_CI_END="-0.1839259515863105" LOG_CI_START="-0.43610052673834704" LOG_EFFECT_SIZE="-0.31001323916232876" NO="4" P_CHI2="0.8654793149360497" P_Z="1.442787243029759E-6" STUDIES="3" TAU2="0.0" TOTAL_1="953" TOTAL_2="364" WEIGHT="100.0" Z="4.819001147299918">
<NAME>sleepiness</NAME>
<DICH_DATA CI_END="0.8871649029012755" CI_START="0.32642174610781693" EFFECT_SIZE="0.538135593220339" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" LOG_CI_END="-0.051995647627388716" LOG_CI_START="-0.48622091640091064" LOG_EFFECT_SIZE="-0.2691082820141497" ORDER="272" O_E="0.0" SE="0.2550660723273131" STUDY_ID="STD-Davidson-2007" TOTAL_1="354" TOTAL_2="127" VAR="0.06505870125248212" WEIGHT="32.518508315314826"/>
<DICH_DATA CI_END="0.7815121291944064" CI_START="0.24340659604240028" EFFECT_SIZE="0.4361481481481482" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="-0.10706427727202003" LOG_CI_START="-0.6136676570591073" LOG_EFFECT_SIZE="-0.3603659671655636" ORDER="273" O_E="0.0" SE="0.2975813330141091" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.0885546497584541" WEIGHT="26.95166108453246"/>
<DICH_DATA CI_END="0.7641729755449622" CI_START="0.3098598341700449" EFFECT_SIZE="0.48660714285714285" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" LOG_CI_END="-0.1168083249035964" LOG_CI_START="-0.5088347158834821" LOG_EFFECT_SIZE="-0.31282152039353917" ORDER="274" O_E="0.0" SE="0.23027824262351718" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.05302806902577545" WEIGHT="40.52983060015271"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="251.2429794825116" CI_END="13.713868263033905" CI_START="8.93896952360548" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="11.326418893319692" ESTIMABLE="YES" I2="96.81583142483116" I2_Q="99.1829454334929" ID="CMP-003.13" MODIFIED="2009-03-17 12:32:55 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="9.992007221626409E-16" P_Q="1.1102230246251565E-15" P_Z="1.4262331929613767E-20" Q="244.78169292291034" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="654" TOTAL_2="688" UNITS="" WEIGHT="300.0" Z="9.298363930280107">
<NAME>Adverse effect: 4. Endocrine: average change in serum level</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.16786597906231907" CI_END="0.5617918281108474" CI_START="-5.668888530908131" DF="2" EFFECT_SIZE="-2.5535483513986414" ESTIMABLE="YES" I2="0.0" ID="CMP-003.13.01" NO="1" P_CHI2="0.9194929020485432" P_Z="0.10815924638564206" STUDIES="3" TAU2="0.0" TOTAL_1="320" TOTAL_2="336" WEIGHT="100.0" Z="1.6065220852738418">
<NAME>insulin (mmol/L)</NAME>
<CONT_DATA CI_END="2.5800156441141704" CI_START="-8.980015644114172" EFFECT_SIZE="-3.2" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="2.1" ORDER="275" SD_1="23.63" SD_2="21.14" SE="2.949041762862071" STUDY_ID="STD-Davidson-2007" TOTAL_1="113" TOTAL_2="119" WEIGHT="29.050454069702898"/>
<CONT_DATA CI_END="1.4229339518941142" CI_START="-6.422933951894114" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="1.5" ORDER="276" SD_1="14.6" SD_2="15.0" SE="2.00153369288299" STUDY_ID="STD-Kane-2007" TOTAL_1="104" TOTAL_2="115" WEIGHT="63.065081346650835"/>
<CONT_DATA CI_END="10.494797321860336" CI_START="-11.694797321860335" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="4.0" ORDER="277" SD_1="48.4" SD_2="30.8" SE="5.6607148954647535" STUDY_ID="STD-Marder-2007" TOTAL_1="103" TOTAL_2="102" WEIGHT="7.884464583646266"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.861866454210557" CI_END="30.679765312520885" CI_START="22.93962691827759" DF="2" EFFECT_SIZE="26.809696115399237" ESTIMABLE="YES" I2="65.88117427063854" ID="CMP-003.13.02" MODIFIED="2009-03-17 12:32:55 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.05334732097985251" P_Z="5.442006282816605E-42" STUDIES="3" TAU2="0.0" TOTAL_1="198" TOTAL_2="235" WEIGHT="100.0" Z="13.577545037625388">
<NAME>prolactin (ng/ml) - men</NAME>
<CONT_DATA CI_END="36.366252058843735" CI_START="24.953747941156266" EFFECT_SIZE="30.66" ESTIMABLE="YES" MEAN_1="29.17" MEAN_2="-1.49" ORDER="278" SD_1="22.1" SD_2="13.28" SE="2.9114065890260843" STUDY_ID="STD-Davidson-2007" TOTAL_1="74" TOTAL_2="94" WEIGHT="45.99764079947441"/>
<CONT_DATA CI_END="35.64291007604093" CI_START="20.457089923959074" EFFECT_SIZE="28.05" ESTIMABLE="YES" MEAN_1="25.41" MEAN_2="-2.64" ORDER="279" SD_1="24.5" SD_2="15.41" SE="3.8740048980148774" STUDY_ID="STD-Kane-2007" TOTAL_1="55" TOTAL_2="58" WEIGHT="25.978911330639896"/>
<CONT_DATA CI_END="26.650682893202273" CI_START="12.029317106797727" EFFECT_SIZE="19.34" ESTIMABLE="YES" MEAN_1="23.62" MEAN_2="4.28" ORDER="280" SD_1="28.89" SD_2="12.28" SE="3.7300087914206626" STUDY_ID="STD-Marder-2007" TOTAL_1="69" TOTAL_2="83" WEIGHT="28.023447869885693"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.431554126328419" CI_END="94.94490049068033" CI_START="68.30925710589331" DF="2" EFFECT_SIZE="81.62707879828682" ESTIMABLE="YES" I2="0.0" ID="CMP-003.13.03" MODIFIED="2009-03-17 12:32:55 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8059150665318482" P_Z="3.038634364300565E-33" STUDIES="3" TAU2="0.0" TOTAL_1="136" TOTAL_2="117" WEIGHT="100.00000000000001" Z="12.012935621388557">
<NAME>prolactin (ng/ml) - women</NAME>
<CONT_DATA CI_END="113.39651634856507" CI_START="59.10348365143493" EFFECT_SIZE="86.25" ESTIMABLE="YES" MEAN_1="83.96" MEAN_2="-2.29" ORDER="281" SD_1="78.03" SD_2="38.17" SE="13.850517949663018" STUDY_ID="STD-Davidson-2007" TOTAL_1="43" TOTAL_2="29" WEIGHT="24.067899039089706"/>
<CONT_DATA CI_END="103.3245365071378" CI_START="63.8154634928622" EFFECT_SIZE="83.57" ESTIMABLE="YES" MEAN_1="68.19" MEAN_2="-15.38" ORDER="282" SD_1="54.4" SD_2="58.7" SE="10.079030361251052" STUDY_ID="STD-Kane-2007" TOTAL_1="59" TOTAL_2="67" WEIGHT="45.44987603793277"/>
<CONT_DATA CI_END="99.20180844330442" CI_START="50.95819155669558" EFFECT_SIZE="75.08" ESTIMABLE="YES" MEAN_1="80.97" MEAN_2="5.89" ORDER="283" SD_1="69.53" SD_2="13.96" SE="12.30727127313265" STUDY_ID="STD-Marder-2007" TOTAL_1="34" TOTAL_2="21" WEIGHT="30.48222492297753"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.6034930287811022" CI_END="2.028399759179336" CI_START="0.8168852462781105" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2872334041764424" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="0.3071535503144613" LOG_CI_START="-0.08783894763956039" LOG_EFFECT_SIZE="0.10965730133745046" METHOD="MH" NO="14" P_CHI2="0.6262046128299936" P_Q="0.5754961168956996" P_Z="0.2764868559162398" Q="1.9851428301786151" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1271" TOTAL_2="564" WEIGHT="400.0" Z="1.0882452825130704">
<NAME>Adverse effect: 5. Gastrointestinal events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7778564436318485" CI_START="0.3409629205604453" DF="0" EFFECT_SIZE="0.9732142857142857" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-003.14.01" LOG_CI_END="0.443709798151244" LOG_CI_START="-0.4672928476103601" LOG_EFFECT_SIZE="-0.011791524729557983" NO="1" P_CHI2="1.0" P_Z="0.9595347549260078" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="109" WEIGHT="100.0" Z="0.050737424090412236">
<NAME>constipation</NAME>
<DICH_DATA CI_END="2.7778564436318494" CI_START="0.34096292056044525" EFFECT_SIZE="0.9732142857142857" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.4437097981512442" LOG_CI_START="-0.46729284761036016" LOG_EFFECT_SIZE="-0.011791524729557983" ORDER="284" O_E="0.0" SE="0.5351274636561918" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.28636140235910884" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9402462750585672" CI_START="0.5296849410631508" DF="0" EFFECT_SIZE="1.013764880952381" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" I2="0.0" ID="CMP-003.14.02" LOG_CI_END="0.2878568583378208" LOG_CI_START="-0.27598237387607366" LOG_EFFECT_SIZE="0.005937242230873601" NO="2" P_CHI2="1.0" P_Z="0.9670751113483429" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="109" WEIGHT="100.0" Z="0.041276946601644236">
<NAME>dyspepsia</NAME>
<DICH_DATA CI_END="1.9402462750585672" CI_START="0.5296849410631508" EFFECT_SIZE="1.013764880952381" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.2878568583378208" LOG_CI_START="-0.27598237387607366" LOG_EFFECT_SIZE="0.005937242230873601" ORDER="285" O_E="0.0" SE="0.33120195605165453" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.1096947356924421" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.865055978130783" CI_START="0.6036880049668403" DF="0" EFFECT_SIZE="2.6763392857142856" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-003.14.03" LOG_CI_END="1.074269791515512" LOG_CI_START="-0.21918745331410244" LOG_EFFECT_SIZE="0.42754116910070467" NO="3" P_CHI2="1.0" P_Z="0.1950793850856108" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="109" WEIGHT="100.0" Z="1.2956984804795997">
<NAME>nausea</NAME>
<DICH_DATA CI_END="11.865055978130783" CI_START="0.6036880049668402" EFFECT_SIZE="2.6763392857142856" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.074269791515512" LOG_CI_START="-0.21918745331410253" LOG_EFFECT_SIZE="0.42754116910070467" ORDER="286" O_E="0.0" SE="0.7597831883295391" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.5772704932681998" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7760822964905885" CI_END="4.525142936159315" CI_START="0.6335115875865507" DF="1" EFFECT_SIZE="1.6931421929484698" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" I2="0.0" ID="CMP-003.14.04" LOG_CI_END="0.6556323018627332" LOG_CI_START="-0.1982454370096273" LOG_EFFECT_SIZE="0.22869343242655302" NO="4" P_CHI2="0.3783420390115627" P_Z="0.2937772765806981" STUDIES="2" TAU2="0.0" TOTAL_1="599" TOTAL_2="237" WEIGHT="100.0" Z="1.0498713589812674">
<NAME>vomiting</NAME>
<DICH_DATA CI_END="26.403642787536555" CI_START="0.4412589784748965" EFFECT_SIZE="3.4133333333333336" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.4216638485890483" LOG_CI_START="-0.3553064447487491" LOG_EFFECT_SIZE="0.5331787019201495" ORDER="287" O_E="0.0" SE="1.0438011464514367" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="1.0895208333333335" WEIGHT="21.696147945576765"/>
<DICH_DATA CI_END="3.7912904751645415" CI_START="0.3903461648327595" EFFECT_SIZE="1.2165178571428572" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.5787870597966055" LOG_CI_START="-0.4085500832396085" LOG_EFFECT_SIZE="0.08511848827849847" ORDER="288" O_E="0.0" SE="0.5799667252171531" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.3363614023591088" WEIGHT="78.30385205442323"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.2130943003025183" CI_END="-0.3741639872609005" CI_START="-1.37966903997662" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8769165136187603" ESTIMABLE="YES" I2="9.62879441121824" I2_Q="0.0" ID="CMP-003.15" NO="15" P_CHI2="0.3306991240736058" P_Q="1.0" P_Z="6.293728417549031E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="328" UNITS="" WEIGHT="100.0" Z="3.418629830848046">
<NAME>Adverse effect: 6a. Metabolic - average change in weight (kg)</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.21625697704961333" CI_START="-1.6162569770496136" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.2" ORDER="289" SD_1="3.14" SD_2="3.94" SE="0.4674866396918166" STUDY_ID="STD-Davidson-2007" TOTAL_1="118" TOTAL_2="115" WEIGHT="30.107447232180746"/>
<CONT_DATA CI_END="-0.0041505947289506295" CI_START="-1.3958494052710495" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="1.3" ORDER="290" SD_1="2.7" SD_2="2.8" SE="0.35503173056230664" STUDY_ID="STD-Kane-2007" TOTAL_1="117" TOTAL_2="123" WEIGHT="52.20090140594322"/>
<CONT_DATA CI_END="-0.5047188366918716" CI_START="-2.8952811633081286" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="2.7" ORDER="291" SD_1="3.9" SD_2="4.4" SE="0.6098485343283621" STUDY_ID="STD-Marder-2007" TOTAL_1="97" TOTAL_2="90" WEIGHT="17.691651361876033"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2243208958024789E-31" CI_END="-0.10951456623503045" CI_START="-0.49048543376496956" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.16" NO="16" P_CHI2="0.9999999999999997" P_Q="1.0" P_Z="0.0020232810979981712" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="235" TOTAL_2="236" UNITS="" WEIGHT="100.0" Z="3.086793482001919">
<NAME>Adverse effect: 6b. Metabolic - average change in BMI</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.01094293551092318" CI_START="-0.6109429355109233" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.8" ORDER="292" SD_1="1.08" SD_2="1.32" SE="0.15864727003332788" STUDY_ID="STD-Davidson-2007" TOTAL_1="118" TOTAL_2="114" WEIGHT="37.52858189176113"/>
<CONT_DATA CI_END="-0.05899775458465839" CI_START="-0.5410022454153416" EFFECT_SIZE="-0.3" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.5" ORDER="293" SD_1="0.9" SD_2="1.0" SE="0.12296258875996526" STUDY_ID="STD-Kane-2007" TOTAL_1="117" TOTAL_2="122" WEIGHT="62.471418108238865"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.311085703057159" CI_END="0.12149945209111575" CI_START="-0.22192895608358953" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.05021475199623689" ESTIMABLE="YES" I2="62.34291608495862" I2_Q="0.0" ID="CMP-003.17" MODIFIED="2009-03-17 12:32:41 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.07026083522513304" P_Q="1.0" P_Z="0.5665387642714892" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="328" TOTAL_2="345" UNITS="" WEIGHT="100.00000000000001" Z="0.5731564603424907">
<NAME>Adverse effect: 6c. Metabolic - average change in serum level</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.311085703057159" CI_END="0.12149945209111575" CI_START="-0.22192895608358953" DF="2" EFFECT_SIZE="-0.05021475199623689" ESTIMABLE="YES" I2="62.34291608495862" ID="CMP-003.17.01" MODIFIED="2009-03-17 12:32:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07026083522513304" P_Z="0.5665387642714892" STUDIES="3" TAU2="0.0" TOTAL_1="328" TOTAL_2="345" WEIGHT="100.00000000000001" Z="0.5731564603424907">
<NAME>glucose (mmol/L)</NAME>
<CONT_DATA CI_END="0.41194750998902485" CI_START="-0.21194750998902487" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.0" ORDER="294" SD_1="1.22" SD_2="1.24" SE="0.1591598174505384" STUDY_ID="STD-Davidson-2007" TOTAL_1="116" TOTAL_2="123" WEIGHT="30.30047213645584"/>
<CONT_DATA CI_END="0.23455142452571165" CI_START="-0.23455142452571165" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" ORDER="295" SD_1="0.96" SD_2="0.89" SE="0.11967129313386539" STUDY_ID="STD-Kane-2007" TOTAL_1="114" TOTAL_2="127" WEIGHT="53.59648303700562"/>
<CONT_DATA CI_END="-0.07209021237688962" CI_START="-0.9279097876231104" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.5" ORDER="296" SD_1="1.3" SD_2="1.7" SE="0.21832533199508164" STUDY_ID="STD-Marder-2007" TOTAL_1="98" TOTAL_2="95" WEIGHT="16.103044826538547"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.524699782569107" CI_END="5.594045259426817" CI_START="2.0860992254945283" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="3.416099161773794" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="0.7477259757716197" LOG_CI_START="0.3193349618373281" LOG_EFFECT_SIZE="0.5335304688044739" METHOD="MH" MODIFIED="2008-05-18 19:38:35 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.7177410480748496" P_Q="0.5719086252908332" P_Z="1.050201344411451E-6" Q="1.1175525951335998" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2525" TOTAL_2="965" WEIGHT="300.0" Z="4.881990842468669">
<NAME>Adverse effect: 7a. Movement disorder - various events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5220204171824558" CI_END="6.180879722634698" CI_START="1.442181741761147" DF="2" EFFECT_SIZE="2.9856242034129927" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="8" I2="0.0" ID="CMP-003.18.01" LOG_CI_END="0.7910502924828966" LOG_CI_START="0.15901999302591968" LOG_EFFECT_SIZE="0.4750351427544082" NO="1" P_CHI2="0.7702730692088932" P_Z="0.0032167819314913473" STUDIES="3" TAU2="0.0" TOTAL_1="963" TOTAL_2="364" WEIGHT="100.0" Z="2.946225116072496">
<NAME>extrapyramidal disorder</NAME>
<DICH_DATA CI_END="7.282436640524475" CI_START="0.9402654679761882" EFFECT_SIZE="2.616758241758242" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="4" LOG_CI_END="0.8622767148183732" LOG_CI_START="-0.026749513421171336" LOG_EFFECT_SIZE="0.4177636006986009" ORDER="297" O_E="0.0" SE="0.5222184072187126" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="127" VAR="0.2727120648380491" WEIGHT="51.11153690806695"/>
<DICH_DATA CI_END="18.434250550987286" CI_START="1.0681164963365746" EFFECT_SIZE="4.437333333333333" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="2" LOG_CI_END="1.2656254859515268" LOG_CI_START="0.028618622502445647" LOG_EFFECT_SIZE="0.6471220542269862" ORDER="298" O_E="0.0" SE="0.7266239548727194" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.5279823717948717" WEIGHT="25.6999533928239"/>
<DICH_DATA CI_END="9.96181988106328" CI_START="0.48133041098008145" EFFECT_SIZE="2.189732142857143" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.998338685020588" LOG_CI_START="-0.31755669825697896" LOG_EFFECT_SIZE="0.3403909933818045" ORDER="299" O_E="0.0" SE="0.772963461924443" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.5974725134702199" WEIGHT="23.188509699109147"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6179256203388395" CI_END="6.423375467302722" CI_START="1.5304433533698765" DF="2" EFFECT_SIZE="3.1353807249092696" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="8" I2="23.603635471463893" ID="CMP-003.18.02" LOG_CI_END="0.8077633086888354" LOG_CI_START="0.18481725959544923" LOG_EFFECT_SIZE="0.4962902841421423" NO="2" P_CHI2="0.27010020282303926" P_Z="0.0017905519202473066" STUDIES="3" TAU2="0.0" TOTAL_1="963" TOTAL_2="364" WEIGHT="100.0" Z="3.1229384445455546">
<NAME>hyperkinesia</NAME>
<DICH_DATA CI_END="20.900435983661517" CI_START="1.2245748435694892" EFFECT_SIZE="5.059065934065934" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="2" LOG_CI_END="1.320155345600217" LOG_CI_START="0.08798533348353448" LOG_EFFECT_SIZE="0.7040703395418758" ORDER="300" O_E="0.0" SE="0.7237827644572682" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="127" VAR="0.5238614901254054" WEIGHT="25.202950637870458"/>
<DICH_DATA CI_END="4.364607280342916" CI_START="0.6673478102438274" EFFECT_SIZE="1.7066666666666668" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="5" LOG_CI_END="0.6399451727488189" LOG_CI_START="-0.17564776023648218" LOG_EFFECT_SIZE="0.23214870625616835" ORDER="301" O_E="0.0" SE="0.47908332608569604" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.22952083333333334" WEIGHT="63.36286247075102"/>
<DICH_DATA CI_END="51.139689210377746" CI_START="0.9075173699057607" EFFECT_SIZE="6.8125" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.7087580843741628" LOG_CI_START="-0.04214505380476478" LOG_EFFECT_SIZE="0.8333065152846989" ORDER="302" O_E="0.0" SE="1.0284891704766173" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="1.0577899737876801" WEIGHT="11.434186891378513"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.835165494846411E-6" CI_END="68.50668059391333" CI_START="1.2558437568167224" DF="1" EFFECT_SIZE="9.275434605672308" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="0" I2="0.0" ID="CMP-003.18.03" LOG_CI_END="1.8357329248296805" LOG_CI_START="0.09893561091932147" LOG_EFFECT_SIZE="0.9673342678745012" NO="3" P_CHI2="0.9989191204990568" P_Z="0.029016645207580325" STUDIES="2" TAU2="0.0" TOTAL_1="599" TOTAL_2="237" WEIGHT="100.0" Z="2.183260315824392">
<NAME>hypertonia</NAME>
<DICH_DATA CI_END="154.7231341021311" CI_START="0.5545950705410683" EFFECT_SIZE="9.263297872340425" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="0" LOG_CI_END="2.189555253982176" LOG_CI_START="-0.25602399492102607" LOG_EFFECT_SIZE="0.9667656295305752" ORDER="303" O_E="0.0" SE="1.436545356618263" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="2.0636625616214928" WEIGHT="52.57424296178809"/>
<DICH_DATA CI_END="158.13941010449616" CI_START="0.5456164072770264" EFFECT_SIZE="9.28888888888889" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.1990401144485827" LOG_CI_START="-0.26311257844919944" LOG_EFFECT_SIZE="0.9679637679996915" ORDER="304" O_E="0.0" SE="1.4462806796605503" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="2.091727804359383" WEIGHT="47.42575703821191"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1269511808672945" CI_END="1.048476295839621" CI_START="0.8387964356034973" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9377943163428919" ESTIMABLE="YES" EVENTS_1="347" EVENTS_2="125" I2="0.0" I2_Q="0.0" ID="CMP-003.19" LOG_CI_END="0.020558616296430937" LOG_CI_START="-0.0763434237014738" LOG_EFFECT_SIZE="-0.027892403702521426" METHOD="MH" NO="19" P_CHI2="0.5464796888779531" P_Q="0.6787500729312426" P_Z="0.2591861097177295" Q="1.5152721384514745" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1875" TOTAL_2="635" WEIGHT="400.0" Z="1.1283169415293162">
<NAME>Adverse effect: 7b. Movement disorder - akathisia (BARS)</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9835042140499605" CI_START="0.8178115440097996" DF="0" EFFECT_SIZE="0.8968395061728395" ESTIMABLE="YES" EVENTS_1="286" EVENTS_2="108" I2="0.0" ID="CMP-003.19.01" LOG_CI_END="-0.007223774906084771" LOG_CI_START="-0.0873467633532526" LOG_EFFECT_SIZE="-0.0472852691296687" NO="1" P_CHI2="1.0" P_Z="0.020701803723479042" STUDIES="1" TAU2="0.0" TOTAL_1="375" TOTAL_2="127" WEIGHT="100.0" Z="2.313379126005634">
<NAME>absent</NAME>
<DICH_DATA CI_END="0.9835042140499604" CI_START="0.8178115440097996" EFFECT_SIZE="0.8968395061728395" ESTIMABLE="YES" EVENTS_1="286" EVENTS_2="108" LOG_CI_END="-0.0072237749060848205" LOG_CI_START="-0.0873467633532526" LOG_EFFECT_SIZE="-0.0472852691296687" ORDER="305" O_E="0.0" SE="0.04706464002905571" STUDY_ID="STD-Davidson-2007" TOTAL_1="375" TOTAL_2="127" VAR="0.0022150803410645927" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1797240509450124" CI_START="0.6445839373575619" DF="0" EFFECT_SIZE="1.1853333333333333" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="12" I2="0.0" ID="CMP-003.19.02" LOG_CI_END="0.3384015162020779" LOG_CI_START="-0.19072052104505063" LOG_EFFECT_SIZE="0.07384049757851366" NO="2" P_CHI2="1.0" P_Z="0.5843531855584485" STUDIES="1" TAU2="0.0" TOTAL_1="375" TOTAL_2="127" WEIGHT="100.0" Z="0.5470371886507142">
<NAME>questionable</NAME>
<DICH_DATA CI_END="2.1797240509450124" CI_START="0.6445839373575619" EFFECT_SIZE="1.1853333333333333" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="12" LOG_CI_END="0.3384015162020779" LOG_CI_START="-0.19072052104505063" LOG_EFFECT_SIZE="0.07384049757851366" ORDER="306" O_E="0.0" SE="0.31080890387528953" STUDY_ID="STD-Davidson-2007" TOTAL_1="375" TOTAL_2="127" VAR="0.09660217472815898" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7395382508796096" CI_START="0.37679926522966556" DF="0" EFFECT_SIZE="1.016" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="0.0" ID="CMP-003.19.03" LOG_CI_END="0.43767736866193796" LOG_CI_START="-0.423889952766137" LOG_EFFECT_SIZE="0.006893707947900456" NO="3" P_CHI2="1.0" P_Z="0.9749786574084205" STUDIES="1" TAU2="0.0" TOTAL_1="375" TOTAL_2="127" WEIGHT="100.0" Z="0.031364744139614806">
<NAME>mild</NAME>
<DICH_DATA CI_END="2.73953825087961" CI_START="0.37679926522966545" EFFECT_SIZE="1.016" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.437677368661938" LOG_CI_START="-0.42388995276613717" LOG_EFFECT_SIZE="0.006893707947900456" ORDER="307" O_E="0.0" SE="0.5060889094338746" STUDY_ID="STD-Davidson-2007" TOTAL_1="375" TOTAL_2="127" VAR="0.25612598425196853" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="56.51550997046808" CI_START="0.16609693462994068" DF="0" EFFECT_SIZE="3.0638297872340425" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-003.19.04" LOG_CI_END="1.752167650832066" LOG_CI_START="-0.7796383825130017" LOG_EFFECT_SIZE="0.4862646341595322" NO="4" P_CHI2="1.0" P_Z="0.45152767979888075" STUDIES="1" TAU2="0.0" TOTAL_1="375" TOTAL_2="127" WEIGHT="100.0" Z="0.752870604900982">
<NAME>moderate</NAME>
<DICH_DATA CI_END="56.51550997046808" CI_START="0.16609693462994068" EFFECT_SIZE="3.0638297872340425" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.752167650832066" LOG_CI_START="-0.7796383825130017" LOG_EFFECT_SIZE="0.4862646341595322" ORDER="308" O_E="0.0" SE="1.4871953966288818" STUDY_ID="STD-Davidson-2007" TOTAL_1="375" TOTAL_2="127" VAR="2.2117501477541373" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.19.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="375" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>marked</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="309" O_E="0.0" SE="0.0" STUDY_ID="STD-Davidson-2007" TOTAL_1="375" TOTAL_2="127" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.833722886432009" CI_END="1.8970829563786598" CI_START="1.0357632721407208" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4017591984435676" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="48" I2="20.758211571799258" I2_Q="0.0" ID="CMP-003.20" LOG_CI_END="0.2780863223012967" LOG_CI_START="0.015260507001032028" LOG_EFFECT_SIZE="0.14667341465116435" METHOD="MH" NO="20" P_CHI2="0.26481571455717345" P_Q="0.46690515614513606" P_Z="0.028701118955383603" Q="4.597804683396217" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2083" TOTAL_2="909" WEIGHT="600.0" Z="2.1875675331007125">
<NAME>Adverse effect: 8. Other events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9589301265496065E-32" CI_END="8.062090193066792" CI_START="0.35978694062731725" DF="0" EFFECT_SIZE="1.7031249999999998" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="100.0" ID="CMP-003.20.01" LOG_CI_END="0.9064476524293007" LOG_CI_START="-0.443954604515828" LOG_EFFECT_SIZE="0.2312465239567364" NO="1" P_CHI2="0.0" P_Z="0.5020555302300391" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="109" WEIGHT="100.0" Z="0.6712590358528979">
<NAME>pain - body pain</NAME>
<DICH_DATA CI_END="8.062090193066792" CI_START="0.3597869406273173" EFFECT_SIZE="1.703125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.9064476524293007" LOG_CI_START="-0.44395460451582797" LOG_EFFECT_SIZE="0.23124652395673648" ORDER="310" O_E="0.0" SE="0.7932329703285482" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.6292185452162515" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.273359837154138" CI_END="2.0372395802644236" CI_START="1.026347815548223" DF="2" EFFECT_SIZE="1.4460001358757786" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="36" I2="53.198418195180395" ID="CMP-003.20.02" LOG_CI_END="0.30904210522427034" LOG_CI_START="0.0112945623111466" LOG_EFFECT_SIZE="0.16016833376770848" NO="2" P_CHI2="0.11804618101497011" P_Z="0.03497394058311103" STUDIES="3" TAU2="0.0" TOTAL_1="963" TOTAL_2="364" WEIGHT="100.0" Z="2.108659991461931">
<NAME>pain - headache</NAME>
<DICH_DATA CI_END="2.1856880609082863" CI_START="0.7832114538984309" EFFECT_SIZE="1.308379120879121" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="16" LOG_CI_END="0.33958817998647745" LOG_CI_START="-0.10612096991723802" LOG_EFFECT_SIZE="0.11673360503461973" ORDER="311" O_E="0.0" SE="0.2618117609493172" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="127" VAR="0.06854539817138242" WEIGHT="45.80122603710451"/>
<DICH_DATA CI_END="1.723453020431627" CI_START="0.3422338717723113" EFFECT_SIZE="0.768" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.23639944948148536" LOG_CI_START="-0.46567700941846135" LOG_EFFECT_SIZE="-0.114638779968488" ORDER="312" O_E="0.0" SE="0.4124031872923497" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.17007638888888887" WEIGHT="23.029817643812585"/>
<DICH_DATA CI_END="3.851112888314325" CI_START="1.1993887114142696" EFFECT_SIZE="2.1491815476190474" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="12" LOG_CI_END="0.5855862493558941" LOG_CI_START="0.07895995696335595" LOG_EFFECT_SIZE="0.332273103159625" ORDER="313" O_E="0.0" SE="0.2975947919919702" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.088562660220744" WEIGHT="31.168956319082902"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="34.13048576036585" CI_START="0.5619523719794064" DF="0" EFFECT_SIZE="4.379464285714286" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" ID="CMP-003.20.03" LOG_CI_END="1.5331424693962816" LOG_CI_START="-0.25030049130471016" LOG_EFFECT_SIZE="0.6414209890457857" NO="3" P_CHI2="1.0" P_Z="0.15859440947329098" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="109" WEIGHT="100.0" Z="1.40981468447263">
<NAME>pain - musculoskeletal</NAME>
<DICH_DATA CI_END="34.13048576036585" CI_START="0.5619523719794062" EFFECT_SIZE="4.379464285714286" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.5331424693962816" LOG_CI_START="-0.2503004913047103" LOG_EFFECT_SIZE="0.6414209890457857" ORDER="314" O_E="0.0" SE="1.0476032233007972" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="1.09747251347022" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.097515941041698" CI_START="0.2212624721552826" DF="0" EFFECT_SIZE="0.68125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-003.20.04" LOG_CI_END="0.32170527013489164" LOG_CI_START="-0.6550922395654938" LOG_EFFECT_SIZE="-0.16669348471530113" NO="4" P_CHI2="1.0" P_Z="0.503528841505319" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="109" WEIGHT="100.0" Z="0.6689477056502354">
<NAME>pain - toothache</NAME>
<DICH_DATA CI_END="2.097515941041698" CI_START="0.2212624721552826" EFFECT_SIZE="0.68125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.32170527013489164" LOG_CI_START="-0.6550922395654938" LOG_EFFECT_SIZE="-0.16669348471530113" ORDER="315" O_E="0.0" SE="0.573775692423661" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.32921854521625166" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9679213613878046" CI_START="0.006692906657903017" DF="0" EFFECT_SIZE="0.16296296296296298" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.20.05" LOG_CI_END="0.5985630564625433" LOG_CI_START="-2.174385231808143" LOG_EFFECT_SIZE="-0.7879110876727998" NO="5" P_CHI2="1.0" P_Z="0.2653580659577488" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="109" WEIGHT="100.0" Z="1.1138161944026281">
<NAME>rash</NAME>
<DICH_DATA CI_END="3.9679213613878046" CI_START="0.006692906657903017" EFFECT_SIZE="0.16296296296296298" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5985630564625433" LOG_CI_START="-2.174385231808143" LOG_EFFECT_SIZE="-0.7879110876727998" ORDER="316" O_E="0.0" SE="1.6288435508456032" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="2.653131313131313" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.28436358948443" CI_START="0.40328008609344124" DF="0" EFFECT_SIZE="1.4598214285714286" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-003.20.06" LOG_CI_END="0.7229926915076552" LOG_CI_START="-0.39439322285540857" LOG_EFFECT_SIZE="0.16429973432612327" NO="6" P_CHI2="1.0" P_Z="0.5643558040493579" STUDIES="1" TAU2="0.0" TOTAL_1="224" TOTAL_2="109" WEIGHT="100.0" Z="0.5763837861375956">
<NAME>upper respiratory infection</NAME>
<DICH_DATA CI_END="5.28436358948443" CI_START="0.40328008609344124" EFFECT_SIZE="1.4598214285714286" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.7229926915076552" LOG_CI_START="-0.39439322285540857" LOG_EFFECT_SIZE="0.16429973432612327" ORDER="317" O_E="0.0" SE="0.6563580172463449" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.4308058468035532" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7853832905436293" CI_END="1.996538034648587" CI_START="0.3642394683214222" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8527707500986994" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.21" LOG_CI_END="0.300277588049346" LOG_CI_START="-0.43861299663694386" LOG_EFFECT_SIZE="-0.06916770429379895" METHOD="MH" MODIFIED="2009-06-08 11:12:40 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.9999854000264803" P_Q="0.9994247931049655" P_Z="0.7136598297630781" Q="0.3143041825081576" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4815" TOTAL_2="1820" WEIGHT="700.0" Z="0.3669452882979139">
<NAME>Adverse effect: 9. Potentially prolactin-related events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.740321241366637" CI_START="0.03701484094636065" DF="0" EFFECT_SIZE="0.8970588235294118" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.21.01" LOG_CI_END="1.3372659570604017" LOG_CI_START="-1.4316241124513405" LOG_EFFECT_SIZE="-0.04717907769546927" MODIFIED="2008-05-18 19:02:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9467476140849657" STUDIES="3" TAU2="0.0" TOTAL_1="591" TOTAL_2="245" WEIGHT="100.00000000000001" Z="0.06679159575536525">
<NAME>gynaecomastia - men</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 19:02:17 +0100" MODIFIED_BY="[Empty name]" ORDER="382" O_E="0.0" SE="0.0" STUDY_ID="STD-Davidson-2007" TOTAL_1="234" TOTAL_2="97" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="21.740321241366637" CI_START="0.03701484094636065" EFFECT_SIZE="0.8970588235294118" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3372659570604017" LOG_CI_START="-1.4316241124513405" LOG_EFFECT_SIZE="-0.04717907769546927" MODIFIED="2008-05-18 18:40:50 +0100" MODIFIED_BY="[Empty name]" ORDER="354" O_E="0.0" SE="1.6264597330580928" STUDY_ID="STD-Kane-2007" TOTAL_1="203" TOTAL_2="60" VAR="2.645371263259402" WEIGHT="100.00000000000001"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 18:59:46 +0100" MODIFIED_BY="[Empty name]" ORDER="383" O_E="0.0" SE="0.0" STUDY_ID="STD-Marder-2007" TOTAL_1="154" TOTAL_2="88" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1288382479435238" CI_END="4.543961893222966" CI_START="0.0752198408622941" DF="1" EFFECT_SIZE="0.5846332957440589" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-003.21.02" LOG_CI_END="0.6574346806183711" LOG_CI_START="-1.1236675897211263" LOG_EFFECT_SIZE="-0.23311645455137753" MODIFIED="2008-05-18 19:02:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7196397163848145" P_Z="0.6079143092318602" STUDIES="3" TAU2="0.0" TOTAL_1="591" TOTAL_2="245" WEIGHT="100.0" Z="0.5130529141791261">
<NAME>impotence - men</NAME>
<DICH_DATA CI_END="6.560546169900161" CI_START="0.02619218668539502" EFFECT_SIZE="0.41452991452991456" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.8169399961896964" LOG_CI_START="-1.5818282424774923" LOG_EFFECT_SIZE="-0.382444123143898" MODIFIED="2008-05-18 19:02:28 +0100" MODIFIED_BY="[Empty name]" ORDER="384" O_E="0.0" SE="1.409048337487391" STUDY_ID="STD-Davidson-2007" TOTAL_1="234" TOTAL_2="97" VAR="1.9854172173759803" WEIGHT="64.74752537276031"/>
<DICH_DATA CI_END="21.740321241366637" CI_START="0.03701484094636065" EFFECT_SIZE="0.8970588235294118" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3372659570604017" LOG_CI_START="-1.4316241124513405" LOG_EFFECT_SIZE="-0.04717907769546927" MODIFIED="2008-05-18 18:41:04 +0100" MODIFIED_BY="[Empty name]" ORDER="353" O_E="0.0" SE="1.6264597330580928" STUDY_ID="STD-Kane-2007" TOTAL_1="203" TOTAL_2="60" VAR="2.645371263259402" WEIGHT="35.2524746272397"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 19:01:53 +0100" MODIFIED_BY="[Empty name]" ORDER="385" O_E="0.0" SE="0.0" STUDY_ID="STD-Marder-2007" TOTAL_1="154" TOTAL_2="88" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3120828001175278" CI_END="3.9294151826160157" CI_START="0.14050523097870335" DF="2" EFFECT_SIZE="0.7430365992632443" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-003.21.03" LOG_CI_END="0.5943279188583601" LOG_CI_START="-0.8523075067703157" LOG_EFFECT_SIZE="-0.12898979395597784" MODIFIED="2008-05-18 19:02:49 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8555237884463485" P_Z="0.726697565048104" STUDIES="3" TAU2="0.0" TOTAL_1="372" TOTAL_2="119" WEIGHT="100.00000000000001" Z="0.34952185747434045">
<NAME>lactation nonpuerperal - women</NAME>
<DICH_DATA CI_END="24.028742419215327" CI_START="0.05826258681833758" EFFECT_SIZE="1.183206106870229" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.3807310419363532" LOG_CI_START="-1.2346102369072989" LOG_EFFECT_SIZE="0.07306040251452725" MODIFIED="2008-05-18 19:02:49 +0100" MODIFIED_BY="[Empty name]" ORDER="386" O_E="0.0" SE="1.5362644133408843" STUDY_ID="STD-Davidson-2007" TOTAL_1="130" TOTAL_2="30" VAR="2.3601083476976115" WEIGHT="26.90615641480932"/>
<DICH_DATA CI_END="6.231175240606422" CI_START="0.025083663522121734" EFFECT_SIZE="0.3953488372093023" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.7945699651784001" LOG_CI_START="-1.6006090335810252" LOG_EFFECT_SIZE="-0.40301953420131265" MODIFIED="2008-05-18 18:41:18 +0100" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="1.4069400001985468" STUDY_ID="STD-Kane-2007" TOTAL_1="172" TOTAL_2="68" VAR="1.9794801641586868" WEIGHT="47.69167572151698"/>
<DICH_DATA CI_END="22.013386294398693" CI_START="0.039254036225354436" EFFECT_SIZE="0.9295774647887324" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3426868547228852" LOG_CI_START="-1.4061156810772983" LOG_EFFECT_SIZE="-0.03171441317720662" MODIFIED="2008-05-18 19:01:40 +0100" MODIFIED_BY="[Empty name]" ORDER="387" O_E="0.0" SE="1.6146602163210275" STUDY_ID="STD-Marder-2007" TOTAL_1="70" TOTAL_2="21" VAR="2.6071276141698676" WEIGHT="25.402167863673707"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.577484773991213" CI_START="0.07288882799614398" DF="0" EFFECT_SIZE="0.7906976744186046" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-003.21.04" LOG_CI_END="0.9333599558069091" LOG_CI_START="-1.1373390328815722" LOG_EFFECT_SIZE="-0.10198953853733142" MODIFIED="2009-06-08 11:12:40 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8469034698939548" STUDIES="3" TAU2="0.0" TOTAL_1="372" TOTAL_2="119" WEIGHT="100.0" Z="0.19307086488668015">
<NAME>amenorrhoea - women</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 19:03:06 +0100" MODIFIED_BY="[Empty name]" ORDER="388" O_E="0.0" SE="0.0" STUDY_ID="STD-Davidson-2007" TOTAL_1="130" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.577484773991213" CI_START="0.07288882799614398" EFFECT_SIZE="0.7906976744186046" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.9333599558069091" LOG_CI_START="-1.1373390328815722" LOG_EFFECT_SIZE="-0.10198953853733142" MODIFIED="2008-05-18 18:41:37 +0100" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="1.2163388360809197" STUDY_ID="STD-Kane-2007" TOTAL_1="172" TOTAL_2="68" VAR="1.4794801641586868" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 19:01:32 +0100" MODIFIED_BY="[Empty name]" ORDER="389" O_E="0.0" SE="0.0" STUDY_ID="STD-Marder-2007" TOTAL_1="70" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.036194604522652E-5" CI_END="9.959357498566867" CI_START="0.10873151307174463" DF="1" EFFECT_SIZE="1.040622895213055" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.21.05" LOG_CI_END="0.9982313219751621" LOG_CI_START="-0.9636445684278577" LOG_EFFECT_SIZE="0.017293376773652093" MODIFIED="2008-05-18 19:03:26 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9924155113046821" P_Z="0.9724361415975913" STUDIES="3" TAU2="0.0" TOTAL_1="963" TOTAL_2="364" WEIGHT="100.00000000000001" Z="0.03455304773685435">
<NAME>anorgasmia</NAME>
<DICH_DATA CI_END="25.66207363985571" CI_START="0.043130547679306554" EFFECT_SIZE="1.0520547945205478" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.4092917468931667" LOG_CI_START="-1.3652150270710544" LOG_EFFECT_SIZE="0.022038359911056054" MODIFIED="2008-05-18 19:03:26 +0100" MODIFIED_BY="[Empty name]" ORDER="390" O_E="0.0" SE="1.6297590130566142" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="127" VAR="2.656114440639269" WEIGHT="49.85893700989741"/>
<DICH_DATA CI_END="25.108065504069003" CI_START="0.042192279282714865" EFFECT_SIZE="1.0292553191489362" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3998132530047445" LOG_CI_START="-1.3747670128222438" LOG_EFFECT_SIZE="0.012523120091250364" MODIFIED="2008-05-18 18:41:53 +0100" MODIFIED_BY="[Empty name]" ORDER="357" O_E="0.0" SE="1.6298021825405944" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="2.6562551542140853" WEIGHT="50.141062990102604"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 19:01:23 +0100" MODIFIED_BY="[Empty name]" ORDER="391" O_E="0.0" SE="0.0" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.108065504069003" CI_START="0.042192279282714865" DF="0" EFFECT_SIZE="1.0292553191489362" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.21.06" LOG_CI_END="1.3998132530047445" LOG_CI_START="-1.3747670128222438" LOG_EFFECT_SIZE="0.012523120091250364" MODIFIED="2008-05-18 19:03:34 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.9858840294689855" STUDIES="3" TAU2="0.0" TOTAL_1="963" TOTAL_2="364" WEIGHT="99.99999999999999" Z="0.01769266844086405">
<NAME>abnormal sexual function</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 19:03:34 +0100" MODIFIED_BY="[Empty name]" ORDER="392" O_E="0.0" SE="0.0" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="127" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="25.108065504069003" CI_START="0.042192279282714865" EFFECT_SIZE="1.0292553191489362" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3998132530047445" LOG_CI_START="-1.3747670128222438" LOG_EFFECT_SIZE="0.012523120091250364" MODIFIED="2008-05-18 18:42:01 +0100" MODIFIED_BY="[Empty name]" ORDER="358" O_E="0.0" SE="1.6298021825405944" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="2.6562551542140853" WEIGHT="99.99999999999999"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 19:00:57 +0100" MODIFIED_BY="[Empty name]" ORDER="393" O_E="0.0" SE="0.0" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.020815284422286938" CI_END="11.871494553137069" CI_START="0.13146432864497534" DF="1" EFFECT_SIZE="1.2492710120068609" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.21.07" LOG_CI_END="1.0745053975831624" LOG_CI_START="-0.8811920720733195" LOG_EFFECT_SIZE="0.09665666275492144" MODIFIED="2008-05-18 19:04:05 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8852833045943609" P_Z="0.8463833424638915" STUDIES="3" TAU2="0.0" TOTAL_1="963" TOTAL_2="364" WEIGHT="100.0" Z="0.19373505442920658">
<NAME>decreased libido</NAME>
<DICH_DATA CI_END="25.66207363985571" CI_START="0.043130547679306554" EFFECT_SIZE="1.0520547945205478" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.4092917468931667" LOG_CI_START="-1.3652150270710544" LOG_EFFECT_SIZE="0.022038359911056054" MODIFIED="2008-05-18 19:04:05 +0100" MODIFIED_BY="[Empty name]" ORDER="394" O_E="0.0" SE="1.6297590130566142" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="127" VAR="2.656114440639269" WEIGHT="52.43353344768439"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-18 19:03:49 +0100" MODIFIED_BY="[Empty name]" ORDER="395" O_E="0.0" SE="0.0" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="35.71129225249023" CI_START="0.06023615992112714" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.552805565901868" LOG_CI_START="-1.2201427223688182" LOG_EFFECT_SIZE="0.16633142176652496" MODIFIED="2008-05-18 19:01:15 +0100" MODIFIED_BY="[Empty name]" ORDER="396" O_E="0.0" SE="1.6288435508456032" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="2.653131313131313" WEIGHT="47.56646655231561"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.331998437665484" CI_END="1.1520271154133777" CI_START="0.44146859121278464" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7131506065905517" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-003.22" LOG_CI_END="0.061462701253700056" LOG_CI_START="-0.3551001893643281" LOG_EFFECT_SIZE="-0.146818744055314" METHOD="MH" MODIFIED="2008-05-18 20:06:04 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.648946486707537" P_Q="0.9586721390638089" P_Z="0.16709779053699336" Q="0.002685312407584191" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1926" TOTAL_2="728" WEIGHT="200.0" Z="1.3815894650475904">
<NAME>Adverse effect: 10. Psychiatric event, serious</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.867463754583307" CI_END="2.3039039789097715" CI_START="0.2082862552376439" DF="2" EFFECT_SIZE="0.6927276031704122" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-003.22.01" LOG_CI_END="0.36246437479517296" LOG_CI_START="-0.6813393881002499" LOG_EFFECT_SIZE="-0.15943750665253847" MODIFIED="2008-05-18 20:06:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.39308408797061234" P_Z="0.5493357539862456" STUDIES="3" TAU2="0.0" TOTAL_1="963" TOTAL_2="364" WEIGHT="99.99999999999999" Z="0.5987557852004961">
<NAME>Suicide attempt</NAME>
<DICH_DATA CI_END="9.972036194517242" CI_START="0.10986600629587746" EFFECT_SIZE="1.0467032967032968" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.998783846150487" LOG_CI_START="-0.9591366620973605" LOG_EFFECT_SIZE="0.019823592026563336" MODIFIED="2008-05-18 20:05:38 +0100" MODIFIED_BY="[Empty name]" ORDER="414" O_E="0.0" SE="1.1500921984076098" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="127" VAR="1.322712064838049" WEIGHT="25.518973937082347"/>
<DICH_DATA CI_END="1.866403419913154" CI_START="0.015606010362146908" EFFECT_SIZE="0.17066666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.27100552156797797" LOG_CI_START="-1.8067081090556414" LOG_EFFECT_SIZE="-0.7678512937438317" MODIFIED="2008-05-18 20:04:11 +0100" MODIFIED_BY="[Empty name]" ORDER="415" O_E="0.0" SE="1.2204592714766573" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="1.4895208333333334" WEIGHT="51.3259025644516"/>
<DICH_DATA CI_END="13.872117677461802" CI_START="0.15362316359085645" EFFECT_SIZE="1.4598214285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1421427642768536" LOG_CI_START="-0.8135432956246071" LOG_EFFECT_SIZE="0.16429973432612327" MODIFIED="2008-05-18 20:06:04 +0100" MODIFIED_BY="[Empty name]" ORDER="416" O_E="0.0" SE="1.1487796723882444" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="1.319694735692442" WEIGHT="23.155123498466033"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4609561935436728" CI_END="1.2099475540700992" CI_START="0.4250661677467965" DF="2" EFFECT_SIZE="0.7171525430361291" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="21" I2="0.0" ID="CMP-003.22.02" LOG_CI_END="0.08276654595976563" LOG_CI_START="-0.3715434604188965" LOG_EFFECT_SIZE="-0.14438845722956545" MODIFIED="2008-05-18 20:05:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4816787307800514" P_Z="0.21282738964906545" STUDIES="3" TAU2="0.0" TOTAL_1="963" TOTAL_2="364" WEIGHT="100.0" Z="1.2458284958723813">
<NAME>Treatment-emergent psychiatric disorder</NAME>
<DICH_DATA CI_END="2.40332363578636" CI_START="0.4558636111324544" EFFECT_SIZE="1.0467032967032968" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="7" LOG_CI_END="0.38081225760047305" LOG_CI_START="-0.3411650735473464" LOG_EFFECT_SIZE="0.019823592026563336" MODIFIED="2008-05-18 20:05:12 +0100" MODIFIED_BY="[Empty name]" ORDER="412" O_E="0.0" SE="0.4240930581616566" STUDY_ID="STD-Davidson-2007" TOTAL_1="364" TOTAL_2="127" VAR="0.17985492198090625" WEIGHT="35.003528534048435"/>
<DICH_DATA CI_END="2.347036499009973" CI_START="0.1378907264704874" EFFECT_SIZE="0.5688888888888889" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.3705198434099998" LOG_CI_START="-0.8604649403369881" LOG_EFFECT_SIZE="-0.24497254846349412" MODIFIED="2008-05-18 20:03:53 +0100" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="0.7230865554459346" STUDY_ID="STD-Kane-2007" TOTAL_1="375" TOTAL_2="128" VAR="0.5228541666666666" WEIGHT="15.086150345958007"/>
<DICH_DATA CI_END="1.1643660269993639" CI_START="0.2420162657271075" EFFECT_SIZE="0.5308441558441559" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.06608952543222092" LOG_CI_START="-0.6161554444404996" LOG_EFFECT_SIZE="-0.27503295950413936" MODIFIED="2008-05-18 20:04:38 +0100" MODIFIED_BY="[Empty name]" ORDER="417" O_E="0.0" SE="0.4007540724703032" STUDY_ID="STD-Marder-2007" TOTAL_1="224" TOTAL_2="109" VAR="0.16060382660153302" WEIGHT="49.910321119993554"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-02-20 02:13:00 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>SENSITIVITY ANALYSIS: 2. INCREASING DOSES OF PALPERIDONE versus OLANZAPINE (primary outcomes only)</NAME>
<DICH_OUTCOME CHI2="8.458383001210304" CI_END="1.1657249031212145" CI_START="0.9307846519705527" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0416519803874449" ESTIMABLE="YES" EVENTS_1="364" EVENTS_2="354" I2="17.24186527143102" I2_Q="38.16059705308004" ID="CMP-004.01" LOG_CI_END="0.06659607430598871" LOG_CI_START="-0.03115078655790344" LOG_EFFECT_SIZE="0.017722643874042633" METHOD="MH" NO="1" P_CHI2="0.29391276353264384" P_Q="0.16679447674376569" P_Z="0.47725245211832046" Q="6.468367754833293" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.005639695410152599" TOTALS="SUB" TOTAL_1="966" TOTAL_2="988" WEIGHT="500.0" Z="0.710728577817366">
<NAME>Leaving the study early: any reason</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9802399259196262" CI_START="1.0416562248135444" DF="0" EFFECT_SIZE="1.4362204724409449" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="40" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.29671781257989355" LOG_CI_START="0.017724413492987395" LOG_EFFECT_SIZE="0.1572211130364405" NO="1" P_CHI2="1.0" P_Z="0.02717488529326502" STUDIES="1" TAU2="0.0" TOTAL_1="127" TOTAL_2="128" WEIGHT="100.0" Z="2.2089964864346956">
<NAME>3 mg</NAME>
<DICH_DATA CI_END="1.9802399259196262" CI_START="1.0416562248135444" EFFECT_SIZE="1.4362204724409449" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="40" LOG_CI_END="0.29671781257989355" LOG_CI_START="0.017724413492987395" LOG_EFFECT_SIZE="0.1572211130364405" ORDER="318" O_E="0.0" SE="0.16388210366324724" STUDY_ID="STD-Davidson-2007" TOTAL_1="127" TOTAL_2="128" VAR="0.02685734390109131" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.580967266154677" CI_END="1.2831167802486954" CI_START="0.8604322346141726" DF="1" EFFECT_SIZE="1.0507307164541861" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="98" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.10826618459751686" LOG_CI_START="-0.06528332788379862" LOG_EFFECT_SIZE="0.02149142835685914" NO="2" P_CHI2="0.4459335676685402" P_Z="0.6273766241819547" STUDIES="2" TAU2="0.0" TOTAL_1="235" TOTAL_2="238" WEIGHT="100.0" Z="0.48542257426740537">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="1.6868827903954244" CI_START="0.8220429834496706" EFFECT_SIZE="1.1775780915703893" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="38" LOG_CI_END="0.22708490757257835" LOG_CI_START="-0.08510547323008481" LOG_EFFECT_SIZE="0.07098971717124676" ORDER="319" O_E="0.0" SE="0.18338217505079268" STUDY_ID="STD-Kane-2007" TOTAL_1="123" TOTAL_2="128" VAR="0.03362902212635957" WEIGHT="30.903506585907444"/>
<DICH_DATA CI_END="1.269827738537811" CI_START="0.7851663605169854" EFFECT_SIZE="0.9985119047619048" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="60" LOG_CI_END="0.1037448097144952" LOG_CI_START="-0.10503831548416155" LOG_EFFECT_SIZE="-6.467528848331671E-4" ORDER="320" O_E="0.0" SE="0.12264024123482867" STUDY_ID="STD-Marder-2007" TOTAL_1="112" TOTAL_2="110" VAR="0.015040628770136968" WEIGHT="69.09649341409255"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5329761302892422" CI_END="1.4262780133476767" CI_START="0.8564972625200115" DF="1" EFFECT_SIZE="1.1052616043384325" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="78" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.15420418743352013" LOG_CI_START="-0.06727402075959533" LOG_EFFECT_SIZE="0.043465083336962425" NO="3" P_CHI2="0.4653583915208257" P_Z="0.4417237914115124" STUDIES="2" TAU2="0.0" TOTAL_1="247" TOTAL_2="256" WEIGHT="100.0" Z="0.7692855980774226">
<NAME>9 mg</NAME>
<DICH_DATA CI_END="1.6939721192879598" CI_START="0.8546127905626445" EFFECT_SIZE="1.2032" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="40" LOG_CI_END="0.22890625809679252" LOG_CI_START="-0.06823061160165841" LOG_EFFECT_SIZE="0.08033782324756704" ORDER="321" O_E="0.0" SE="0.17453966811209665" STUDY_ID="STD-Davidson-2007" TOTAL_1="125" TOTAL_2="128" VAR="0.03046409574468085" WEIGHT="55.55829571615935"/>
<DICH_DATA CI_END="1.4570780642473031" CI_START="0.6780399234020786" EFFECT_SIZE="0.993960310612597" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="38" LOG_CI_END="0.16348282010467324" LOG_CI_START="-0.16874473385747876" LOG_EFFECT_SIZE="-0.002630956876402765" ORDER="322" O_E="0.0" SE="0.1951521097502832" STUDY_ID="STD-Kane-2007" TOTAL_1="122" TOTAL_2="128" VAR="0.03808434593998657" WEIGHT="44.44170428384065"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9410208830241038" CI_END="1.1050736146894224" CI_START="0.7223663954443831" DF="1" EFFECT_SIZE="0.8934584734300152" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="98" I2="0.0" ID="CMP-004.01.04" LOG_CI_END="0.04339120959445133" LOG_CI_START="-0.1412424656465571" LOG_EFFECT_SIZE="-0.048925628026052895" NO="4" P_CHI2="0.3320155998308232" P_Z="0.29892933117397436" STUDIES="2" TAU2="0.0" TOTAL_1="242" TOTAL_2="238" WEIGHT="99.99999999999997" Z="1.0387321676492174">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="1.1403456409424293" CI_START="0.4951371704343224" EFFECT_SIZE="0.751417004048583" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="38" LOG_CI_END="0.05703650677718414" LOG_CI_START="-0.30527446953082904" LOG_EFFECT_SIZE="-0.12411898137682245" ORDER="323" O_E="0.0" SE="0.21282326095158435" STUDY_ID="STD-Kane-2007" TOTAL_1="130" TOTAL_2="128" VAR="0.04529374040206617" WEIGHT="25.96921648228247"/>
<DICH_DATA CI_END="1.2154727734819675" CI_START="0.7415792616606973" EFFECT_SIZE="0.9494047619047619" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="60" LOG_CI_END="0.08474523511767286" LOG_CI_START="-0.1298424237829988" LOG_EFFECT_SIZE="-0.02254859433266294" ORDER="324" O_E="0.0" SE="0.12604985306429745" STUDY_ID="STD-Marder-2007" TOTAL_1="112" TOTAL_2="110" VAR="0.01588856545753098" WEIGHT="74.03078351771751"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3508971021032077" CI_START="0.6241800528418403" DF="0" EFFECT_SIZE="0.9182608695652174" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" I2="0.0" ID="CMP-004.01.05" LOG_CI_END="0.13062227005039753" LOG_CI_START="-0.20469011436203402" LOG_EFFECT_SIZE="-0.03703392215581825" NO="5" P_CHI2="1.0" P_Z="0.6650580064175413" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="128" WEIGHT="100.0" Z="0.43294048777145416">
<NAME>15 mg</NAME>
<DICH_DATA CI_END="1.3508971021032077" CI_START="0.6241800528418403" EFFECT_SIZE="0.9182608695652174" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" LOG_CI_END="0.13062227005039753" LOG_CI_START="-0.20469011436203402" LOG_EFFECT_SIZE="-0.03703392215581825" ORDER="325" O_E="0.0" SE="0.1969641544269344" STUDY_ID="STD-Davidson-2007" TOTAL_1="115" TOTAL_2="128" VAR="0.03879487812911726" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.00969689588724824" CI_END="1.0857025144381043" CI_START="0.7535391291813356" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9044994899278139" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="114" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.035710843635478294" LOG_CI_START="-0.12289419106492597" LOG_EFFECT_SIZE="-0.043591673714723826" METHOD="MH" NO="2" P_CHI2="0.9215568558007657" P_Q="0.921557876606202" P_Z="0.2813152574264557" Q="0.009696642694016062" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="222" TOTAL_2="210" WEIGHT="200.0" Z="1.0773694626790096">
<NAME>Global state: 1. No clinically important change</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1802255568212747" CI_START="0.705900181421705" DF="0" EFFECT_SIZE="0.9127548601232812" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="57" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.07196501469738963" LOG_CI_START="-0.15125670648732345" LOG_EFFECT_SIZE="-0.03964584589496689" NO="1" P_CHI2="1.0" P_Z="0.4862982687096614" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="105" WEIGHT="100.0" Z="0.6962085022761819">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="1.1802255568212747" CI_START="0.705900181421705" EFFECT_SIZE="0.9127548601232812" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="57" LOG_CI_END="0.07196501469738963" LOG_CI_START="-0.15125670648732345" LOG_EFFECT_SIZE="-0.03964584589496689" ORDER="326" O_E="0.0" SE="0.13112154398924097" STUDY_ID="STD-Marder-2007" TOTAL_1="111" TOTAL_2="105" VAR="0.017192859298122455" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1616723827093562" CI_START="0.6913321981131384" DF="0" EFFECT_SIZE="0.8961593172119487" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="57" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="0.06508366467823172" LOG_CI_START="-0.16031321581071625" LOG_EFFECT_SIZE="-0.04761477556624227" NO="2" P_CHI2="1.0" P_Z="0.4076256009176237" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="105" WEIGHT="100.0" Z="0.8280792976313497">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="1.1616723827093562" CI_START="0.6913321981131384" EFFECT_SIZE="0.8961593172119487" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="57" LOG_CI_END="0.06508366467823172" LOG_CI_START="-0.16031321581071625" LOG_EFFECT_SIZE="-0.04761477556624227" ORDER="327" O_E="0.0" SE="0.13239924333176073" STUDY_ID="STD-Marder-2007" TOTAL_1="111" TOTAL_2="105" VAR="0.01752955963482279" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.827060428018343" CI_END="1.3233841146018852" CI_START="0.5458434365033914" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8499179565865702" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.12168591723356277" LOG_CI_START="-0.26293190750243967" LOG_EFFECT_SIZE="-0.07062299513443843" METHOD="MH" NO="3" P_CHI2="0.5600819204020904" P_Q="0.8963116424241443" P_Z="0.47166553198420724" Q="1.0871117987974954" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="963" TOTAL_2="983" WEIGHT="500.0" Z="0.7197717736501468">
<NAME>Global state: 2. Recurrence of psychotic symptoms</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Olanzapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.732995996034431" CI_START="0.4762335077954314" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.5720575241076373" LOG_CI_START="-0.32218005089103746" LOG_EFFECT_SIZE="0.12493873660829993" NO="1" P_CHI2="1.0" P_Z="0.5839156332853626" STUDIES="1" TAU2="0.0" TOTAL_1="127" TOTAL_2="127" WEIGHT="100.0" Z="0.5476741995024459">
<NAME>3 mg</NAME>
<DICH_DATA CI_END="3.732995996034431" CI_START="0.4762335077954314" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5720575241076373" LOG_CI_START="-0.32218005089103746" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="328" O_E="0.0" SE="0.5252795781016083" STUDY_ID="STD-Davidson-2007" TOTAL_1="127" TOTAL_2="127" VAR="0.27591863517060367" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2532936624444183" CI_END="1.6793046623278047" CI_START="0.3615514718138693" DF="1" EFFECT_SIZE="0.7792015607585181" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.22512949373473892" LOG_CI_START="-0.4418298661883508" LOG_EFFECT_SIZE="-0.10835018622680595" NO="2" P_CHI2="0.6147654338749409" P_Z="0.5242500458326202" STUDIES="2" TAU2="0.0" TOTAL_1="235" TOTAL_2="237" WEIGHT="100.00000000000001" Z="0.6368078041433769">
<NAME>6 mg</NAME>
<DICH_DATA CI_END="4.069319793723206" CI_START="0.26612636102660114" EFFECT_SIZE="1.0406504065040652" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6095218208908771" LOG_CI_START="-0.5749121044739361" LOG_EFFECT_SIZE="0.01730485820847048" ORDER="329" O_E="0.0" SE="0.6957423508017799" STUDY_ID="STD-Kane-2007" TOTAL_1="123" TOTAL_2="128" VAR="0.484057418699187" WEIGHT="31.708599958786678"/>
<DICH_DATA CI_END="1.7252272500275383" CI_START="0.26900894504917655" EFFECT_SIZE="0.68125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.23684630922532124" LOG_CI_START="-0.5702332786559235" LOG_EFFECT_SIZE="-0.16669348471530113" ORDER="330" O_E="0.0" SE="0.47408254502983543" STUDY_ID="STD-Marder-2007" TOTAL_1="112" TOTAL_2="109" VAR="0.22475425950196593" WEIGHT="68.29140004121334"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4100738986879264" CI_END="10.16757989421585" CI_START="0.04139669105798627" DF="1" EFFECT_SIZE="0.6487712722433432" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="70.6751223079135" ID="CMP-004.03.03" LOG_CI_END="1.0072175936638645" LOG_CI_START="-1.383034371746002" LOG_EFFECT_SIZE="-0.18790838904106874" NO="3" P_CHI2="0.06479964031332974" P_Z="0.7579582630121722" STUDIES="2" TAU2="2.9499032526659295" TOTAL_1="246" TOTAL_2="255" WEIGHT="100.0" Z="0.3081630558143128">
<NAME>9 mg</NAME>
<DICH_DATA CI_END="4.920908493141646" CI_START="0.7164760077014375" EFFECT_SIZE="1.8776881720430108" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.6920452891769097" LOG_CI_START="-0.14479834804030334" LOG_EFFECT_SIZE="0.2736234705683032" ORDER="331" O_E="0.0" SE="0.49156609494420367" STUDY_ID="STD-Davidson-2007" TOTAL_1="124" TOTAL_2="127" VAR="0.24163722569869384" WEIGHT="61.76781162988517"/>
<DICH_DATA CI_END="2.1418840544643407" CI_START="0.006339984865468313" EFFECT_SIZE="0.11653116531165311" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.33079595768667663" LOG_CI_START="-2.1979117788456244" LOG_EFFECT_SIZE="-0.9335579105794739" ORDER="332" O_E="0.0" SE="1.4853754417442457" STUDY_ID="STD-Kane-2007" TOTAL_1="122" TOTAL_2="128" VAR="2.206340202936913" WEIGHT="38.23218837011483"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.372389979807332" CI_END="1.5427825108259596" CI_START="0.3149871044211586" DF="1" EFFECT_SIZE="0.6971058713256357" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="0.0" ID="CMP-004.03.04" LOG_CI_END="0.18830470700575555" LOG_CI_START="-0.5017072258718981" LOG_EFFECT_SIZE="-0.15670125943307128" NO="4" P_CHI2="0.5417046845127532" P_Z="0.37335149105085375" STUDIES="2" TAU2="0.0" TOTAL_1="242" TOTAL_2="237" WEIGHT="100.0" Z="0.8902130823738792">
<NAME>12 mg</NAME>
<DICH_DATA CI_END="3.852576890103672" CI_START="0.2516412996484578" EFFECT_SIZE="0.9846153846153847" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5857513151683948" LOG_CI_START="-0.5992180804863316" LOG_EFFECT_SIZE="-0.0067333826589683786" ORDER="333" O_E="0.0" SE="0.6960568887006955" STUDY_ID="STD-Kane-2007" TOTAL_1="130" TOTAL_2="128" VAR="0.48449519230769234" WEIGHT="33.907747067899834"/>
<DICH_DATA CI_END="1.5514444371873322" CI_START="0.21977749789658813" EFFECT_SIZE="0.5839285714285715" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.19073622654922884" LOG_CI_START="-0.6580167752410575" LOG_EFFECT_SIZE="-0.2336402743459143" ORDER="334" O_E="0.0" SE="0.49856171464673227" STUDY_ID="STD-Marder-2007" TOTAL_1="112" TOTAL_2="109" VAR="0.2485637833114897" WEIGHT="66.09225293210017"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.4578769645442396E-32" CI_END="2.98593751641745" CI_START="0.29376993515170485" DF="0" EFFECT_SIZE="0.9365781710914455" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="100.0" ID="CMP-004.03.05" LOG_CI_END="0.4750807154589881" LOG_CI_START="-0.5319926526091634" LOG_EFFECT_SIZE="-0.028455968575087663" NO="5" P_CHI2="0.0" P_Z="0.9118051687095591" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="127" WEIGHT="100.00000000000001" Z="0.11076188750649414">
<NAME>15 mg</NAME>
<DICH_DATA CI_END="2.98593751641745" CI_START="0.29376993515170485" EFFECT_SIZE="0.9365781710914455" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4750807154589881" LOG_CI_START="-0.5319926526091634" LOG_EFFECT_SIZE="-0.028455968575087663" ORDER="335" O_E="0.0" SE="0.5915598814968027" STUDY_ID="STD-Davidson-2007" TOTAL_1="113" TOTAL_2="127" VAR="0.3499430933965113" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2009-02-20 02:13:31 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>PALIPERIDONE - ANY DOSE OR FLEXIBLE DOSES versus RISPERIDONE (fixed dose, all short term)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-01-07 21:42:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-01-02 18:03:52 +0000" MODIFIED_BY="[Empty name]" ORDER="475" O_E="0.0" SE="0.0" STUDY_ID="STD-Cleton-2007" TOTAL_1="75" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.1019181818208885" CI_START="0.007133004968201173" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.17105263157894737" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.6129869935413471" LOG_CI_START="-2.146727473489256" LOG_EFFECT_SIZE="-0.7668702399739545" METHOD="MH" MODIFIED="2009-01-07 21:42:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.2760345475245848" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="38" WEIGHT="100.0" Z="1.0892706974731179">
<NAME>Global state: Relapse: recurrence of psychotic symptoms</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.1019181818208885" CI_START="0.007133004968201173" EFFECT_SIZE="0.17105263157894737" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6129869935413471" LOG_CI_START="-2.146727473489256" LOG_EFFECT_SIZE="-0.7668702399739545" MODIFIED="2009-01-02 18:05:09 +0000" MODIFIED_BY="[Empty name]" ORDER="476" O_E="0.0" SE="1.6210699387407068" STUDY_ID="STD-Cleton-2007" TOTAL_1="75" TOTAL_2="38" VAR="2.627867746288799" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4247944645696156" CI_END="1.1158639940755506" CI_START="0.4769441223514942" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.729523661931535" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.04761126429512153" LOG_CI_START="-0.32153249889679447" LOG_EFFECT_SIZE="-0.13696061730083642" METHOD="MH" MODIFIED="2009-01-07 21:35:13 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.49046709240259034" P_Q="0.4904826588228287" P_Z="0.14584064537099128" Q="1.424730989562831" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="216" TOTAL_2="110" WEIGHT="99.99999999999999" Z="1.4543812139145007">
<NAME>Adverse effect: 1. Cardiovascular events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1506091973827002" CI_START="0.48122015372431703" DF="0" EFFECT_SIZE="0.7441077441077442" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="18" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.06092784123179762" LOG_CI_START="-0.3176561924960009" LOG_EFFECT_SIZE="-0.12836417563210162" MODIFIED="2009-01-07 21:35:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.18381299099428602" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="34" WEIGHT="83.65263322163797" Z="1.3291060305252365">
<NAME>blood pressure - hypotension</NAME>
<DICH_DATA CI_END="1.1506091973827002" CI_START="0.48122015372431703" EFFECT_SIZE="0.7441077441077442" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="18" LOG_CI_END="0.06092784123179762" LOG_CI_START="-0.3176561924960009" LOG_EFFECT_SIZE="-0.12836417563210162" MODIFIED="2009-01-07 21:35:13 +0000" MODIFIED_BY="[Empty name]" ORDER="486" O_E="0.0" SE="0.2223821354328996" STUDY_ID="STD-Cleton-2007" TOTAL_1="66" TOTAL_2="34" VAR="0.04945381415969651" WEIGHT="83.65263322163797"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9362331155592005" CI_START="0.058925666668779464" DF="0" EFFECT_SIZE="0.3377777777777778" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="0.2869576436264277" LOG_CI_START="-1.22969549528757" LOG_EFFECT_SIZE="-0.4713689258305711" MODIFIED="2009-01-02 18:26:57 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.22311158647922447" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="38" WEIGHT="14.020621014621542" Z="1.2182958573122231">
<NAME>pulse rate - tachycardia</NAME>
<DICH_DATA CI_END="1.9362331155592005" CI_START="0.058925666668779464" EFFECT_SIZE="0.3377777777777778" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.2869576436264277" LOG_CI_START="-1.22969549528757" LOG_EFFECT_SIZE="-0.4713689258305711" MODIFIED="2009-01-02 18:26:57 +0000" MODIFIED_BY="[Empty name]" ORDER="478" O_E="0.0" SE="0.8908895613522002" STUDY_ID="STD-Cleton-2007" TOTAL_1="75" TOTAL_2="38" VAR="0.7936842105263158" WEIGHT="14.020621014621542"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="52.14280014512358" CI_START="0.12625473900416084" DF="0" EFFECT_SIZE="2.5657894736842106" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-005.03.03" LOG_CI_END="1.717194349711525" LOG_CI_START="-0.8987523115480718" LOG_EFFECT_SIZE="0.4092210190817267" MODIFIED="2009-01-07 21:34:28 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5397394514274358" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="38" WEIGHT="2.326745763740479" Z="0.6132070435494016">
<NAME>palpitation</NAME>
<DICH_DATA CI_END="52.14280014512358" CI_START="0.12625473900416084" EFFECT_SIZE="2.5657894736842106" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.717194349711525" LOG_CI_START="-0.8987523115480718" LOG_EFFECT_SIZE="0.4092210190817267" MODIFIED="2009-01-02 18:24:45 +0000" MODIFIED_BY="[Empty name]" ORDER="477" O_E="0.0" SE="1.5366200179687015" STUDY_ID="STD-Cleton-2007" TOTAL_1="75" TOTAL_2="38" VAR="2.3612010796221323" WEIGHT="2.326745763740479"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4755305394699745" CI_END="1.1077261119300617" CI_START="0.23302882489208349" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5080670370781191" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" I2="19.209237449835232" I2_Q="16.30823087637949" ID="CMP-005.04" LOG_CI_END="0.04443239326124908" LOG_CI_START="-0.6325903548654254" LOG_EFFECT_SIZE="-0.29407898080208816" METHOD="MH" MODIFIED="2009-01-07 21:43:50 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.29003172130237886" P_Q="0.30274620454719714" P_Z="0.08862373019559554" Q="2.389721260457303" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="225" TOTAL_2="114" WEIGHT="100.0" Z="1.702702642052123">
<NAME>Adverse effect: 2. Central nervous system - levels of arousal</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3216142451314268" CI_START="0.0485601437894578" DF="0" EFFECT_SIZE="0.25333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.12110471108150617" LOG_CI_START="-1.313720035959248" LOG_EFFECT_SIZE="-0.596307662438871" MODIFIED="2009-01-02 18:30:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.10329036298955889" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="38" WEIGHT="34.789097399388915" Z="1.6291070313582467">
<NAME>anxiety</NAME>
<DICH_DATA CI_END="1.321614245131427" CI_START="0.04856014378945778" EFFECT_SIZE="0.25333333333333335" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.12110471108150624" LOG_CI_START="-1.3137200359592482" LOG_EFFECT_SIZE="-0.596307662438871" MODIFIED="2009-01-02 18:30:07 +0000" MODIFIED_BY="[Empty name]" ORDER="480" O_E="0.0" SE="0.8428231589087847" STUDY_ID="STD-Cleton-2007" TOTAL_1="75" TOTAL_2="38" VAR="0.7103508771929825" WEIGHT="34.789097399388915"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2021819071547724" CI_START="0.15688481128369838" DF="0" EFFECT_SIZE="0.4342857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="0.0799701875471108" LOG_CI_START="-0.8044191003581169" LOG_EFFECT_SIZE="-0.3622244564055031" MODIFIED="2009-01-02 18:29:53 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.1083821284001565" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="38" WEIGHT="60.88092044893061" Z="1.6055076618034836">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="1.2021819071547726" CI_START="0.15688481128369836" EFFECT_SIZE="0.4342857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.07997018754711088" LOG_CI_START="-0.804419100358117" LOG_EFFECT_SIZE="-0.3622244564055031" MODIFIED="2009-01-02 18:29:53 +0000" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.5194946455131102" STUDY_ID="STD-Cleton-2007" TOTAL_1="75" TOTAL_2="38" VAR="0.26987468671679204" WEIGHT="60.88092044893061"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1942885494012035E-32" CI_END="67.80720670731237" CI_START="0.19029275571404933" DF="0" EFFECT_SIZE="3.5921052631578942" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="100.0" ID="CMP-005.04.03" LOG_CI_END="1.8312758541456708" LOG_CI_START="-0.7205777446257419" LOG_EFFECT_SIZE="0.5553490547599647" MODIFIED="2009-01-02 18:29:16 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.3936164660566689" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="38" WEIGHT="4.329982151680464" Z="0.8530772664246357">
<NAME>sleepiness</NAME>
<DICH_DATA CI_END="67.80720670731243" CI_START="0.19029275571404936" EFFECT_SIZE="3.5921052631578947" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8312758541456713" LOG_CI_START="-0.7205777446257418" LOG_EFFECT_SIZE="0.5553490547599647" MODIFIED="2009-01-02 18:29:16 +0000" MODIFIED_BY="[Empty name]" ORDER="479" O_E="0.0" SE="1.4989714357973662" STUDY_ID="STD-Cleton-2007" TOTAL_1="75" TOTAL_2="38" VAR="2.246915365336418" WEIGHT="4.329982151680464"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1942885494012035E-32" CI_END="67.80720670731237" CI_START="0.19029275571404933" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.5921052631578942" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="100.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="1.8312758541456708" LOG_CI_START="-0.7205777446257419" LOG_EFFECT_SIZE="0.5553490547599647" METHOD="MH" MODIFIED="2009-01-07 21:44:04 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.3936164660566689" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="38" WEIGHT="100.0" Z="0.8530772664246357">
<NAME>Adverse effect: 3. Gastrointestinal events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1942885494012035E-32" CI_END="67.80720670731237" CI_START="0.19029275571404933" DF="0" EFFECT_SIZE="3.5921052631578942" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="100.0" ID="CMP-005.05.01" LOG_CI_END="1.8312758541456708" LOG_CI_START="-0.7205777446257419" LOG_EFFECT_SIZE="0.5553490547599647" MODIFIED="2009-01-02 18:32:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.3936164660566689" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="38" WEIGHT="100.0" Z="0.8530772664246357">
<NAME>nausea</NAME>
<DICH_DATA CI_END="67.80720670731243" CI_START="0.19029275571404936" EFFECT_SIZE="3.5921052631578947" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8312758541456713" LOG_CI_START="-0.7205777446257418" LOG_EFFECT_SIZE="0.5553490547599647" MODIFIED="2009-01-02 18:32:36 +0000" MODIFIED_BY="[Empty name]" ORDER="482" O_E="0.0" SE="1.4989714357973662" STUDY_ID="STD-Cleton-2007" TOTAL_1="75" TOTAL_2="38" VAR="2.246915365336418" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1474909880966328" CI_END="3.548252481212226" CI_START="0.4890765581930178" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3173333333333332" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.5500145151326211" LOG_CI_START="-0.31062315274076496" LOG_EFFECT_SIZE="0.11969568119592805" METHOD="MH" MODIFIED="2009-01-07 21:44:11 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7009448282752793" P_Q="0.7010071903046148" P_Z="0.5856329203234396" Q="0.1474263680094986" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="76" WEIGHT="100.0" Z="0.5451753577755803">
<NAME>Adverse effect: 4. Movement disorder - various events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.2894197625455135" CI_START="0.4367964925680485" DF="0" EFFECT_SIZE="1.52" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" I2="0.0" ID="CMP-005.06.01" LOG_CI_END="0.7234080335199201" LOG_CI_START="-0.35972085763037503" LOG_EFFECT_SIZE="0.18184358794477254" MODIFIED="2009-01-02 18:35:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5104699391944733" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="38" WEIGHT="60.0" Z="0.6581061332650596">
<NAME>extrapyramidal disorder</NAME>
<DICH_DATA CI_END="5.2894197625455135" CI_START="0.4367964925680485" EFFECT_SIZE="1.52" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.7234080335199201" LOG_CI_START="-0.35972085763037503" LOG_EFFECT_SIZE="0.18184358794477254" MODIFIED="2009-01-02 18:35:01 +0000" MODIFIED_BY="[Empty name]" ORDER="483" O_E="0.0" SE="0.6362352722361649" STUDY_ID="STD-Cleton-2007" TOTAL_1="75" TOTAL_2="38" VAR="0.40479532163742693" WEIGHT="60.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.286456980525706" CI_START="0.19424057515783114" DF="0" EFFECT_SIZE="1.0133333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-005.06.02" LOG_CI_END="0.7231647024094685" LOG_CI_START="-0.7116600446312858" LOG_EFFECT_SIZE="0.0057523288890913415" MODIFIED="2009-01-02 18:35:12 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9874615133331061" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="38" WEIGHT="40.0" Z="0.0157153094454233">
<NAME>hyperkinesia</NAME>
<DICH_DATA CI_END="5.286456980525708" CI_START="0.1942405751578311" EFFECT_SIZE="1.0133333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.7231647024094686" LOG_CI_START="-0.711660044631286" LOG_EFFECT_SIZE="0.0057523288890913415" MODIFIED="2009-01-02 18:35:12 +0000" MODIFIED_BY="[Empty name]" ORDER="484" O_E="0.0" SE="0.8428231589087847" STUDY_ID="STD-Cleton-2007" TOTAL_1="75" TOTAL_2="38" VAR="0.7103508771929825" WEIGHT="40.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="83.61109906920848" CI_START="0.25510743497983424" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.618421052631579" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="1.9222639322782635" LOG_CI_START="-0.5932768839081981" LOG_EFFECT_SIZE="0.6644935241850327" METHOD="MH" MODIFIED="2009-01-07 21:44:18 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.3004495397817407" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="38" WEIGHT="100.0" Z="1.0354698814524996">
<NAME>Adverse effect: 5. Other events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="83.61109906920848" CI_START="0.25510743497983424" DF="0" EFFECT_SIZE="4.618421052631579" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-005.07.01" LOG_CI_END="1.9222639322782635" LOG_CI_START="-0.5932768839081981" LOG_EFFECT_SIZE="0.6644935241850327" MODIFIED="2009-01-02 18:36:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3004495397817407" STUDIES="1" TAU2="0.0" TOTAL_1="75" TOTAL_2="38" WEIGHT="100.0" Z="1.0354698814524996">
<NAME>pain - headache</NAME>
<DICH_DATA CI_END="83.61109906920848" CI_START="0.25510743497983424" EFFECT_SIZE="4.618421052631579" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9222639322782635" LOG_CI_START="-0.5932768839081981" LOG_EFFECT_SIZE="0.6644935241850327" MODIFIED="2009-01-02 18:36:26 +0000" MODIFIED_BY="[Empty name]" ORDER="485" O_E="0.0" SE="1.4776411275557928" STUDY_ID="STD-Cleton-2007" TOTAL_1="75" TOTAL_2="38" VAR="2.1834233018443547" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2011-11-25 23:23:04 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>PALIPERIDONE - ANY DOSE OR FLEXIBLE DOSES versus QUETIAPINE (flexible dose, all short term)</NAME>
<DICH_OUTCOME CHI2="4.325150109372553" CI_END="0.8495256119428265" CI_START="0.48697363698279716" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6431924882629108" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="106" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-0.0708235232601907" LOG_CI_START="-0.31249454930447124" LOG_EFFECT_SIZE="-0.191659036282331" METHOD="MH" MODIFIED="2009-05-14 14:50:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6327651984439746" P_Q="0.6333403327771513" P_Z="0.001878942639138794" Q="4.320874015505726" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1099" TOTAL_2="1099" WEIGHT="700.0" Z="3.108728543703837">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9282691604382521" CI_START="0.44333515687227176" DF="0" EFFECT_SIZE="0.6415094339622641" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="53" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-0.03232607772073879" LOG_CI_START="-0.35326782739632906" LOG_EFFECT_SIZE="-0.19279695255853393" MODIFIED="2009-05-14 14:50:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.018533215867771166" STUDIES="1" TAU2="0.0" TOTAL_1="157" TOTAL_2="157" WEIGHT="100.0" Z="2.354789202250952">
<NAME>any reason</NAME>
<DICH_DATA CI_END="0.9282691604382521" CI_START="0.44333515687227176" EFFECT_SIZE="0.6415094339622641" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="53" LOG_CI_END="-0.03232607772073879" LOG_CI_START="-0.35326782739632906" LOG_EFFECT_SIZE="-0.19279695255853393" MODIFIED="2009-05-14 14:50:30 +0100" MODIFIED_BY="[Empty name]" ORDER="468" O_E="0.0" SE="0.18852277244672466" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="157" VAR="0.03554083573099953" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.334401057952181" CI_START="0.2927343302615984" DF="0" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.12528637761516542" LOG_CI_START="-0.533526342927015" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2009-05-14 14:50:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.22455248151277585" STUDIES="1" TAU2="0.0" TOTAL_1="157" TOTAL_2="157" WEIGHT="100.0" Z="1.2145115054891806">
<NAME>adverse event</NAME>
<DICH_DATA CI_END="1.334401057952181" CI_START="0.2927343302615984" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.12528637761516542" LOG_CI_START="-0.533526342927015" LOG_EFFECT_SIZE="-0.2041199826559248" MODIFIED="2009-05-14 14:50:32 +0100" MODIFIED_BY="[Empty name]" ORDER="467" O_E="0.0" SE="0.386989853222039" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="157" VAR="0.1497611464968153" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0694319864472608" CI_START="0.08415682450175" DF="0" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="0.029153169599549732" LOG_CI_START="-1.0749106601602247" LOG_EFFECT_SIZE="-0.5228787452803376" MODIFIED="2009-05-14 14:50:39 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.06338844756076234" STUDIES="1" TAU2="0.0" TOTAL_1="157" TOTAL_2="157" WEIGHT="100.0" Z="1.856456993530779">
<NAME>lack of efficacy</NAME>
<DICH_DATA CI_END="1.0694319864472608" CI_START="0.08415682450175" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.029153169599549732" LOG_CI_START="-1.0749106601602247" LOG_EFFECT_SIZE="-0.5228787452803376" MODIFIED="2009-05-14 14:50:39 +0100" MODIFIED_BY="[Empty name]" ORDER="466" O_E="0.0" SE="0.6485325588049906" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="157" VAR="0.42059447983014864" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2484995409751036" CI_START="0.1281538316586298" DF="0" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" ID="CMP-006.01.04" LOG_CI_END="0.09638838701414575" LOG_CI_START="-0.8922684043582209" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2009-05-13 16:04:37 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.11461307831310485" STUDIES="1" TAU2="0.0" TOTAL_1="157" TOTAL_2="157" WEIGHT="100.0" Z="1.5777934098284907">
<NAME>loss to follow up</NAME>
<DICH_DATA CI_END="1.2484995409751036" CI_START="0.1281538316586298" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.09638838701414575" LOG_CI_START="-0.8922684043582209" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2009-05-13 16:04:37 +0100" MODIFIED_BY="[Empty name]" ORDER="465" O_E="0.0" SE="0.5807418931821737" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="157" VAR="0.33726114649681527" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.923837123462746" CI_START="0.21889044190055226" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-006.01.05" LOG_CI_END="0.4659531759631279" LOG_CI_START="-0.6597732019792407" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2009-05-13 16:04:34 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.7357750846017976" STUDIES="1" TAU2="0.0" TOTAL_1="157" TOTAL_2="157" WEIGHT="100.0" Z="0.3374534681940671">
<NAME>unspecified participant reason</NAME>
<DICH_DATA CI_END="2.923837123462746" CI_START="0.21889044190055226" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4659531759631279" LOG_CI_START="-0.6597732019792407" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2009-05-13 16:04:34 +0100" MODIFIED_BY="[Empty name]" ORDER="464" O_E="0.0" SE="0.6612572468387892" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="157" VAR="0.4372611464968153" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="73.0843795240753" CI_START="0.12314532953016649" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.01.06" LOG_CI_END="1.863824564216216" LOG_CI_START="-0.9095820547768908" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-05-13 16:04:14 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.5000809898977212" STUDIES="1" TAU2="0.0" TOTAL_1="157" TOTAL_2="157" WEIGHT="100.0" Z="0.6743623305035633">
<NAME>unspecified reason</NAME>
<DICH_DATA CI_END="73.0843795240753" CI_START="0.12314532953016649" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.863824564216216" LOG_CI_START="-0.9095820547768908" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-05-13 16:04:14 +0100" MODIFIED_BY="[Empty name]" ORDER="463" O_E="0.0" SE="1.6291127765807267" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="157" VAR="2.654008438818565" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.15753231080505" CI_START="0.4634924793440824" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" ID="CMP-006.01.07" LOG_CI_END="0.3339573083498267" LOG_CI_START="-0.3339573083498267" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-13 16:04:17 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="157" TOTAL_2="157" WEIGHT="100.0" Z="0.0">
<NAME>withdrawal of consent</NAME>
<DICH_DATA CI_END="2.15753231080505" CI_START="0.4634924793440824" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.3339573083498267" LOG_CI_START="-0.3339573083498267" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-13 16:04:17 +0100" MODIFIED_BY="[Empty name]" ORDER="462" O_E="0.0" SE="0.39233635208005124" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="157" VAR="0.15392781316348195" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-05-14 13:40:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="157" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-14 13:40:16 +0100" MODIFIED_BY="[Empty name]" ORDER="525" O_E="0.0" SE="0.0" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="157" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0213358495396785" CI_START="0.7323602275562052" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8648616971401781" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="108" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.00916857618853926" LOG_CI_START="-0.1352752490534192" LOG_EFFECT_SIZE="-0.06305333643243995" METHOD="MH" MODIFIED="2011-11-25 22:50:33 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.08705408346701546" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="157" WEIGHT="100.0" Z="1.711146437802466">
<NAME>Global State: 1. No clinically important change</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0213358495396785" CI_START="0.7323602275562052" EFFECT_SIZE="0.8648616971401781" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="108" LOG_CI_END="0.00916857618853926" LOG_CI_START="-0.1352752490534192" LOG_EFFECT_SIZE="-0.06305333643243995" MODIFIED="2011-11-25 22:50:33 +0000" MODIFIED_BY="[Empty name]" ORDER="528" O_E="0.0" SE="0.08484701795559285" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="157" VAR="0.007199016455956697" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6321319137722317E-31" CI_END="1.4512178488683265" CI_START="0.2883874859354" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6469258589511753" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" I2="100.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.16173261123845142" LOG_CI_START="-0.5400235889842202" LOG_EFFECT_SIZE="-0.18914548887288438" METHOD="MH" MODIFIED="2011-11-25 22:49:11 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.2907195119870073" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0" Z="1.0565445546799408">
<NAME>Global State: 2. Recurrence of psychotic symptoms</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4512178488683267" CI_START="0.2883874859354001" EFFECT_SIZE="0.6469258589511754" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.1617326112384515" LOG_CI_START="-0.54002358898422" LOG_EFFECT_SIZE="-0.18914548887288432" MODIFIED="2008-11-26 21:14:41 +0000" MODIFIED_BY="[Empty name]" ORDER="425" O_E="0.0" SE="0.4122150657600123" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.16992126043953126" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7193959667371541" CI_START="0.5012839868562594" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.928388746803069" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.23537590365973796" LOG_CI_START="-0.29991616837924656" LOG_EFFECT_SIZE="-0.032270132359754296" METHOD="MH" MODIFIED="2011-11-25 22:47:58 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.8131896277665787" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="121" WEIGHT="100.0" Z="0.2363132222770999">
<NAME>Global State: 3. Use of additional benzodiazepine</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7193959667371541" CI_START="0.5012839868562595" EFFECT_SIZE="0.928388746803069" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.23537590365973796" LOG_CI_START="-0.29991616837924645" LOG_EFFECT_SIZE="-0.032270132359754296" MODIFIED="2009-05-14 15:02:53 +0100" MODIFIED_BY="[Empty name]" ORDER="493" O_E="0.0" SE="0.3144332128541905" STUDY_ID="STD-Canuso-2009" TOTAL_1="138" TOTAL_2="121" VAR="0.0988682453458087" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-4.179692767168139" CI_START="-5.020307232831857" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.599999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.06" MODIFIED="2011-11-25 22:46:31 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="157" TOTAL_2="157" UNITS="" WEIGHT="100.0" Z="21.45058096702078">
<NAME>Mental state: Average change score (PANSS total, decline=good)</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.179692767168139" CI_START="-5.020307232831857" EFFECT_SIZE="-4.599999999999998" ESTIMABLE="YES" MEAN_1="-31.2" MEAN_2="-26.6" MODIFIED="2011-11-25 20:06:05 +0000" MODIFIED_BY="[Empty name]" ORDER="421" SD_1="1.9" SD_2="1.9" SE="0.21444640623357814" STUDY_ID="STD-Canuso-2009" TOTAL_1="157" TOTAL_2="157" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.954036642508598" CI_END="1.8305000820975312" CI_START="1.0698684668110257" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.399426424050633" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="64" I2="66.40934344069899" I2_Q="66.40793474369289" ID="CMP-006.07" LOG_CI_END="0.26256975269556354" LOG_CI_START="0.029330387358545526" LOG_EFFECT_SIZE="0.14595007002705454" METHOD="MH" MODIFIED="2011-11-25 22:46:34 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.050944619873813046" P_Q="0.05095098024745037" P_Z="0.014170816964652656" Q="5.953786957544946" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="474" TOTAL_2="477" WEIGHT="100.0" Z="2.4529039545343414">
<NAME>Adverse effect: 1. Anticholinergic events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9043227174429354" CI_START="1.0722997757895683" DF="0" EFFECT_SIZE="1.428987341772152" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="50" I2="0.0" ID="CMP-006.07.01" LOG_CI_END="0.27974054831753403" LOG_CI_START="0.03031621518063665" LOG_EFFECT_SIZE="0.15502838174908534" MODIFIED="2009-05-13 21:00:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.014833835639330587" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="78.125" Z="2.436410601871509">
<NAME>use of anticholinergic medication</NAME>
<DICH_DATA CI_END="1.9043227174429354" CI_START="1.0722997757895683" EFFECT_SIZE="1.428987341772152" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="50" LOG_CI_END="0.27974054831753403" LOG_CI_START="0.03031621518063665" LOG_EFFECT_SIZE="0.15502838174908534" MODIFIED="2009-05-13 21:00:24 +0100" MODIFIED_BY="[Empty name]" ORDER="511" O_E="0.0" SE="0.14651308795497506" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.02146608494210226" WEIGHT="78.125"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4388715159473604" CI_START="0.17595356400957024" DF="0" EFFECT_SIZE="0.5031645569620253" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="0.0" ID="CMP-006.07.02" LOG_CI_END="0.15802201533596105" LOG_CI_START="-0.7546019319318656" LOG_EFFECT_SIZE="-0.2982899582979523" MODIFIED="2009-05-14 15:50:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.20011521161674556" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="15.625" Z="1.281223393193228">
<NAME>salivation - decreased</NAME>
<DICH_DATA CI_END="1.4388715159473604" CI_START="0.17595356400957024" EFFECT_SIZE="0.5031645569620253" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.15802201533596105" LOG_CI_START="-0.7546019319318656" LOG_EFFECT_SIZE="-0.2982899582979523" MODIFIED="2009-05-13 16:35:17 +0100" MODIFIED_BY="[Empty name]" ORDER="495" O_E="0.0" SE="0.5360798241865187" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.2873815778998488" WEIGHT="15.625"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.813671143913444" CI_START="1.089971885552442" DF="0" EFFECT_SIZE="3.2705696202531644" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" I2="0.0" ID="CMP-006.07.03" LOG_CI_END="0.9918315006821231" LOG_CI_START="0.03741529600768334" LOG_EFFECT_SIZE="0.5146233983449032" MODIFIED="2009-05-14 15:50:05 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.034546529498278966" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="6.25" Z="2.113634117731012">
<NAME>salivation - increased</NAME>
<DICH_DATA CI_END="9.813671143913444" CI_START="1.089971885552442" EFFECT_SIZE="3.2705696202531644" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.9918315006821231" LOG_CI_START="0.03741529600768334" LOG_EFFECT_SIZE="0.5146233983449032" MODIFIED="2009-05-13 16:41:43 +0100" MODIFIED_BY="[Empty name]" ORDER="497" O_E="0.0" SE="0.5606288030621738" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.3143046548229257" WEIGHT="6.25"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5987546071741412" CI_START="0.10570881975241242" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.25158227848101267" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="-0.22275113184442216" LOG_CI_START="-0.9758887760794449" LOG_EFFECT_SIZE="-0.5993199539619335" METHOD="MH" MODIFIED="2011-11-25 22:46:36 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.0018125775860183032" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="316" TOTAL_2="318" WEIGHT="100.0" Z="3.1193382351102756">
<NAME>Adverse effect: 2. Cardiovascular events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5987546071741412" CI_START="0.10570881975241242" DF="0" EFFECT_SIZE="0.25158227848101267" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="24" I2="0.0" ID="CMP-006.08.01" LOG_CI_END="-0.22275113184442216" LOG_CI_START="-0.9758887760794449" LOG_EFFECT_SIZE="-0.5993199539619335" MODIFIED="2008-11-26 21:15:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0018125775860183032" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0" Z="3.1193382351102756">
<NAME>dizziness</NAME>
<DICH_DATA CI_END="0.5987546071741412" CI_START="0.10570881975241242" EFFECT_SIZE="0.25158227848101267" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="24" LOG_CI_END="-0.22275113184442216" LOG_CI_START="-0.9758887760794449" LOG_EFFECT_SIZE="-0.5993199539619335" MODIFIED="2008-11-26 21:15:48 +0000" MODIFIED_BY="[Empty name]" ORDER="438" O_E="0.0" SE="0.4423967803151172" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.19571491123318205" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-05-14 13:29:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="0.0" Z="0.0">
<NAME>ECG - prolonged QTc LD</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-14 13:29:20 +0100" MODIFIED_BY="[Empty name]" ORDER="521" O_E="0.0" SE="0.0" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.6904562843800175" CI_END="1.2058880568458665" CI_START="0.6377297405670319" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8769439421338154" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="70" I2="36.04033769613229" I2_Q="35.83462352141952" ID="CMP-006.09" LOG_CI_END="0.08130699391475117" LOG_CI_START="-0.19536332918967314" LOG_EFFECT_SIZE="-0.05702816763746099" METHOD="MH" MODIFIED="2011-11-25 22:46:42 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.1959183298294941" P_Q="0.1971670362218615" P_Z="0.41909748029894334" Q="4.675418683160774" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="632" TOTAL_2="636" WEIGHT="400.0" Z="0.8079880300826441">
<NAME>Adverse effect: 3. Central nervous system - levels of arousal</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.345331986820981" CI_START="0.45678641946370946" DF="0" EFFECT_SIZE="1.4088607594936708" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-006.09.01" LOG_CI_END="0.6380229624962023" LOG_CI_START="-0.3402868164076686" LOG_EFFECT_SIZE="0.14886807304426689" MODIFIED="2009-05-13 16:44:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5508478513479241" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0" Z="0.596490125942636">
<NAME>agitation or aggression</NAME>
<DICH_DATA CI_END="4.345331986820981" CI_START="0.45678641946370946" EFFECT_SIZE="1.4088607594936708" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6380229624962023" LOG_CI_START="-0.3402868164076686" LOG_EFFECT_SIZE="0.14886807304426689" MODIFIED="2009-05-13 16:43:57 +0100" MODIFIED_BY="[Empty name]" ORDER="499" O_E="0.0" SE="0.5746640068396416" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.3302387207569916" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9584592862693468" CI_START="0.39284271976294977" DF="0" EFFECT_SIZE="0.6136153133683235" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="41" I2="0.0" ID="CMP-006.09.02" LOG_CI_END="-0.01842633048972709" LOG_CI_START="-0.40578129087361103" LOG_EFFECT_SIZE="-0.21210381068166903" MODIFIED="2008-11-26 21:16:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.03183840972994604" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0" Z="2.1464334909137746">
<NAME>sleepiness</NAME>
<DICH_DATA CI_END="0.9584592862693468" CI_START="0.39284271976294977" EFFECT_SIZE="0.6136153133683235" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="41" LOG_CI_END="-0.01842633048972709" LOG_CI_START="-0.40578129087361103" LOG_EFFECT_SIZE="-0.21210381068166903" MODIFIED="2008-11-26 21:16:26 +0000" MODIFIED_BY="[Empty name]" ORDER="428" O_E="0.0" SE="0.22753422116747135" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.05177182180228777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.238250070360433" CI_START="0.6380264813198872" DF="0" EFFECT_SIZE="1.1950158227848102" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" I2="0.0" ID="CMP-006.09.03" LOG_CI_END="0.34990860681719776" LOG_CI_START="-0.19516129549133168" LOG_EFFECT_SIZE="0.07737365566293307" MODIFIED="2009-05-13 16:44:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5779095258436318" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0" Z="0.5564408447770548">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="2.238250070360433" CI_START="0.6380264813198872" EFFECT_SIZE="1.1950158227848102" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.34990860681719776" LOG_CI_START="-0.19516129549133168" LOG_EFFECT_SIZE="0.07737365566293307" MODIFIED="2008-11-26 21:16:12 +0000" MODIFIED_BY="[Empty name]" ORDER="426" O_E="0.0" SE="0.3201767587555617" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.10251315684721715" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.104025100612584" CI_START="0.5097707073406615" DF="0" EFFECT_SIZE="1.2579113924050633" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-006.09.04" LOG_CI_END="0.4919252245105909" LOG_CI_START="-0.29262512376242034" LOG_EFFECT_SIZE="0.0996500503740853" MODIFIED="2009-05-13 16:57:35 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6185604577920806" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0" Z="0.4978915890375574">
<NAME>fatigue</NAME>
<DICH_DATA CI_END="3.104025100612584" CI_START="0.5097707073406615" EFFECT_SIZE="1.2579113924050633" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4919252245105909" LOG_CI_START="-0.29262512376242034" LOG_EFFECT_SIZE="0.0996500503740853" MODIFIED="2009-05-13 16:57:35 +0100" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="0.46084875816242443" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.21238157789984874" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1904.4687396722272" CI_END="25.509296023881003" CI_START="24.579967374629103" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="25.044631699255053" ESTIMABLE="YES" I2="99.94749191839337" I2_Q="99.94749191839337" ID="CMP-006.10" MODIFIED="2011-11-25 22:46:45 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="1904.4687396722272" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="159" UNITS="" WEIGHT="100.00000000000001" Z="105.63878812113316">
<NAME>Adverse effect: 4. Endocrine: average change in serum level</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="23.771224352113016" CI_START="22.828775647886978" DF="0" EFFECT_SIZE="23.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-006.10.01" MODIFIED="2009-05-13 21:07:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="107" WEIGHT="97.23513201385889" Z="96.91171654225226">
<NAME>prolactin (ng/ml) - men</NAME>
<CONT_DATA CI_END="23.771224352113016" CI_START="22.828775647886978" EFFECT_SIZE="23.299999999999997" ESTIMABLE="YES" MEAN_1="20.9" MEAN_2="-2.4" MODIFIED="2009-05-13 21:07:29 +0100" MODIFIED_BY="[Empty name]" ORDER="513" SD_1="1.7" SD_2="1.8" SE="0.24042500567866318" STUDY_ID="STD-Canuso-2009" TOTAL_1="105" TOTAL_2="107" WEIGHT="97.23513201385889"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="89.19448723490439" CI_START="83.6055127650956" DF="0" EFFECT_SIZE="86.39999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-006.10.02" MODIFIED="2009-05-13 21:07:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="2.764867986141127" Z="60.598197103610595">
<NAME>prolactin (ng/ml) - women</NAME>
<CONT_DATA CI_END="89.19448723490439" CI_START="83.6055127650956" EFFECT_SIZE="86.39999999999999" ESTIMABLE="YES" MEAN_1="76.6" MEAN_2="-9.8" MODIFIED="2009-05-13 21:07:32 +0100" MODIFIED_BY="[Empty name]" ORDER="512" SD_1="7.1" SD_2="7.5" SE="1.425784992452392" STUDY_ID="STD-Canuso-2009" TOTAL_1="53" TOTAL_2="52" WEIGHT="2.764867986141127"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.9204362430493167" CI_END="1.0826624378216168" CI_START="0.4048553002699326" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6620586275816123" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="38" I2="23.477903630780666" I2_Q="22.971929278451604" ID="CMP-006.11" LOG_CI_END="0.034493069512353855" LOG_CI_START="-0.3927001706698413" LOG_EFFECT_SIZE="-0.1791035505787437" METHOD="MH" MODIFIED="2011-11-25 22:47:25 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.2701848010719661" P_Q="0.27306326933363745" P_Z="0.10028875562979528" Q="3.8946840702330587" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="632" TOTAL_2="636" WEIGHT="100.0" Z="1.6434553528415892">
<NAME>Adverse effect 5: Gastrointestinal events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.452211567579699" CI_START="0.2372923683112022" DF="0" EFFECT_SIZE="0.5870253164556962" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" I2="0.0" ID="CMP-006.11.01" LOG_CI_END="0.16202989180419858" LOG_CI_START="-0.6247162291388769" LOG_EFFECT_SIZE="-0.23134316866733912" MODIFIED="2009-05-13 16:51:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2490511472445015" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="31.578947368421055" Z="1.152657170050838">
<NAME>constipation</NAME>
<DICH_DATA CI_END="1.452211567579699" CI_START="0.23729236831120226" EFFECT_SIZE="0.5870253164556962" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.16202989180419858" LOG_CI_START="-0.6247162291388768" LOG_EFFECT_SIZE="-0.23134316866733912" MODIFIED="2009-05-13 16:51:43 +0100" MODIFIED_BY="[Empty name]" ORDER="501" O_E="0.0" SE="0.4621385658980701" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.2135720540903249" WEIGHT="31.578947368421055"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.637259498080334" CI_START="0.15463313645737597" DF="0" EFFECT_SIZE="0.5031645569620253" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" ID="CMP-006.11.02" LOG_CI_END="0.21411751854008973" LOG_CI_START="-0.8106974351359945" LOG_EFFECT_SIZE="-0.2982899582979523" MODIFIED="2009-05-13 16:52:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.25388566188521633" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="21.05263157894737" Z="1.140962225652162">
<NAME>dyspepsia</NAME>
<DICH_DATA CI_END="1.637259498080334" CI_START="0.15463313645737597" EFFECT_SIZE="0.5031645569620253" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.21411751854008973" LOG_CI_START="-0.8106974351359945" LOG_EFFECT_SIZE="-0.2982899582979523" MODIFIED="2009-05-13 16:52:07 +0100" MODIFIED_BY="[Empty name]" ORDER="502" O_E="0.0" SE="0.6019813767051675" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.36238157789984876" WEIGHT="21.05263157894737"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7140500462435764" CI_START="0.5373097423841687" DF="0" EFFECT_SIZE="1.2075949367088608" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="0.0" ID="CMP-006.11.03" LOG_CI_END="0.43361785165350175" LOG_CI_START="-0.26977528482619445" LOG_EFFECT_SIZE="0.08192128341365369" MODIFIED="2009-05-13 16:52:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6480033223408939" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="26.315789473684212" Z="0.45653776453274925">
<NAME>vomiting</NAME>
<DICH_DATA CI_END="2.7140500462435764" CI_START="0.5373097423841687" EFFECT_SIZE="1.2075949367088608" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.43361785165350175" LOG_CI_START="-0.26977528482619445" LOG_EFFECT_SIZE="0.08192128341365369" MODIFIED="2009-05-13 16:52:30 +0100" MODIFIED_BY="[Empty name]" ORDER="503" O_E="0.0" SE="0.4131766102203537" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.17071491123318208" WEIGHT="26.315789473684212"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1662354085948903" CI_START="0.054271755409960994" DF="0" EFFECT_SIZE="0.25158227848101267" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" ID="CMP-006.11.04" LOG_CI_END="0.06678622309422211" LOG_CI_START="-1.2654261310180892" LOG_EFFECT_SIZE="-0.5993199539619335" MODIFIED="2009-06-08 11:15:42 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.07782447465318815" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="21.05263157894737" Z="1.763450881318828">
<NAME>diarrhoea</NAME>
<DICH_DATA CI_END="1.1662354085948903" CI_START="0.054271755409960994" EFFECT_SIZE="0.25158227848101267" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.06678622309422211" LOG_CI_START="-1.2654261310180892" LOG_EFFECT_SIZE="-0.5993199539619335" MODIFIED="2009-05-13 16:54:35 +0100" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.7825481313630802" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.6123815778998487" WEIGHT="21.05263157894737"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="14.906402351696597" CI_START="-16.306402351696597" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.12" MODIFIED="2011-11-25 23:23:04 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.9299473957960578" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="159" UNITS="" WEIGHT="100.0" Z="0.08791102255728327">
<NAME>Adverse effect: 6. Metabolic - average change in weight (kg)</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.906402351696597" CI_START="-16.306402351696597" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="1.1" MODIFIED="2011-11-25 23:23:04 +0000" MODIFIED_BY="[Empty name]" ORDER="517" SD_1="70.66" SD_2="71.11" SE="7.962596494016169" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.8155026402900964" CI_END="3.5679656797752353" CI_START="1.5295724655174279" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.336121157323689" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-006.13" LOG_CI_END="0.5524206682500724" LOG_CI_START="0.18457005708325808" LOG_EFFECT_SIZE="0.3684953626666652" METHOD="MH" MODIFIED="2011-11-25 22:47:28 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.4034304366086614" P_Q="0.4042628500047776" P_Z="8.608399105681018E-5" Q="1.8113802104086731" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="474" TOTAL_2="477" WEIGHT="300.0" Z="3.9267986371193846">
<NAME>Adverse effect: 7. Movement disorder - various events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.768122794211612" CI_START="1.3072802313076353" DF="0" EFFECT_SIZE="3.1867088607594938" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" I2="0.0" ID="CMP-006.13.01" LOG_CI_END="0.8903160820424579" LOG_CI_START="0.11636869382797041" LOG_EFFECT_SIZE="0.5033423879352142" MODIFIED="2008-11-26 21:18:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.01079226753045299" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0" Z="2.5493540446498817">
<NAME>hypertonia</NAME>
<DICH_DATA CI_END="7.768122794211612" CI_START="1.3072802313076353" EFFECT_SIZE="3.1867088607594938" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" LOG_CI_END="0.8903160820424579" LOG_CI_START="0.11636869382797041" LOG_EFFECT_SIZE="0.5033423879352142" MODIFIED="2008-11-26 21:18:46 +0000" MODIFIED_BY="[Empty name]" ORDER="433" O_E="0.0" SE="0.4546205269385488" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.2066798235138838" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.8760255774009496" CI_START="1.386037547023356" DF="0" EFFECT_SIZE="2.5996835443037973" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" I2="0.0" ID="CMP-006.13.02" LOG_CI_END="0.6880659750626199" LOG_CI_START="0.14177499524273354" LOG_EFFECT_SIZE="0.4149204851526767" MODIFIED="2008-11-26 21:19:01 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.0029082312976338016" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0" Z="2.977274886051593">
<NAME>tremor</NAME>
<DICH_DATA CI_END="4.8760255774009496" CI_START="1.386037547023356" EFFECT_SIZE="2.5996835443037973" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="12" LOG_CI_END="0.6880659750626199" LOG_CI_START="0.14177499524273354" LOG_EFFECT_SIZE="0.4149204851526767" MODIFIED="2008-11-26 21:19:01 +0000" MODIFIED_BY="[Empty name]" ORDER="434" O_E="0.0" SE="0.3208940257301639" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.1029729757493111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.25776101189591" CI_START="0.6994285750626832" DF="0" EFFECT_SIZE="1.509493670886076" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" I2="0.0" ID="CMP-006.13.03" LOG_CI_END="0.5129192214636521" LOG_CI_START="-0.15525662862023187" LOG_EFFECT_SIZE="0.1788312964217101" MODIFIED="2009-06-08 11:17:08 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2941166038277484" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0" Z="1.0491336981160149">
<NAME>akathisia (no BARS data)</NAME>
<DICH_DATA CI_END="3.25776101189591" CI_START="0.6994285750626832" EFFECT_SIZE="1.509493670886076" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.5129192214636521" LOG_CI_START="-0.15525662862023187" LOG_EFFECT_SIZE="0.1788312964217101" MODIFIED="2008-11-26 21:19:37 +0000" MODIFIED_BY="[Empty name]" ORDER="432" O_E="0.0" SE="0.3924898018630744" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.15404824456651542" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.146188926305688" CI_START="0.6914497041706196" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2181878747501667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-006.14" LOG_CI_END="0.33166794970848634" LOG_CI_START="-0.16023940484690072" LOG_EFFECT_SIZE="0.08571427243079281" METHOD="MH" MODIFIED="2011-11-25 22:47:30 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.49457980631082044" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0" Z="0.6830427940125158">
<NAME>Adverse effect: 8. Other events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.146188926305688" CI_START="0.6914497041706196" DF="0" EFFECT_SIZE="1.2181878747501667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="19" I2="0.0" ID="CMP-006.14.01" LOG_CI_END="0.33166794970848634" LOG_CI_START="-0.16023940484690072" LOG_EFFECT_SIZE="0.08571427243079281" MODIFIED="2008-11-26 21:17:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49457980631082044" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0" Z="0.6830427940125158">
<NAME>headache</NAME>
<DICH_DATA CI_END="2.146188926305688" CI_START="0.6914497041706196" EFFECT_SIZE="1.2181878747501667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="19" LOG_CI_END="0.33166794970848634" LOG_CI_START="-0.16023940484690072" LOG_EFFECT_SIZE="0.08571427243079281" MODIFIED="2008-11-26 21:17:26 +0000" MODIFIED_BY="[Empty name]" ORDER="430" O_E="0.0" SE="0.2889488150465102" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="0.08349141771678237" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.910529688456532E-5" CI_END="29.009323259736824" CI_START="0.3180867332179469" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.037676886792453" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.15" LOG_CI_END="1.462537597537924" LOG_CI_START="-0.49745444409726125" LOG_EFFECT_SIZE="0.48254157672033143" METHOD="MH" MODIFIED="2011-11-25 22:47:30 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.9956954875174553" P_Q="0.9956954905144104" P_Z="0.3345100954260609" Q="2.910525635589418E-5" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="263" TOTAL_2="266" WEIGHT="100.0" Z="0.965069338369341">
<NAME>Adverse effect: 9.Potentially prolactin-related events</NAME>
<GROUP_LABEL_1>Paliperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>Quetiapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours paliperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours quetiapine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="74.19334187351464" CI_START="0.12592540506695618" DF="0" EFFECT_SIZE="3.056603773584906" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.15.01" LOG_CI_END="1.870364933347297" LOG_CI_START="-0.8998866434636128" LOG_EFFECT_SIZE="0.48523914494184195" MODIFIED="2009-05-14 13:31:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4923239652611263" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="107" WEIGHT="49.84375" Z="0.6866172415068985">
<NAME>impotence - men</NAME>
<DICH_DATA CI_END="74.19334187351457" CI_START="0.12592540506695618" EFFECT_SIZE="3.056603773584906" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8703649333472965" LOG_CI_START="-0.8998866434636128" LOG_EFFECT_SIZE="0.48523914494184195" MODIFIED="2009-05-14 13:31:45 +0100" MODIFIED_BY="[Empty name]" ORDER="522" O_E="0.0" SE="1.6272594891851933" STUDY_ID="STD-Canuso-2009" TOTAL_1="105" TOTAL_2="107" VAR="2.6479734451432564" WEIGHT="49.84375"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="73.549290836206" CI_START="0.12391096422726482" DF="0" EFFECT_SIZE="3.018867924528302" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-006.15.02" LOG_CI_END="1.8665784896072974" LOG_CI_START="-0.906890263497026" LOG_EFFECT_SIZE="0.47984411305513575" MODIFIED="2009-05-14 13:31:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.49764767404387866" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="50.15625" Z="0.6781956196398196">
<NAME>abnormal sexual function</NAME>
<DICH_DATA CI_END="73.54929083620593" CI_START="0.12391096422726487" EFFECT_SIZE="3.018867924528302" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.866578489607297" LOG_CI_START="-0.9068902634970257" LOG_EFFECT_SIZE="0.47984411305513575" MODIFIED="2009-05-14 13:31:25 +0100" MODIFIED_BY="[Empty name]" ORDER="523" O_E="0.0" SE="1.6291492744652238" STUDY_ID="STD-Canuso-2009" TOTAL_1="158" TOTAL_2="159" VAR="2.6541273584905656" WEIGHT="50.15625"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-08-06 09:40:23 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-08-06 09:40:23 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2012-03-14 13:47:25 +0000" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2009-08-06 10:53:19 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-03-17 12:12:52 +0000" MODIFIED_BY="[Empty name]">First edition</TITLE>
<DATE_SUBMITTED>
<DATE DAY="1" MONTH="5" YEAR="2008"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2009-08-06 10:53:19 +0100" MODIFIED_BY="[Empty name]">
<P>The manufacturers provided us with additional data, asked us to consider excluding the data from paliperidone 15 mg, to describe paliperidone as paliperidone OROS or Extended-Release and sexual outcome data.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2009-06-08 11:18:08 +0100" MODIFIED_BY="[Empty name]">
<P>We appreciated the additional data, especially the sexual outcome data, and incorporated it into this edition of the review. We declined to exclude the data from paliperidone 15 mg because while it is higher than the FDA recommended maximum dose of 12 mg, it is a clinically relevant outcome that increases knowledge about the efficacy and adverse effects of paliperidone. We declined to describe paliperidone as 'paliperidone Extended-Release' because oral paliperidone is only commercially available in the extended-release format and this clarification, is therefore, redundant. Describing paliperidone as 'paliperidone OROS' would involve the use of a trademarked name and would therefore constitute participation in the manufacturer's marketing plan.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2009-03-17 12:22:57 +0000" MODIFIED_BY="[Empty name]">
<P>Abraham Nussbaum and T. Scott Stroup.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" MODIFIED="2012-03-14 13:47:25 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-03-14 13:42:17 +0000" MODIFIED_BY="[Empty name]">Feeback response</TITLE>
<DATE_SUBMITTED>
<DATE DAY="6" MONTH="3" YEAR="2012"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2012-03-14 13:47:04 +0000" MODIFIED_BY="[Empty name]">
<P>See section below.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2012-03-14 13:45:34 +0000" MODIFIED_BY="[Empty name]">
<P>Abraham Nussbaum, MD</P>
<P>Assistant Professor, University of Colorado Department of Psychiatry</P>
<P>Medical Director, Adult Inpatient Psychiatry Service, Denver Health</P>
<P>777 Bannock Street, MC 0490</P>
<P>Denver, CO 80204-4507</P>
<P>
<A HREF="mailto:Abraham.Nussbaum@dhha.org">Abraham.Nussbaum@dhha.org</A>
</P>
<P>6 March 2012</P>
<P>Re: Feedback submitted for &#8220;Oral paliperidone for schizophrenia&#8221;</P>
<P>On 20 October 2011, Paul Hutton submitted formal feedback for the Cochrane review entitled &#8220;Oral paliperidone for schizophrenia.&#8221; He identified four areas of concern that I appreciate the opportunity to address.</P>
<P>First, he observed that our review included the results of the trial referenced as Marder 2007, in which the total attrition exceeded 50%, despite our declared intent to exclude studies where <U>&gt;</U>50% of participants are lost to follow up. In the review, I had interpreted this literally, excluding only studies where <U>&gt;</U>50% of participants were &#8216;lost to follow up,&#8217; not simply studies where <U>&gt;</U>50% of participants discontinued treatment. Following the CATIE trials, discontinuation of treatment was a primary outcome of the review, so we wanted to include all participants randomised to paliperidone. After discussion with the editors, I understand that the question of how to handle attrition in a study remains a matter of debate within the Cochrane Schizophrenia Group. Regardless, I have revised the portion of the Methods entitled &#8220;Dealing with missing data&#8221; to resolve this ambiguity. This revision did not alter the results or conclusion of the review.</P>
<P>In the original text, the relevant section read as follows:</P>
<P>2. Overall loss of credibility<BR/>At some degree of loss to follow up data must lose credibility (Xia 2007). We are forced to make a judgment where this is for the trials likely to be included in this review. We excluded data from studies where more than 50% of participants in any group were lost to follow up, barring the outcome of 'leaving the study early', within the first six months of initiating treatment. In studies with less than 50% dropout rate, we considered people leaving early to have had the negative outcome, except for the event of death. We analysed the impact of including studies with high attrition rates (25-50%) in a sensitivity analysis for primary outcomes. If inclusion of data from this latter group resulted in a substantive change in the estimate of effect, we did not add the data to trials with less attrition, but presented the data separately.</P>
<P>3. Binary<BR/>Where attrition for a binary outcome is between 0 and 50%, and outcomes of these people are described, we included these data as reported. Where the outcomes of such people were not clearly described, we assumed the worst primary outcome, and rates of adverse effects similar to those who did continue to have their data recorded.</P>
<P>4. Continuous<BR/>In the case where attrition for a continuous outcome is between 0 and 50% and completer-only data were reported, we have reproduced these.</P>
<P>In the amended version of the review, the text now reads as:</P>
<P>2. Overall loss of credibility<BR/>At some degree of loss to follow up data must lose credibility (Xia 2007). We are forced to make a judgment where this is for the trials likely to be included in this review. Since we had identified discontinuation as a primary outcome, we planned to exclude data from studies only where more than 50% of participants in any group discontinued treatment because they were 'lost to follow up.' If participants left a study early for any reason, we considered them to have had the negative outcome, except for the event of death. If we had identified a study as having a high rate (25-50%) of subjects &#8216;lost to follow up,&#8217; we would have analysed the impact of including these studies in a sensitivity analysis for primary outcomes. If inclusion of data from this latter group resulted in a substantive change in the estimate of effect, we would not add the data to trials with less attrition, but would present the data separately.</P>
<P>3. Binary<BR/>If attrition had been reported as a binary outcome between 0 and 50%, and outcomes of these subjects had been described, we would have included these data as reported. Where the outcomes of such people were not clearly described, we would assumed the worst primary outcome, and rates of adverse effects similar to those who did continue to have their data recorded. Attrition was not reported in this fashion in the studies we included, so we did not report the data in this fashion.</P>
<P>4. Continuous<BR/>In the case where attrition for a continuous outcome is between 0 and 50% and completer-only data were reported, we would have reproduced these. Attrition was not reported in this fashion in the studies we included, so we did not report the data in this fashion.</P>
<P>Second, he observed that the review referenced a sensitivity analysis for primary outcomes on the impact of including studies whose attrition rates ranging between 25-50% in our review. As the reviewer noted, we made no further reference to such an analysis. Indeed, the analysis was never conducted because I interpreted the methods section to indicate that such a sensitivity analysis should be conducted if 25-50% of participants were lost to follow up, not simply if participants discontinued treatment. Since none of the included studies met those criteria, no sensitivity analysis was conducted. Our review should have, but did not, indicated that an analysis would have been conducted if necessary, but was not conducted. I revised the portion of the Methods entitled &#8220;Dealing with missing data&#8221; to resolve this ambiguity; this text is reproduced above in response to the first concern. This revision did not alter the results or conclusion of the review.</P>
<P>Third, he observed that some of the Canuso 2009 trial continuous summary data was presented with standard error (SE) instead of standard deviation (SD). The authors of the study reported the data using standard error and I used the standard error in the review. I regret this error and have converted the standard error into standard deviation in the revised version of the review. Converting to standard deviation affected only two outcomes, the average change in PANSS score and the average change in weight, and the updated data is presented in the results. This revision did not alter the conclusions of the review.</P>
<P>In the original text, the relevant sections read as follows:</P>
<P>6.1.1.2 No clinically important change in global state (&gt;% 30 change in PANSS and CGI-C score <U>&lt;</U>2).</P>
<P>The authors reported change in CGI-S and PANSS data, but not did not report data for change in clinically important change in global state. In their study, they defined a treatment response as defined by PANSS total score reduction <U>&gt;</U>30% and CGI-C score <U>&lt;</U>2.</P>
<P>6.2.4.6.1 Average change in weight (kg) (data likely to be skewed)</P>
<P>The authors found that patients receiving paliperidone and quetiapine both experienced, on average, increase in weight. However, the authors found that participants receiving paliperidone experienced a comparatively smaller increase in weight (n=317, 1 RCT, WMD -0.70 CI -0.74 to -0.66).</P>
<P>In the amended version of the review, the text now reads as:</P>
<P>6.1.1.2 No clinically important change in global state (&gt;% 30 change in PANSS and CGI-C score <U>&lt;</U>2).</P>
<P>The authors defined a treatment response as defined by PANSS total score reduction <U>&gt;</U>30% and CGI-C score <U>&lt;</U>2. On this basis, we observed no difference between subjects randomised to paliperidone and those who received quetiapine (n=315, 1 RCT, RR 0.86 CI 0.73 to 1.02).</P>
<P>6.2.4.6.1 Average change in weight (kg) (data likely to be skewed)</P>
<P>The authors found that patients receiving paliperidone and quetiapine both experienced, on average, increase in weight and were unable to identify in the weight gain between participants receiving paliperidone (n=317, 1 RCT, WMD -0.70 CI -16.31 to 14.91).</P>
<P>Fourth, he observed that no data from the Canuso 2009 trial was presented for the outcome &#8220;no clinically important change.&#8221; I initially excluded the data on this outcome from the review because the authors of Canuso 2009 defined a treatment response as both a PANSS total score reduction of at least 30% and a decrease in CGI-C score of at least two points. In the other studies included in the review, a clinically important change was defined only by the former criteria, a PANSS total score reduction of at least 30%. At the behest of the reviewer, I reconsidered this decision. Since the criteria for a &#8216;treatment response&#8217; are so similar to those in the other studies, I have included data from Canuso 2009 in the outcome &#8220;no clinically important change.&#8221; The addition of this data is reflected in the results section of the review, but did not alter the conclusions of the review.</P>
<P>In the original text, the relevant sections read as follows:</P>
<P>1.1.1.2 No clinically important change<BR/>Davidson 2007, Kane 2007, Marder 2007, and Tzimos 2008 defined a clinically important favourable change in global state as reduction in PANSS score from baseline to the endpoint by at least 30%. Participants whose PANSS score increased or decreased by less than 30% were considered not to experience a clinically important change. By this criteria, those receiving any dose of paliperidone were significantly more likely to have an improvement in global state (n=1420, 4 RCTs, RR 0.69 CI 0.63 to 0.75, NNT 5 CI 4 to 6).</P>
<P>In the amended version of the review, the text now reads as:<BR/>
<BR/>1.1.1.2 No clinically important change<BR/>Davidson 2007, Kane 2007, Marder 2007, and Tzimos 2008 defined a clinically important favourable change in global state as reduction in PANSS score from baseline to the endpoint by at least 30%. Participants whose PANSS score increased or decreased by less than 30% were considered not to experience a clinically important change. The Canuso 2009 trial defined treatment response by PANSS total score reduction by at least 30% and CGI-C score by 2 or less. The number of respondents was reported only as a composite; by this criteria, participants whose PANSS score increased or decreased by less than 30% and whose CGI-C were considered not to experience a clinically important change. By this criteria, those receiving any dose of paliperidone were significantly more likely to have an improvement in global state (n=1658, 5 RCTs, RR 0.71 CI 0.66 to 0.77, NNT 5 CI 5 to 6).</P>
<P>The section of our amended review entitled &#8220;Agreements and disagreements with other studies or reviews&#8221; has been updated to reflect the changes we made in response to Paul Hutton&#8217;s concerns.</P>
<P>I am grateful for a careful reader, who identified several areas of ambiguity and one frank error in our review. I have clarified the ambiguities and corrected the error.</P>
<P>Best</P>
<P>Abraham M Nussbaum</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2012-03-14 13:47:25 +0000" MODIFIED_BY="[Empty name]">
<P>Paul Hutton and Abraham M Nussbaum.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>